0001493152-24-014351.txt : 20240411 0001493152-24-014351.hdr.sgml : 20240411 20240411172546 ACCESSION NUMBER: 0001493152-24-014351 CONFORMED SUBMISSION TYPE: 10-K PUBLIC DOCUMENT COUNT: 57 CONFORMED PERIOD OF REPORT: 20231231 FILED AS OF DATE: 20240411 DATE AS OF CHANGE: 20240411 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Qualis Innovations, Inc. CENTRAL INDEX KEY: 0001871181 STANDARD INDUSTRIAL CLASSIFICATION: SURGICAL & MEDICAL INSTRUMENTS & APPARATUS [3841] ORGANIZATION NAME: 08 Industrial Applications and Services IRS NUMBER: 842488498 STATE OF INCORPORATION: NV FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 10-K SEC ACT: 1934 Act SEC FILE NUMBER: 333-260982 FILM NUMBER: 24839365 BUSINESS ADDRESS: STREET 1: 6898 S. UNIVERSITY BLVD., STREET 2: SUITE 100 CITY: CENTENNIAL STATE: CO ZIP: 80122 BUSINESS PHONE: 303-874-7474 MAIL ADDRESS: STREET 1: 6898 S. UNIVERSITY BLVD., STREET 2: SUITE 100 CITY: CENTENNIAL STATE: CO ZIP: 80122 10-K 1 form10-k.htm

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, DC 20549

FORM 10-K

☒ ANNUAL REPORT PURSUANT TO SECTION 13 or 15(d) OF THE SECURITIES AND EXCHANGE ACT OF 1934

For the fiscal year ended December 31, 2023

☐ TRANSITION REPORT PURSUANT TO SECTION 13 or 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from _________ to _________

Commission File Number 333-260982

QUALIS INNOVATIONS, INC.

(Exact name of registrant as specified in its charter)

Nevada

84-2488498

(State or other jurisdiction

of incorporation or organization)

(I.R.S. Employer

Identification Number)

6898 S. University Blvd., Suite 100, Centennial, CO		80122
(Address of principal executive offices)		(Zip Code)

Registrant’s telephone number (484) 483-2134

Securities registered pursuant to Section 12(g) of the Act:

Common Stock, $0.001 Par Value

Indicate by check mark if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Yes ☐ No ☒

Indicate by check mark if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act. Yes ☐ No ☒

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes ☒ No ☐

Indicate by checkmark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes ☒ No ☐

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

Large accelerated filer	☐	Accelerated filer	☐
Non-accelerated filer	☒	Smaller reporting company	☒

		Emerging Growth Company	☒

If an emerging growth company, indicate by check mark if the Registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards pursuant to Section 13(a) of the Exchange Act. ☒

Indicate by check mark whether the registrant has filed a report on and attestation to its management’s assessment of the effectiveness of its internal control over financial reporting under Section 404(b) of the Sarbanes-Oxley Act (15 U.S.C. 7262(b)) by the registered public accounting firm that prepared or issued its audit report. ☐

If securities are registered pursuant to Section 12(b) of the Act, indicate by check mark whether the financial statements of the registrant included in the filing reflect the correction of an error to previously issued financial statements. ☐

Indicate by check mark whether any of those error corrections are restatements that required a recovery analysis of incentive-based compensation received by any of the registrant’s executive officers during the relevant recovery period pursuant to §240.10D-1(b). ☐

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes ☐ No ☒

As of June 30, 2023 (the last business day of the registrant’s most recently completed second fiscal quarter), the aggregate market value of the issued and outstanding common stock held by non-affiliates of the registrant was $1,915,000. For purposes of the above statement only, all directors, executive officers and 10% shareholders are assumed to be affiliates. This determination of affiliate status is not necessarily a conclusive determination for any other purpose.

As of April 11, 2024, there were 20,439,950 shares of common stock outstanding.

QUALIS INNOVATIONS, INC

TABLE OF CONTENTS

PART I
Item 1.	Business	4
Item 1A.	Risk Factors	10
Item 1B.	Unresolved Staff Comments	10
Item 1C.	Cybersecurity	10
Item 2.	Properties	10
Item 3.	Legal Proceedings	10
Item 4.	Mine Safety Disclosures	10

PART II
Item 5.	Market for the Registrant’s Common Stock, Related Stockholder Matters and Issuer Repurchases of Equity Securities	11
Item 6.	Selected Financial Data	11
Item 7.	Management’s Discussion and Analysis of Financial Condition and Results of Operations	11
Item 7A.	Quantitative and Qualitative Disclosures About Market Risk	22
Item 8.	Financial Statements and Supplementary Data	22
Item 9.	Changes in and Disagreements with Accountants on Accounting and Financial Disclosure	22
Item 9A	Controls and Procedures	22
Item 9B	Other Information	22

PART III
Item 10.	Directors, Executive Officers and Corporate Governance	22
Item 11.	Executive Compensation	25
Item 12.	Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters	28
Item 13.	Certain Relationships and Related Transactions, and Director Independence	29
Item 14.	Principal Accounting Fees and Services	30

PART IV
Item 15.	Exhibits, Financial Statement Schedules	31

DISCLOSURE REGARDING FORWARD LOOKING STATEMENTS

This report contains forward-looking statements. The forward-looking statements are contained principally in the sections entitled “Description of Business,” “Risk Factors,” and “Management’s Discussion and Analysis of Financial Condition and Results of Operations.” These statements involve known and unknown risks, uncertainties and other factors which may cause our actual results, performance or achievements to be materially different from any future results, performances or achievements expressed or implied by the forward-looking statements. In some cases, you can identify forward-looking statements by terms such as “anticipates,” “believes,” “seeks,” “could,” “estimates,” “expects,” “intends,” “may,” “plans,” “potential,” “predicts,” “projects,” “should,” “would” and similar expressions intended to identify forward-looking statements. Forward-looking statements reflect our current views with respect to future events and are based on assumptions and subject to risks and uncertainties. These risks and uncertainties include, but are not limited to, the factors described in the section captioned “Risk Factors” below. Given these uncertainties, you should not place undue reliance on these forward-looking statements. Such statements may include, but are not limited to, information related to: anticipated operating results; licensing arrangements; relationships with our customers; consumer demand; financial resources and condition; changes in revenues; changes in profitability; changes in accounting treatment; cost of sales; selling, general and administrative expenses; interest expense; the ability to secure materials and subcontractors; the ability to produce the liquidity or enter into agreements to acquire the capital necessary to continue our operations and take advantage of opportunities; legal proceedings and claims.

Also, forward-looking statements represent our estimates and assumptions only as of the date of this report. You should read this report and the documents that we reference and filed as exhibits to this report completely and with the understanding that our actual future results may be materially different from what we expect. Except as required by law, we assume no obligation to update any forward-looking statements publicly, or to update the reasons actual results could differ materially from those anticipated in any forward-looking statements, even if new information becomes available in the future.

USE OF CERTAIN DEFINED TERMS

Except as otherwise indicated by the context, references in this report to “we,” “us,” “our,” “our Company,” or “the Company” is of Sigyn Therapeutics, Inc.

In addition, unless the context otherwise requires and for the purposes of this report only:

	●	“Qualis” refers to Qualis Innovations, Inc., a Nevada corporation;
	●	“Commission” refers to the Securities and Exchange Commission;
	●	“Exchange Act” refers to the Securities Exchange Act of 1934, as amended; and
	●	“Securities Act” refers to the Securities Act of 1933, as amended.

PART I

Item 1. Business

Background

Description of Business

Qualis Innovations, Inc. (the “Company” or “Qualis”), formerly known as Hoopsoft Development Corp., Yellowstone Mining, Inc. and Sky Digital Holding Corp. was incorporated in the state of Nevada on March 23, 2006 under the name Hoopsoft Development Corp (“Hoopsoft”). On January 12, 2007, the Company entered into an agreement and plan of merger (“Agreement and Plan of Merger”) with Yellowcake Mining, Inc. (“Yellowcake”), a Nevada corporation and wholly-owned subsidiary of Hoopsoft Development Corp., incorporated for the sole purpose of effecting the merger. Pursuant to the terms of the Agreement and Plan of Merger, Yellowcake merged with and into Hoopsoft, with Hoopsoft carrying on as the surviving corporation under the name “Yellowcake Mining, Inc.”

On April 6, 2011, Yellowcake restated its articles of incorporation and changed its name to Sky Digital Stores Corp (“SKYC”). On May 5, 2011, the Company entered into a Share Exchange Agreement (“Exchange Agreement”) by and among SKYC and Hong Kong First Digital Holding Ltd. (“First Digital”), and the shareholders of First Digital (the “FDH Shareholders”) entered into a Share “FDH”), and the shareholders of FDH (the “FDH Shareholders”). The closing of the transaction (the “Closing”) took place on May 5, 2011 (the “Closing Date”). On the Closing Date, pursuant to the terms of the Exchange Agreement, the Company acquired all of the outstanding shares (the “Shares”) of FDH from the FDH Shareholders; and FDH Shareholders transferred and contributed all of their Shares to us. In exchange, the Company issued to the FDH Shareholders, their designees or assigns, an aggregate of 23,716,035 shares (the “Shares Component”) or 97.56% of the shares of common stock of the Company issued and outstanding after the Closing (the “Share Exchange”), at $0.20 per share.

Mr. Lin Xiangfeng planned, organized and executed the Share Exchange. Prior to the Share Exchange, Mr. Lin Xiangfeng was the largest shareholder and sole officer of FDH. He was also the CEO of SKYC but did not own any shares of the Company. The parties involved in the Share Exchange Agreement are SKYC, FDH and all FDH Shareholders. Mr. Lin Jinshui, an FDH Shareholder, is the father of Mr. Lin Xiangfeng and Mr. Lin Xiuzi, an FDH Shareholder, is the brother of Mr. Lin Xiangfeng. Other than Mr. Lin Xiangfeng, no third party played a substantial role in the agreement.

FDH owned (i) 100% of the issued and outstanding capital stock of Shenzhen Dong Sen Mobile Communication Technology Co., Ltd (also known and doing business as Shenzhen Donxon Mobile Communication Technology Co., Ltd, “Donxon”), a company organized under the laws of the People’s Republic of China (“China” or the “PRC”); and (ii) 100% of the issued and outstanding capital stock of Shenzhen Xing Tian Kong Digital Company Limited (“XTK”), a PRC company. XTK was the holder of 100% of the issued and outstanding capital stock of Shenzhen Da Sheng Communication Technology Company Limited (also known and do business as Shenzhen Dasen Communication Technology Company Limited, “Dasen”), a PRC company. Dasen is the holder of 70% of the issued and outstanding capital stock of Foshan Da Sheng Communication Chain Service Company Limited (also known and do business as Foshan Dasen Communication Chain Service Co. Ltd, “FDSC”), a PRC company. Pursuant to the Exchange Agreement, FDH became a wholly-owned subsidiary of the Company, and the Company owned 100% of Donxon, 100% of XKT, 100% of Dasen and 70% of FDSC indirectly through FDH.

On February 13, 2018, a change of control occurred, and new officers and directors of the Company were appointed. The name change of ‘Sky Digital Stores Corp.’ (SKYC) to Qualis Innovations, Inc. and the 1 – 1,000 reverse split was announced on FINRA’s Daily List. Echo Resources LLLP took over control of Qualis owning 232,689 of the 396,650 common shares outstanding. Since that event Qualis did not have any business operations or any assets or liabilities.

In July 2019, John Ballard and Charles Achoa, formed a new company named EMF Medical Devices Inc. for the development, maintenance, marketing and sale of an electronic device for the treatment of pain that would make use of certain intellectual property interests held by LCMD. In May 2021 the Company changed its name to mPathix Health Inc. Presently, John Ballard is the Chief Financial Officer and Charles Achoa does not participate in any management or board position.

On June 28, 2021, the Company entered into a Share Exchange Agreement (“Exchange Agreement”) by and among mPathix Health, Inc. (formerly EMF Medical Devices, Inc., a Delaware corporation) (“mPathix”) and Qualis. The closing of the transaction (the “Closing”) took place on June 29, 2021 (the “Closing Date”). On the Closing Date, pursuant to the terms of the Exchange Agreement, the Company acquired all of the outstanding shares (the “Shares”) of mPathix. In exchange, the Company issued to the mPathix shareholder’s, their designees or assigns, an aggregate of 6,988,300 shares of Company common stock (the “Shares Component”) or 93.36% of the shares of common stock of the Company issued and outstanding after the Closing (the “Share Exchange”), at a valuation of $0.50 per share, and the Company issued warrants to purchase an additional 1,098,830 shares (698,830 warrants issued to the Company’s previous CEO and 400,000 to CreoMed which is beneficially owned by Dr. Joseph Pergolizzi, the Company’s previous acting CEO and chairman of the board) of the Company’s common stock, exercisable for 10 years at a $0.50 per share exercise price, subject to adjustment. In connection with the closing of the mPathix acquisition, the officers and directors of mPathix were appointed as the officers and directors of the Company. On June 29, 2021, the Company issued 496,650 common shares for the recapitalization of Qualis in conjunction with the reverse acquisition for a net book value of $0.

The acquisition was accounted for as a “reverse merger’’ and recapitalization since the stockholders of mPathix owned a majority of the outstanding shares of the common stock immediately following the completion of the transaction assuming that holders of 10% of the Public Shares exercise their conversion rights. mPathix was deemed to be the accounting acquirer in the transaction and, consequently, the transaction was treated as a recapitalization of mPathix. As a result, Qualis was considered to be the continuation of the predecessor mPathix. Accordingly, the assets and liabilities and the historical operations that are reflected in the consolidated financial statements are those of mPathix and are recorded at the historical cost basis of mPathix. Qualis’s assets, liabilities and results of operations will be consolidated with the assets, liabilities and results of operations of mPathix after consummation of the acquisition.

The Company is now the holding company under which mPathix operates. mPathix is a clinical stage company focused on the development, production, and distribution of pain management and other central nervous system (CNS) based solutions.

We are developing a product designed to address the unmet needs of patients who seek alternatives to traditional pain medications and interventions or adjunctive therapies to their current treatment regimen. We believe that our product will provide clinicians and patients with new and differentiated set of pain management tools to meet the diversity of patient needs.

A key element to the Company’s growth strategy is to acquire the rights to or develop existing devices. Large device companies have increased the minimum market opportunity they require in order to commit marketing resources to their products. As a result, there are many products that are unsupported by such companies and are currently scheduled to be phased out or “sunsetted.” Qualis Innovations believes that it can create significant value by developing or acquiring rights to a portfolio of such products, expanding their therapeutic uses and/or markets, improving or enhancing such products and dedicating the appropriate amount of marketing and other resources to maximize the value of the Company’s portfolio.

There are several key criteria the Company uses when evaluating product opportunities:

	●	The disease or condition largely has been ignored due to lack of interest by other, larger companies and, as a result, overall competition in the space is limited.
	●	The device is not selling well for various reasons (including, among other things, poor management, poor reimbursement, improper or no available billing codes, inaccurate pricing, and limited and/or poor clinical outcomes) which, Qualis would attempt to eliminate, thereby increasing product revenues.
	●	The device should be easy to manufacture, thereby avoiding the need for costly investment by the Company develop products and complicated manufacturing facilities.
	●	There should be a large, underserved patient population. The device should have clear regulatory and reimbursement paths with the FDA and CMS, respectively (or already be approved).
	●	The device should be relatively easy to distribute/dispense and administer. Most importantly, the product must have a history of limited adverse events to patients.

Our planned product, which is our sole product and is in the development pipeline, is SOLACE, a non-invasive medical device that uses electromagnetic induction to generate deep heat below the surface of the skin to reduce and relieve pain. SOLACE™ delivers radio frequency (RF) energy continuously and thereby delivers thermal effects to the tissue and utilizes several differentiated features vs other radio frequency devices currently on the market. We have not yet finalized development of the planned SOLACE device and have not generated any cash flows from operations in connection with the planned device.

The SOLACE device is based on proprietary high-frequency magnetic induction technology, which we refer to as Electromagnetic Induction (“EMI”). Electromagnetic or magnetic induction is the use of electric currents or a derivative of a current in the form of a sound or an acoustic wave or an electromagnetic energy wave. Administered electric currents or their derivatives have two attributes: (1) pain relief and (2) regeneration of tissues.

Magnetic fields are induced beneath the skin surface to create localized, planar heat in the dermis and deeper muscle, while selectively avoiding sensitive structures in the epidermis and fat layers. By comparison, our SOLACE device creates currents in discreet planes beneath the tissue surface rather than directing energy through the planes and penetrating the epidermis. Therefore, our EMI technology may provide for shorter duration of treatments and a more comfortable patient experience vs. other energy-based technologies.

SOLACE™ delivers RF energy via a user-friendly hand-held applicator that allows for targeted and ergonomic application of RF energy to discrete areas of concern. In contrast, competitor diathermy devices utilize a large drum applicator wherein the RF energy is emitted across a large surface area. Diathermy is the controlled production of deep heating beneath the skin in the subcutaneous tissue, deep muscles and joints for therapeutic purposes. There are two types of diathermy devices on the market today: radio or high frequency and microwave. The drum applicator design limits the tissue targeting to larger joints, while smaller joints or tissue areas (e.g. acromion of the shoulder, plantar aspect of foot, neck) are largely unaddressed. The hand-held applicator from the SOLACE™ device provides a small surface area (approx. 3 cm²) which is coated in Teflon® that can easily be positioned to target smaller body parts providing a differentiation compared to large drum-type radio frequency devices fail to adequately treat.

Presently, the Company is in the process of preparing the documents necessary to submit an application to the FDA for clearance of our planned device. We plan on also filing a provisional patent for the changes and new development of our device over our previous licensed device from LCMD, The Company has an accumulated deficit of $4,430,308. It is anticipated that the total expected financial outlay to complete the development and FDA application is approximately $250,000, combined with operating expenses the Company may not be able to have enough cash flow to support the Company’s daily operations resulting in an opinion by the auditors of the Company continuing as a going concern.

We anticipate that our SOLACE device will be cleared by the FDA via the 510k process and that it will be deemed to be substantially equivalent to the identified predicate device called the Bebe device, The Bebe device was originally cleared by the FDA in 2014 by the Marchitto Entities and subsequently sold to LCMD via an Asset Purchase Agreement and an Intellectual Property License Agreement. The Bebe device is indicated for use in the treatment of selected medical conditions such as pain relief, muscle spasms, and joint contractures, but not for the treatment of malignancies.

Overview

Qualis Innovations, Inc. (hereinafter the “Company,” “We,” “Qualis”) was incorporated in the state of Nevada on March 23, 2006. On June 28, 2021, the Company entered into a Share Exchange Agreement by and among mPathix Health, Inc. (formerly known as EMF Medical Devices, Inc.), a Delaware corporation (“mPathix”), pursuant to which mPathix was acquired by the Company. Qualis is now the holding company under which mPathix operates. mPathix is a clinical stage company focused on the development, production, and distribution of pain management and other central nervous system (CNS) based solutions.

Competition

The medical device industry is constantly evolving, and scientific advances are expected to continue at a rapid pace. This results in intense competition among companies operating in the industry. Other, larger companies may have, or may be developing, products that compete with our product and may significantly limit the market acceptance of our product or render them obsolete. Our technical and/or business competitors would include major pharmaceutical companies, large and small medical device companies, universities and nonprofit research institutions and foundations. Most of these competitors have significantly greater research and development capabilities than we have, as well as substantial marketing, financial and managerial resources.

Our product is expected to primarily compete with manufacturers who develop and market alternative devices utilizing vastly different technology. There are many other companies, both public and private, that service the same markets as we do, all of which compete to some degree with our company. This includes medical device companies, drug companies and other companies and industries addressing the pain treatment market. These organizations are also expected to compete with us for acquisitions, joint ventures, or other collaborations and to attract qualified personnel. In addition, as current or new products gain market acceptance, we may experience increased competition for our product, and we may not be able to compete effectively. Failure to effectively compete could adversely affect our market share, financial condition, and growth prospects.

The primary competitive factors facing us include ease of use, safety, price, quality, innovative design and technical capability, breadth of product line, service, and distribution capabilities. Our current and future competitors may have greater resources, more widely accepted and innovative products, greater technical capabilities and stronger name recognition than we do. Our ability to compete is affected by our ability to:

	1.	obtain regulatory clearance and compliance for our product in regards to future modifications and design; This process of regulatory clearance involves getting FDA approval for our planned product which includes filing an application for 510(k) approval for our type of medical device. The application consists of safety testing, design review, modifications made to the device to ensure safety of those modifications, quality management systems, labeling, distribution manufacturing, sales, promotion and other compliance requirements associated with a Class II medical device which the SOLACE device is a part of. A Class II medical device are those devices that have a moderated to high risk to the patient, 43% of all medical devices fall under this category.

	2.	manufacture and sell or lease our product cost effectively;

	3.	meet all relevant quality standards for our product in their particular markets;

	4.	develop or acquire new products and innovative technologies;

	5.	respond to competitive pressures specific to each of our geographic and product markets;

	6.	protect the proprietary technology of our product and avoid infringement of the proprietary rights of others

	7.	market our product;

	8.	attract and retain skilled employees, including sales representatives; and

	9.	maintain and establish distribution relationships.

Competitors could develop products that are more effective, achieve more favorable reimbursement status from third-party payors, cost less or are ready for commercial introduction before our product. If our competitors are better able to develop and patent products earlier than we can or develop more effective and/or less expensive products that render our product obsolete or non-competitive, our business will be harmed and our commercial opportunities will be reduced or eliminated.

Currently, we are not a manufacturer. To the extent that we engage third party manufacturers to produce our product, our manufacturing capabilities may not be adequate or sufficient to compete with large scale, direct or third-party manufacturers, which may be able to secure inventory from vendors on more favorable terms, operate with a lower cost structure or adopt more aggressive pricing policies.

Manufacturing

We will use Shanghai Zhiting Intelligent Technology Co., Ltd (“SZIT”) as our CMO to manufacture the SOLACE device, and to warehouse our product in their facilities in the San Francisco. SZIT is ISO 13482:2016 certified. We also intend to identify a back-up manufacture to ensure the integrity of our product supply chain in case of natural disaster or political uncertainty.

We plan use Kanban inventory management by which our SOLACE inventory will be held by Supertech Medical Devices Inc.(“Supertech”) at their warehouse until customer orders are received. Devices will be shipped from Supertech’s warehouse.

Product Distribution

We plan to initially offer our SOLACE device via a purchase or leasing model and we will generate demand with a combination of direct and independent sales representatives in the United States. Field sales representatives will be engaged to sell in predefined geographic markets and will be compensated based on a commission amount of the revenues generated by the medical device. The focus will be to market our device to a target audience of professionals who specialize in the use of multi-modal, or multi-disciplinary, pain management techniques.

Our target audience includes chiropractors, physical therapists, and pain management specialists. However, our sales and promotional effort will be focused on using an account-based approach to further segment the market which will allow us to promote the SOLACE device in the most efficient manner. Our primary promotional targets will be multi-practitioner clinics and high throughput, solo-practitioner offices. We also intend to have a Corporate Accounts team to target large national and regional chiropractic and physical therapy chains. Examples of corporate accounts targets include The Joint, a national chiropractic franchise with over 500 locations, and ATI Physical Therapy with 900 locations across the US.

At launch, we will sell our SOLACE™ device directly to customers who will be able to either buy it outright or lease it via a third-party financing partner, Coastal Capital Group. If the device is to be leased, mPathix will be paid 50% of the purchase price upon leasing signing and 50% upon device delivery to the customer.

Although we plan to sell or lease the SOLACE™ device to target accounts at launch, we are also developing a proprietary method of revenue sharing that will allow for greater utilization of our device with customers, and thus expanding our market penetration into a broader subset of customers for whom purchasing or leasing the SOLACE device is not practical. Based on this approach, we may be able to accelerate the number of devices placed based on a greatly reduced acquisition cost for our customer. Further, it may be possible for mPathix to have real-time revenue recognition, which could lead to significantly lower days sales outstanding.

mPathix is also evaluating unique distribution models to fully maximize our reach with our target audience. Potential distribution models include “device sharing” or “on-demand” availability of the SOLACE™ device, allowing even the lowest patient throughput practices to access our technology. Such distribution models will be test marketed prior to any potential national implementation.

Regardless of which distribution model, or combination of models, is utilized, each account that accesses the SOLACE device will incorporate a monthly fee for device calibration and maintenance.

Reimbursement

Based on our target market (i.e., chiropractors and physical therapists), we believe many, if not most, patients will pay out of pocket for treatment with the SOLACE™ device. However, there will be certain practitioners, including medical doctors, who will treat patients with medical insurance plans and attempt get reimbursement for their service. In this revenue stream, revenue will be derived from patients with insurance plans held by private health insurance carriers, typically known as HMOs or PPOs, who pay on behalf of their insureds and worker’s compensation claims. This will continue to create revenue which will become recurring as patients are treated on a regular basis.

The Current Procedural Terminology (CPT) code 97024, as maintained by American Medical Association, is a medical procedural code under the category of Supervised Physical Medicine and Rehabilitation Modalities. CPT 97024 includes the application of a modality to 1 or more areas; Diathermy (e.g., microwave). This is the code healthcare professionals may be able to use for billing and reimbursement, in addition to the ICD-10 diagnosis code, for payment by insurers. The provider fee for 97024 is assumed to about $30.

Government Regulation

The Company cannot commence sales of our planned SOLACE device until the device has been approved by the FDA. The Company has not yet filed a 510(k) application with the FDA to receive approval for the planned SOLACE device. Once the Company has done so, and if and when the Company receives FDA approval of its 510(k) application for the SOLACE device, we would then be subject to extensive regulation by the FDA and foreign and state regulatory authorities. In the United States, medical device companies must comply with laws and regulations promulgated by the FDA. These laws and regulations require various authorizations prior to a product being marketed in the United States. Manufacturing facilities and practices are also subject to FDA regulations. The FDA regulates the clinical testing, manufacture, labeling, sale, distribution and promotion of medical devices in the United States. If and when we receive FDA approval for our planned SOLACE device, failure to comply with regulatory requirements, including any future changes to such requirements, could have a material adverse effect on our business, prospects, financial condition and results of operations as such failure could prevent us from selling or licensing our SOLACE device in the United States.

Even after clearance or approval of our planned device, we would still be subject to continuing regulation by the FDA, including the requirements of registering our facilities and listing our product with the FDA. We would be subject to medical device reporting regulations. These regulations would require us to report to the FDA if any of our products may have caused or contributed to a death or serious injury or has malfunctioned and such product or a similar product that we market would likely cause or contribute to a death or serious injury if the malfunction were to recur. We would also be required, unless an exemption applies, to report corrections and removals to the FDA where the correction or removal was initiated to reduce a risk to health posed by the device or to remedy a violation of the Federal Food, Drug and Cosmetic Act. Additionally, we would be required by the FDA to maintain records of corrections or removals, regardless of whether such corrections and removals are required to be reported to the FDA. In addition, the FDA would closely regulate any device promotion and advertising, and our future promotional and advertising activities with respect to our planned SOLACE device could come under scrutiny by the FDA.

We would also be subject to arbitrary impounding and inspections of our device shipments by the FDA, despite having FDA approval and 510(k) clearance. While we would expect after our first few initial shipments for this to be a less likely event, there is no assurance that the FDA may not arbitrarily impound our planned devices without notice and with no definitive timeline to provide a venue for the Company to prove our compliance and to have the product released to our distributor(s) or customer(s).

The FDA will also require that we, or our contract manufacturers, manufacture our product in accordance with its Quality System Regulation, or QSR. The QSR covers the methods and documentation of the design, testing, control, manufacturing, labeling, quality assurance, packaging, storage and shipping of our planned devices. Failure to maintain compliance with the QSR requirements could result in the shutdown of, or restrictions on, our future manufacturing operations and the recall or seizure of our product, which would be expected to have a material adverse effect on our future business. Similarly, in the event that one of our suppliers fails to maintain compliance with quality requirements, we would likely have to qualify a new supplier and could experience manufacturing delays as a result.

The FDA has broad enforcement powers. If we violate applicable regulatory requirements before or after we receive FDA approval for our planned SOLACE device, the FDA may bring enforcement actions against us, which may include the following sanctions:

	●	Form 483 deficiency observations, warning letters, fines, injunctions, consent decrees and civil penalties;
	●	mandatory repair, replacement, recall or seizure of our product, which may include refunds by us of the purchase price;
	●	operating restrictions, partial suspension or total shutdown of production;
	●	refusing or delaying our requests for 510(k) clearance or PMA of new products or new intended uses of our existing product;
	●	withdrawing 510(k) clearances, or PMAs that have already been granted; or
	●	criminal prosecution.

If any of these events were to occur, they would likely have a material adverse effect on our business, prospects, financial condition and results of operations.

Employees

As of the date of this filing, we have no full-time employees.

Where You Can Find our Reports

Any person or entity may read and copy our reports with the Commission at the Commission’s Public Reference Room at 100 F Street N.E., Washington, D.C. 20549. The public may obtain information on the operation of the Public Room by calling the Commission toll free at 1-800-SEC-0330. The Commission also maintains an Internet site at http://www.sec.gov where reports, proxies and other disclosure statements on public companies may be viewed by the public.

Item 1A. Risk Factors

This item is not applicable because we are a “smaller reporting company” as defined in Exchange Act Rule 12b-2.

Item 1B. Unresolved Staff Comments

Not applicable.

Item 1C. Cybersecurity

Our board of directors and senior management recognize the critical importance of maintaining the trust and confidence of our clients, business partners and employees. Our management, led by our Chief Executive Officer, are actively involved in oversight of our risk management efforts, and cybersecurity represents an important component of the Company’s overall approach to enterprise risk management (“ERM”). Our cybersecurity processes and practices are fully integrated into the Company’s ERM efforts. In general, we seek to address cybersecurity risks through a cross-functional approach that is focused on preserving the confidentiality, security and availability of the information that we collect and store by identifying, preventing and mitigating cybersecurity threats and effectively responding to cybersecurity incidents when they occur.

Risk Management and Strategy

As one of the critical elements of our overall ERM approach, our cybersecurity efforts are focused on the following key areas:

	●	Governance: Management oversees cybersecurity risk mitigation and reports to the board of directors any cybersecurity incidents.
	●	Collaborative Approach: We have implemented a cross-functional approach to identifying, preventing and mitigating cybersecurity threats and incidents, while also implementing controls and procedures that provide for the prompt escalation of certain cybersecurity incidents so that decisions regarding the public disclosure and reporting of such incidents can be made by management in a timely manner.
	●	Technical Safeguards: We deploy technical safeguards that are designed to protect our information systems from cybersecurity threats, including firewalls, intrusion prevention and detection systems, anti-malware functionality and access controls, which are evaluated and improved through vulnerability assessments and cybersecurity threat intelligence.

We have not engaged third-party service providers to conduct evaluations of our security controls, independent audits or consulting on best practices to address new challenges.

While we have not experienced any cybersecurity threats in the past in the normal course of business, in the future, we may not be successful in preventing or mitigating a cybersecurity incident that could have a material adverse effect on us.

Item 2. Properties

The Company has an office located at 6898 S. University Blvd., Suite 100, Centennial, Colorado 80122 with telephone number: (484) 483-2134. As of the date of this filing, the Company does not have any physical property other than its prototype medical device equipment.

Item 3. Legal Proceedings

From time to time, we may become party to litigation or other legal proceedings that we consider to be a part of the ordinary course of our business. We are not currently involved in legal proceedings that could reasonably be expected to have a material adverse effect on our business, prospects, financial condition or results of operations. We may become involved in material legal proceedings in the future. To the best our knowledge, none of our directors, officers or affiliates is involved in a legal proceeding adverse to our business or has a material interest adverse to our business.

Item 4. Mine Safety Disclosures

There is no information required to be disclosed by us under this Item.

PART II

Item 5. Market for Registrant’s Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities

(a) Market Information

Our stock is quoted on the OTC markets under the symbol “QLIS.” We were listed on May 23, 2016. There are 20,439,950 shares outstanding as of April 11, 2024.

(b) Transfer Agent

The transfer agent and registrar for our common stock is Securities Stock Transfer Corporation located at 2901 N. Dallas Parkway, Suite 380, Plano, TX 75093 telephone number (469) 633-0088.

(b) Shareholders of Record

The number of beneficial holders of record of our common stock as of the close of business on December 31, 2023 was 150.

We do not expect to pay cash dividends in the next term. We intend to retain future earnings, if any, to provide funds for operation of our business. We currently have no restrictions affecting our ability to pay cash dividends.

(d) Equity Compensation Plans

In June 2021, the board of directors of the Company authorized the adoption and implementation of the Company’s 2021 Equity Incentive Plan (the “2021 Plan”). The principal purpose of the 2021 Plan is to attract, retain and motivate employees, officers, directors, consultants, agents, advisors and independent contractors of the Company and its related companies by providing them the opportunity to acquire a proprietary interest in the Company and to link their interests and efforts to the long-term interests of the Company’s shareholders. Under the 2021 Plan, an aggregate of 1,000,000 shares of the Company’s common stock have initially been reserved for issuance pursuant to a variety of stock-based compensation awards, including stock options, stock awards, restricted stock, restricted stock units and other stock and cash-based awards. The exercise price for each option may not be less than fair market value of the common stock on the date of grant, and shall vest as determined by the Company’s board of directors but shall not exceed a ten-year period.

Recent Sales of Unregistered Securities

In January 2024, the Company issued a total of 10,000,000 common shares valued at $500,000 (based on the estimated fair value of the stock on the date of grant) to two affiliates in settlement of a dispute.

In January 2024, the Company issued 2,000,000 common shares to two (2) affiliates for aggregate gross proceeds of $100,000.

Item 6. Selected Financial Data

Because we are a smaller reporting company, this Item 6 is not applicable.

Item 7. Management’s Discussion and Analysis of Financial Condition and Results of Operations

You should read the following discussion and analysis of our financial condition and results of operations together with our consolidated financial statements and related notes included elsewhere in this filing. This discussion and other parts of this filing contain forward-looking statements that involve risk and uncertainties, such as statements of our plans, objectives, expectations, intentions, and beliefs. Our actual results may differ materially from those discussed in these forward-looking statements as a result of various factors, including those set forth under “Risk Factors” and in other parts of this filing, and you should not place undue certain on these forward-looking statements, which apply only as of the date of this filing. See “Disclosure Regarding Forward-Looking Statements”.

We are an emerging growth company as defined in Section 2(a) (19) of the Securities Act. Pursuant to Section 107 of the Jumpstart Our Business Startups Act, we may take advantage of the extended transition period provided in Section 7(a)(2)(B) of the Securities Act for complying with new or revised accounting standards, meaning that we can delay the adoption of certain accounting standards until those standards would otherwise apply to private companies. We have chosen to take advantage of the extended transition period for complying with new or revised accounting standards applicable to public companies to delay adoption of such standards until such standards are made applicable to private companies. Accordingly, our consolidated financial statements may not be comparable to the financial statements of public companies that comply with such new or revised accounting standards.

OVERVIEW:

Historical Development

Our Company

Qualis Innovations Inc. (hereinafter the “Company,” “We,” “Qualis”) was incorporated in the State of Nevada on March 23, 2006. On June 28, 2021, the Company entered into a Share Exchange Agreement by and among mPathix Health, Inc. (formerly known as EMF Medical Devices, Inc.), a Delaware corporation (“mPathix”), pursuant to which mPathix was acquired by the Company. Qualis is now the holding company under which mPathix operates. mPathix is a clinical stage company focused on the development, production, and distribution of pain management and other central nervous system (CNS) based solutions.

Recent Developments

We have prepared our consolidated financial statements in accordance with accounting principles generally accepted in the United States of America (“GAAP”).

Impairment of Assets

In the 4^th quarter of 2023, the Company determined that the third party manufacturer of its SOLACE device was unable to deliver the remaining SOLACE devices and that it may not be economically feasible to pursue the manufacturer for the return of the tooling and deposits. As a result, the Company determined that the value of the tooling and deposits related to its SOLACE device was $0 and recorded an impairment of assets totaling $76,008 in the year ended December 31, 2023 and is classified in other expenses in the consolidated Statements of Operations.

Financing Transactions

Short Term Note Payable

The Company borrows funds from the Company’s CEO for working capital purposes from time to time. The Company has recorded the principal balance due of $9,102 and $0 under short term note payable in the accompanying Balance Sheets at December 31, 2023 and 2022, respectively. The Company received advances of $9,102 and $0 and no repayments for the years ended December 31, 2023 and 2022. The advance from our CEO was not made pursuant to any loan agreements or promissory notes, are interest bearing at 10% per annum and due on demand.

Insurance Financing Agreement

On July 20, 2022, the Company entered into a loan to finance its directors and officer’s insurance policy effective June 28, 2022. The loan has a principal balance of $90,225, bears interest at 8.83% per annum, and is due and payable in nine monthly payments of $10,397. During the years ended December 31, 2023 and 2022, the Company made repayments of $18,456 and $59,033. In February 2023, the Company cancelled the insurance policy.

Acquisition of mPathix

On June 28, 2021, the Company entered into a Share Exchange Agreement (“Exchange Agreement”) by and among mPathix Health, Inc. (formerly EMF Medical Devices, Inc., a Delaware corporation) (“mPathix”) and Qualis. The closing of the transaction (the “Closing”) took place on June 29, 2021 (the “Closing Date”). On the Closing Date, pursuant to the terms of the Exchange Agreement, the Company acquired all of the outstanding shares (the “Shares”) of mPathix. In exchange, the Company issued to the mPathix shareholder’s, their designees or assigns, an aggregate of 6,988,300 shares of Company common stock (the “Shares Component”) or 93.36% of the shares of common stock of the Company issued and outstanding after the Closing (the “Share Exchange”), at a valuation of $0.50 per share, and the Company issued warrants to purchase an additional 1,098,830 shares (698,830 warrants issued to the Company’s previous CEO and 400,000 to CreoMed which is beneficially owned by Dr. Joseph Pergolizzi, the Company’s acting CEO and chairman of the board) of the Company’s common stock, exercisable for 10 years at a $0.50 per share exercise price, subject to adjustment. In connection with the closing of the mPathix acquisition, the officers and directors of mPathix were appointed as the officers and directors of the Company.

The acquisition was accounted for as a “reverse merger” and recapitalization since the stockholders of mPathix prior to the acquisition acquired a majority of the outstanding shares of the common stock of the Company immediately following the completion of the transaction. mPathix was deemed to be the accounting acquirer in the transaction, and, consequently, the transaction was treated as a recapitalization of mPathix. As a result, the Company was considered to be the continuation of the predecessor, mPathix. Accordingly, the assets and liabilities and the historical operations that are reflected in the Company’s consolidated financial statements are those of mPathix and are recorded at the historical cost basis of mPathix. The Company’s assets, liabilities and results of operations were consolidated with the assets, liabilities and results of operations of mPathix after consummation of the acquisition.

Stock Based Compensation

Employment Agreement

On March 1, 2021, Mr. Ahmet Demir Bingol, the Company’s CEO entered into an Employment Agreement with the Company, with an effective date of March 16, 2021, in which he receives an annual base salary of $250,000, plus bonus compensation not to exceed 80% of base salary. In addition, Mr. Bingol was granted 698,830 warrants to purchase 698,830 of the Company’s common stock, valued at $165,378 (based on the Black Scholes valuation model on the date of grant). The warrants are exercisable for a period of ten at $0.50 per share in whole or in part, as either a cash exercise or as a cashless exercise, and fully vest at grant date. Mr. Bingol’s employment also provides for medical insurance, disability benefits and one year of severance pay if his employment is terminated without cause or due to a change in control. Mr. Bingol’s compensation was approved by the Company’s Board of Directors on March 1, 2021.

On February 24, 2022, Mr. Bingol entered into a separation agreement whereby he will terminate his employment effective April 15, 2022. He received no severance payment and there were no disagreements between he or the Company. A total of 300,000 warrants have vested with the remaining 398,830 unvested warrants expiring. As a result of Mr. Bingol’s termination, the Company reversed the remaining warrant modification balance of $94,101 during the year ended December 31, 2022.

Consulting Agreement

On January 27, 2022 the Company hired an engineering consultant to assist in completing the design history file, updating new software, system design, pre 510(k) preparation, and testing of the SOLACE device. This work has been placed on hold and the cost of the contract is $77,850.

On October 3, 2022, the Company entered into an Independent Contractor Services Agreement (“Agreement”) with a third party to provide professional services to the Company. The Agreement terminates January 3, 2023. Under this Agreement, the contractor will be entitled to a monthly consulting fee of $6,000 and a total of 36,000 common shares, valued at $18,000 (based on the estimated fair value of the stock on the date of grant) for services rendered. In 2023, the Agreement was mutually cancelled with no consulting fees paid and the 36,000 common shares cancelled.

Common Stock

In January 2024, the Company issued 2,000,000 common shares to two (2) affiliates for aggregate gross proceeds of $100,000.

On July 20, 2022, the Company issued 200,000 common shares to an affiliate for aggregate gross proceeds of $100,000.

Warrants

On March 16, 2021, the Company granted 698,830 warrants to purchase 698,830 shares of the Company’s common stock to Ahmet Demir Bingol, valued at $166,141 (based on the Black Scholes valuation model on the date of grant), pursuant to his Employment Agreement. The warrants are exercisable for a period of ten years at $0.50 per share in whole or in part, as either a cash exercise or as a cashless exercise, and fully vest at grant date.

On February 1, 2022, the Company granted 30,000 warrants to purchase 30,000 of the Company’s common stock to a third party for consulting services, valued at $13,547 (based on the Black Scholes valuation model on the date of grant). The options are exercisable for a period of three years at $1.00 per share in whole or in part, and fully vest at grant date.

On March 29, 2022, the Board of Directors approved the granting of 400,000 warrants, with effect from April 1, 2022, convertible to the Company’s common shares with an exercise price of $1.10, valued at $290,276 (based on the Black Scholes valuation model on the date of grant), to our acting CEO and Chairman Joseph V. Pergolizzi Jr., MD through his company, CreoMed, Inc. with an expiration period of 10 years. These warrants were issued as compensation for the first quarter to Joseph V. Pergolizzi Jr., MD.

On August 1, 2022, based on a revised agreement signed by the relevant parties, the Company granted 60,000 warrants to purchase 60,000 of the Company’s common stock to a third party for consulting services, valued at $7,632 (based on the Black Scholes valuation model on the date of grant). The options are exercisable for a period of three years at $1.10 per share in whole or in part, and fully vest at grant date.

On September 1, 2022, the Company granted 300,000 warrants to purchase 300,000 of the Company’s common stock to a third party for consulting services, valued at $60,916 (based on the Black Scholes valuation model on the date of grant). The options are exercisable for a period of four years at $1.10 per share in whole or in part and vest 50% in six months and the remaining 50% in twelve months from the grant date.

On April 3, 2023, the Company granted 3,333,333 warrants to purchase 3,333,333 of the Company’s common stock to Jim Holt, the Company’s previous CEO, valued at $1,597,635 (based on the Black Scholes valuation model on the date of grant). The options are exercisable for a period of seven years at $0.03 per share in whole or in part and vest immediately. On December 13, 2023, Mr. Holt, entered into a cancellation agreement whereby a total of 100,000 warrants, valued at $45,763 (based on the Black Scholes valuation model on the date of grant) have vested with the remaining 3,233,333 warrants cancelled. The warrants are exercisable for a period of three years at $0.03 per share in whole or in part and vest immediately.

Limited Operating History; Need for Additional Capital

There is limited historical financial information about us on which to base an evaluation of our performance. We have not finalized development of our planned SOLACE device, nor have we generated any cash flow from operations. The Company’s cash position may not be sufficient to support the Company’s daily operations. We cannot guarantee we will be successful in our business operations. Our business is subject to risks inherent in the establishment of a new business enterprise, including limited capital resources, and possible cost overruns due to increases in the cost of services. To become profitable and competitive, we must receive additional capital. We have no assurance that future financing will materialize. If that financing is not available, we may be unable to continue operations.

Overview of Presentation

The following Management’s Discussion and Analysis (“MD&A”) or Plan of Operations includes the following sections:

	●	Results of Operations

	●	Liquidity and Capital Resources

	●	Capital Expenditures

	●	Going Concern

	●	Critical Accounting Policies

	●	Off-Balance Sheet Arrangements

General and administrative expenses consist primarily of personnel costs and professional fees required to support our operations and growth.

Depending on the extent of our future growth, we may experience significant strain on our management, personnel, and information systems. We will need to implement and improve operational, financial, and management information systems. In addition, we are implementing new information systems that will provide better record-keeping. However, there can be no assurance that our management resources or information systems will be sufficient to manage any future growth in our business, and the failure to do so could have a material adverse effect on our business, results of operations and financial condition.

Results of Operations

Year Ended December 31, 2023 Compared to Year Ended December 31, 2022

The following discussion represents a comparison of our results of operations for the years ended December 31, 2023 and 2022. The results of operations for the periods shown in our audited consolidated financial statements are not necessarily indicative of operating results for the entire period. In the opinion of management, the audited consolidated financial statements recognize all adjustments of a normal recurring nature considered necessary to fairly state our financial position, results of operations and cash flows for the periods presented.

	Year Ended			Year Ended
	December 31, 2023			December 31, 2022

Net revenues	$	-		$	-
Cost of sales		-			-
Gross Profit		-			-
Operating expenses		230,241			920,515
Other expense		574,780			-
Net loss before income taxes	$	(805,021	)	$	(920,515	)

Revenues

For the years ended December 31, 2023 and 2022, we had no revenues.

Cost of Sales

For the years ended December 31, 2023 and 2022, we had no cost of sales.

Operating expenses

Operating expenses decreased by $690,274, or 75.0%, to $230,241 for year ended December 31, 2023 from $920,515 for the year ended December 31, 2022 primarily due to a decrease in stock based compensation of $171,812, compensation costs of $43,288, research and development costs of $74,860, consulting fees of $102,833, professional fees of $133,790, travel costs of $1,661, insurance costs of $123,935, and general and administration costs of $38,095 as a result of reorganizing our administrative infrastructure.

For the year ended December 31, 2023, we had research and development costs of $1,500, stock based compensation of $76,111, and general and administrative expenses of $152,630 primarily due to professional fees of $32,203, depreciation costs of $17,250, consulting fees of $85,061, insurance costs of $20,492, and general and administration costs of $(2,376) as a result of reorganizing our administrative infrastructure due to refocusing our personnel and marketing initiatives to generate anticipated sales growth.

For the year ended December 31, 2022, we had research and development costs of $76,360 and general and administrative expenses of $844,155 primarily due to professional fees of $165,993, compensation costs of $43,288, depreciation costs of $17,102, consulting fees of $187,894, insurance costs of $144,427, travel costs of $1,686, stock-based compensation of $247,923, and general and administration costs of $35,842.

Other Expense

Other expense for the year ended December 31, 2023 of $574,780 is comprised of impairment of assets of $76,008, inventory adjustment of $40,175, and settlement of dispute of $500,000, offset partially by a gain on settlement of shares for services of $18,000 and other income of $23,403. Other expense for the year ended December 31, 2022 was none.

Net loss before income taxes

Net loss before income for year ended December 31, 2023 totaled $805,021 primarily due to (increases/decreases) in professional fees, consulting fees, stock based compensation, depreciation, insurance costs, research and development costs, and general and administration costs compared to a loss of $920,515 for year ended December 31, 2022 primarily due to (increases/decreases) in compensation costs, professional fees, consulting fees, depreciation, insurance costs, research and development costs, and general and administration costs.

Assets and Liabilities

Assets were $2,431 as of December 31, 2023. Assets consisted primarily of cash of $2,431. Liabilities were $525,387 as of December 31, 2023. Liabilities consisted primarily of accounts payable and accrued expenses of $16,285, short-term note payable of $9,102, and short term – share settlement of $500,000.

Liquidity and Capital Resources

Going Concern

The accompanying consolidated financial statements have been prepared assuming the Company will continue as a going concern, which contemplates, among other things, the realization of assets and satisfaction of liabilities in the normal course of business. The Company had an accumulated deficit of $4,430,308 at December 31, 2023, had working capital deficit of $522,956 at December 31, 2023, had net losses of $805,021 and $920,515 for the years ended December 31, 2023 and 2022, respectively, and net cash used in operating activities of $76,529 and $558,426 for the years ended December 31, 2023 and 2022, respectively, with no revenue earned since inception, and a lack of operational history. These matters raise substantial doubt about the Company’s ability to continue as a going concern.

While the Company is attempting to expand operations and increase revenues, the Company’s cash position may not be significant enough to support the Company’s daily operations. Management intends to raise additional funds by way of a public offering or an asset sale transaction. Management believes that the actions presently being taken to further implement its business plan and generate revenues provide the opportunity for the Company to continue as a going concern. While management believes in the viability of its strategy to generate revenues and in its ability to raise additional funds or transact an asset sale, there can be no assurances to that effect or on terms acceptable to the Company. The ability of the Company to continue as a going concern is dependent upon the Company’s ability to further implement its business plan and generate revenues.

The consolidated financial statements do not include any adjustments that might be necessary if we are unable to continue as a going concern.

General – Overall, we had a decrease in cash flows for years ended December 31, 2023 of $67,427 resulting from cash used in operating activities of $76,529, offset partially by cash provided by financing activities of $9,102.

The following is a summary of our cash flows provided by (used in) operating, investing, and financing activities during the periods indicated:

	Year Ended			Year Ended
	December 31, 2023			December 31, 2022

Net cash provided by (used in):
Operating activities	$	(76,529	)	$	(558,426	)
Investing activities		-			-
Financing activities		9,102			100,000
	$	(67,427	)	$	(458,426	)

Year Ended December 31, 2023 Compared to Year Ended December 31, 2022

Cash Flows from Operating Activities – For the year ended December 31, 2023, net cash used in operations was $76,529 compared to net cash used in operations of $558,426 for the year ended December 31, 2022. Net cash used in operations was primarily due to a net loss of $805,021 for the year ended December 31, 2023 and the changes in operating assets and liabilities of $59,123, primarily due to other current assets of $92,170 and inventory of $40,175, offset partially by short-term notes payable of $31,192 and accounts payable and accrued expenses of $42,030. In addition, net cash used in operating activities includes adjustments to reconcile net profit from depreciation expense of $17,250, impairment of assets of $76,008, issuance of common stock in settlement of dispute of $500,000, warrants issued for services of $30,348, and stock-based compensation – related party of $45,763.

Net cash used in operations was primarily due to a net loss of $920,515 for the year ended December 31, 2022 and the changes in operating assets and liabilities of $70,933, primarily due to other current assets of $8,974, inventory of $20,100, short-term notes payable of $31,192, and accounts payable and accrued expenses of $22,067, offset partially by other current liabilities of $11,400. In addition, net cash used in operating activities includes adjustments to reconcile net profit from depreciation expense of $17,102, warrants issued for services of $342,024, options issued for services of $8,131, issuance of common stock for services of $18,000, and warrants forfeited in conjunction with compensation – related parties of $94,101.

Cash Flows from Investing Activities – For the years ended December 31, 2023 and 2022, net cash used in investing was none.

Cash Flows from Financing Activities – For years ended December 31, 2023, net cash provided by financing was $9,102 due to advance from shareholder. For year ended December 31, 2022, cash flows provided by financing activities was $100,000 due to proceeds from issuance of common stock for cash.

Financing – We expect that our current working capital position, together with our expected future cash flows from operations will be insufficient to fund our operations in the ordinary course of business, anticipated capital expenditures, debt payment requirements and other contractual obligations for at least the next twelve months. However, this belief is based upon many assumptions and is subject to numerous risks, and there can be no assurance that we will not require additional funding in the future.

We have no present agreements or commitments with respect to any material acquisitions of other businesses, products, product rights or technologies or any other material capital expenditures. However, we will continue to evaluate acquisitions of and/or investments in products, technologies, capital equipment or improvements or companies that complement our business and may make such acquisitions and/or investments in the future. Accordingly, we may need to obtain additional sources of capital in the future to finance any such acquisitions and/or investments. We may not be able to obtain such financing on commercially reasonable terms, if at all. Due to the ongoing global economic crisis, we believe it may be difficult to obtain additional financing if needed. Even if we are able to obtain additional financing, it may contain undue restrictions on our operations, in the case of debt financing, or cause substantial dilution for our shareholders, in the case of equity financing.

Board of Directors Resolutions

On April 3, 2023, by unanimous written consent, the Company’s Board of Directors granted 3,333,333 warrants to purchase 3,333,333 shares of the Company’s common stock to Mr. Jim Holt, the Company’s previous CEO and Director as compensation. The warrants are exercisable for a period of seven years at $0.03 per share in whole or in part, as either a cash exercise or as a cashless exercise, and fully vest at grant date. On December 13, 2023, Mr. Holt, entered into a cancellation agreement whereby a total of 100,000 warrants, valued at $45,763 (based on the Black Scholes valuation model on the date of grant) have vested with the remaining 3,233,333 warrants cancelled. The warrants are exercisable for a period of three years at $0.03 per share in whole or in part and vest immediately.

Acquisition of mPathix

On June 28, 2021, the Company entered into a Share Exchange Agreement (“Exchange Agreement”) by and among mPathix Health, Inc. (formerly EMF Medical Devices, Inc., a Delaware corporation) (“mPathix”) and Qualis. The closing of the transaction (the “Closing”) took place on June 29, 2021 (the “Closing Date”). On the Closing Date, pursuant to the terms of the Exchange Agreement, the Company acquired all of the outstanding shares (the “Shares”) of mPathix. In exchange, the Company issued to the mPathix shareholder’s, their designees or assigns, an aggregate of 6,988,300 shares of Company common stock (the “Shares Component”) or 93.36% of the shares of common stock of the Company issued and outstanding after the Closing (the “Share Exchange”), at a valuation of $0.50 per share, and the Company issued warrants to purchase an additional 1,098,830 shares (698,830 warrants issued to the Company’s previous CEO and 400,000 to CreoMed which is beneficially owned by Dr. Joseph Pergolizzi, the Company’s acting CEO and chairman of the board) of the Company’s common stock, exercisable for 10 years at a $0.50 per share exercise price, subject to adjustment. In connection with the closing of the mPathix acquisition, the officers and directors of mPathix were appointed as the officers and directors of the Company.

The acquisition was accounted for as a “reverse merger” and recapitalization since the stockholders of mPathix prior to the acquisition acquired a majority of the outstanding shares of the common stock of the Company immediately following the completion of the transaction. mPathix was deemed to be the accounting acquirer in the transaction, and, consequently, the transaction was treated as a recapitalization of mPathix. As a result, the Company is considered to be the continuation of the predecessor, mPathix. Accordingly, the assets and liabilities and the historical operations that are reflected in the Company’s consolidated financial statements are those of mPathix and are recorded at the historical cost basis of mPathix. The Company’s assets, liabilities and results of operations were consolidated with the assets, liabilities and results of operations of mPathix after consummation of the acquisition.

Stock Based Compensation

Employment Agreement

On March 1, 2021, Mr. Ahmet Demir Bingol, the Company’s CEO entered into an Employment Agreement with the Company, with an effective date of March 16, 2021, in which he receives an annual base salary of $250,000, plus bonus compensation not to exceed 80% of base salary. In addition, Mr. Bingol was granted 698,830 warrants to purchase 698,830 of the Company’s common stock, valued at $165,378 (based on the Black Scholes valuation model on the date of grant). The warrants are exercisable for a period of ten years at $0.50 per share in whole or in part, as either a cash exercise or as a cashless exercise, and fully vest at grant date. Mr. Bingol’s employment also provides for medical insurance, disability benefits and one year of severance pay if his employment is terminated without cause or due to a change in control. Mr. Bingol’s compensation was approved by the Company’s Board of Directors on March 1, 2021.

On February 24, 2022, Mr. Bingol, the Company’s previous CEO, entered into a separation agreement whereby he will terminate his employment effective April 15, 2022. He received no severance payment and there were no disagreements between he or the Company. A total of 300,000 warrants have vested with the remaining 398,830 unvested warrants expiring. As a result of Mr. Bingol’s termination, the Company reversed the remaining warrant modification balance of $94,101 during the year ended December 31, 2022.

Consulting Agreement

On January 27, 2022 the Company hired an engineering consultant to assist in completing the design history file, updating new software, system design, pre 510(k) preparation, and testing of the SOLACE device. This work is expected to be completed by the end of September 2022 and the cost of the contract is $77,850.

Common Stock

In January 2024, the Company issued 2,000,000 common shares to two (2) affiliates for aggregate gross proceeds of $100,000.

On July 20, 2022, the Company issued 200,000 common shares to an affiliate for aggregate gross proceeds of $100,000.

Warrants

On March 29, 2022, the Board of Directors approved the granting of 400,000 warrants, with effect from April 1, 2022, convertible to the Company’s common shares with an exercise price of $1.10, valued at $290,276 (based on the Black Scholes valuation model on the date of grant), to our acting CEO and Chairman Joseph V. Pergolizzi Jr., MD through his company, CreoMed Inc with an expiration period of 10 years. These warrants were issued as compensation for the first quarter to Joseph V. Pergolizzi Jr., MD.

On August 1, 2022, the Company granted 60,000 warrants to purchase 60,000 of the Company’s common stock to a third party for consulting services, valued at $7,632 (based on the Black Scholes valuation model on the date of grant). The options are exercisable for a period of three years at $1.10 per share in whole or in part, and fully vest at grant date.

On April 3, 2023, the Company granted 3,333,333 warrants to purchase 3,333,333 shares of the Company’s common stock to Jim Holt, the Company’s previous CEO, valued at $1,597,635 (based on the Black Scholes valuation model on the date of grant). The warrants are exercisable for a period of seven years at $0.03 per share in whole or in part and vest immediately. On December 13, 2023, Mr. Holt, entered into a cancellation agreement whereby a total of 100,000 warrants, valued at $45,763 (based on the Black Scholes valuation model on the date of grant) have vested with the remaining 3,233,333 warrants cancelled. The warrants are exercisable for a period of three years at $0.03 per share in whole or in part and vest immediately.

Insurance Financing Agreement

Impairment of Assets

Capital Expenditures

Other Capital Expenditures

We expect to purchase approximately $30,000 of equipment in connection with the expansion of our business during the next twelve months.

Fiscal year end

Our fiscal year end is December 31.

Critical Accounting Policies

Refer to Note 3 in the accompanying notes to the consolidated financial statements for critical accounting policies.

Recent Accounting Pronouncements

Refer to Note 3 in the accompanying notes to the consolidated financial statements.

Contractual Obligations and Off-Balance Sheet Arrangements

Refer to Note 10 in the accompanying notes to the consolidated financial statements for future contractual obligations and commitments. Future contractual obligations and commitments are based on the terms of the relevant agreements and appropriate classification of items under U.S. GAAP as currently in effect. Future events could cause actual payments to differ from these amounts.

We incur contractual obligations and financial commitments in the normal course of our operations and financing activities. Contractual obligations include future cash payments required under existing contracts, such as debt and lease agreements. These obligations may result from both general financing activities and from commercial arrangements that are directly supported by related operating activities. Details on these obligations are set forth below.

Off-Balance Sheet Arrangements

As of December 31, 2023, we have not entered into any transaction, agreement or other contractual arrangement with an entity unconsolidated under which it has:

	●	a retained or contingent interest in assets transferred to the unconsolidated entity or similar arrangement that serves as credit;

	●	liquidity or market risk support to such entity for such assets;

	●	an obligation, including a contingent obligation, under a contract that would be accounted for as a derivative instrument; or

	●	an obligation, including a contingent obligation, arising out of a variable interest in an unconsolidated entity that is held by, and material to us, where such entity provides financing, liquidity, market risk or credit risk support to or engages in leasing, hedging, or research and development services with us.

Inflation

We do not believe that inflation has had a material effect on our results of operations.

Item 7A. Quantitative and Qualitative Disclosure About Market Risk

We are a smaller reporting company as defined by Rule 12b-2 of the Securities Exchange Act of 1934 and are not required to provide the information under this item.

Item 8. Financial Statements and Supplementary Data

The financial statements and supplementary financial information which are required to be filed under this item are presented under Item 15. Exhibits, Financial Statement Schedules and Reports on Form 10-K in this document, and are incorporated herein by reference.

Item 9. Changes in and Disagreements with Accountants on Accounting and Financial Disclosure

None.

Item 9A. Controls and Procedures

Evaluation of Disclosure Controls and Procedures

Disclosure Controls and Procedures. We maintain disclosure controls and procedures designed to ensure that information required to be disclosed in our reports filed under the Securities Exchange Act of 1934, as amended (the Exchange Act), is recorded, processed, summarized, and reported accurately, in accordance with U.S. Generally Accepted Accounting Principles and within the required time periods, and that such information is accumulated and communicated to our management, including our Chief Executive Officer, who is also our acting Chief Financial Officer, as appropriate, to allow for timely decisions regarding disclosure. As of the end of the period covered by this report (March 31, 2024), we carried out an evaluation, under the supervision and with the participation of our management, including our Chief Executive Officer, and our Chief Financial Officer, of the effectiveness of the design and operation of our disclosure controls and procedures (as defined in Exchange Act Rule 13a-15(e) and 15d-15(e)). Based upon that evaluation, our Chief Executive Officer and our Chief Financial Officer concluded that as of the end of the period covered by this Annual Report on Form 10-K our disclosure controls and procedures were not effective to enable us to accurately record, process, summarize and report certain information required to be included in the Company’s periodic SEC filings within the required time periods, and to accumulate and communicate to our management, including the Chief Executive Officer and Chief Financial Officer, to allow timely decisions regarding required disclosure.

Changes in Internal Controls

There have been no changes in our internal controls over financial reporting during the quarter ended March 31, 2024 that have materially affected or are reasonably likely to materially affect our internal controls.

Item 9B. Other Information

There have been no events required to be reported under this Item.

PART III

Item 10. Directors, Executive Officers and Corporate Governance

The following table sets forth the names, ages, and biographical information of each of our current directors and executive officers and the positions with the Company held by each person. Our executive officers are elected annually by the board of directors. The directors serve one-year terms until their successors are elected. The executive officers serve terms of one year or until their death, resignation or removal by the board of directors. Unless described below, there are no family relationships among any of the directors and officers.

Name	Age	Position	Director Since
Patrick Adams ⁽¹⁾	63	Acting CEO and Chairman of the Board	November 2023
Ulderico Conte ⁽⁶⁾	54	Director of Acquisitions and Board Member	November 2023
Jim Holt ⁽²⁾	66	Board Member	June 2021
Robert Bilkovski, MD	45	Chief Scientific Officer	July 2021
Madding King III ⁽⁵⁾	44	Board Member	June 2021
Dr. Joseph V. Pergolizzi, Jr ⁽³⁾	52	Acting CEO and Chairman of the Board	October 2021
John Ballard ⁽⁴⁾	62	Chief Financial Officer and board member	August 2019

(1)	Mr. Adams was appointed Acting CEO and Chairman of the Board on November 17, 2023.
(2)	Mr. Holt resigned from all positions in the Company on August 16, 2023.
(3)	Dr. Pergolizzi resigned from all positions in the Company on December 30, 2022.
(4)	Mr. Ballard resigned from all positions in the Company on January 7, 2023.
(5)	Mr. King resigned from all positions in the Company on November 15, 2022.
(6)	Mr. Conte was appointed Director of Acquisitions and Board Member on November 17, 2023

Patrick Adams – Mr. Adams is the Acting CEO and Chairman of the Board for Qualis. Mr. Adams has been an executive in the financial services industry for over 38 years. Since 2008, Mr. Adams has been the CEO of PVG Asset Management Corporation.

The Company believes that Mr. Adams is qualified to serve as a director due to his experience in the capital markets and/or the medical field and his general business experience and knowledge.

Ulderico Conte – Mr. Conte has been in the financial services sector for over 30 years and most recently, since 2017 he is the owner and CEO of CM Capital Partners, a wealth management firm. He was head of Capital markets for Aeon Capital Inc from 2018 until 2022, and then Managing Director of Investment Banking for CIM Securities LLC since September of 2022.

Board Composition

Our By-Laws provide that the Board of Directors shall consist of not less than one nor more than fifteen directors. Each director of the Company serves until his successor is elected and qualified, subject to removal by the Company’s majority shareholders. Each officer shall hold their offices for such terms and shall exercise such powers and perform such duties as shall be determined by the Board of Directors, and shall hold his office until his successor is elected and qualified, or until his earlier resignation or removal. Presently, Board members receive 25,000 restricted common shares for their service and serve for a period of one year whereby through the annual meeting new directors may be elected. The role of the board is to advise on both financial and product matters. Additionally, the board must approve major decisions involving new products, potential acquisitions or funding matters.

No Committees of the Board of Directors; No Financial Expert

We do not presently have a separately constituted audit committee, compensation committee, nominating committee, executive committee or any other committees of our Board of Directors, nor do we have (i) any directors that would qualify as independent under relevant SEC or securities exchange rules, (ii) an audit committee, or (iii) a financial expert. Management has determined not to establish an audit committee at present because our limited resources and limited operating activities do not warrant the formation of an audit committee or the expense of doing so. As such, our entire Board of Directors acts as our audit committee. We do not have a financial expert serving on the Board of Directors or employed as an officer based on management’s belief that the cost of obtaining the services of a person who meets the criteria for a financial expert under Section 407 of the Sarbanes-Oxley Act of 2002 and Item 407(d) of Regulation S-K is beyond our limited financial resources and the financial skills of such an expert are not required or necessary for us to maintain effective internal controls and procedures for financial reporting in light of the limited scope and simplicity of accounting issues raised in our consolidated financial statements at this stage of our development.

Advisory Board

The Company has also formed an Advisory Board of individuals with expertise relevant to the medical device, medical, and electronics industries. The advisory board was selected from individuals who were familiar with our medical device either through using the LCMD device or assisted in the development of our current medical device. The following members have had experience with the LCMD device in using the device in their practice these individuals include Dr. Ben Edwards and Vanessa Burbage. The Advisory Board’s role is to review our device design plans, and assist in the development of our medical device product the SOLACE. The members of our advisory board serve for a period of two years and are not compensated for being on the board but have received compensation for their consulting in the testing, engineering and designing of our product. The Advisory Board has no ability to bind the Company, nor are its members fiduciaries or other agents of the Company.

Dr. Ben Edwards – Dr. Edwards currently works as the medical director of Veritas Medical where he has been employed since 2010. Veritas Medical is a nutrition and lifestyle focused clinic. He graduated from Baylor University in 1993 with a B.A. in Biology and then received his Medical Degree from the University of Texas-Houston Medical School in 2002. He completed his family practice residency in 2005 at McLennan County Medical Education and Research Foundation in Waco, TX where he was Chief Resident. Upon completion of his medical training, Dr. Edwards was the sole physician in the county at Garza County Health Clinic, garnering notoriety from the Lubbock Avalanche Journal, Texas Monthly, and the Washington Post for his very successful operation of a rural county health clinic. In 2012, Dr. Edwards founded Veritas Medical where he and his team have successfully helped educate and support thousands of patients on their journey from chronically ill to well.

Vanessa Burbage – Ms. Burbage is an experienced and practicing electrologist, she currently owns her own medical spa since 1997. She started out as an electrologist in 1997 and then added laser and aesthetic services thereafter steadily building a loyal customer base. Dermatologist and Plastic surgeons refer patients to her because of the success of her skin detailing, hair removal, permanent makeup, and facial skincare.

Auditor

Our independent registered public accounting firm is:

Victor Mokuolu CPA PLLC

8990 Kirby Drive, Suite 220

Houston, TX 77054

Phone: (713) 588-6622

Code of Ethics

The Company currently does not have a Code of Ethics.

Potential Conflicts of Interest

Since we do not have an audit or compensation committee comprised of independent directors, the functions that would have been performed by such committees are performed by our directors. Thus, there is a potential conflict of interest in that our directors and officers have the authority to determine issues concerning management compensation and audit issues that may affect management decisions. We are not aware of any other conflicts of interest with any of our executives or directors.

Director Independence

Our board of directors has undertaken a review of the independence of each director and considered whether any director has a material relationship with us that could compromise his ability to exercise independent judgment in carrying out his responsibilities. As a result of this review, our board of directors determined that our directors do not meet independence requirements, according to the applicable rules and regulations of the SEC.

Involvement in Legal Proceedings

From time to time, we may be involved in litigation relating to claims arising out of our operations in the normal course of business. Other than disclosed herein, there were no pending or threatened lawsuits that could reasonably be expected to have a material effect on the results of our operations.

Item 11. Executive Compensation

The following is a discussion and analysis of compensation arrangements of our named executive officers, or NEOs. This discussion contains forward looking statements that are based on our current plans, considerations, expectations and determinations regarding future compensation programs. Actual compensation programs that we adopt may differ materially from currently planned programs as summarized in this discussion. As an “emerging growth company” as defined in the JOBS Act, we are not required to include a Compensation Discussion and Analysis section and have elected to comply with the scaled disclosure requirements applicable to emerging growth companies.

Summary Compensation Table

The particulars of the compensation paid to the following persons: (1) our principal executive officer; and (2) each of our two most highly compensated executive officers who were serving as executive officers at the end of the fiscal year ended December 31, 2023, who we will collectively refer to as the “named executive officers” of the Company, are set out in the following summary compensation table:

Summary Compensation Table

							Stock		Option		All Other
	Fiscal		Salary		Bonus		Awards		Awards		Compensation		Total
Name and Principal Position	Year		(1)		(2)		(3)		(4)		(5)		($)

Mr. Patrick Adams^.(10)		2023	$	-	$	-	$	-	$	-	$	-	$	-
Acting CEO and Chairman of the Board		2022	$	-	$	-	$	-	$	-	$	-	$	-
		2021	$	-	$	-	$	-	$	-	$	-	$	-

Dr. Joseph V. Pergolizzi, Jr^.(8)		2023	$	-	$	-	$	-	$	-	$	-	$	-
Acting CEO and Chairman of the Board		2022	$	-	$	-	$	-	$	290,276	$	-	$	290,276
		2021	$	-	$	-	$	-	$	109,512	$	-	$	109,512

John Ballard⁽⁹⁾		2023	$	-	$	-	$	-	$	-	$	-	$	-
CFO & Director		2022	$	-	$	-	$	-	$	-	$	120,000	$	120,000
		2021	$	-	$	-	$	130,000	$	-	$	115,000	$	245,000

Demir Bingol⁽⁶⁾		2023	$	-	$	-	$	-	$	-	$	-	$	-
President		2022	$	-	$	-	$	-	$	-	$	-	$	-
		2021	$	210,562	$	-	$	-	$	166,141	$	-	$	376,703

Robert Bilkovski, MD		2023	$	-	$	-	$	-	$	-	$	-	$	-
Chief Scientific Officer		2022	$	-	$	-	$	-	$	-	$	-	$	-
		2021	$	-	$	-	$	-	$	9,161	$	-	$	9,161

Austin Adams⁽⁷⁾		2023	$	-	$	-	$	-	$	-	$	-	$	-
		2022	$	-	$	-	$	-	$	-	$	-	$	-
		20211	$	-	$	-	$	50,000	$	-	$	-	$	50,000

(1)	The dollar value of salary (cash and non-cash) earned.
(2)	The dollar value of bonus (cash and non-cash) earned.

(3)	The value of the shares of restricted stock issued as compensation for services computed in accordance with ASC 718 on the date of grant.
(4)	The value of all stock options computed in accordance with ASC 718 on the date of grant.
(5)	All other compensation received that could not be properly reported in any other column of the table.
(6)	Mr. Bingol was initially appointed Chairman of the Board and Chief Executive Officer in March 2021. His modified employment agreement on October 1, 2021, changed his position from CEO to President. On February 24, 2022, Mr. Bingol entered into a separation agreement whereby his employment was terminated effective April 15, 2022. He received no severance payment in connection with that termination, and there were no disagreements between him and the Company. A total of 300,000 warrants issued to Mr. Bingol have vested, with the remaining 398,830 unvested warrants expiring.
(7)	Mr. Austin Adams’s position as sole officer and director of the Company was terminated on June 29, 2021.
(8)	Dr. Pergolizzi resigned from all positions in the Company on December 30, 2022.
(9)	Mr. Ballard resigned from all positions in the Company on January 7, 2023.
(10)	Mr. Patrick Adams was appointed Acting CEO and Chairman of the Board on November 17, 2023

Long-Term Incentive Plans. The Company does not provide its officers or employees with pension, stock appreciation rights, long-term incentive or other plans, nor does it provide non-qualified deferred compensation to its officers or employees, and therefore, the Summary Compensation Table above does not include columns for nonequity incentive plan compensation and nonqualified deferred compensation earnings, since there were none.

Employee Pension, Profit Sharing or other Retirement Plans. The Company does not have a defined benefit, pension plan, profit sharing or other retirement plan, although it may adopt one or more of such plans in the future.

Compensation Committee Interlocks and Insider Participation. During the year ended December 31, 2020, none of the Company’s officers was also a member of the compensation committee or a director of another entity, which other entity had one of its executive officers serving as one of the Company’s directors.

Outstanding Equity Awards

Our directors and officers do not have any unexercised options, stock that has not vested, or equity incentive plan awards.

Compensation of Directors

Director Compensation Table

	Fiscal		Fees Earned or Paid in Cash		Stock Awards		Option Awards		All Other Compensation		Total
Name	Year		(1)		(3)		(4)		(5)		($)

Mr. Patrick Adams		2023	$	-	$	-	$	-	$	-	$	-
Acting CEO and Chairman of the Board ⁽¹⁰⁾		2022	$	-	$	-	$	-	$	-	$	-
		2021	$	-	$	-	$	-	$	-	$	-

Ulderico Conte		2023	$	-	$	-	$	-	$	-	$	-
Director of Acquisitions and Board Member ⁽¹¹⁾		2022	$	-	$	-	$	-	$	-	$	-
		2021	$	-	$	-	$	-	$	-	$	-

Dr. Joseph V. Pergolizzi, Jr.		2023	$	-	$	-	$	-	$	-	$	-
Acting CEO and Chairman of the Board ^{(6), (7)}		2022	$	-	$	-	$	290,276	$	-	$	290,276
		2021	$	-	$	-	$	109,512	$	-	$	109,512

John Ballard		2023	$	-	$	-	$	-	$	-	$	-
CFO and Director ^{(6), (8)}		2022	$	-	$	-	$	-	$	120,000	$	120,000
		2021	$	-	$	130,000	$	-	$	115,000	$	245,000

Madding King		2023	$	-	$	-	$	-	$	-	$	-
Director ^{(6), (9)}		2022	$	-	$	-	$	-	$	-	$	-
		2021	$	-	$	5,000	$	-	$	-	$	5,000

Jim Holt		2023	$	-	$	-	$	45,736	$	-	$	45,763
Director ⁽⁶⁾		2022	$	-	$	-	$	-	$	-	$	-
		2021	$	-	$	5,000	$	-	$	-	$	5,000

(1)	The dollar value of salary (cash and non-cash) earned.
(2)	The dollar value of bonus (cash and non-cash) earned.
(3)	The value of the shares of restricted stock issued as compensation for services computed in accordance with ASC 718 on the date of grant.
(4)	The value of all stock options computed in accordance with ASC 718 on the date of grant.
(5)	All other compensation received that could not be properly reported in any other column of the table.
(6)	Mr. Holt was appointed as a member of the Company’s Board of Directors on June 29, 2021 and resigned from all positions in the Company on August 16, 2023.
(7)	Dr. Pergolizzi resigned from all positions in the Company on December 30, 2022.
(8)	Mr. Ballard resigned from all positions in the Company on January 7, 2023.
(9)	Mr. King resigned from all positions in the Company on November 15, 2022.
(10)	Mr. Patrick Adams was appointed Acting CEO and Chairman of the Board on November 17, 2023.
(11)	Mr. Ulderico Conte was appointed Director of Acquisitions and Board member on November 17, 2023.

Indebtedness of Directors, Senior Officers, Executive Officers and Other Management

None of our directors or executive officers or any associate or affiliate of the Company during the last two fiscal years, is or has been indebted to the Company by way of guarantee, support agreement, letter of credit or other similar agreement or understanding currently outstanding.

Outstanding Equity Awards at Fiscal Year-End Table

The following table sets forth certain information concerning outstanding stock awards held by the Named Executive Officers for our year ended December 31, 2023:

Option Awards						Stock Awards
Name	Number of Securities Underlying Unexercised Options (#) Exercisable	Number of Securities Underlying Unexercised Options (#) Unexercisable	Equity Incentive Plan Awards: Number of Securities Underlying Unexercised Unearned Options (#)	Option Exercise Price ($)	Option Expiration Date	Number of Shares or Units of Stock That Have Not Vested (#)	Market Value of Shares or Units of Stock That Have Not Vested ($)	Equity Incentive Plan Awards: Number of Unearned Shares, Units or Other Rights That Have Not Vested (#)	Equity Incentive Plan Awards: Market or Payout Value of Unearned Shares, Units or Other Rights That Have Not Vested ($)

None.	-0-	-0-	-0-	-0-	-0-	-0-	-0-	-0-	-0-

Item 12. Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters

The following table lists, as of April 11, 2024, the number of shares of voting capital stock of our Company that are beneficially owned by (i) each person or entity known to our Company to be the beneficial owner of more than 5% of the outstanding class of stock; (ii) each officer and director of our Company; and (iii) all officers and directors as a group. Information relating to beneficial ownership of common stock by our principal shareholders and management is based upon information furnished by each person using beneficial ownership concepts under the rules of the Securities and Exchange Commission. Under these rules, a person is deemed to be a beneficial owner of a security if that person has or shares voting power, which includes the power to vote or direct the voting of the security, or investment power, which includes the power to vote or direct the voting of the security. The person is also deemed to be a beneficial owner of any security of which that person has a right to acquire beneficial ownership within 60 days. Under the Securities and Exchange Commission rules, more than one person may be deemed to be a beneficial owner of the same securities, and a person may be deemed to be a beneficial owner of securities as to which he or she may not have any pecuniary beneficial interest. Except as noted below, each person has sole voting and investment power.

The percentages below are calculated based on 20,439,950 shares of our common stock issued and outstanding as of April 11, 2024. We do not have any other outstanding options, warrants exercisable for, or other securities convertible into shares of our common stock within the next 60 days. Unless otherwise indicated, the address of each person listed below is in care of Qualis Innovations, Inc., 225 Wilmington West Chester Pike, Suite 200 #145, Chadds Ford, Pennsylvania.

Name of Beneficial Owner	Title of Class	Amount and Nature of Beneficial Ownership		Percent of Class
Hill Blalock Jr.	Common Stock		7,221,045		35.3	%
Jim Holt ⁽¹⁾	Common Stock		1,913,955		9.4	%
Sharon Adams ⁽²⁾	Common Stock		1,132,689		5.5	%
Austin Adams ⁽³⁾	Common Stock		600,000		2.9	%
John Ballard ⁽⁴⁾	Common Stock		424,500		2.1	%
Dr. Joseph Pergolizzi ⁽⁵⁾	Common Stock		650,000		3.2	%
Madding King ⁽⁶⁾	Common Stock		35,000		-	%
All Officers and Directors as a Group	Common Stock		9,732,689		47.5	%

⁽¹⁾Jim Holt currently serves as the sole officer and director of Life Care Medical Devices Limited and is the previous CEO of Qualis Innovations, Inc. Mr. Holt is deemed to be the beneficial owner of 1,878,955 shares held in the name of Life Care Medical Devices Limited. Mr. Holt resigned from all positions in the Company on August 16, 2023.

⁽²⁾Ms. Sharon Adams is deemed to be the beneficial owner of 1,132,689 shares held in the name of Echo Resources LLP. Ms. Adams is the mother of Austin Adams, the former sole officer and director of Qualis Innovations, Inc.

⁽³⁾Mr. Austin Adams is deemed to be the beneficial owner of 450,000 shares held in the name of Cynergy Brookline Healthcare Fund, LLC, and 150,000 shares held in the name of Cynergy Healthcare Investors Emerging Bridge LLC. Mr. Adams is a former officer and director of Qualis Innovations, Inc.

⁽⁴⁾John Ballard is the previous CFO and Director of the Company. Mr. Ballard resigned from all positions in the Company on January 7, 2023.

⁽⁵⁾Dr. Joseph Pergolizzi, our acting CEO and Chairman of the Board of Directors, is deemed to be the beneficial owner of 250,000 shares held in the name of the CreoMed Inc. Dr. Joseph Pergolizzi is sole officer and director of CreoMed Inc. CreoMed Inc. also has 400,000 warrants to purchase common stock exercisable at $0.50 per share for ten years. Dr. Pergolizzi resigned from all positions in the Company on December 30, 2022.

⁽⁶⁾Madding King, a director of Qualis Innovations, Inc. is deemed to be the beneficial owner of the shares held in the name of Brookline Special Situations Fund LLC, where he is an officer and director. Mr. King resigned from all positions in the Company on November 15, 2022.

Equity Compensation Plans

The following represents a summary of the Equity Compensation grants and options awards outstanding at December 31, 2023 and 2022 and changes during the years then ended:

2023 and 2022
Plan category	Number of securities to be issued upon exercise of outstanding options, warrants and rights		Weighted-average exercise price of outstanding options, warrants and rights		Number of securities remaining available for future issuance under equity compensation plan (excluding securities reflected in column (a))
	(a)		(b)		(c)
Equity compensation plans approved by security holders		-0-	$	-0-		-0-
Equity compensation plans not approved by security holders		-0-	$	-0-		-0-
Total		-0-	$	-0-		-0-

Item 13. Certain Relationships and Related Transactions, and Director Independence

Other than compensation arrangements, we describe below transactions and series of similar transactions, since January 1, 2020 (i.e., the last two completed fiscal years), to which we were a party or will be a party, in which the amounts involved exceeded or will exceed the lesser of $120,000 or 1% of the average of our total assets at year-end for the last two completed fiscal years; and any of our directors, executive officers, or holders of more than 5% of our capital stock, or any member of the immediate family of the foregoing persons, had or will have a direct or indirect material interest. Compensation arrangements, including employment agreements, for our directors and named executive officers are described elsewhere in “Executive Compensation - Agreements with Executive Officers.” Neither of our directors is independent.

Employment Contracts

On March 16, 2021, the Company granted 698,830 warrants to purchase 698,830 of the Company’s common stock to Ahmet Demir Bingol, valued at $165,378 (based on the Black Scholes valuation model on the date of grant), pursuant to his Employment Agreement. The warrants are exercisable for a period of ten years at $0.50 per share in whole or in part, as either a cash exercise or as a cashless exercise, and fully vest at grant date.

On February 24, 2022, Mr. Bingol entered into a separation agreement whereby he will terminate his employment effective April 15, 2022. He received no severance payment and there were no disagreements between he or the Company. A total of 300,000 warrants have vested with the remaining 398,830 unvested warrants expiring. As a result of Mr. Bingol’s termination, the Company reversed the amount of $94,101 against the 398,830 unvested warrants as of March 31, 2022.

Indemnification Agreements

We have entered or intend to enter into indemnification agreements with each of our directors and executive officers. These agreements, among other things, will require us to indemnify each individual to the fullest extent permitted by Delaware law, including indemnification of expenses such as attorneys’ fees, judgments, fines and settlement amounts incurred by the individual in any action or proceeding, including any action or proceeding by or in right of us, arising out of the person’s services as a director, officer or other employee.

Policies and Procedures for Related Party Transactions

Given our small size and limited financial resources, we have not adopted formal policies and procedures for the review, approval or ratification of transactions with our executive officer(s), director(s) and significant shareholders. We rely on our board to review related party transactions on an ongoing basis to prevent conflicts of interest. Our board reviews a transaction in light of the affiliations of the director, officer or employee and the affiliations of such person’s immediate family. Transactions are presented to our board for approval before they are entered into or, if this is not possible, for ratification after the transaction has occurred. If our board finds that a conflict of interest exists, then it will determine the appropriate remedial action, if any. Our board approves or ratifies a transaction if it determines that the transaction is consistent with the best interests of the Company. We intend to establish formal policies and procedures in the future, once we have sufficient resources and have appointed additional directors, so that such transactions will be subject to the review, approval or ratification of our board of directors, or an appropriate committee thereof.

Item 14. Principal Accounting Fees and Services

The aggregate fees billed for the most recently completed fiscal period for the audit of our annual consolidated financial statements and services normally provided by the independent registered public accounting firm for this fiscal period were as follows:

	FY 2023		FY 2022
Audit Fees - Paris, Kreit & Chiu LLP (formerly Benjamin & Ko)	$	-	$	59,805
Audit Fees - Victor Mokuolu CPA PLLC		25,500		17,000-
Total Fees	$	25,500	$	76,805

In the above table, “audit fees” are fees billed by our external auditor for services provided in auditing our annual consolidated financial statements for the subject year. All of the services described above were approved in advance by the Board of Directors or the Company’s Audit Committee.

PART IV

Item 15. Exhibits, Financial Statement Schedules.

(a)	The following documents are filed as a part of this Annual Report:

1.	Financial Statements. The following consolidated financial statements of the Company are included below:

	Report of Independent Registered Public Accounting Firm.	F-2

	Consolidated Balance Sheets as of December 31, 2023 and 2022.	F-4

	Consolidated Statement of Operations for the Years ended December 31, 2023 and 2022.	F-5

	Consolidated Statements of Changes in Stockholders’ (Deficit) Equity for the Years ended December 31, 2023 and 2022.	F-6

	Consolidated Statements of Cash Flows for the Years ended December 31, 2023 and 2022.	F-7

	Notes to Consolidated Financial Statements.	F-8

2.	Financial Statement Schedule(s):

All schedules are omitted for the reason that the information is included in the consolidated financial statements or the notes thereto or that they are not required or are not applicable.

Exhibits.

31. Certification of CEO and CFO.

32. Certification pursuant to 18 U.S.C. Section 1350 of CEO and CFO

101. INS Inline XBRL Instance Document

101. SCH Inline XBRL Taxonomy Extension Schema Document

101. CAL Inline XBRL Taxonomy Extension Calculation Linkbase Document

101. DEF Inline XBRL Taxonomy Extension Definition Linkbase Document

101. LAB Inline XBRL Taxonomy Extension Label Linkbase Document

101. PRE Inline XBRL Taxonomy Extension Presentation Linkbase Document

104 Cover Page Interactive Data File (embedded within the Inline XBRL document)

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

	QUALIS INNOVATIONS, INC.

Dated: April 11, 2024	By:	/s Patrick Adams
		Patrick Adams
		Acting CEO and Chairman

QUALIS INNOVATIONS, INC.

Index to Financial Statements

CONTENTS

	Page
Report of Independent Registered Public Accounting Firm (PCAOB ID NO. 6651)	F-2
Consolidated Balance Sheets	F-4
Consolidated Statements of Operations	F-5
Consolidated Statements of Changes in Stockholders’ (Deficit) Equity	F-6
Consolidated Statements of Cash Flows	F-7
Notes to Consolidated Financial Statements	F-8

F-1

REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM

To the Board of Directors and

Stockholders of Qualis Innovations Inc.

Opinion on the Financial Statements

We have audited the accompanying consolidated balance sheets of Qualis Innovations Inc. (the “Company”) as of December 31, 2023, and December 31, 2022, and the related consolidated statements of operations, changes in stockholders’ equity (deficit), and cash flows for the years ended December 31, 2023, and December 31, 2022, and the related notes (collectively referred to as the financial statements). In our opinion, the financial statements present fairly, in all material respects, the financial position of the Company as of December 31, 2023, and December 31, 2022, and the results of its operations and its cash flows for the years then ended, in conformity with accounting principles generally accepted in the United States of America.

Substantial Doubt about the Company’s ability to continue as a Going Concern

The accompanying financial statements have been prepared assuming that the Company will continue as a going concern. As discussed in Note 2 to the financial statements, the Company has suffered recurring losses, had a working capital deficit of $522,956 as of December 31, 2023, and had accumulated deficit of $4,430,308 and $3,625,287 as of December 31, 2023 and December 31, 2022 respectively. These factors raise substantial doubt about the Company’s ability to continue as a going concern. Management’s plans in regard to these matters are also described in Note 2. The financial statements do not include any adjustments that might result from the outcome of this uncertainty.

Basis for Opinion

The financial statements are the responsibility of the Company’s management. Our responsibility is to express an opinion on the Company’s financial statements based on our audits. We are a public accounting firm registered with the Public Company Accounting Oversight Board (United States) (PCAOB) and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.

We conducted our audits in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audits to obtain reasonable assurance about whether the financial statements are free of material misstatement, whether due to error or fraud. The Company is not required to have, nor were we engaged to perform, an audit of its internal control over financial reporting. As part of our audits, we are required to obtain an understanding of internal control over financial reporting, but not for the purpose of expressing an opinion on the effectiveness of the Company’s internal control over financial reporting. Accordingly, we express no such opinion.

Our audits included performing procedures to assess the risks of material misstatement of the financial statements, whether due to error or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the financial statements. Our audits also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the financial statements. We believe that our audits provide a reasonable basis for our opinion.

F-2

Critical Audit Matters

The critical audit matters communicated below are matters arising from the current period audit of the financial statements that were communicated or required to be communicated to the audit committee and that: (1) relate to accounts or disclosures that are material to the financial statements and (2) involved our especially challenging, subjective, or complex judgments. The communication of critical audit matters does not alter in any way our opinion on the financial statements, taken as a whole, and we are not, by communicating the critical audit matters below, providing separate opinions on the critical audit matters or on the accounts or disclosures to which they relate.

Stock based compensation - warrants Issued for Services

During the year ended December 31, 2023, the Company recognized $45,763 in expenses related to warrants issued for services. As discussed in Note 6 and 9 to the consolidated financial statements, the Company has issued 100,000 warrants to former management, with total outstanding warrants of 1,590,000 as of December 31, 2023. Warrants issued for services were recorded at their fair value on their measurement dates based upon the Black-Scholes options pricing model. Our audit procedures to evaluate the appropriateness and accuracy of the accounting and fair value determined by management included reviewing the agreements supporting the issuances as well as independently recomputing the valuations made by Management.

Victor Mokuolu CPA PLLC


We have served as the Company’s auditor since 2023.

Houston, Texas

April 11, 2024 PCAOB ID: 6771

F-3

QUALIS INNOVATIONS, INC.

CONSOLIDATED BALANCE SHEETS


	December 31,
	2023			2022

ASSETS
Current assets:
Cash	$	2,431		$	69,858
Inventory		-			40,175
Deposits		-			54,000
Other current assets		-			92,170
Total current assets		2,431			256,203

Property and equipment, net		-			39,258
Total assets	$	2,431		$	295,461

LIABILITIES AND STOCKHOLDERS’ (DEFICIT) EQUITY
Current liabilities:
Accounts payable and accrued expenses	$	16,285		$	40,315
Short-term – share settlement		500,000			-
Short-term note payable		9,102			31,192
Total current liabilities		525,387			71,507
Total liabilities		525,387			71,507

Stockholders’(deficit) equity
Preferred stock, $0.001 par value, 25,000,000 shares authorized, no shares issued and outstanding at December 31, 2023 and 2022, respectively		-			-
Common stock, $0.001 par value, 750,000,000 shares authorized; 8,439,950 and 8,475,950 shares issued and outstanding at December 31, 2023 and 2022, respectively		8,440			8,476
Additional paid-in-capital		3,898,912			3,840,765
Accumulated deficit		(4,430,308	)		(3,625,287	)
Total stockholders’ (deficit) equity		(522,956	)		223,954
Total liabilities and stockholders’ (deficit) equity	$	2,431		$	295,461

See accompanying notes to consolidated financial statements.

F-4

QUALIS INNOVATIONS, INC.

CONSOLIDATED STATEMENTS OF OPERATIONS


	For the Years Ended December 31,
	2023			2022

Net revenue	$	-		$	-

Gross Profit	$	-			-

Operating expenses:
Research and development		1,500			76,360
Warrants issued for services		30,348			342,024
Stock based compensation - related party		45,763			(94,101	)
General and administrative		152,630			596,232
Total operating expenses		230,241			920,515
Loss from operations		(230,241	)		(920,515	)

Operating (income) expenses:
Settlement of dispute		500,000			-
Impairment of assets		76,008			-
Inventory adjustment		40,175			-
Gain on cancellation of shares for services		(18,000	)		-
Other income		(23,403	)		-
Total other expenses		574,780			-

Loss before income taxes		(805,021	)		(920,515	)
Income taxes		-			-

Net loss	$	(805,021	)	$	(920,515	)

Net loss per share, basic and diluted	$	(0.09	)	$	(0.11	)

Weighted average number of shares outstanding
Basic and diluted		8,475,950			8,333,660

See accompanying notes to consolidated financial statements.

F-5

QUALIS INNOVATIONS, INC.

CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS’ (DEFICIT) EQUITY


	Common Stock						Additional Paid			Accumulated			Total Stockholders’
	Shares			Amount			in Capital			Deficit			(Deficit) Equity
Balance as of January 1, 2022		8,239,950		$	8,240		$	3,466,947		$	(2,704,772	)	$	770,415
Warrants issued to third parties in conjunction with services		-			-			342,024			-			342,024
Stock based compensation - related party		-			-			(94,101	)		-			(94,101	)
Options issued to third parties in conjunction with services		-			-			8,131			-			8,131
Issuance of common stock for cash		200,000			200			99,800			-			100,000
Issuance of common stock for services		36,000			36			17,964			-			18,000
Net loss		-			-			-			(920,515	)		(920,515	)
Balance as of December 31, 2022		8,475,950		$	8,476		$	3,840,765		$	(3,625,287	)	$	223,954

Balance as of January 1, 2023		8,475,950		$	8,476		$	3,840,765		$	(3,625,287	)	$	223,954
Balance		8,475,950		$	8,476		$	3,840,765		$	(3,625,287	)	$	223,954
Warrants issued to third parties in conjunction with services		-			-			30,348			-			30,348
Stock based compensation - related party		-			-			45,763			-			45,763
Cancellation of common stock for services		(36,000	)		(36	)		(17,964	)					(18,000	)
Net loss		-			-			-			(805,021	)		(805,021	)
Balance as of December 31, 2023		8,439,950		$	8,440		$	3,897,485		$	(4,430,308	)	$	(522,956	)
Balance		8,439,950		$	8,440		$	3,897,485		$	(4,430,308	)	$	(522,956	)

See accompanying notes to consolidated financial statements

F-6

QUALIS INNOVATIONS, INC.

CONSOLIDATED STATEMENTS OF CASH FLOWS


	For the Years Ended December 31,
	2023			2022

Cash flows from operating activities:
Net loss	$	(805,021	)	$	(920,515	)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation expense		17,250			17,102
Impairment of assets		76,008			-
Warrants issued for services		30,348			342,024
Options issued for services		-			8,131
Stock based compensation - related parties		45,763			(94,101	)
Issuance of common stock for services		-			18,000
Issuance of common stock in settlement of dispute		500,000			-
Changes in operating assets and liabilities:
Inventory		40,175			20,100
Other current assets		92,170			8,974
Accounts payable and accrued expenses		(42,030	)		22,067
Short-term note payable		(31,192	)		31,192
Other current liabilities		-			(11,400	)
Net cash used in operating activities		(76,529	)		(558,426	)

Cash flows from investing activities:
None		-			-
Net cash used in investing activities		-			-

Cash flows from financing activities:
Advance from shareholder		9,102			-
Issuance of common stock for cash		-			100,000
Net cash provided by financing activities		9,102			100,000

Net (decrease) increase in cash		(67,427	)		(458,426	)

Cash at beginning of period		69,858			528,284
Cash at end of period	$	2,431		$	69,858

Supplemental disclosures of cash flow information:
Cash paid during the period for:
Interest	$	-		$	-
Income taxes	$	-		$	-

Non-cash investing and financing activities:
Insurance policy financed by short-term note payable	$	-		$	62,384

See accompanying notes to consolidated financial statements

F-7

QUALIS INNOVATIONS, INC.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

FOR THE YEARS ENDED DECEMBER 31, 2023 AND 2022

NOTE 1 – ORGANIZATION AND PRINCIPAL ACTIVITIES

Corporate History and Background

In July, 2019, John Ballard and Charles Achoa, formed a new company named EMF Medical Devices Inc. for the development, maintenance, marketing and sale of an electronic device for the treatment of pain that would make use of certain intellectual property interests held by LCMD. In May 2021 the Company changed its name to mPathix Health Inc. John Ballard is the Company’s previous Chief Financial Officer and Charles Achoa does not participate in any management or board position.

F-8

On June 28, 2021, the Company entered into a Share Exchange Agreement (“Exchange Agreement”) by and among mPathix Health, Inc. (formerly EMF Medical Devices, Inc., a Delaware corporation) (“mPathix”) and Qualis. The closing of the transaction (the “Closing”) took place on June 29, 2021 (the “Closing Date”). On the Closing Date, pursuant to the terms of the Exchange Agreement, the Company acquired all of the outstanding shares (the “Shares”) of mPathix. In exchange, the Company issued to the mPathix shareholder’s, their designees or assigns, an aggregate of 6,988,300 shares of Company common stock (the “Shares Component”) or 93.36% of the shares of common stock of the Company issued and outstanding after the Closing (the “Share Exchange”), at a valuation of $0.50 per share, and the Company issued warrants to purchase an additional 1,098,830 shares (698,830 warrants issued to the Company’s previous CEO and 400,000 to CreoMed which is beneficially owned by Dr. Joseph Pergolizzi, the Company’s acting CEO and chairman of the board) of the Company’s common stock, exercisable for 10 years at a $0.50 per share exercise price, subject to adjustment. In connection with the closing of the mPathix acquisition, the officers and directors of mPathix were appointed as the officers and directors of the Company. On June 29, 2021, the Company issued 496,650 common shares for the recapitalization of Qualis in conjunction with the reverse acquisition for a net book value of $0.

NOTE 2 – BASIS OF PRESENTATION

The accompanying consolidated financial statements have been prepared in conformity with accounting principles generally accepted in the United States of America (“GAAP”) and stated in U.S. dollars. Any reference in these notes to applicable guidance is meant to refer to the authoritative GAAP as found in the Accounting Standards Codification and Accounting Standards Updates (“ASU”) of the Financial Accounting Standards Board (“FASB”).

The Company currently operates in one business segment. The Company is not organized by market and is managed and operated as one business. A single management team reports to the chief operating decision maker, the Chief Executive Officer, who comprehensively manages the entire business. The Company does not currently operate any separate lines of businesses or separate business entities.

Going Concern

The accompanying consolidated financial statements have been prepared assuming the Company will continue as a going concern, which contemplates, among other things, the realization of assets and satisfaction of liabilities in the normal course of business. The Company had an accumulated deficit of $4,430,308 at December 31, 2023, had a working capital deficit of $522,956 and working capital of $184,696 at December 31, 2023 and December 31, 2022, respectively, had a net loss of $805,021 and $920,515 for years ended December 31, 2023 and 2022, respectively, and net cash used in operating activities of $76,529 and $558,426 or years ended December 31, 2023 and 2022, respectively, with no revenue earned since inception, and a lack of operational history. These matters raise substantial doubt about the Company’s ability to continue as a going concern.

While the Company is attempting to expand operations and generate revenues, the Company’s cash position may not be significant enough to support the Company’s daily operations. Management intends to raise additional funds by way of a private offering. Management believes that the actions presently being taken to further implement its business plan and generate revenues provide the opportunity for the Company to continue as a going concern. While management believes in the viability of its strategy to generate revenues and in its ability to raise additional funds or transact an asset sale, there can be no assurances to that effect or on terms acceptable to the Company. The ability of the Company to continue as a going concern is dependent upon the Company’s ability to further implement its business plan and generate revenues.

F-9

The consolidated financial statements do not include any adjustments that might be necessary if the Company is unable to continue as a going concern.

NOTE 3 – SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

This summary of significant accounting policies of the Company is presented to assist in understanding the Company’s consolidated financial statements. The consolidated financial statements and notes are representations of the Company’s management, which is responsible for their integrity and objectivity. These accounting policies conform to GAAP and have been consistently applied in the preparation of the consolidated financial statements.

Use of Estimates

The preparation of these consolidated financial statements in accordance with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosures of contingent assets and liabilities at the dates of the consolidated financial statements and the reported amounts of net sales and expenses during the reported periods. Actual results may differ from those estimates and such differences may be material to the consolidated financial statements. The more significant estimates and assumptions by management include among others: common stock valuation, amortization of intangible assets, depreciation of property and equipment, the recoverability of intangibles. The current economic environment has increased the degree of uncertainty inherent in these estimates and assumptions.

For the year ended December 31, 2023, the accompanying consolidated financial statements includes a change in accounting estimate of accrued expenses that resulted in a $41,403 reduction in expenses from operations comprised of accounts payable of $23,403, common stock of $36, and additional paid in capital of $17,964 (due to the cancellation of 36,000 common shares). The Financial Accounting Standards Board’s, ASC 250-10-45-17 requires specific financial statement disclosures to include the effect on income from operations, net income, and any related per-share amounts.

Cash

The Company’s cash is held in bank accounts in the United States and is insured by the Federal Deposit Insurance Corporation (FDIC) up to $250,000. The Company has not experienced any cash losses.

Related Parties

The Company follows ASC 850, “Related Party Disclosures,” for the identification of related parties and disclosure of related party transactions. Related parties are any entities or individuals that, through employment, ownership or other means, possess the ability to direct or cause the direction of the management and policies of the Company.

Income Taxes

Income taxes are accounted for under an asset and liability approach. This process involves calculating the temporary and permanent differences between the carrying amounts of the assets and liabilities for financial reporting purposes and the amounts used for income tax purposes. The temporary differences result in deferred tax assets and liabilities, which would be recorded on the Balance Sheets in accordance with ASC 740, which established financial accounting and reporting standards for the effect of income taxes. The likelihood that its deferred tax assets will be recovered from future taxable income must be assessed and, to the extent that recovery is not likely, a valuation allowance is established. Changes in the valuation allowance in a period are recorded through the income tax provision in the consolidated Statements of Operations.

F-10

ASC 740-10 clarifies the accounting for uncertainty in income taxes recognized in an entity’s consolidated financial statements and prescribes a recognition threshold and measurement attributes for financial statement disclosure of tax positions taken or expected to be taken on a tax return. Under ASC 740-10, the impact of an uncertain income tax position on the income tax return must be recognized at the largest amount that is more-likely-than-not to be sustained upon audit by the relevant taxing authority. An uncertain income tax position will not be recognized if it has less than a 50% likelihood of being sustained. Additionally, ASC 740-10 provides guidance on derecognition, classification, interest and penalties, accounting in interim periods, disclosure and transition. The Company does not have a liability for unrecognized income tax benefits.

Advertising and Marketing Costs

Advertising and marketing expenses are recorded as marketing expenses when they are incurred. The Company had no advertising and marketing expense for the years ended December 31, 2023 and 2022, respectively.

Research and Development

All research and development costs are expensed as incurred. Research and development expenses comprise costs incurred in performing research and development activities, including clinical trial costs, manufacturing costs for both clinical and pre-clinical materials as well as other contracted services, license fees, and other external costs. Nonrefundable advance payments for goods and services that will be used in future research and development activities are expensed when the activity is performed or when the goods have been received, rather than when payment is made, in accordance with ASC 730, Research and Development.

With respect to the current status of the patent, there has been no movement during the period ended December 31, 2023 and to date. The Company has a disagreement with the specific vendor and the project relating to collection of data, testing and filing the patent application has been kept on hold. The Company and the vendor are trying to resolve this disagreement, about achieving a particular milestone, which they expect to be completed later in fiscal 2023.

General and Administrative Expenses

General and administrative expenses consisted of professional service fees, and other general and administrative overhead costs. Expenses are recognized when incurred.

Inventories

Inventories are valued at the lower of cost or net realizable value. The Company’s inventories are valued under the first in, first out (FIFO) method or average cost method. Net realizable value is estimated based on current selling prices. The Company records a provision for excess and obsolete inventory based primarily on forecasted product demand and production requirements. Once inventory provisions are established, the written-down value of the inventory becomes its new cost basis.

Deposits

Deposits consist of amounts paid to a vendor in advance to manufacture pain treatment products. Deposits are included in current assets in the accompanying Condensed Consolidated Balance Sheets.

Property and Equipment

Property and equipment are carried at cost and are depreciated on a straight-line basis over the estimated useful lives of the assets, generally five years. The cost of repairs and maintenance is expensed as incurred; major replacements and improvements are capitalized. When assets are retired or disposed of, the cost and accumulated depreciation are removed from the accounts, and any resulting gains or losses are included in income in the year of disposition. Fixed assets are examined for the possibility of decreases in value when events or changes in circumstances reflect the fact that their recorded value may not be recoverable.

F-11

Impairment of Long-lived Assets

The Company periodically evaluates whether the carrying value of property, equipment and intangible assets has been impaired when circumstances indicate the carrying value of those assets may not be recoverable. The carrying amount is not recoverable if it exceeds the sum of the undiscounted cash flows expected to result from the use and eventual disposition of the asset. If the carrying value is not recoverable, the impairment loss is measured as the excess of the asset’s carrying value over its fair value.

The Company’s impairment analyses require management to apply judgment in estimating future cash flows as well as asset fair values, including forecasting useful lives of the assets, assessing the probability of different outcomes, and selecting the discount rate that reflects the risk inherent in future cash flows. If the carrying value is not recoverable, we assess the fair value of long-lived assets using commonly accepted techniques, and may use more than one method, including, but not limited to, recent third-party comparable sales and discounted cash flow models. If actual results are not consistent with the Company’s assumptions and estimates, or the assumptions and estimates change due to new information, the Company may be exposed to an impairment charge in the future.

Fair Value of Financial Instruments

The provisions of accounting guidance, FASB Topic ASC 825 requires all entities to disclose the fair value of financial instruments, both assets and liabilities recognized and not recognized on the balance sheet, for which it is practicable to estimate fair value, and defines fair value of a financial instrument as the amount at which the instrument could be exchanged in a current transaction between willing parties. As of December 31, 2023, there were no financial instruments requiring fair value.

Fair Value Measurements

Fair value is defined as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability, in an orderly transaction between market participants on the measurement date. Valuation techniques used to measure fair value must maximize the use of observable inputs and minimize the use of unobservable inputs. The fair value hierarchy is based on three levels of inputs, of which the first two are considered observable and the last unobservable, as follows:

	●	Level 1 – Quoted prices in active markets for identical assets or liabilities.

	●	Level 2 – Inputs other than Level 1 that are observable, either directly or indirectly, such as quoted prices for similar assets or liabilities; quoted prices in markets that are not active; or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities.

	●	Level 3 – Unobservable inputs that are supported by little or no market activity and that are significant to the measurement of the fair value of the assets or liabilities

The carrying value of financial assets and liabilities recorded at fair value are measured on a recurring or nonrecurring basis. Financial assets and liabilities measured on a non-recurring basis are those that are adjusted to fair value when a significant event occurs. There were no financial assets or liabilities carried and measured on a nonrecurring basis during the reporting periods. Financial assets and liabilities measured on a recurring basis are those that are adjusted to fair value each time a financial statement is prepared. There have been no transfers between levels.

Basic and diluted earnings per share

The computation of net profit (loss) per share included in the Statements of Operations, represents the net profit (loss) per share that would have been reported had the Company been subject to ASC 260, “Earnings Per Share as a corporation for all periods presented.

F-12

Diluted earnings (loss) per share are computed on the basis of the weighted average number of common shares (including common stock subject to redemption) plus dilutive potential common shares outstanding for the reporting period. In periods where losses are reported, the weighted-average number of common stock outstanding excludes common stock equivalents, because their inclusion would be anti-dilutive.

Potentially dilutive securities were excluded from the calculation of diluted net loss per share because the effects were anti-dilutive based on the application of the treasury stock method and because the Company incurred net losses during the period.

There were 1,710,000 and 1,610,000 dilutive securities outstanding for the years ended December 31, 2023 and 2022, respectively. These potential dilutive securities outstanding have not been considered as the inclusion would be anti-dilutive.

Employee Stock Based Compensation

Stock based compensation issued to employees and members of our board of directors is measured at the date of grant based on the estimated fair value of the award, net of estimated forfeitures. The grant date fair value of a stock-based award is recognized as an expense over the requisite service period of the award on a straight-line basis.

For purposes of determining the variables used in the calculation of stock-based compensation issued to employees, the Company performs an analysis of current market data and historical data to calculate an estimate of implied volatility, the expected term of the option and the expected forfeiture rate. With the exception of the expected forfeiture rate, which is not an input, we use these estimates as variables in the Black-Scholes option pricing model. Depending upon the number of stock options granted any fluctuations in these calculations could have a material effect on the results presented in our consolidated statements of operations. In addition, any differences between estimated forfeitures and actual forfeitures could also have a material impact on our consolidated financial statements.

Non-Employee Stock Based Compensation

Issuances of the Company’s common stock or warrants for acquiring goods or services are measured at the fair value of the consideration received or the fair value of the equity instruments issued, whichever is more reliably measurable. The measurement date for the fair value of the equity instruments issued to consultants or vendors is determined at the earlier of (i) the date at which a commitment for performance to earn the equity instruments is reached (a “performance commitment” which would include a penalty considered to be of a magnitude that is a sufficiently large disincentive for nonperformance) or (ii) the date at which performance is complete. Although situations may arise in which counter performance may be required over a period of time, the equity award granted to the party performing the service is fully vested and non-forfeitable on the date of the agreement. As a result, in this situation in which vesting periods do not exist as the instruments fully vested on the date of agreement, the Company determines such date to be the measurement date and will record the estimated fair market value of the instruments granted as a prepaid expense and amortize such amount to general and administrative expense in the accompanying statement of operations over the contract period. When it is appropriate for the Company to recognize the cost of a transaction during financial reporting periods prior to the measurement date, for purposes of recognition of costs during those periods, the equity instrument is measured at the then-current fair values at each of those interim financial reporting dates.

Non-Cash Equity Transactions

Shares of equity instruments issued for non-cash consideration are recorded at the fair value of the consideration received based on the market value of services to be rendered, or at the value of the stock given, considered in reference to contemporaneous cash sale of stock.

Concentrations, Risks, and Uncertainties

Business Risk

Substantial business risks and uncertainties are inherent to an entity, including the potential risk of business failure.

F-13

The Company is headquartered and operates in the United States. To date, the Company has generated no revenues from operations. There can be no assurance that the Company will be able to raise additional capital and failure to do so would have a material adverse effect on the Company’s financial position, results of operations and cash flows. Also, the success of the Company’s operations is subject to numerous contingencies, some of which are beyond management’s control. Currently, these contingencies include general economic conditions, price of components, competition, and governmental and political conditions.

Interest rate risk

Financial assets and liabilities do not have material interest rate risk.

Credit risk

The Company is not exposed to credit risk.

Seasonality

The business is not subject to substantial seasonal fluctuations.

Major Suppliers

The Company has not entered into any contracts that obligate it to purchase a minimum quantity or exclusively from any supplier.

Recent Accounting Pronouncements

Recently issued accounting updates are not expected to have a material impact on the Company’s consolidated financial statements.

NOTE 4 –PROPERTY AND EQUIPMENT

Property and equipment consisted of the following as of:

SCHEDULE OF PROPERTY AND EQUIPMENT

		December 31,			December 31,
	Estimated Life	2023			2022

Tooling	5 years	$	82,530		$	82,530
Computer Equipment	3 years		1,787			1,787
Impairment of tooling			(22,008	)		-
Accumulated depreciation			(62,309	)		(45,059	)
Total		$	-		$	39,258

Depreciation expense was $17,250 and $17,102 for the years ended December 31, 2023 and 2022, respectively, and is classified in general and administrative expenses in the consolidated Statements of Operations.

NOTE 5 – SHORT TERM LOAN

F-14

NOTE 6 – STOCKHOLDERS’ (DEFICIT) EQUITY

The Company has authorized 25,000,000 preferred stock with a par value of $0.001 with no preferred shares outstanding at December 31, 2023 and December 31, 2022.

The Company has authorized 750,000,000 shares of par value $0.001 common stock, of which 8,439,950 and 8,475,950 shares are outstanding at December 31, 2023 and December 31, 2022, respectively.

Common Stock

On July 20, 2022, the Company issued 200,000 common shares to an affiliate for aggregate gross proceeds of $100,000.

Warrants

On March 29, 2022, the Board of Directors approved the granting of 400,000 warrants, with effect from April 1, 2022, convertible to the Company’s common shares with an exercise price of $1.10, valued at $290,276 (based on the Black Scholes valuation model on the date of grant), to our acting CEO and Chairman Joseph V. Pergolizzi Jr., MD through his company, CreoMed Inc with an expiration period of 10 years. These warrants were issued as compensation for the first quarter to Joseph V. Pergolizzi Jr., MD.

F-15

On April 3, 2023, the Company granted 3,333,333 shares warrants to purchase 3,333,333 of the Company’s common stock to Jim Holt, the Company’s previous CEO, valued at $1,597,635 (based on the Black Scholes valuation model on the date of grant). The warrants are exercisable for a period of seven years at $0.03 per share in whole or in part and vest immediately. On December 13, 2023, Mr. Holt, entered into a cancellation agreement whereby a total of 100,000 warrants, valued at $45,763 (based on the Black Scholes valuation model on the date of cancellation) have vested with the remaining 3,233,333 warrants cancelled. The warrants are exercisable for a period of three years at $0.03 per share in whole or in part and vest immediately.

The following represents a summary of the warrants outstanding at December 31, 2023 and changes during the periods then ended:

SUMMARY OF WARRANTS OUTSTANDING

	Warrants			Weighted Average Exercise Price		Weighted Average Contract Life (in Years)		Aggregate Intrinsic Value *
Outstanding at January 1, 2022		1,098,830		$	0.50		8.4	$	769,181
Granted		790,000			0.82		6.7		-
Exercised		-			-		-		-
Expired/Forfeited		(398,830	)		0.50		-		(538,421	)
Outstanding at December 31, 2022		1,490,000		$	0.50		8.4	$	-
Granted		100,000			0.05		3.0		52,000
Exercised		-			-		-		-
Expired/Forfeited		-			-		-		-
Outstanding at December 31, 2023		1,590,000		$	0.77		5.5	$	101,000
Exercisable at December 31, 2023		1,590,000		$	0.77		5.5	$	101,000
Expected to be vested		1,590,000		$	0.77		5.5	$	101,000

Based on the fair value of the Company’s stock on December 31, 2023 and December 31, 2022, respectively

Options

The following represents a summary of the options outstanding at December 31, 2023 and changes during the periods then ended:

SUMMARY OF STOCK OPTIONS OUTSTANDING

	Options		Weighted Average Exercise Price		Weighted Average Contract Life (in Years)		Aggregate Intrinsic Value *
Outstanding at January 1, 2022		120,000	$	0.50		5.2	$	84,000
Granted		-		-		-		-
Exercised		-		-		-		-
Expired/Forfeited		-		-		-		-
Outstanding at December 31, 2022		120,000	$	0.50		4.2	$	-
Granted		-		-		-		-
Exercised		-		-		-		-
Expired/Forfeited		-		-		-		-
Outstanding at December 31, 2023		120,000	$	0.50		3.2	$	8,400
Exercisable at December 31, 2023		120,000	$	0.50		3.2	$	8,400
Expected to be vested		120,000	$	0.50		4.0	$	-

Based on the fair value of the Company’s stock on December 31, 2023 and 2022, respectively

F-16

NOTE 7 – RELATED PARTY TRANSACTIONS

Other than as set forth below, and as disclosed in Notes 5, 6 and 10, there have not been any transaction entered into or been a participant in which a related person had or will have a direct or indirect material interest.

NOTE 8 – INCOME TAXES

At December 31, 2023, net operating loss carry forwards for Federal and state income tax purposes totaling approximately $617,000 are available to reduce future income which under the Tax Cuts and Jobs Act of 2018, allows for an indefinite carryforward period, with carryforwards limited to 80% of each subsequent year’s net income. There is no income tax affect due to the recognition of a full valuation allowance on the expected tax benefits of future loss carry forwards based on uncertainty surrounding realization of such assets.

A reconciliation of the statutory income tax rates and the effective tax rate is as follows:

	Year Ended			Year Ended
	December 31, 2023			December 31, 2022

Statutory U.S. federal rate		21.0	%		21.0	%
State income tax, net of federal benefit		3.7	%		3.7	%
Permanent differences		0.0	%		0.0	%
Valuation allowance		(24.7	)%		(24.7	)%
Provision for income taxes		0.0	%		0.0	%

The tax effects of the temporary differences and carry forwards that give rise to deferred tax assets consist of the following:

SCHEDULE OF DEFERRED TAX ASSETS

	2023			2022
	December 31,
	2023			2022

Deferred tax assets:
Net operating loss carry forwards	$	617,573		$	470,354
Depreciation and amortization		253,712			249,495
Impairment of Intangible asset		63,964			35,316
Stock based compensation		157,163			138,748
Valuation allowance		(1,092,412	)		(893,912	)
Deferred tax assets, net	$	-		$	-

Major tax jurisdictions are the United States and Delaware All of the tax years will remain open three and four years for examination by the Federal and state tax authorities, respectively, from the date of utilization of the net operating loss. There are no tax audits pending.

NOTE 9 – EARNINGS PER SHARE

FASB ASC Topic 260, Earnings Per Share, requires a reconciliation of the numerator and denominator of the basic and diluted earnings (loss) per share (EPS) computations.

Basic earnings (loss) per share are computed by dividing net earnings available to common shareholders by the weighted-average number of common shares outstanding during the period. Diluted earnings (loss) per share is computed similar to basic earnings per share except that the denominator is increased to include the number of additional common shares that would have been outstanding if the potential common shares had been issued and if the additional common shares were dilutive. In periods where losses are reported, the weighted-average number of common stock outstanding excludes common stock equivalents, because their inclusion would be anti-dilutive.

F-17

The following potentially dilutive securities were excluded from the calculation of diluted net loss per share because the effects were anti-dilutive based on the application of the treasury stock method and because the Company incurred net losses during the period:

	2023		2022
	For the Years Ended December 31,
	2023		2022
Options to purchase shares of common stock		120,000		120,000
Warrants to purchase shares of common stock granted on February 14, 2021 to CreoMed, Inc.*		400,000		400,000
Warrants to purchase shares of common stock granted on March 16, 2021 to Demir Bingol*		300,000		300,000
Warrants to purchase shares of common stock granted on April 1, 2022 to CreoMed, Inc.		400,000		400,000
Warrants to purchase shares of common stock		490,000		390,000
Total potentially dilutive shares		1,710,000		1,610,000

*	The Company has cancelled and regranted these warrants to purchase 1,098,830 shares (698,830 warrants issued to the Ahmet Demir Bingol and 400,000 to CreoMed Inc.) of the Company’s common stock on June 29, 2021 in conjunction with the share exchange agreement.

The following table sets forth the computation of basic and diluted net income per share:

	2023			2022
	For the Years Ended December 31,
	2023			2022
Net loss attributable to the common stockholders	$	(805,021	)	$	(920,515	)

Basic weighted average outstanding shares of common stock		8,475,950			8,333,660
Dilutive effect of options and warrants		-			-
Diluted weighted average common stock and common stock equivalents		8,475,950			8,333,660

Loss per share:
Basic and diluted	$	(0.09	)	$	(0.11	)

NOTE 10 – COMMITMENTS AND CONTINGENCIES

Legal

From time to time, various lawsuits and legal proceedings may arise in the ordinary course of business. However, litigation is subject to inherent uncertainties and an adverse result in these or other matters may arise from time to time that may harm our business. We are currently not aware of any legal proceedings or claims that it believes will have a material adverse effect on its business, financial condition or operating results.

2021 Equity Incentive Plan

F-18

Employment Agreement

On March 1, 2021, Mr. Ahmet Demir Bingol, the Company’s Chief Executive Officer (“CEO”) entered into an Employment Agreement with the Company, with an effective date of March 16, 2021, in which he receives an annual base salary of $250,000, plus bonus compensation not to exceed 80% of salary. In addition, Mr. Bingol was granted 698,830 warrants to purchase 698,830 of the Company’s common stock, valued at $165,378 (based on the Black Scholes valuation model on the date of grant). The warrants are exercisable for a period of ten years at $0.50 per share in whole or in part, as either a cash exercise or as a cashless exercise, and fully vest at grant date. Mr. Bingol’s employment also provides for medical insurance, disability benefits and one year of severance pay if his employment is terminated without cause or due to a change in control. Mr. Bingol’s compensation was approved by the Company’s Board of Directors on March 1, 2021.

Consulting Agreement

On January 27, 2022 the Company hired an engineering consultant to assist in completing the design history file, updating new software, system design, pre 510(k) preparation, and testing of the SOLACE device. This work is expected to be completed by the end of September 2022 and the cost of the contract is $77,850.

NOTE 11 – SUBSEQUENT EVENTS

The Company evaluated all events or transactions that occurred after December 31, 2023 up through the date the consolidated financial statements were available to be issued. During this period, the Company did not have any material recognizable subsequent events required to be disclosed as of and for the period ended December 31, 2023.

In January 2024, the Company issued 2,000,000 common shares to two (2) affiliates for aggregate gross proceeds of $100,000.

F-19

GRAPHIC 2 form10-k_001.jpg begin 644 form10-k_001.jpg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end GRAPHIC 3 form10-k_002.jpg begin 644 form10-k_002.jpg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end EX-31.1 4 ex31-1.htm

EXHIBIT 31.1

SECTION 302 CERTIFICATION

I, Patrick Adams, certify that:

1. I have reviewed this annual report on Form 10-K of Qualis Innovations, Inc.

2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

4. I am responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

c) Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

d) Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

5. I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):

a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and

b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

Date: April 11, 2024

/s Patrick Adams

Patrick Adams

Acting CEO and Chairman

EX-32.1 5 ex32-1.htm

EXHIBIT 32.1

CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350, AS ADOPTED

PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

In connection with the Annual Report of Qualis Innovations, Inc. (the “Company”) on Form 10-K for the year ended December 31, 2023 as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I, Patrick Adams, Chief Executive Officer of the Company, certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, to the best of my knowledge, that:

(1) The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

(2) The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company for the dates and periods covered by the Report.

This certificate is being made for the exclusive purpose of compliance by the Acting Chief Executive Officer of the Company with the requirements of Section 906 of the Sarbanes-Oxley Act of 2002, and may not be disclosed, distributed or used by any person or for any reason other than as specifically required by law.

Date: April 11, 2024

/s Patrick Adams
Patrick Adams
Acting CEO and Chairman

EX-101.SCH 6 qlis-20231231.xsd XBRL SCHEMA FILE 00000001 - Document - Cover link:presentationLink link:calculationLink link:definitionLink 00000002 - Statement - Consolidated Balance Sheets link:presentationLink link:calculationLink link:definitionLink 00000003 - Statement - Consolidated Balance Sheets (Parenthetical) link:presentationLink link:calculationLink link:definitionLink 00000004 - Statement - Consolidated Statements of Operations link:presentationLink link:calculationLink link:definitionLink 00000005 - Statement - Consolidated Statements of Changes in Stockholders' (Deficit) Equity link:presentationLink link:calculationLink link:definitionLink 00000006 - Statement - Consolidated Statements of Cash Flows link:presentationLink link:calculationLink link:definitionLink 00000007 - Disclosure - ORGANIZATION AND PRINCIPAL ACTIVITIES link:presentationLink link:calculationLink link:definitionLink 00000008 - Disclosure - BASIS OF PRESENTATION link:presentationLink link:calculationLink link:definitionLink 00000009 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES link:presentationLink link:calculationLink link:definitionLink 00000010 - Disclosure - PROPERTY AND EQUIPMENT link:presentationLink link:calculationLink link:definitionLink 00000011 - Disclosure - SHORT TERM LOAN link:presentationLink link:calculationLink link:definitionLink 00000012 - Disclosure - STOCKHOLDERS’ (DEFICIT) EQUITY link:presentationLink link:calculationLink link:definitionLink 00000013 - Disclosure - RELATED PARTY TRANSACTIONS link:presentationLink link:calculationLink link:definitionLink 00000014 - Disclosure - INCOME TAXES link:presentationLink link:calculationLink link:definitionLink 00000015 - Disclosure - EARNINGS PER SHARE link:presentationLink link:calculationLink link:definitionLink 00000016 - Disclosure - COMMITMENTS AND CONTINGENCIES link:presentationLink link:calculationLink link:definitionLink 00000017 - Disclosure - SUBSEQUENT EVENTS link:presentationLink link:calculationLink link:definitionLink 00000018 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies) link:presentationLink link:calculationLink link:definitionLink 00000019 - Disclosure - PROPERTY AND EQUIPMENT (Tables) link:presentationLink link:calculationLink link:definitionLink 00000020 - Disclosure - STOCKHOLDERS’ (DEFICIT) EQUITY (Tables) link:presentationLink link:calculationLink link:definitionLink 00000021 - Disclosure - INCOME TAXES (Tables) link:presentationLink link:calculationLink link:definitionLink 00000022 - Disclosure - EARNINGS PER SHARE (Tables) link:presentationLink link:calculationLink link:definitionLink 00000023 - Disclosure - ORGANIZATION AND PRINCIPAL ACTIVITIES (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000024 - Disclosure - BASIS OF PRESENTATION (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000025 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000026 - Disclosure - SCHEDULE OF PROPERTY AND EQUIPMENT (Details) link:presentationLink link:calculationLink link:definitionLink 00000027 - Disclosure - PROPERTY AND EQUIPMENT (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000028 - Disclosure - SHORT TERM LOAN (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000029 - Disclosure - SUMMARY OF WARRANTS OUTSTANDING (Details) link:presentationLink link:calculationLink link:definitionLink 00000030 - Disclosure - SUMMARY OF STOCK OPTIONS OUTSTANDING (Details) link:presentationLink link:calculationLink link:definitionLink 00000031 - Disclosure - STOCKHOLDERS’ (DEFICIT) EQUITY (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000032 - Disclosure - SCHEDULE OF RECONCILIATION OF STATUTORY INCOME TAX RATES (Details) link:presentationLink link:calculationLink link:definitionLink 00000033 - Disclosure - SCHEDULE OF DEFERRED TAX ASSETS (Details) link:presentationLink link:calculationLink link:definitionLink 00000034 - Disclosure - INCOME TAXES (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000035 - Disclosure - SCHEDULE OF POTENTIALLY DILUTIVE SECURITIES WERE EXCLUDED FROM CALCULATION OF DILUTED NET LOSS PER SHARE (Details) link:presentationLink link:calculationLink link:definitionLink 00000036 - Disclosure - SCHEDULE OF POTENTIALLY DILUTIVE SECURITIES WERE EXCLUDED FROM CALCULATION OF DILUTED NET LOSS PER SHARE (Details) (Parenthetical) link:presentationLink link:calculationLink link:definitionLink 00000037 - Disclosure - SCHEDULE OF COMPUTATION OF BASIC AND DILUTED NET INCOME PER SHARE (Details) link:presentationLink link:calculationLink link:definitionLink 00000038 - Disclosure - COMMITMENTS AND CONTINGENCIES (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000039 - Disclosure - SUBSEQUENT EVENTS (Details Narrative) link:presentationLink link:calculationLink link:definitionLink EX-101.CAL 7 qlis-20231231_cal.xml XBRL CALCULATION FILE EX-101.DEF 8 qlis-20231231_def.xml XBRL DEFINITION FILE EX-101.LAB 9 qlis-20231231_lab.xml XBRL LABEL FILE Equity Components [Axis] Common Stock [Member] Additional Paid-in Capital [Member] Retained Earnings [Member] Collaborative Arrangement and Arrangement Other than Collaborative [Axis] Share Exchange Agreement [Member] Investment, Name [Axis] FDH [Member] Donxon [Member] Dasen [Member] FDSC [Member] XKT [Member] Legal Entity [Axis] Echo Resources LLLP [Member] Parent [Member] MPathix [Member] CreoMed Inc [Member] Title of Individual [Axis] Dr Joseph Pergolizzi [Member] Long-Lived Tangible Asset [Axis] Solace [Member] Tools, Dies and Molds [Member] Computer Equipment [Member] Impairment of Tooling [Member] Chief Executive Officer [Member] Related Party, Type [Axis] Two Affiliate [Member] Subsequent Event Type [Axis] Subsequent Event [Member] Independent Contractor Services Agreement [Member] Affiliate [Member] Warrant [Member] Ahmet Demir Bingol [Member] Vesting [Axis] Share-Based Payment Arrangement, Tranche One [Member] Third Party [Member] Share-Based Payment Arrangement, Tranche Two [Member] Jim Holt [Member] Mr. Holt [Member] Antidilutive Securities [Axis] Options to Purchase Shares of Common Stock [Member] Warrants to Purchase Shares of Common Stock [Member] Award Type [Axis] February 14, 2021 [Member] Demir Bingol [Member] March 16, 2021 [Member] April 1, 2022 [Member] Mr Bingol [Member] Plan Name [Axis] 2021 Plan [Member] Product and Service [Axis] SOLACE Device [Member] Cover [Abstract] Document Type Amendment Flag Amendment Description Document Registration Statement Document Annual Report Document Quarterly Report Document Transition Report Document Shell Company Report Document Shell Company Event Date Document Period Start Date Document Period End Date Document Fiscal Period Focus Document Fiscal Year Focus Current Fiscal Year End Date Entity File Number Entity Registrant Name Entity Central Index Key Entity Primary SIC Number Entity Tax Identification Number Entity Incorporation, State or Country Code Entity Address, Address Line One Entity Address, Address Line Two Entity Address, Address Line Three Entity Address, City or Town Entity Address, State or Province Entity Address, Country Entity Address, Postal Zip Code Country Region City Area Code Local Phone Number Extension Written Communications Soliciting Material Pre-commencement Tender Offer Pre-commencement Issuer Tender Offer Title of 12(b) Security No Trading Symbol Flag Trading Symbol Security Exchange Name Title of 12(g) Security Security Reporting Obligation Annual Information Form Audited Annual Financial Statements Entity Well-known Seasoned Issuer Entity Voluntary Filers Entity Current Reporting Status Entity Interactive Data Current Entity Filer Category Entity Small Business Entity Emerging Growth Company Elected Not To Use the Extended Transition Period Document Accounting Standard Other Reporting Standard Item Number Entity Shell Company Entity Public Float Entity Bankruptcy Proceedings, Reporting Current Entity Common Stock, Shares Outstanding Documents Incorporated by Reference [Text Block] ICFR Auditor Attestation Flag Document Financial Statement Error Correction [Flag] Auditor Firm ID Auditor Name Auditor Location Statement of Financial Position [Abstract] ASSETS Current assets: Cash Inventory Deposits Other current assets Total current assets Property and equipment, net Total assets LIABILITIES AND STOCKHOLDERS’ (DEFICIT) EQUITY Current liabilities: Accounts payable and accrued expenses Short-term – share settlement Short-term note payable Total current liabilities Total liabilities Stockholders’(deficit) equity Preferred stock, $0.001 par value, 25,000,000 shares authorized, no shares issued and outstanding at December 31, 2023 and 2022, respectively Common stock, $0.001 par value, 750,000,000 shares authorized; 8,439,950 and 8,475,950 shares issued and outstanding at December 31, 2023 and 2022, respectively Additional paid-in-capital Accumulated deficit Total stockholders’ (deficit) equity Total liabilities and stockholders’ (deficit) equity Preferred stock, par value Preferred stock, shares authorized Preferred stock, shares issued Preferred stock, shares outstanding Common stock, par value Common stock, shares authorized Common stock, shares issued Common stock, shares outstanding Income Statement [Abstract] Net revenue Gross Profit Operating expenses: Research and development Warrants issued for services Stock based compensation - related party General and administrative Total operating expenses Loss from operations Operating (income) expenses: Settlement of dispute Impairment of assets Inventory adjustment Gain on cancellation of shares for services Other income Total other expenses Loss before income taxes Income taxes Net loss Net loss per share, basic Net loss per share, diluted Weighted average number of shares outstanding, basic Weighted average number of shares outstanding, diluted Statement [Table] Statement [Line Items] Balance Balance, shares Warrants issued to third parties in conjunction with services Stock based compensation - related party Options issued to third parties in conjunction with services Issuance of common stock for cash Issuance of common stock for cash, shares Issuance of common stock for services Issuance of common stock for services, shares Net loss Cancellation of common stock for services Cancellation of common stock for services, shares Balance Balance, shares Statement of Cash Flows [Abstract] Cash flows from operating activities: Adjustments to reconcile net loss to net cash used in operating activities: Depreciation expense Warrants issued for services EX-101.PRE 10 qlis-20231231_pre.xml XBRL PRESENTATION FILE XML 12 R1.htm IDEA: XBRL DOCUMENT

Cover - USD ($)	12 Months Ended
Cover - USD ($)	Dec. 31, 2023	Apr. 11, 2024	Jun. 30, 2023
Cover [Abstract]
Document Type	10-K
Amendment Flag	false
Document Annual Report	true
Document Transition Report	false
Document Period End Date	Dec. 31, 2023
Document Fiscal Period Focus	FY
Document Fiscal Year Focus	2023
Current Fiscal Year End Date	--12-31
Entity File Number	333-260982
Entity Registrant Name	QUALIS INNOVATIONS, INC.
Entity Central Index Key	0001871181
Entity Tax Identification Number	84-2488498
Entity Incorporation, State or Country Code	NV
Entity Address, Address Line One	6898 S. University Blvd
Entity Address, Address Line Two	Suite 100
Entity Address, City or Town	Centennial
Entity Address, State or Province	CO
Entity Address, Postal Zip Code	80122
City Area Code	(484)
Local Phone Number	483-2134
Entity Well-known Seasoned Issuer	No
Entity Voluntary Filers	No
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Non-accelerated Filer
Entity Small Business	true
Entity Emerging Growth Company	true
Elected Not To Use the Extended Transition Period	true
Entity Shell Company	false
Entity Public Float			$ 1,915,000
Entity Common Stock, Shares Outstanding		20,439,950
ICFR Auditor Attestation Flag	false
Document Financial Statement Error Correction [Flag]	false
Auditor Firm ID	6651
Auditor Name	Victor Mokuolu CPA PLLC
Auditor Location	Houston, Texas

XML 13 R2.htm IDEA: XBRL DOCUMENT

Consolidated Balance Sheets - USD ($)	Dec. 31, 2023	Dec. 31, 2022
Current assets:
Cash	$ 2,431	$ 69,858
Inventory		40,175
Deposits		54,000
Other current assets		92,170
Total current assets	2,431	256,203
Property and equipment, net		39,258
Total assets	2,431	295,461
Current liabilities:
Accounts payable and accrued expenses	16,285	40,315
Short-term – share settlement	500,000
Short-term note payable	9,102	31,192
Total current liabilities	525,387	71,507
Total liabilities	525,387	71,507
Stockholders’(deficit) equity
Preferred stock, $0.001 par value, 25,000,000 shares authorized, no shares issued and outstanding at December 31, 2023 and 2022, respectively
Common stock, $0.001 par value, 750,000,000 shares authorized; 8,439,950 and 8,475,950 shares issued and outstanding at December 31, 2023 and 2022, respectively	8,440	8,476
Additional paid-in-capital	3,898,912	3,840,765
Accumulated deficit	(4,430,308)	(3,625,287)
Total stockholders’ (deficit) equity	(522,956)	223,954
Total liabilities and stockholders’ (deficit) equity	$ 2,431	$ 295,461

XML 14 R3.htm IDEA: XBRL DOCUMENT

Consolidated Balance Sheets (Parenthetical) - $ / shares	Dec. 31, 2023	Dec. 31, 2022
Statement of Financial Position [Abstract]
Preferred stock, par value	$ 0.001	$ 0.001
Preferred stock, shares authorized	25,000,000	25,000,000
Preferred stock, shares issued	0	0
Preferred stock, shares outstanding	0	0
Common stock, par value	$ 0.001	$ 0.001
Common stock, shares authorized	750,000,000	750,000,000
Common stock, shares issued	8,439,950	8,475,950
Common stock, shares outstanding	8,439,950	8,475,950

XML 15 R4.htm IDEA: XBRL DOCUMENT

Consolidated Statements of Operations - USD ($)	12 Months Ended
Consolidated Statements of Operations - USD ($)	Dec. 31, 2023	Dec. 31, 2022
Income Statement [Abstract]
Net revenue
Gross Profit
Operating expenses:
Research and development	1,500	76,360
Warrants issued for services	30,348	342,024
Stock based compensation - related party	45,763	(94,101)
General and administrative	152,630	596,232
Total operating expenses	230,241	920,515
Loss from operations	(230,241)	(920,515)
Operating (income) expenses:
Settlement of dispute	500,000
Impairment of assets	76,008
Inventory adjustment	40,175
Gain on cancellation of shares for services	(18,000)
Other income	(23,403)
Total other expenses	574,780
Loss before income taxes	(805,021)	(920,515)
Income taxes
Net loss	$ (805,021)	$ (920,515)
Net loss per share, basic	$ (0.09)	$ (0.11)
Net loss per share, diluted	$ (0.09)	$ (0.11)
Weighted average number of shares outstanding, basic	8,475,950	8,333,660
Weighted average number of shares outstanding, diluted	8,475,950	8,333,660

XML 16 R5.htm IDEA: XBRL DOCUMENT

Consolidated Statements of Changes in Stockholders' (Deficit) Equity - USD ($)	Common Stock [Member]	Additional Paid-in Capital [Member]	Retained Earnings [Member]	Total
Balance at Dec. 31, 2021	$ 8,240	$ 3,466,947	$ (2,704,772)	$ 770,415
Balance, shares at Dec. 31, 2021	8,239,950
Warrants issued to third parties in conjunction with services		342,024		342,024
Stock based compensation - related party		(94,101)		(94,101)
Options issued to third parties in conjunction with services		8,131		8,131
Issuance of common stock for cash	$ 200	99,800		100,000
Issuance of common stock for cash, shares	200,000
Issuance of common stock for services	$ 36	17,964		18,000
Issuance of common stock for services, shares	36,000
Net loss			(920,515)	(920,515)
Balance at Dec. 31, 2022	$ 8,476	3,840,765	(3,625,287)	223,954
Balance, shares at Dec. 31, 2022	8,475,950
Warrants issued to third parties in conjunction with services		30,348		30,348
Stock based compensation - related party		45,763		45,763
Net loss			(805,021)	(805,021)
Cancellation of common stock for services	$ (36)	(17,964)		(18,000)
Cancellation of common stock for services, shares	(36,000)
Balance at Dec. 31, 2023	$ 8,440	$ 3,897,485	$ (4,430,308)	$ (522,956)
Balance, shares at Dec. 31, 2023	8,439,950

XML 17 R6.htm IDEA: XBRL DOCUMENT

Consolidated Statements of Cash Flows - USD ($)	12 Months Ended
Consolidated Statements of Cash Flows - USD ($)	Dec. 31, 2023	Dec. 31, 2022
Cash flows from operating activities:
Net loss	$ (805,021)	$ (920,515)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation expense	17,250	17,102
Impairment of assets	76,008
Warrants issued for services	30,348	342,024
Options issued for services		8,131
Stock based compensation - related parties	45,763	(94,101)
Issuance of common stock for services		18,000
Issuance of common stock in settlement of dispute	500,000
Changes in operating assets and liabilities:
Inventory	40,175	20,100
Other current assets	92,170	8,974
Accounts payable and accrued expenses	(42,030)	22,067
Short-term note payable	(31,192)	31,192
Other current liabilities		(11,400)
Net cash used in operating activities	(76,529)	(558,426)
Cash flows from investing activities:
None
Net cash used in investing activities
Cash flows from financing activities:
Advance from shareholder	9,102
Issuance of common stock for cash		100,000
Net cash provided by financing activities	9,102	100,000
Net (decrease) increase in cash	(67,427)	(458,426)
Cash at beginning of period	69,858	528,284
Cash at end of period	2,431	69,858
Supplemental disclosures of cash flow information:
Interest
Income taxes
Non-cash investing and financing activities:
Insurance policy financed by short-term note payable		$ 62,384

XML 18 R7.htm IDEA: XBRL DOCUMENT

ORGANIZATION AND PRINCIPAL ACTIVITIES

12 Months Ended

Dec. 31, 2023

Organization, Consolidation and Presentation of Financial Statements [Abstract]

ORGANIZATION AND PRINCIPAL ACTIVITIES

NOTE 1 – ORGANIZATION AND PRINCIPAL ACTIVITIES

Corporate History and Background

On June 28, 2021, the Company entered into a Share Exchange Agreement (“Exchange Agreement”) by and among mPathix Health, Inc. (formerly EMF Medical Devices, Inc., a Delaware corporation) (“mPathix”) and Qualis. The closing of the transaction (the “Closing”) took place on June 29, 2021 (the “Closing Date”). On the Closing Date, pursuant to the terms of the Exchange Agreement, the Company acquired all of the outstanding shares (the “Shares”) of mPathix. In exchange, the Company issued to the mPathix shareholder’s, their designees or assigns, an aggregate of 6,988,300 shares of Company common stock (the “Shares Component”) or 93.36% of the shares of common stock of the Company issued and outstanding after the Closing (the “Share Exchange”), at a valuation of $0.50 per share, and the Company issued warrants to purchase an additional 1,098,830 shares (698,830 warrants issued to the Company’s previous CEO and 400,000 to CreoMed which is beneficially owned by Dr. Joseph Pergolizzi, the Company’s acting CEO and chairman of the board) of the Company’s common stock, exercisable for 10 years at a $0.50 per share exercise price, subject to adjustment. In connection with the closing of the mPathix acquisition, the officers and directors of mPathix were appointed as the officers and directors of the Company. On June 29, 2021, the Company issued 496,650 common shares for the recapitalization of Qualis in conjunction with the reverse acquisition for a net book value of $0.

XML 19 R8.htm IDEA: XBRL DOCUMENT

BASIS OF PRESENTATION

12 Months Ended

Dec. 31, 2023

Accounting Policies [Abstract]

BASIS OF PRESENTATION

NOTE 2 – BASIS OF PRESENTATION

Going Concern

The accompanying consolidated financial statements have been prepared assuming the Company will continue as a going concern, which contemplates, among other things, the realization of assets and satisfaction of liabilities in the normal course of business. The Company had an accumulated deficit of $4,430,308 at December 31, 2023, had a working capital deficit of $522,956 and working capital of $184,696 at December 31, 2023 and December 31, 2022, respectively, had a net loss of $805,021 and $920,515 for years ended December 31, 2023 and 2022, respectively, and net cash used in operating activities of $76,529 and $558,426 or years ended December 31, 2023 and 2022, respectively, with no revenue earned since inception, and a lack of operational history. These matters raise substantial doubt about the Company’s ability to continue as a going concern.

The consolidated financial statements do not include any adjustments that might be necessary if the Company is unable to continue as a going concern.

XML 20 R9.htm IDEA: XBRL DOCUMENT

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

12 Months Ended

Dec. 31, 2023

Accounting Policies [Abstract]

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

NOTE 3 – SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

Use of Estimates

Cash

The Company’s cash is held in bank accounts in the United States and is insured by the Federal Deposit Insurance Corporation (FDIC) up to $250,000. The Company has not experienced any cash losses.

Related Parties

Income Taxes

Advertising and Marketing Costs

Research and Development

General and Administrative Expenses

General and administrative expenses consisted of professional service fees, and other general and administrative overhead costs. Expenses are recognized when incurred.

Inventories

Deposits

Deposits consist of amounts paid to a vendor in advance to manufacture pain treatment products. Deposits are included in current assets in the accompanying Condensed Consolidated Balance Sheets.

Property and Equipment

Impairment of Long-lived Assets

Fair Value of Financial Instruments

Fair Value Measurements

	●	Level 1 – Quoted prices in active markets for identical assets or liabilities.

	●	Level 2 – Inputs other than Level 1 that are observable, either directly or indirectly, such as quoted prices for similar assets or liabilities; quoted prices in markets that are not active; or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities.

	●	Level 3 – Unobservable inputs that are supported by little or no market activity and that are significant to the measurement of the fair value of the assets or liabilities

Basic and diluted earnings per share

Employee Stock Based Compensation

Non-Employee Stock Based Compensation

Non-Cash Equity Transactions

Concentrations, Risks, and Uncertainties

Business Risk

Substantial business risks and uncertainties are inherent to an entity, including the potential risk of business failure.

Interest rate risk

Financial assets and liabilities do not have material interest rate risk.

Credit risk

The Company is not exposed to credit risk.

Seasonality

The business is not subject to substantial seasonal fluctuations.

Major Suppliers

The Company has not entered into any contracts that obligate it to purchase a minimum quantity or exclusively from any supplier.

Recent Accounting Pronouncements

Recently issued accounting updates are not expected to have a material impact on the Company’s consolidated financial statements.

XML 21 R10.htm IDEA: XBRL DOCUMENT

PROPERTY AND EQUIPMENT

12 Months Ended

Dec. 31, 2023

Property, Plant and Equipment [Abstract]

PROPERTY AND EQUIPMENT

NOTE 4 –PROPERTY AND EQUIPMENT

Property and equipment consisted of the following as of:

SCHEDULE OF PROPERTY AND EQUIPMENT

		December 31,			December 31,
	Estimated Life	2023			2022

Tooling	5 years	$	82,530		$	82,530
Computer Equipment	3 years		1,787			1,787
Impairment of tooling			(22,008	)		-
Accumulated depreciation			(62,309	)		(45,059	)
Total		$	-		$	39,258

XML 22 R11.htm IDEA: XBRL DOCUMENT

SHORT TERM LOAN

12 Months Ended

Dec. 31, 2023

Debt Disclosure [Abstract]

SHORT TERM LOAN

NOTE 5 – SHORT TERM LOAN

XML 23 R12.htm IDEA: XBRL DOCUMENT

STOCKHOLDERS’ (DEFICIT) EQUITY

12 Months Ended

Dec. 31, 2023

Equity [Abstract]

STOCKHOLDERS’ (DEFICIT) EQUITY

NOTE 6 – STOCKHOLDERS’ (DEFICIT) EQUITY

The Company has authorized 25,000,000 preferred stock with a par value of $0.001 with no preferred shares outstanding at December 31, 2023 and December 31, 2022.

The Company has authorized 750,000,000 shares of par value $0.001 common stock, of which 8,439,950 and 8,475,950 shares are outstanding at December 31, 2023 and December 31, 2022, respectively.

Common Stock

On July 20, 2022, the Company issued 200,000 common shares to an affiliate for aggregate gross proceeds of $100,000.

Warrants

On March 29, 2022, the Board of Directors approved the granting of 400,000 warrants, with effect from April 1, 2022, convertible to the Company’s common shares with an exercise price of $1.10, valued at $290,276 (based on the Black Scholes valuation model on the date of grant), to our acting CEO and Chairman Joseph V. Pergolizzi Jr., MD through his company, CreoMed Inc with an expiration period of 10 years. These warrants were issued as compensation for the first quarter to Joseph V. Pergolizzi Jr., MD.

The following represents a summary of the warrants outstanding at December 31, 2023 and changes during the periods then ended:

SUMMARY OF WARRANTS OUTSTANDING

	Warrants			Weighted Average Exercise Price		Weighted Average Contract Life (in Years)		Aggregate Intrinsic Value *
Outstanding at January 1, 2022		1,098,830		$	0.50		8.4	$	769,181
Granted		790,000			0.82		6.7		-
Exercised		-			-		-		-
Expired/Forfeited		(398,830	)		0.50		-		(538,421	)
Outstanding at December 31, 2022		1,490,000		$	0.50		8.4	$	-
Granted		100,000			0.05		3.0		52,000
Exercised		-			-		-		-
Expired/Forfeited		-			-		-		-
Outstanding at December 31, 2023		1,590,000		$	0.77		5.5	$	101,000
Exercisable at December 31, 2023		1,590,000		$	0.77		5.5	$	101,000
Expected to be vested		1,590,000		$	0.77		5.5	$	101,000

Based on the fair value of the Company’s stock on December 31, 2023 and December 31, 2022, respectively

Options

The following represents a summary of the options outstanding at December 31, 2023 and changes during the periods then ended:

SUMMARY OF STOCK OPTIONS OUTSTANDING

	Options		Weighted Average Exercise Price		Weighted Average Contract Life (in Years)		Aggregate Intrinsic Value *
Outstanding at January 1, 2022		120,000	$	0.50		5.2	$	84,000
Granted		-		-		-		-
Exercised		-		-		-		-
Expired/Forfeited		-		-		-		-
Outstanding at December 31, 2022		120,000	$	0.50		4.2	$	-
Granted		-		-		-		-
Exercised		-		-		-		-
Expired/Forfeited		-		-		-		-
Outstanding at December 31, 2023		120,000	$	0.50		3.2	$	8,400
Exercisable at December 31, 2023		120,000	$	0.50		3.2	$	8,400
Expected to be vested		120,000	$	0.50		4.0	$	-

Based on the fair value of the Company’s stock on December 31, 2023 and 2022, respectively

- Definition

The entire disclosure for equity.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 13
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481112/505-10-50-13

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 13
-Subparagraph (h)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481112/505-10-50-13

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 14
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481112/505-10-50-14

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 235
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481062/946-235-50-2

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 235
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (d)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481062/946-235-50-2

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 505
-Name Accounting Standards Codification
-Section 50
-Paragraph 6
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481004/946-505-50-6

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Topic 815
-SubTopic 40
-Name Accounting Standards Codification
-Section 50
-Paragraph 6
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480237/815-40-50-6

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.3-04)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Topic 235
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(e)(1))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1

Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef
-Topic 505
-Name Accounting Standards Codification
-Publisher FASB
-URI https://asc.fasb.org//505/tableOfContent

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 13
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481112/505-10-50-13

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 13
-Subparagraph (g)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481112/505-10-50-13

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 13
-Subparagraph (i)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481112/505-10-50-13

Reference 14: http://www.xbrl.org/2003/role/disclosureRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 14
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481112/505-10-50-14

Reference 15: http://www.xbrl.org/2003/role/disclosureRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 14
-Subparagraph (c)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481112/505-10-50-14

Reference 16: http://www.xbrl.org/2003/role/disclosureRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 16
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481112/505-10-50-16

Reference 17: http://www.xbrl.org/2003/role/disclosureRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 18
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481112/505-10-50-18

Reference 18: http://www.xbrl.org/2003/role/disclosureRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 18
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481112/505-10-50-18

Reference 19: http://www.xbrl.org/2003/role/disclosureRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 18
-Subparagraph (d)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481112/505-10-50-18

+ Details

XML 24 R13.htm IDEA: XBRL DOCUMENT

RELATED PARTY TRANSACTIONS

12 Months Ended

Dec. 31, 2023

RELATED PARTY TRANSACTIONS

NOTE 7 – RELATED PARTY TRANSACTIONS

- Definition

The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480990/946-20-50-2

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 5
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480990/946-20-50-5

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 6
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480990/946-20-50-6

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 235
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (c)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481062/946-235-50-2

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 235
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (e)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481062/946-235-50-2

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Topic 850
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (d)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483326/850-10-50-1

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 220
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.6-07(2)(g)(3))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 220
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.6-07(2)(c))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 220
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.6-07(2)(e))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Topic 850
-Name Accounting Standards Codification
-Publisher FASB
-URI https://asc.fasb.org//850/tableOfContent

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Topic 850
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 6
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483326/850-10-50-6

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Topic 850
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483326/850-10-50-1

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Topic 850
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483326/850-10-50-1

+ Details

XML 25 R14.htm IDEA: XBRL DOCUMENT

INCOME TAXES

12 Months Ended

Dec. 31, 2023

Income Tax Disclosure [Abstract]

INCOME TAXES

NOTE 8 – INCOME TAXES

A reconciliation of the statutory income tax rates and the effective tax rate is as follows:

	Year Ended			Year Ended
	December 31, 2023			December 31, 2022

Statutory U.S. federal rate		21.0	%		21.0	%
State income tax, net of federal benefit		3.7	%		3.7	%
Permanent differences		0.0	%		0.0	%
Valuation allowance		(24.7	)%		(24.7	)%
Provision for income taxes		0.0	%		0.0	%

The tax effects of the temporary differences and carry forwards that give rise to deferred tax assets consist of the following:

SCHEDULE OF DEFERRED TAX ASSETS

	2023			2022
	December 31,
	2023			2022

Deferred tax assets:
Net operating loss carry forwards	$	617,573		$	470,354
Depreciation and amortization		253,712			249,495
Impairment of Intangible asset		63,964			35,316
Stock based compensation		157,163			138,748
Valuation allowance		(1,092,412	)		(893,912	)
Deferred tax assets, net	$	-		$	-

- Definition

The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 13
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480990/946-20-50-13

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Topic 235
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(h)(2))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Topic 740
-Name Accounting Standards Codification
-Publisher FASB
-URI https://asc.fasb.org//740/tableOfContent

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Topic 740
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 14
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482685/740-10-50-14

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Topic 740
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 21
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482685/740-10-50-21

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Topic 740
-SubTopic 270
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482526/740-270-50-1

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Topic 740
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 17
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482685/740-10-50-17

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Topic 740
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SAB TOPIC 6.I.5.Q1)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Topic 740
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 2
-Subparagraph (SAB Topic 11.C)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147479360/740-10-S99-2

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Topic 740
-SubTopic 30
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482603/740-30-50-2

+ Details

XML 26 R15.htm IDEA: XBRL DOCUMENT

EARNINGS PER SHARE

12 Months Ended

Dec. 31, 2023

Earnings Per Share [Abstract]

EARNINGS PER SHARE

NOTE 9 – EARNINGS PER SHARE

FASB ASC Topic 260, Earnings Per Share, requires a reconciliation of the numerator and denominator of the basic and diluted earnings (loss) per share (EPS) computations.

	2023		2022
	For the Years Ended December 31,
	2023		2022
Options to purchase shares of common stock		120,000		120,000
Warrants to purchase shares of common stock granted on February 14, 2021 to CreoMed, Inc.*		400,000		400,000
Warrants to purchase shares of common stock granted on March 16, 2021 to Demir Bingol*		300,000		300,000
Warrants to purchase shares of common stock granted on April 1, 2022 to CreoMed, Inc.		400,000		400,000
Warrants to purchase shares of common stock		490,000		390,000
Total potentially dilutive shares		1,710,000		1,610,000

*	The Company has cancelled and regranted these warrants to purchase 1,098,830 shares (698,830 warrants issued to the Ahmet Demir Bingol and 400,000 to CreoMed Inc.) of the Company’s common stock on June 29, 2021 in conjunction with the share exchange agreement.

The following table sets forth the computation of basic and diluted net income per share:

	2023			2022
	For the Years Ended December 31,
	2023			2022
Net loss attributable to the common stockholders	$	(805,021	)	$	(920,515	)

Basic weighted average outstanding shares of common stock		8,475,950			8,333,660
Dilutive effect of options and warrants		-			-
Diluted weighted average common stock and common stock equivalents		8,475,950			8,333,660

Loss per share:
Basic and diluted	$	(0.09	)	$	(0.11	)

XML 27 R16.htm IDEA: XBRL DOCUMENT

COMMITMENTS AND CONTINGENCIES

12 Months Ended

Dec. 31, 2023

Commitments and Contingencies Disclosure [Abstract]

COMMITMENTS AND CONTINGENCIES

NOTE 10 – COMMITMENTS AND CONTINGENCIES

Legal

2021 Equity Incentive Plan

Employment Agreement

Consulting Agreement

On January 27, 2022 the Company hired an engineering consultant to assist in completing the design history file, updating new software, system design, pre 510(k) preparation, and testing of the SOLACE device. This work is expected to be completed by the end of September 2022 and the cost of the contract is $77,850.

XML 28 R17.htm IDEA: XBRL DOCUMENT

SUBSEQUENT EVENTS

12 Months Ended

Dec. 31, 2023

Subsequent Events [Abstract]

SUBSEQUENT EVENTS

NOTE 11 – SUBSEQUENT EVENTS

In January 2024, the Company issued 2,000,000 common shares to two (2) affiliates for aggregate gross proceeds of $100,000.

XML 29 R18.htm IDEA: XBRL DOCUMENT

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)

12 Months Ended

Dec. 31, 2023

Accounting Policies [Abstract]

Use of Estimates

Use of Estimates

Cash

Cash

The Company’s cash is held in bank accounts in the United States and is insured by the Federal Deposit Insurance Corporation (FDIC) up to $250,000. The Company has not experienced any cash losses.

Related Parties

Related Parties

Income Taxes

Income Taxes

Advertising and Marketing Costs

Advertising and Marketing Costs

Research and Development

Research and Development

General and Administrative Expenses

General and Administrative Expenses

General and administrative expenses consisted of professional service fees, and other general and administrative overhead costs. Expenses are recognized when incurred.

Inventories

Inventories

Deposits

Deposits

Deposits consist of amounts paid to a vendor in advance to manufacture pain treatment products. Deposits are included in current assets in the accompanying Condensed Consolidated Balance Sheets.

Property and Equipment

Property and Equipment

Impairment of Long-lived Assets

Impairment of Long-lived Assets

Fair Value of Financial Instruments

Fair Value of Financial Instruments

Fair Value Measurements

Fair Value Measurements

	●	Level 1 – Quoted prices in active markets for identical assets or liabilities.

	●	Level 2 – Inputs other than Level 1 that are observable, either directly or indirectly, such as quoted prices for similar assets or liabilities; quoted prices in markets that are not active; or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities.

	●	Level 3 – Unobservable inputs that are supported by little or no market activity and that are significant to the measurement of the fair value of the assets or liabilities

Basic and diluted earnings per share

Basic and diluted earnings per share

Employee Stock Based Compensation

Employee Stock Based Compensation

Non-Employee Stock Based Compensation

Non-Employee Stock Based Compensation

Non-Cash Equity Transactions

Non-Cash Equity Transactions

Concentrations, Risks, and Uncertainties

Concentrations, Risks, and Uncertainties

Business Risk

Substantial business risks and uncertainties are inherent to an entity, including the potential risk of business failure.

Interest rate risk

Financial assets and liabilities do not have material interest rate risk.

Credit risk

The Company is not exposed to credit risk.

Seasonality

The business is not subject to substantial seasonal fluctuations.

Major Suppliers

The Company has not entered into any contracts that obligate it to purchase a minimum quantity or exclusively from any supplier.

Recent Accounting Pronouncements

Recent Accounting Pronouncements

Recently issued accounting updates are not expected to have a material impact on the Company’s consolidated financial statements.

XML 30 R19.htm IDEA: XBRL DOCUMENT

PROPERTY AND EQUIPMENT (Tables)

12 Months Ended

Dec. 31, 2023

Property, Plant and Equipment [Abstract]

SCHEDULE OF PROPERTY AND EQUIPMENT

Property and equipment consisted of the following as of:

SCHEDULE OF PROPERTY AND EQUIPMENT

		December 31,			December 31,
	Estimated Life	2023			2022

Tooling	5 years	$	82,530		$	82,530
Computer Equipment	3 years		1,787			1,787
Impairment of tooling			(22,008	)		-
Accumulated depreciation			(62,309	)		(45,059	)
Total		$	-		$	39,258

XML 31 R20.htm IDEA: XBRL DOCUMENT

STOCKHOLDERS’ (DEFICIT) EQUITY (Tables)

12 Months Ended

Dec. 31, 2023

Equity [Abstract]

SUMMARY OF WARRANTS OUTSTANDING

The following represents a summary of the warrants outstanding at December 31, 2023 and changes during the periods then ended:

SUMMARY OF WARRANTS OUTSTANDING

	Warrants			Weighted Average Exercise Price		Weighted Average Contract Life (in Years)		Aggregate Intrinsic Value *
Outstanding at January 1, 2022		1,098,830		$	0.50		8.4	$	769,181
Granted		790,000			0.82		6.7		-
Exercised		-			-		-		-
Expired/Forfeited		(398,830	)		0.50		-		(538,421	)
Outstanding at December 31, 2022		1,490,000		$	0.50		8.4	$	-
Granted		100,000			0.05		3.0		52,000
Exercised		-			-		-		-
Expired/Forfeited		-			-		-		-
Outstanding at December 31, 2023		1,590,000		$	0.77		5.5	$	101,000
Exercisable at December 31, 2023		1,590,000		$	0.77		5.5	$	101,000
Expected to be vested		1,590,000		$	0.77		5.5	$	101,000

Based on the fair value of the Company’s stock on December 31, 2023 and December 31, 2022, respectively

SUMMARY OF STOCK OPTIONS OUTSTANDING

The following represents a summary of the options outstanding at December 31, 2023 and changes during the periods then ended:

SUMMARY OF STOCK OPTIONS OUTSTANDING

	Options		Weighted Average Exercise Price		Weighted Average Contract Life (in Years)		Aggregate Intrinsic Value *
Outstanding at January 1, 2022		120,000	$	0.50		5.2	$	84,000
Granted		-		-		-		-
Exercised		-		-		-		-
Expired/Forfeited		-		-		-		-
Outstanding at December 31, 2022		120,000	$	0.50		4.2	$	-
Granted		-		-		-		-
Exercised		-		-		-		-
Expired/Forfeited		-		-		-		-
Outstanding at December 31, 2023		120,000	$	0.50		3.2	$	8,400
Exercisable at December 31, 2023		120,000	$	0.50		3.2	$	8,400
Expected to be vested		120,000	$	0.50		4.0	$	-

Based on the fair value of the Company’s stock on December 31, 2023 and 2022, respectively

XML 32 R21.htm IDEA: XBRL DOCUMENT

INCOME TAXES (Tables)

12 Months Ended

Dec. 31, 2023

Income Tax Disclosure [Abstract]

SCHEDULE OF RECONCILIATION OF STATUTORY INCOME TAX RATES

A reconciliation of the statutory income tax rates and the effective tax rate is as follows:

	Year Ended			Year Ended
	December 31, 2023			December 31, 2022

Statutory U.S. federal rate		21.0	%		21.0	%
State income tax, net of federal benefit		3.7	%		3.7	%
Permanent differences		0.0	%		0.0	%
Valuation allowance		(24.7	)%		(24.7	)%
Provision for income taxes		0.0	%		0.0	%

SCHEDULE OF DEFERRED TAX ASSETS

The tax effects of the temporary differences and carry forwards that give rise to deferred tax assets consist of the following:

SCHEDULE OF DEFERRED TAX ASSETS

	2023			2022
	December 31,
	2023			2022

Deferred tax assets:
Net operating loss carry forwards	$	617,573		$	470,354
Depreciation and amortization		253,712			249,495
Impairment of Intangible asset		63,964			35,316
Stock based compensation		157,163			138,748
Valuation allowance		(1,092,412	)		(893,912	)
Deferred tax assets, net	$	-		$	-

XML 33 R22.htm IDEA: XBRL DOCUMENT

EARNINGS PER SHARE (Tables)

12 Months Ended

Dec. 31, 2023

Earnings Per Share [Abstract]

SCHEDULE OF POTENTIALLY DILUTIVE SECURITIES WERE EXCLUDED FROM CALCULATION OF DILUTED NET LOSS PER SHARE

	2023		2022
	For the Years Ended December 31,
	2023		2022
Options to purchase shares of common stock		120,000		120,000
Warrants to purchase shares of common stock granted on February 14, 2021 to CreoMed, Inc.*		400,000		400,000
Warrants to purchase shares of common stock granted on March 16, 2021 to Demir Bingol*		300,000		300,000
Warrants to purchase shares of common stock granted on April 1, 2022 to CreoMed, Inc.		400,000		400,000
Warrants to purchase shares of common stock		490,000		390,000
Total potentially dilutive shares		1,710,000		1,610,000

*	The Company has cancelled and regranted these warrants to purchase 1,098,830 shares (698,830 warrants issued to the Ahmet Demir Bingol and 400,000 to CreoMed Inc.) of the Company’s common stock on June 29, 2021 in conjunction with the share exchange agreement.

SCHEDULE OF COMPUTATION OF BASIC AND DILUTED NET INCOME PER SHARE

The following table sets forth the computation of basic and diluted net income per share:

	2023			2022
	For the Years Ended December 31,
	2023			2022
Net loss attributable to the common stockholders	$	(805,021	)	$	(920,515	)

Basic weighted average outstanding shares of common stock		8,475,950			8,333,660
Dilutive effect of options and warrants		-			-
Diluted weighted average common stock and common stock equivalents		8,475,950			8,333,660

Loss per share:
Basic and diluted	$	(0.09	)	$	(0.11	)

XML 34 R23.htm IDEA: XBRL DOCUMENT

ORGANIZATION AND PRINCIPAL ACTIVITIES (Details Narrative) - USD ($)	Jun. 29, 2021	Feb. 13, 2018	May 05, 2011	Dec. 31, 2023	Dec. 31, 2022
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Reverse stock split		1 – 1,000 reverse split
Common stock, outstanding				8,439,950	8,475,950
Parent [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Common stock, outstanding		396,650
Echo Resources LLLP [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Common stock, outstanding		232,689
Donxon [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Equity ownership percentage			100.00%
Dasen [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Equity ownership percentage			100.00%
FDSC [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Equity ownership percentage			70.00%
XKT [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Equity ownership percentage			100.00%
Share Exchange Agreement [Member] \| FDH [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Stock issued during period, shares			23,716,035
Equity ownership percentage			97.56%
Share price			$ 0.20
Share Exchange Agreement [Member] \| MPathix [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Stock issued during period, shares	6,988,300
Equity ownership percentage	93.36%
Share price	$ 0.50
Warrants to purchase shares	1,098,830
Warrants issued	698,830
Warrants term	10 years
Warrants exercise price	$ 0.50
Recapitalization of qualis in conjunction with reverse acquisition, shares	496,650
Recapitalization of qualis in conjunction with reverse acquisition	$ 0
Recapitalization of qualis in conjunction with reverse acquisition, rate	10.00%
Share Exchange Agreement [Member] \| MPathix [Member] \| CreoMed Inc [Member] \| Dr Joseph Pergolizzi [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Warrants issued	400,000

XML 35 R24.htm IDEA: XBRL DOCUMENT

BASIS OF PRESENTATION (Details Narrative) - USD ($)	12 Months Ended
BASIS OF PRESENTATION (Details Narrative) - USD ($)	Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2021
Accounting Policies [Abstract]
Accumulated deficit	$ 4,430,308	$ 3,625,287
Working capital deficit	522,956	(223,954)	$ (770,415)
Working capital	184,696	184,696
Net loss	805,021	920,515
Net cash used in operating activities	$ 76,529	$ 558,426

- Definition

The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 235
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(g)(1)(ii))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Topic 323
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 3
-Subparagraph (c)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481687/323-10-50-3

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Topic 825
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 28
-Subparagraph (f)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482907/825-10-50-28

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Topic 220
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 6
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482765/220-10-50-6

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 3
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483443/250-10-50-3

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (b)(2)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483443/250-10-50-1

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Topic 815
-SubTopic 40
-Name Accounting Standards Codification
-Section 65
-Paragraph 1
-Subparagraph (f)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480175/815-40-65-1

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 8
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483443/250-10-50-8

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 9
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483443/250-10-50-9

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 11
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483443/250-10-50-11

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 11
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483443/250-10-50-11

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 4
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483443/250-10-50-4

Reference 13: http://www.xbrl.org/2003/role/exampleRef
-Topic 946
-SubTopic 830
-Name Accounting Standards Codification
-Section 55
-Paragraph 10
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480167/946-830-55-10

Reference 14: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 220
-Name Accounting Standards Codification
-Section 45
-Paragraph 7
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483581/946-220-45-7

Reference 15: http://www.xbrl.org/2003/role/disclosureRef
-Topic 944
-SubTopic 220
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-04(18))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1

Reference 16: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 22
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482810/280-10-50-22

Reference 17: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 220
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.6-07(9))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1

Reference 18: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 220
-Name Accounting Standards Codification
-Section S99
-Paragraph 3
-Subparagraph (SX 210.6-09(1)(d))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3

Reference 19: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(i))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A

Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(ii))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A

Reference 21: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(iii)(A))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A

Reference 22: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(iv))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A

Reference 23: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(5))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A

Reference 24: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(i))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B

Reference 25: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(iii)(A))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B

Reference 26: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(iii)(B))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B

Reference 27: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(iv))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B

Reference 28: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(5))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B

Reference 29: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 30
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482810/280-10-50-30

Reference 30: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 32
-Subparagraph (f)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482810/280-10-50-32

Reference 31: http://www.xbrl.org/2003/role/disclosureRef
-Topic 260
-SubTopic 10
-Name Accounting Standards Codification
-Section 45
-Paragraph 60B
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B

Reference 32: http://www.xbrl.org/2003/role/exampleRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 31
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482810/280-10-50-31

Reference 33: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 32
-Subparagraph (c)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482810/280-10-50-32

Reference 34: http://www.xbrl.org/2003/role/disclosureRef
-Topic 205
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 7
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483499/205-20-50-7

Reference 35: http://fasb.org/us-gaap/role/ref/legacyRef
-Topic 230
-SubTopic 10
-Name Accounting Standards Codification
-Section 45
-Paragraph 28
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482740/230-10-45-28

Reference 36: http://www.xbrl.org/2003/role/disclosureRef
-Topic 220
-SubTopic 10
-Name Accounting Standards Codification
-Section 45
-Paragraph 1A
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482790/220-10-45-1A

Reference 37: http://www.xbrl.org/2003/role/disclosureRef
-Topic 220
-SubTopic 10
-Name Accounting Standards Codification
-Section 45
-Paragraph 1B
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482790/220-10-45-1B

Reference 38: http://fasb.org/us-gaap/role/ref/legacyRef
-Topic 220
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03(20))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2

Reference 39: http://fasb.org/us-gaap/role/ref/legacyRef
-Topic 942
-SubTopic 220
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-04(22))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1

+ Details

- Definition

Amount of accumulated undistributed earnings (deficit).

+ References + Details

- Definition

Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest.

+ References

Reference 1: http://www.xbrl.org/2003/role/exampleRef
-Topic 852
-SubTopic 10
-Name Accounting Standards Codification
-Section 55
-Paragraph 10
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481372/852-10-55-10

Reference 2: http://www.xbrl.org/2003/role/exampleRef
-Topic 946
-SubTopic 830
-Name Accounting Standards Codification
-Section 55
-Paragraph 12
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480167/946-830-55-12

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 210
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.6-04(19))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 210
-Name Accounting Standards Codification
-Section S99
-Paragraph 2
-Subparagraph (SX 210.6-05(4))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147479617/946-210-S99-2

Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 946
-SubTopic 220
-Name Accounting Standards Codification
-Section S99
-Paragraph 3
-Subparagraph (SX 210.6-09(4)(b))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 220
-Name Accounting Standards Codification
-Section S99
-Paragraph 3
-Subparagraph (SX 210.6-09(6))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 220
-Name Accounting Standards Codification
-Section S99
-Paragraph 3
-Subparagraph (SX 210.6-09(7))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3

Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 235
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(g)(1)(ii))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1

Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 323
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 3
-Subparagraph (c)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481687/323-10-50-3

Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 825
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 28
-Subparagraph (f)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482907/825-10-50-28

Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef
-Topic 210
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(29))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1

Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef
-Topic 210
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(31))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1

Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef
-Topic 210
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(30))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1

Reference 14: http://fasb.org/us-gaap/role/ref/legacyRef
-Topic 310
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 2
-Subparagraph (SAB Topic 4.E)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480418/310-10-S99-2

+ Details

XML 36 R25.htm IDEA: XBRL DOCUMENT

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details Narrative) - USD ($)	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022
Property, Plant and Equipment [Line Items]
Accrued expenses	$ 41,403
Accounts payable	23,403
Additional paid in capital	18,000
FDIC cash	250,000
Advertising and marketing expense	$ 0	$ 0
Estimated useful lives	5 years
Impairment of assets	$ 76,008
Antidilutive securities excluded from computation of earnings per share, amount	1,710,000	1,610,000
Solace [Member]
Property, Plant and Equipment [Line Items]
Impairment of assets	$ 0
Common Stock [Member]
Property, Plant and Equipment [Line Items]
Additional paid in capital	$ 36
Number of cancellation of common shares	36,000
Additional Paid-in Capital [Member]
Property, Plant and Equipment [Line Items]
Additional paid in capital	$ 17,964

XML 37 R26.htm IDEA: XBRL DOCUMENT

SCHEDULE OF PROPERTY AND EQUIPMENT (Details) - USD ($)	Dec. 31, 2023	Dec. 31, 2022
Property, Plant and Equipment [Line Items]
Estimated Life	5 years
Accumulated depreciation	$ (62,309)	$ (45,059)
Property and equipment, net		39,258
Tools, Dies and Molds [Member]
Property, Plant and Equipment [Line Items]
Estimated Life	5 years
Property and equipment, gross	$ 82,530	82,530
Computer Equipment [Member]
Property, Plant and Equipment [Line Items]
Estimated Life	3 years
Property and equipment, gross	$ 1,787	1,787
Impairment of Tooling [Member]
Property, Plant and Equipment [Line Items]
Property and equipment, gross	$ 22,008

XML 38 R27.htm IDEA: XBRL DOCUMENT

PROPERTY AND EQUIPMENT (Details Narrative) - USD ($)	12 Months Ended
PROPERTY AND EQUIPMENT (Details Narrative) - USD ($)	Dec. 31, 2023	Dec. 31, 2022
Property, Plant and Equipment [Abstract]
Depreciation expense	$ 17,250	$ 17,102

XML 39 R28.htm IDEA: XBRL DOCUMENT

SHORT TERM LOAN (Details Narrative) - Chief Executive Officer [Member] - USD ($)	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022
Deferred Compensation Arrangement with Individual, Excluding Share-Based Payments and Postretirement Benefits [Line Items]
Principal balance due	$ 9,102	$ 0
Short term loan	9,102	0
Repayments debt	$ 0	$ 0
Interest percentage	10.00%

XML 40 R29.htm IDEA: XBRL DOCUMENT

SUMMARY OF WARRANTS OUTSTANDING (Details) - USD ($)

12 Months Ended

Dec. 31, 2023

Dec. 31, 2022

Accumulated Other Comprehensive Income (Loss) [Line Items]

Weighted Average Exercise Price Outstanding, Beginning balance

$ 0.50

Options, Weighted Average Contractual Term (in Years), Outstanding

3 years 2 months 12 days

Weighted Average Exercise Price, Granted

Weighted Average Exercise Price, Exercised

Weighted Average Exercise Price, Expired/Forfeited

Average Intrinsic Value, Expired/Forfeited

^[1]

$ (538,421)

Options, Weighted Average Contractual Term (in Years), Outstanding

3 years 2 months 12 days

Weighted Average Exercise Price Outstanding, Ending balance

$ 0.50

Warrant [Member]

Accumulated Other Comprehensive Income (Loss) [Line Items]

Warrants Outstanding, Beginning balance

1,490,000

1,098,830

Weighted Average Exercise Price Outstanding, Beginning balance

$ 0.50

Options, Weighted Average Contractual Term (in Years), Outstanding

8 years 4 months 24 days

Aggregate Intrinsic Value, Beginning balance

^[1]

$ 769,181

Warrants, Granted

100,000

790,000

Weighted Average Exercise Price, Granted

$ 0.05

$ 0.82

Weighted Average Contractual Term (in Years), Granted

3 years

6 years 8 months 12 days

Aggregate Intrinsic Value, Granted

^[1]

$ 52,000

Warrants, Exercised

Weighted Average Exercise Price, Exercised

Aggregate Intrinsic Value, Exercised

^[1]

Warrants, Expired/Forfeited

(398,830)

Weighted Average Exercise Price, Expired/Forfeited

$ 0.50

Average Intrinsic Value, Expired/Forfeited

^[1]

Options, Weighted Average Contractual Term (in Years), Outstanding

8 years 4 months 24 days

Warrants Outstanding, Ending balance

1,590,000

1,490,000

Weighted Average Exercise Price Outstanding, Ending balance

$ 0.77

$ 0.50

Weighted Average Contractual Term (in Years), Outstanding

5 years 6 months

Aggregate Intrinsic Value, Ending balance

^[1]

$ 101,000

Warrants, Exercisable

1,590,000

Weighted Average Exercise Price Outstanding, Exercisable

$ 0.77

Weighted Average Contractual Term (in Years), Exercisable

5 years 6 months

Average Intrinsic Value, Exercisable

^[1]

$ 101,000

Warrants, Expected to be vested

1,590,000

Weighted Average Exercise Price Outstanding, Expected to be vested

$ 0.77

Weighted Average Contractual Term (in Years), Expected to be vested

5 years 6 months

Average Intrinsic Value, Expected to be vested

^[1]

$ 101,000

[1]	Based on the fair value of the Company’s stock on December 31, 2023 and December 31, 2022, respectively

XML 41 R30.htm IDEA: XBRL DOCUMENT

SUMMARY OF STOCK OPTIONS OUTSTANDING (Details) - USD ($)

12 Months Ended

Dec. 31, 2023

Dec. 31, 2022

Equity [Abstract]

Options outstanding, Beginning balance

120,000

Weighted Average Exercise Price Outstanding, Beginning balance

$ 0.50

Options, Weighted Average Contractual Term (in Years), Granted

4 years 2 months 12 days

5 years 2 months 12 days

Options, Aggregate Intrinsic Value, Beginning balance

^[1]

$ 84,000

Options, Granted

Options, Weighted Average Exercise Price, Granted

Options, Aggregate Intrinsic Value, Granted

^[1]

Options, Exercised

Options, Weighted Average Exercise Price, Exercised

Options, Expired/Forfeited

Options, Weighted Average Exercise Price, Expired/Forfeited

Options outstanding, Ending balance

120,000

Weighted Average Exercise Price Outstanding, Ending balance

$ 0.50

Options, Weighted Average Contractual Term (in Years), Outstanding

3 years 2 months 12 days

Options, Aggregate Intrinsic Value, Ending balance

^[1]

$ 8,400

Options, Exercisable

120,000

Options, Weighted Average Exercise Price, Exercisable

$ 0.50

Options, Weighted Average Contractual Term (in Years), Exercisable

3 years 2 months 12 days

Options, Aggregate Intrinsic Value, Exercisable

^[1]

$ 8,400

Options, Expected to be vested

120,000

Options, Weighted Average Exercise Price, Expected to be vested

$ 0.50

Weighted Average Contractual Term (in Years), Expected to be vested

4 years

Options, Aggregate Intrinsic Value, Expected to be vested

^[1]

[1]	Based on the fair value of the Company’s stock on December 31, 2023 and 2022, respectively

XML 42 R31.htm IDEA: XBRL DOCUMENT

STOCKHOLDERS’ (DEFICIT) EQUITY (Details Narrative) - USD ($)											1 Months Ended	12 Months Ended
	Dec. 13, 2023	Apr. 03, 2023	Oct. 03, 2022	Sep. 01, 2022	Aug. 01, 2022	Jul. 20, 2022	Apr. 15, 2022	Mar. 29, 2022	Feb. 01, 2022	Mar. 16, 2021	Jan. 31, 2024	Dec. 31, 2023	Dec. 31, 2022
Accumulated Other Comprehensive Income (Loss) [Line Items]
Preferred stock, shares authorized												25,000,000	25,000,000
Preferred stock, par value												$ 0.001	$ 0.001
Preferred stock, shares outstanding												0	0
Common stock, shares authorized												750,000,000	750,000,000
Common stock, par value												$ 0.001	$ 0.001
Common stock, shares outstanding												8,439,950	8,475,950
Aggregate gross proceeds													$ 100,000
Number of common stock for services, value													18,000
Value of warrants granted												$ 500,000
Common Stock [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Number of shares issued													200,000
Aggregate gross proceeds													$ 200
Number of common stock for services													36,000
Number of common stock for services, value													$ 36
Warrant [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Warrants granted												100,000	790,000
Warrant [Member] \| Ahmet Demir Bingol [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Warrants granted										698,830
Number of common stock for purchase										698,830
Value of warrants granted										$ 165,378
Warrants term										10 years
Warrants exercise price										$ 0.50
Unvested warrants expired							398,830
Warrants modification expense													$ 94,101
Warrant [Member] \| Ahmet Demir Bingol [Member] \| Share-Based Payment Arrangement, Tranche One [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Warrants granted							300,000
Warrant [Member] \| Third Party [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Warrants granted									30,000
Number of common stock for purchase									30,000
Value of warrants granted									$ 13,547
Warrants term									3 years
Warrants exercise price									$ 1.00
Warrant [Member] \| Dr Joseph Pergolizzi [Member] \| CreoMed Inc [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Warrants granted								400,000
Value of warrants granted								$ 290,276
Warrants term								10 years
Warrants exercise price								$ 1.10
Two Affiliate [Member] \| Subsequent Event [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Number of shares issued											2,000,000
Aggregate gross proceeds											$ 100,000
Two Affiliate [Member] \| Subsequent Event [Member] \| Common Stock [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Number of shares issued											10,000,000
Aggregate gross proceeds											$ 500,000
Independent Contractor Services Agreement [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Consulting fee			$ 6,000									$ 0
Number of common stock for services			36,000
Number of common stock for services, value			$ 18,000
Number of shares cancelled												36,000
Affiliate [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Number of shares issued						200,000
Aggregate gross proceeds						$ 100,000
Third Party [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Warrants granted				300,000	60,000
Number of common stock for purchase				300,000	60,000
Value of options granted				$ 60,916	$ 7,632
Options exercisable period				four years	three years
Share exercise price				$ 1.10	$ 1.10
Third Party [Member] \| Share-Based Payment Arrangement, Tranche One [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Vesting percentage				50.00%
Third Party [Member] \| Share-Based Payment Arrangement, Tranche Two [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Vesting percentage				50.00%
Jim Holt [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Warrants granted		3,333,333
Number of common stock for purchase		3,333,333
Warrants exercise price		$ 0.03
Value of options granted		$ 1,597,635
Warrants exercisable period		seven years
Mr. Holt [Member] \| Warrant [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Warrants exercise price	$ 0.03
Warrants exercisable period	three years
Number of warrants	100,000
Warrants, value	$ 45,763
Number of warrants cancelled	3,233,333

XML 43 R32.htm IDEA: XBRL DOCUMENT

SCHEDULE OF RECONCILIATION OF STATUTORY INCOME TAX RATES (Details)	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022
Income Tax Disclosure [Abstract]
Statutory U.S. federal rate	21.00%	21.00%
State income tax, net of federal benefit	3.70%	3.70%
Permanent differences	0.00%	0.00%
Valuation allowance	(24.70%)	(24.70%)
Provision for income taxes	0.00%	0.00%

XML 44 R33.htm IDEA: XBRL DOCUMENT

SCHEDULE OF DEFERRED TAX ASSETS (Details) - USD ($)	Dec. 31, 2023	Dec. 31, 2022
Deferred tax assets:
Net operating loss carry forwards	$ 617,573	$ 470,354
Depreciation and amortization	253,712	249,495
Impairment of Intangible asset	63,964	35,316
Stock based compensation	157,163	138,748
Valuation allowance	(1,092,412)	(893,912)
Deferred tax assets, net

XML 45 R34.htm IDEA: XBRL DOCUMENT

INCOME TAXES (Details Narrative)	12 Months Ended
INCOME TAXES (Details Narrative)	Dec. 31, 2023 USD ($)
Income Tax Disclosure [Abstract]
Net operating loss carry forwards	$ 617,000
Carryforwards limited description	Tax Cuts and Jobs Act of 2018, allows for an indefinite carryforward period, with carryforwards limited to 80% of each subsequent year’s net income

XML 46 R35.htm IDEA: XBRL DOCUMENT

SCHEDULE OF POTENTIALLY DILUTIVE SECURITIES WERE EXCLUDED FROM CALCULATION OF DILUTED NET LOSS PER SHARE (Details) - shares

12 Months Ended

Dec. 31, 2023

Dec. 31, 2022

Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]

Total potentially dilutive shares

1,710,000

1,610,000

Options to Purchase Shares of Common Stock [Member]

Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]

Total potentially dilutive shares

120,000

Warrants to Purchase Shares of Common Stock [Member]

Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]

Total potentially dilutive shares

490,000

390,000

Warrants to Purchase Shares of Common Stock [Member] | CreoMed Inc [Member] | February 14, 2021 [Member]

Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]

Total potentially dilutive shares

^[1]

400,000

Warrants to Purchase Shares of Common Stock [Member] | CreoMed Inc [Member] | April 1, 2022 [Member]

Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]

Total potentially dilutive shares

400,000

Warrants to Purchase Shares of Common Stock [Member] | Demir Bingol [Member] | March 16, 2021 [Member]

Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]

Total potentially dilutive shares

^[1]

300,000

[1]	The Company has cancelled and regranted these warrants to purchase 1,098,830 shares (698,830 warrants issued to the Ahmet Demir Bingol and 400,000 to CreoMed Inc.) of the Company’s common stock on June 29, 2021 in conjunction with the share exchange agreement.

XML 47 R36.htm IDEA: XBRL DOCUMENT

SCHEDULE OF POTENTIALLY DILUTIVE SECURITIES WERE EXCLUDED FROM CALCULATION OF DILUTED NET LOSS PER SHARE (Details) (Parenthetical) - Share Exchange Agreement [Member] - Warrant [Member]	Jun. 29, 2021 shares
Warrants to purchase shares	1,098,830
CreoMed Inc [Member]
Warrants to purchase shares	400,000
Mr Bingol [Member]
Warrants to purchase shares	698,830

XML 48 R37.htm IDEA: XBRL DOCUMENT

SCHEDULE OF COMPUTATION OF BASIC AND DILUTED NET INCOME PER SHARE (Details) - USD ($)	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022
Earnings Per Share [Abstract]
Net loss attributable to the common stockholders	$ (805,021)	$ (920,515)
Basic weighted average outstanding shares of common stock	8,475,950	8,333,660
Dilutive effect of options and warrants
Diluted weighted average common stock and common stock equivalents	8,475,950	8,333,660
Loss per share basic	$ (0.09)	$ (0.11)
Loss per share diluted	$ (0.09)	$ (0.11)

- Definition

The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 3
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483443/250-10-50-3

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Topic 260
-SubTopic 10
-Name Accounting Standards Codification
-Section 55
-Paragraph 15
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482635/260-10-55-15

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Topic 815
-SubTopic 40
-Name Accounting Standards Codification
-Section 65
-Paragraph 1
-Subparagraph (e)(4)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480175/815-40-65-1

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Topic 815
-SubTopic 40
-Name Accounting Standards Codification
-Section 65
-Paragraph 1
-Subparagraph (f)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480175/815-40-65-1

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 11
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483443/250-10-50-11

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 11
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483443/250-10-50-11

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 7
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483443/250-10-50-7

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Topic 260
-SubTopic 10
-Name Accounting Standards Codification
-Section 45
-Paragraph 2
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482689/260-10-45-2

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Topic 260
-SubTopic 10
-Name Accounting Standards Codification
-Section 45
-Paragraph 60B
-Subparagraph (d)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 4
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483443/250-10-50-4

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Topic 260
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482662/260-10-50-1

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Topic 260
-SubTopic 10
-Name Accounting Standards Codification
-Section 45
-Paragraph 10
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482689/260-10-45-10

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Topic 220
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03(25))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2

Reference 14: http://www.xbrl.org/2003/role/disclosureRef
-Topic 942
-SubTopic 220
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-04(27))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1

Reference 15: http://www.xbrl.org/2003/role/disclosureRef
-Topic 944
-SubTopic 220
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-04(23))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1

Reference 16: http://www.xbrl.org/2003/role/exampleRef
-Topic 260
-SubTopic 10
-Name Accounting Standards Codification
-Section 55
-Paragraph 52
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482635/260-10-55-52

Reference 17: http://www.xbrl.org/2003/role/disclosureRef
-Topic 260
-SubTopic 10
-Name Accounting Standards Codification
-Section 45
-Paragraph 7
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482689/260-10-45-7

+ Details

- Definition

The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 3
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483443/250-10-50-3

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Topic 260
-SubTopic 10
-Name Accounting Standards Codification
-Section 55
-Paragraph 15
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482635/260-10-55-15

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Topic 815
-SubTopic 40
-Name Accounting Standards Codification
-Section 65
-Paragraph 1
-Subparagraph (e)(4)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480175/815-40-65-1

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Topic 815
-SubTopic 40
-Name Accounting Standards Codification
-Section 65
-Paragraph 1
-Subparagraph (f)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480175/815-40-65-1

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 11
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483443/250-10-50-11

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 11
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483443/250-10-50-11

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 7
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483443/250-10-50-7

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Topic 260
-SubTopic 10
-Name Accounting Standards Codification
-Section 45
-Paragraph 2
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482689/260-10-45-2

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Topic 260
-SubTopic 10
-Name Accounting Standards Codification
-Section 45
-Paragraph 60B
-Subparagraph (d)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 4
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483443/250-10-50-4

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Topic 260
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482662/260-10-50-1

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Topic 220
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03(25))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Topic 942
-SubTopic 220
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-04(27))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1

Reference 14: http://www.xbrl.org/2003/role/disclosureRef
-Topic 944
-SubTopic 220
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-04(23))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1

Reference 15: http://www.xbrl.org/2003/role/exampleRef
-Topic 260
-SubTopic 10
-Name Accounting Standards Codification
-Section 55
-Paragraph 52
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482635/260-10-55-52

Reference 16: http://www.xbrl.org/2003/role/disclosureRef
-Topic 260
-SubTopic 10
-Name Accounting Standards Codification
-Section 45
-Paragraph 7
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482689/260-10-45-7

+ Details

- Definition

The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.

+ References

+ Details

XML 49 R38.htm IDEA: XBRL DOCUMENT

COMMITMENTS AND CONTINGENCIES (Details Narrative) - USD ($)				12 Months Ended
	Oct. 03, 2022	Apr. 15, 2022	Mar. 16, 2021	Dec. 31, 2023	Dec. 31, 2022	Jan. 27, 2022	Jun. 01, 2021
Product Liability Contingency [Line Items]
Value of warrants granted				$ 500,000
Number of common stock for services, value					$ 18,000
Independent Contractor Services Agreement [Member]
Product Liability Contingency [Line Items]
Consulting fee	$ 6,000			$ 0
Common stock to be issued	36,000
Number of common stock for services, value	$ 18,000
Number of common shares cancelled				36,000
SOLACE Device [Member]
Product Liability Contingency [Line Items]
Cost of contract						$ 77,850
Warrant [Member]
Product Liability Contingency [Line Items]
Warrants granted				100,000	790,000
Ahmet Demir Bingol [Member]
Product Liability Contingency [Line Items]
Annual base salary			$ 250,000
Ahmet Demir Bingol [Member] \| Warrant [Member]
Product Liability Contingency [Line Items]
Warrants granted			698,830
Warrants to purchase of common stock			698,830
Value of warrants granted			$ 165,378
Warrants exercisable term			10 years
Warrants exercise price			$ 0.50
Unvested warrants expired		398,830
Warrants modification expense					$ 94,101
Ahmet Demir Bingol [Member] \| Warrant [Member] \| Share-Based Payment Arrangement, Tranche One [Member]
Product Liability Contingency [Line Items]
Warrants granted		300,000
2021 Plan [Member]
Product Liability Contingency [Line Items]
Common stock reserved for issuance							1,000,000

XML 50 R39.htm IDEA: XBRL DOCUMENT

SUBSEQUENT EVENTS (Details Narrative) - USD ($)	1 Months Ended	12 Months Ended
SUBSEQUENT EVENTS (Details Narrative) - USD ($)	Jan. 31, 2024	Dec. 31, 2022
Subsequent Event [Line Items]
Aggregate gross proceeds		$ 100,000
Two Affiliate [Member] \| Subsequent Event [Member]
Subsequent Event [Line Items]
Number of shares issued	2,000,000
Aggregate gross proceeds	$ 100,000

- Definition

Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.

+ References + Details

EXCEL 51 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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how.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 53 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 55 FilingSummary.xml IDEA: XBRL DOCUMENT 3.24.1.u1 html 91 241 1 true 41 0 false 4 false false R1.htm 00000001 - Document - Cover Sheet http://qualisinnovations.com/role/Cover Cover Cover 1 false false R2.htm 00000002 - Statement - Consolidated Balance Sheets Sheet http://qualisinnovations.com/role/BalanceSheets Consolidated Balance Sheets Statements 2 false false R3.htm 00000003 - Statement - Consolidated Balance Sheets (Parenthetical) Sheet http://qualisinnovations.com/role/BalanceSheetsParenthetical Consolidated Balance Sheets (Parenthetical) Statements 3 false false R4.htm 00000004 - Statement - Consolidated Statements of Operations Sheet http://qualisinnovations.com/role/StatementsOfOperations Consolidated Statements of Operations Statements 4 false false R5.htm 00000005 - Statement - Consolidated Statements of Changes in Stockholders' (Deficit) Equity Sheet http://qualisinnovations.com/role/StatementsOfChangesInStockholdersDeficitEquity Consolidated Statements of Changes in Stockholders' (Deficit) Equity Statements 5 false false R6.htm 00000006 - Statement - Consolidated Statements of Cash Flows Sheet http://qualisinnovations.com/role/StatementsOfCashFlows Consolidated Statements of Cash Flows Statements 6 false false R7.htm 00000007 - Disclosure - ORGANIZATION AND PRINCIPAL ACTIVITIES Sheet http://qualisinnovations.com/role/OrganizationAndPrincipalActivities ORGANIZATION AND PRINCIPAL ACTIVITIES Notes 7 false false R8.htm 00000008 - Disclosure - BASIS OF PRESENTATION Sheet http://qualisinnovations.com/role/BasisOfPresentation BASIS OF PRESENTATION Notes 8 false false R9.htm 00000009 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES Sheet http://qualisinnovations.com/role/SummaryOfSignificantAccountingPolicies SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES Notes 9 false false R10.htm 00000010 - Disclosure - PROPERTY AND EQUIPMENT Sheet http://qualisinnovations.com/role/PropertyAndEquipment PROPERTY AND EQUIPMENT Notes 10 false false R11.htm 00000011 - Disclosure - SHORT TERM LOAN Sheet http://qualisinnovations.com/role/ShortTermLoan SHORT TERM LOAN Notes 11 false false R12.htm 00000012 - Disclosure - STOCKHOLDERS??? (DEFICIT) EQUITY Sheet http://qualisinnovations.com/role/StockholdersDeficitEquity STOCKHOLDERS??? (DEFICIT) EQUITY Notes 12 false false R13.htm 00000013 - Disclosure - RELATED PARTY TRANSACTIONS Sheet http://qualisinnovations.com/role/RelatedPartyTransactions RELATED PARTY TRANSACTIONS Notes 13 false false R14.htm 00000014 - Disclosure - INCOME TAXES Sheet http://qualisinnovations.com/role/IncomeTaxes INCOME TAXES Notes 14 false false R15.htm 00000015 - Disclosure - EARNINGS PER SHARE Sheet http://qualisinnovations.com/role/EarningsPerShare EARNINGS PER SHARE Notes 15 false false R16.htm 00000016 - Disclosure - COMMITMENTS AND CONTINGENCIES Sheet http://qualisinnovations.com/role/CommitmentsAndContingencies COMMITMENTS AND CONTINGENCIES Notes 16 false false R17.htm 00000017 - Disclosure - SUBSEQUENT EVENTS Sheet http://qualisinnovations.com/role/SubsequentEvents SUBSEQUENT EVENTS Notes 17 false false R18.htm 00000018 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies) Sheet http://qualisinnovations.com/role/SummaryOfSignificantAccountingPoliciesPolicies SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies) Policies 18 false false R19.htm 00000019 - Disclosure - PROPERTY AND EQUIPMENT (Tables) Sheet http://qualisinnovations.com/role/PropertyAndEquipmentTables PROPERTY AND EQUIPMENT (Tables) Tables http://qualisinnovations.com/role/PropertyAndEquipment 19 false false R20.htm 00000020 - Disclosure - STOCKHOLDERS??? (DEFICIT) EQUITY (Tables) Sheet http://qualisinnovations.com/role/StockholdersDeficitEquityTables STOCKHOLDERS??? (DEFICIT) EQUITY (Tables) Tables http://qualisinnovations.com/role/StockholdersDeficitEquity 20 false false R21.htm 00000021 - Disclosure - INCOME TAXES (Tables) Sheet http://qualisinnovations.com/role/IncomeTaxesTables INCOME TAXES (Tables) Tables http://qualisinnovations.com/role/IncomeTaxes 21 false false R22.htm 00000022 - Disclosure - EARNINGS PER SHARE (Tables) Sheet http://qualisinnovations.com/role/EarningsPerShareTables EARNINGS PER SHARE (Tables) Tables http://qualisinnovations.com/role/EarningsPerShare 22 false false R23.htm 00000023 - Disclosure - ORGANIZATION AND PRINCIPAL ACTIVITIES (Details Narrative) Sheet http://qualisinnovations.com/role/OrganizationAndPrincipalActivitiesDetailsNarrative ORGANIZATION AND PRINCIPAL ACTIVITIES (Details Narrative) Details http://qualisinnovations.com/role/OrganizationAndPrincipalActivities 23 false false R24.htm 00000024 - Disclosure - BASIS OF PRESENTATION (Details Narrative) Sheet http://qualisinnovations.com/role/BasisOfPresentationDetailsNarrative BASIS OF PRESENTATION (Details Narrative) Details http://qualisinnovations.com/role/BasisOfPresentation 24 false false R25.htm 00000025 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details Narrative) Sheet http://qualisinnovations.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details Narrative) Details http://qualisinnovations.com/role/SummaryOfSignificantAccountingPoliciesPolicies 25 false false R26.htm 00000026 - Disclosure - SCHEDULE OF PROPERTY AND EQUIPMENT (Details) Sheet http://qualisinnovations.com/role/ScheduleOfPropertyAndEquipmentDetails SCHEDULE OF PROPERTY AND EQUIPMENT (Details) Details 26 false false R27.htm 00000027 - Disclosure - PROPERTY AND EQUIPMENT (Details Narrative) Sheet http://qualisinnovations.com/role/PropertyAndEquipmentDetailsNarrative PROPERTY AND EQUIPMENT (Details Narrative) Details http://qualisinnovations.com/role/PropertyAndEquipmentTables 27 false false R28.htm 00000028 - Disclosure - SHORT TERM LOAN (Details Narrative) Sheet http://qualisinnovations.com/role/ShortTermLoanDetailsNarrative SHORT TERM LOAN (Details Narrative) Details http://qualisinnovations.com/role/ShortTermLoan 28 false false R29.htm 00000029 - Disclosure - SUMMARY OF WARRANTS OUTSTANDING (Details) Sheet http://qualisinnovations.com/role/SummaryOfWarrantsOutstandingDetails SUMMARY OF WARRANTS OUTSTANDING (Details) Details 29 false false R30.htm 00000030 - Disclosure - SUMMARY OF STOCK OPTIONS OUTSTANDING (Details) Sheet http://qualisinnovations.com/role/SummaryOfStockOptionsOutstandingDetails SUMMARY OF STOCK OPTIONS OUTSTANDING (Details) Details 30 false false R31.htm 00000031 - Disclosure - STOCKHOLDERS??? (DEFICIT) EQUITY (Details Narrative) Sheet http://qualisinnovations.com/role/StockholdersDeficitEquityDetailsNarrative STOCKHOLDERS??? (DEFICIT) EQUITY (Details Narrative) Details http://qualisinnovations.com/role/StockholdersDeficitEquityTables 31 false false R32.htm 00000032 - Disclosure - SCHEDULE OF RECONCILIATION OF STATUTORY INCOME TAX RATES (Details) Sheet http://qualisinnovations.com/role/ScheduleOfReconciliationOfStatutoryIncomeTaxRatesDetails SCHEDULE OF RECONCILIATION OF STATUTORY INCOME TAX RATES (Details) Details 32 false false R33.htm 00000033 - Disclosure - SCHEDULE OF DEFERRED TAX ASSETS (Details) Sheet http://qualisinnovations.com/role/ScheduleOfDeferredTaxAssetsDetails SCHEDULE OF DEFERRED TAX ASSETS (Details) Details 33 false false R34.htm 00000034 - Disclosure - INCOME TAXES (Details Narrative) Sheet http://qualisinnovations.com/role/IncomeTaxesDetailsNarrative INCOME TAXES (Details Narrative) Details http://qualisinnovations.com/role/IncomeTaxesTables 34 false false R35.htm 00000035 - Disclosure - SCHEDULE OF POTENTIALLY DILUTIVE SECURITIES WERE EXCLUDED FROM CALCULATION OF DILUTED NET LOSS PER SHARE (Details) Sheet http://qualisinnovations.com/role/ScheduleOfPotentiallyDilutiveSecuritiesWereExcludedFromCalculationOfDilutedNetLossPerShareDetails SCHEDULE OF POTENTIALLY DILUTIVE SECURITIES WERE EXCLUDED FROM CALCULATION OF DILUTED NET LOSS PER SHARE (Details) Details 35 false false R36.htm 00000036 - Disclosure - SCHEDULE OF POTENTIALLY DILUTIVE SECURITIES WERE EXCLUDED FROM CALCULATION OF DILUTED NET LOSS PER SHARE (Details) (Parenthetical) Sheet http://qualisinnovations.com/role/ScheduleOfPotentiallyDilutiveSecuritiesWereExcludedFromCalculationOfDilutedNetLossPerShareDetailsParenthetical SCHEDULE OF POTENTIALLY DILUTIVE SECURITIES WERE EXCLUDED FROM CALCULATION OF DILUTED NET LOSS PER SHARE (Details) (Parenthetical) Details 36 false false R37.htm 00000037 - Disclosure - SCHEDULE OF COMPUTATION OF BASIC AND DILUTED NET INCOME PER SHARE (Details) Sheet http://qualisinnovations.com/role/ScheduleOfComputationOfBasicAndDilutedNetIncomePerShareDetails SCHEDULE OF COMPUTATION OF BASIC AND DILUTED NET INCOME PER SHARE (Details) Details 37 false false R38.htm 00000038 - Disclosure - COMMITMENTS AND CONTINGENCIES (Details Narrative) Sheet http://qualisinnovations.com/role/CommitmentsAndContingenciesDetailsNarrative COMMITMENTS AND CONTINGENCIES (Details Narrative) Details http://qualisinnovations.com/role/CommitmentsAndContingencies 38 false false R39.htm 00000039 - Disclosure - SUBSEQUENT EVENTS (Details Narrative) Sheet http://qualisinnovations.com/role/SubsequentEventsDetailsNarrative SUBSEQUENT EVENTS (Details Narrative) Details http://qualisinnovations.com/role/SubsequentEvents 39 false false All Reports Book All Reports form10-k.htm qlis-20231231.xsd qlis-20231231_cal.xml qlis-20231231_def.xml qlis-20231231_lab.xml qlis-20231231_pre.xml form10-k_001.jpg form10-k_002.jpg http://fasb.org/us-gaap/2023 http://xbrl.sec.gov/dei/2023 true true JSON 57 MetaLinks.json IDEA: XBRL DOCUMENT { "version": "2.2", "instance": { "form10-k.htm": { "nsprefix": "QLIS", "nsuri": "http://qualisinnovations.com/20231231", "dts": { "inline": { "local": [ "form10-k.htm" ] }, "schema": { "local": [ "qlis-20231231.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-roles-2023.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-types-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-roles-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-types-2023.xsd", "https://xbrl.sec.gov/country/2023/country-2023.xsd", "https://xbrl.sec.gov/dei/2023/dei-2023.xsd" ] }, "calculationLink": { "local": [ "qlis-20231231_cal.xml" ] }, "definitionLink": { "local": [ "qlis-20231231_def.xml" ] }, "labelLink": { "local": [ "qlis-20231231_lab.xml" ] }, "presentationLink": { "local": [ "qlis-20231231_pre.xml" ] } }, "keyStandard": 205, "keyCustom": 36, "axisStandard": 13, "axisCustom": 0, "memberStandard": 11, "memberCustom": 28, "hidden": { "total": 87, "http://qualisinnovations.com/20231231": 17, "http://fasb.org/us-gaap/2023": 67, "http://xbrl.sec.gov/dei/2023": 3 }, "contextCount": 91, "entityCount": 1, "segmentCount": 41, "elementCount": 380, "unitCount": 4, "baseTaxonomies": { "http://fasb.org/us-gaap/2023": 457, "http://xbrl.sec.gov/dei/2023": 36 }, "report": { "R1": { "role": "http://qualisinnovations.com/role/Cover", "longName": "00000001 - Document - Cover", "shortName": "Cover", "isDefault": "true", "groupType": "document", "subGroupType": "", "menuCat": "Cover", "order": "1", "firstAnchor": { "contextRef": "From2023-01-01to2023-12-31", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "b", "span", "p", "body", "html" ], "reportCount": 1, "baseRef": "form10-k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2023-01-01to2023-12-31", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "b", "span", "p", "body", "html" ], "reportCount": 1, "baseRef": "form10-k.htm", "first": true, "unique": true } }, "R2": { "role": "http://qualisinnovations.com/role/BalanceSheets", "longName": "00000002 - Statement - Consolidated Balance Sheets", "shortName": "Consolidated Balance Sheets", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "2", "firstAnchor": { "contextRef": "AsOf2023-12-31", "name": "us-gaap:Cash", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "td", "tr", "table", "body", "html" ], "reportCount": 1, "baseRef": "form10-k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "AsOf2023-12-31", "name": "us-gaap:Cash", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "td", "tr", "table", "body", "html" ], "reportCount": 1, "baseRef": "form10-k.htm", "first": true, "unique": true } }, "R3": { "role": "http://qualisinnovations.com/role/BalanceSheetsParenthetical", "longName": "00000003 - Statement - Consolidated Balance Sheets (Parenthetical)", "shortName": "Consolidated Balance Sheets (Parenthetical)", "isDefault": "false", "groupType": "statement", "subGroupType": "parenthetical", "menuCat": "Statements", "order": "3", "firstAnchor": { "contextRef": "AsOf2023-12-31", "name": "us-gaap:PreferredStockParOrStatedValuePerShare", "unitRef": "USDPShares", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "span", "span", "td", "tr", "table", "body", "html" ], "reportCount": 1, "baseRef": "form10-k.htm", "first": true }, "uniqueAnchor": { "contextRef": "AsOf2023-12-31", "name": "us-gaap:PreferredStockSharesIssued", "unitRef": "Shares", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "span", "span", "span", "span", "td", "tr", "table", "body", "html" ], "reportCount": 1, "baseRef": "form10-k.htm", "unique": true } }, "R4": { "role": "http://qualisinnovations.com/role/StatementsOfOperations", "longName": "00000004 - Statement - Consolidated Statements of Operations", "shortName": "Consolidated Statements of Operations", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "4", "firstAnchor": { "contextRef": "From2023-01-01to2023-12-31", "name": "us-gaap:ResearchAndDevelopmentExpense", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "td", "tr", "table", "body", "html" ], "reportCount": 1, "baseRef": "form10-k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2023-01-01to2023-12-31", "name": "us-gaap:ResearchAndDevelopmentExpense", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "td", "tr", "table", "body", "html" ], "reportCount": 1, "baseRef": "form10-k.htm", "first": true, "unique": true } }, "R5": { "role": "http://qualisinnovations.com/role/StatementsOfChangesInStockholdersDeficitEquity", "longName": "00000005 - Statement - Consolidated Statements of Changes in Stockholders' (Deficit) Equity", "shortName": "Consolidated Statements of Changes in Stockholders' (Deficit) Equity", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "5", "firstAnchor": { "contextRef": "AsOf2021-12-31_us-gaap_CommonStockMember", "name": "us-gaap:StockholdersEquity", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "td", "tr", "table", "body", "html" ], "reportCount": 1, "baseRef": "form10-k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "AsOf2021-12-31_us-gaap_CommonStockMember", "name": "us-gaap:StockholdersEquity", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "td", "tr", "table", "body", "html" ], "reportCount": 1, "baseRef": "form10-k.htm", "first": true, "unique": true } }, "R6": { "role": "http://qualisinnovations.com/role/StatementsOfCashFlows", "longName": "00000006 - Statement - Consolidated Statements of Cash Flows", "shortName": "Consolidated Statements of Cash Flows", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "6", "firstAnchor": { "contextRef": "From2023-01-01to2023-12-31", "name": "us-gaap:NetIncomeLoss", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "td", "tr", "table", "body", "html" ], "reportCount": 1, "baseRef": "form10-k.htm", "first": true }, "uniqueAnchor": { "contextRef": "From2023-01-01to2023-12-31", "name": "us-gaap:AdjustmentOfWarrantsGrantedForServices", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "td", "tr", "table", "body", "html" ], "reportCount": 1, "baseRef": "form10-k.htm", "unique": true } }, "R7": { "role": "http://qualisinnovations.com/role/OrganizationAndPrincipalActivities", "longName": "00000007 - Disclosure - ORGANIZATION AND PRINCIPAL ACTIVITIES", "shortName": "ORGANIZATION AND PRINCIPAL ACTIVITIES", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "7", "firstAnchor": { "contextRef": "From2023-01-01to2023-12-31", "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "form10-k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2023-01-01to2023-12-31", "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "form10-k.htm", "first": true, "unique": true } }, "R8": { "role": "http://qualisinnovations.com/role/BasisOfPresentation", "longName": "00000008 - Disclosure - BASIS OF PRESENTATION", "shortName": "BASIS OF PRESENTATION", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "8", "firstAnchor": { "contextRef": "From2023-01-01to2023-12-31", "name": "us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "form10-k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2023-01-01to2023-12-31", "name": "us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "form10-k.htm", "first": true, "unique": true } }, "R9": { "role": "http://qualisinnovations.com/role/SummaryOfSignificantAccountingPolicies", "longName": "00000009 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES", "shortName": "SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "9", "firstAnchor": { "contextRef": "From2023-01-01to2023-12-31", "name": "us-gaap:SignificantAccountingPoliciesTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "form10-k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2023-01-01to2023-12-31", "name": "us-gaap:SignificantAccountingPoliciesTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "form10-k.htm", "first": true, "unique": true } }, "R10": { "role": "http://qualisinnovations.com/role/PropertyAndEquipment", "longName": "00000010 - Disclosure - PROPERTY AND EQUIPMENT", "shortName": "PROPERTY AND EQUIPMENT", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "10", "firstAnchor": { "contextRef": "From2023-01-01to2023-12-31", "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "form10-k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2023-01-01to2023-12-31", "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "form10-k.htm", "first": true, "unique": true } }, "R11": { "role": "http://qualisinnovations.com/role/ShortTermLoan", "longName": "00000011 - Disclosure - SHORT TERM LOAN", "shortName": "SHORT TERM LOAN", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "11", "firstAnchor": { "contextRef": "From2023-01-01to2023-12-31", "name": "us-gaap:ShortTermDebtTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "form10-k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2023-01-01to2023-12-31", "name": "us-gaap:ShortTermDebtTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "form10-k.htm", "first": true, "unique": true } }, "R12": { "role": "http://qualisinnovations.com/role/StockholdersDeficitEquity", "longName": "00000012 - Disclosure - STOCKHOLDERS\u2019 (DEFICIT) EQUITY", "shortName": "STOCKHOLDERS\u2019 (DEFICIT) EQUITY", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "12", "firstAnchor": { "contextRef": "From2023-01-01to2023-12-31", "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "form10-k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2023-01-01to2023-12-31", "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "form10-k.htm", "first": true, "unique": true } }, "R13": { "role": "http://qualisinnovations.com/role/RelatedPartyTransactions", "longName": "00000013 - Disclosure - RELATED PARTY TRANSACTIONS", "shortName": "RELATED PARTY TRANSACTIONS", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "13", "firstAnchor": { "contextRef": "From2023-01-01to2023-12-31", "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "form10-k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2023-01-01to2023-12-31", "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "form10-k.htm", "first": true, "unique": true } }, "R14": { "role": "http://qualisinnovations.com/role/IncomeTaxes", "longName": "00000014 - Disclosure - INCOME TAXES", "shortName": "INCOME TAXES", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "14", "firstAnchor": { "contextRef": "From2023-01-01to2023-12-31", "name": "us-gaap:IncomeTaxDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "form10-k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2023-01-01to2023-12-31", "name": "us-gaap:IncomeTaxDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "form10-k.htm", "first": true, "unique": true } }, "R15": { "role": "http://qualisinnovations.com/role/EarningsPerShare", "longName": "00000015 - Disclosure - EARNINGS PER SHARE", "shortName": "EARNINGS PER SHARE", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "15", "firstAnchor": { "contextRef": "From2023-01-01to2023-12-31", "name": "us-gaap:EarningsPerShareTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "form10-k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2023-01-01to2023-12-31", "name": "us-gaap:EarningsPerShareTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "form10-k.htm", "first": true, "unique": true } }, "R16": { "role": "http://qualisinnovations.com/role/CommitmentsAndContingencies", "longName": "00000016 - Disclosure - COMMITMENTS AND CONTINGENCIES", "shortName": "COMMITMENTS AND CONTINGENCIES", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "16", "firstAnchor": { "contextRef": "From2023-01-01to2023-12-31", "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "form10-k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2023-01-01to2023-12-31", "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "form10-k.htm", "first": true, "unique": true } }, "R17": { "role": "http://qualisinnovations.com/role/SubsequentEvents", "longName": "00000017 - Disclosure - SUBSEQUENT EVENTS", "shortName": "SUBSEQUENT EVENTS", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "17", "firstAnchor": { "contextRef": "From2023-01-01to2023-12-31", "name": "us-gaap:SubsequentEventsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "form10-k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2023-01-01to2023-12-31", "name": "us-gaap:SubsequentEventsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "form10-k.htm", "first": true, "unique": true } }, "R18": { "role": "http://qualisinnovations.com/role/SummaryOfSignificantAccountingPoliciesPolicies", "longName": "00000018 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)", "shortName": "SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "policies", "menuCat": "Policies", "order": "18", "firstAnchor": { "contextRef": "From2023-01-01to2023-12-31", "name": "us-gaap:UseOfEstimates", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:SignificantAccountingPoliciesTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "form10-k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2023-01-01to2023-12-31", "name": "us-gaap:UseOfEstimates", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:SignificantAccountingPoliciesTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "form10-k.htm", "first": true, "unique": true } }, "R19": { "role": "http://qualisinnovations.com/role/PropertyAndEquipmentTables", "longName": "00000019 - Disclosure - PROPERTY AND EQUIPMENT (Tables)", "shortName": "PROPERTY AND EQUIPMENT (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "19", "firstAnchor": { "contextRef": "From2023-01-01to2023-12-31", "name": "us-gaap:PropertyPlantAndEquipmentTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "form10-k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2023-01-01to2023-12-31", "name": "us-gaap:PropertyPlantAndEquipmentTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "form10-k.htm", "first": true, "unique": true } }, "R20": { "role": "http://qualisinnovations.com/role/StockholdersDeficitEquityTables", "longName": "00000020 - Disclosure - STOCKHOLDERS\u2019 (DEFICIT) EQUITY (Tables)", "shortName": "STOCKHOLDERS\u2019 (DEFICIT) EQUITY (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "20", "firstAnchor": { "contextRef": "From2023-01-01to2023-12-31", "name": "us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "form10-k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2023-01-01to2023-12-31", "name": "us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "form10-k.htm", "first": true, "unique": true } }, "R21": { "role": "http://qualisinnovations.com/role/IncomeTaxesTables", "longName": "00000021 - Disclosure - INCOME TAXES (Tables)", "shortName": "INCOME TAXES (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "21", "firstAnchor": { "contextRef": "From2023-01-01to2023-12-31", "name": "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:IncomeTaxDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "form10-k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2023-01-01to2023-12-31", "name": "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:IncomeTaxDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "form10-k.htm", "first": true, "unique": true } }, "R22": { "role": "http://qualisinnovations.com/role/EarningsPerShareTables", "longName": "00000022 - Disclosure - EARNINGS PER SHARE (Tables)", "shortName": "EARNINGS PER SHARE (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "22", "firstAnchor": { "contextRef": "From2023-01-01to2023-12-31", "name": "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:EarningsPerShareTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "form10-k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2023-01-01to2023-12-31", "name": "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:EarningsPerShareTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "form10-k.htm", "first": true, "unique": true } }, "R23": { "role": "http://qualisinnovations.com/role/OrganizationAndPrincipalActivitiesDetailsNarrative", "longName": "00000023 - Disclosure - ORGANIZATION AND PRINCIPAL ACTIVITIES (Details Narrative)", "shortName": "ORGANIZATION AND PRINCIPAL ACTIVITIES (Details Narrative)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "23", "firstAnchor": { "contextRef": "From2018-02-122018-02-13", "name": "us-gaap:StockholdersEquityReverseStockSplit", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "span", "p", "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "form10-k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2018-02-122018-02-13", "name": "us-gaap:StockholdersEquityReverseStockSplit", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "span", "p", "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "form10-k.htm", "first": true, "unique": true } }, "R24": { "role": "http://qualisinnovations.com/role/BasisOfPresentationDetailsNarrative", "longName": "00000024 - Disclosure - BASIS OF PRESENTATION (Details Narrative)", "shortName": "BASIS OF PRESENTATION (Details Narrative)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "24", "firstAnchor": { "contextRef": "AsOf2023-12-31", "name": "us-gaap:RetainedEarningsAccumulatedDeficit", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "td", "tr", "table", "body", "html" ], "reportCount": 1, "baseRef": "form10-k.htm", "first": true }, "uniqueAnchor": { "contextRef": "AsOf2023-12-31", "name": "QLIS:WorkingCapital", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "span", "span", "span", "p", "us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "form10-k.htm", "unique": true } }, "R25": { "role": "http://qualisinnovations.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative", "longName": "00000025 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details Narrative)", "shortName": "SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details Narrative)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "25", "firstAnchor": { "contextRef": "AsOf2023-12-31", "name": "us-gaap:AccruedLiabilitiesCurrent", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "span", "span", "p", "us-gaap:UseOfEstimates", "us-gaap:SignificantAccountingPoliciesTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "form10-k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "AsOf2023-12-31", "name": "us-gaap:AccruedLiabilitiesCurrent", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "span", "span", "p", "us-gaap:UseOfEstimates", "us-gaap:SignificantAccountingPoliciesTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "form10-k.htm", "first": true, "unique": true } }, "R26": { "role": "http://qualisinnovations.com/role/ScheduleOfPropertyAndEquipmentDetails", "longName": "00000026 - Disclosure - SCHEDULE OF PROPERTY AND EQUIPMENT (Details)", "shortName": "SCHEDULE OF PROPERTY AND EQUIPMENT (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "26", "firstAnchor": { "contextRef": "AsOf2023-12-31", "name": "us-gaap:PropertyPlantAndEquipmentUsefulLife", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "span", "p", "us-gaap:PropertyPlantAndEquipmentPolicyTextBlock", "us-gaap:SignificantAccountingPoliciesTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "form10-k.htm", "first": true }, "uniqueAnchor": { "contextRef": "AsOf2023-12-31", "name": "us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "td", "tr", "table", "us-gaap:PropertyPlantAndEquipmentTextBlock", "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "form10-k.htm", "unique": true } }, "R27": { "role": "http://qualisinnovations.com/role/PropertyAndEquipmentDetailsNarrative", "longName": "00000027 - Disclosure - PROPERTY AND EQUIPMENT (Details Narrative)", "shortName": "PROPERTY AND EQUIPMENT (Details Narrative)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "27", "firstAnchor": { "contextRef": "From2023-01-01to2023-12-31", "name": "us-gaap:Depreciation", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "td", "tr", "table", "body", "html" ], "reportCount": 1, "baseRef": "form10-k.htm", "first": true }, "uniqueAnchor": null }, "R28": { "role": "http://qualisinnovations.com/role/ShortTermLoanDetailsNarrative", "longName": "00000028 - Disclosure - SHORT TERM LOAN (Details Narrative)", "shortName": "SHORT TERM LOAN (Details Narrative)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "28", "firstAnchor": { "contextRef": "AsOf2023-12-31_srt_ChiefExecutiveOfficerMember", "name": "us-gaap:DebtInstrumentFaceAmount", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "span", "span", "p", "us-gaap:ShortTermDebtTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "form10-k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "AsOf2023-12-31_srt_ChiefExecutiveOfficerMember", "name": "us-gaap:DebtInstrumentFaceAmount", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "span", "span", "p", "us-gaap:ShortTermDebtTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "form10-k.htm", "first": true, "unique": true } }, "R29": { "role": "http://qualisinnovations.com/role/SummaryOfWarrantsOutstandingDetails", "longName": "00000029 - Disclosure - SUMMARY OF WARRANTS OUTSTANDING (Details)", "shortName": "SUMMARY OF WARRANTS OUTSTANDING (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "29", "firstAnchor": { "contextRef": "AsOf2022-12-31", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice", "unitRef": "USDPShares", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "form10-k.htm", "first": true }, "uniqueAnchor": { "contextRef": "From2022-01-012022-12-31", "name": "QLIS:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsForfeituresAndExpirationsInPeriodIntrinsicValue", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock", "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "form10-k.htm", "unique": true } }, "R30": { "role": "http://qualisinnovations.com/role/SummaryOfStockOptionsOutstandingDetails", "longName": "00000030 - Disclosure - SUMMARY OF STOCK OPTIONS OUTSTANDING (Details)", "shortName": "SUMMARY OF STOCK OPTIONS OUTSTANDING (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "30", "firstAnchor": { "contextRef": "AsOf2022-12-31", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber", "unitRef": "Shares", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "form10-k.htm", "first": true }, "uniqueAnchor": { "contextRef": "AsOf2021-12-31", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber", "unitRef": "Shares", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "form10-k.htm", "unique": true } }, "R31": { "role": "http://qualisinnovations.com/role/StockholdersDeficitEquityDetailsNarrative", "longName": "00000031 - Disclosure - STOCKHOLDERS\u2019 (DEFICIT) EQUITY (Details Narrative)", "shortName": "STOCKHOLDERS\u2019 (DEFICIT) EQUITY (Details Narrative)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "31", "firstAnchor": { "contextRef": "AsOf2023-12-31", "name": "us-gaap:PreferredStockSharesAuthorized", "unitRef": "Shares", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "span", "span", "td", "tr", "table", "body", "html" ], "reportCount": 1, "baseRef": "form10-k.htm", "first": true }, "uniqueAnchor": { "contextRef": "From2022-02-012022-02-01_us-gaap_WarrantMember_custom_ThirdPartyMember", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted", "unitRef": "Shares", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "span", "span", "p", "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "form10-k.htm", "unique": true } }, "R32": { "role": "http://qualisinnovations.com/role/ScheduleOfReconciliationOfStatutoryIncomeTaxRatesDetails", "longName": "00000032 - Disclosure - SCHEDULE OF RECONCILIATION OF STATUTORY INCOME TAX RATES (Details)", "shortName": "SCHEDULE OF RECONCILIATION OF STATUTORY INCOME TAX RATES (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "32", "firstAnchor": { "contextRef": "From2023-01-01to2023-12-31", "name": "us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate", "unitRef": "Pure", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock", "us-gaap:IncomeTaxDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "form10-k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2023-01-01to2023-12-31", "name": "us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate", "unitRef": "Pure", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock", "us-gaap:IncomeTaxDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "form10-k.htm", "first": true, "unique": true } }, "R33": { "role": "http://qualisinnovations.com/role/ScheduleOfDeferredTaxAssetsDetails", "longName": "00000033 - Disclosure - SCHEDULE OF DEFERRED TAX ASSETS (Details)", "shortName": "SCHEDULE OF DEFERRED TAX ASSETS (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "33", "firstAnchor": { "contextRef": "AsOf2023-12-31", "name": "us-gaap:DeferredTaxAssetsOperatingLossCarryforwards", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock", "us-gaap:IncomeTaxDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "form10-k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "AsOf2023-12-31", "name": "us-gaap:DeferredTaxAssetsOperatingLossCarryforwards", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock", "us-gaap:IncomeTaxDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "form10-k.htm", "first": true, "unique": true } }, "R34": { "role": "http://qualisinnovations.com/role/IncomeTaxesDetailsNarrative", "longName": "00000034 - Disclosure - INCOME TAXES (Details Narrative)", "shortName": "INCOME TAXES (Details Narrative)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "34", "firstAnchor": { "contextRef": "AsOf2023-12-31", "name": "us-gaap:OperatingLossCarryforwards", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "span", "span", "p", "us-gaap:IncomeTaxDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "form10-k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "AsOf2023-12-31", "name": "us-gaap:OperatingLossCarryforwards", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "span", "span", "p", "us-gaap:IncomeTaxDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "form10-k.htm", "first": true, "unique": true } }, "R35": { "role": "http://qualisinnovations.com/role/ScheduleOfPotentiallyDilutiveSecuritiesWereExcludedFromCalculationOfDilutedNetLossPerShareDetails", "longName": "00000035 - Disclosure - SCHEDULE OF POTENTIALLY DILUTIVE SECURITIES WERE EXCLUDED FROM CALCULATION OF DILUTED NET LOSS PER SHARE (Details)", "shortName": "SCHEDULE OF POTENTIALLY DILUTIVE SECURITIES WERE EXCLUDED FROM CALCULATION OF DILUTED NET LOSS PER SHARE (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "35", "firstAnchor": { "contextRef": "From2023-01-01to2023-12-31", "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "unitRef": "Shares", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "span", "span", "p", "us-gaap:EarningsPerSharePolicyTextBlock", "us-gaap:SignificantAccountingPoliciesTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "form10-k.htm", "first": true }, "uniqueAnchor": { "contextRef": "From2023-01-012023-12-31_custom_OptionsToPurchaseSharesOfCommonStockMember", "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "unitRef": "Shares", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock", "us-gaap:EarningsPerShareTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "form10-k.htm", "unique": true } }, "R36": { "role": "http://qualisinnovations.com/role/ScheduleOfPotentiallyDilutiveSecuritiesWereExcludedFromCalculationOfDilutedNetLossPerShareDetailsParenthetical", "longName": "00000036 - Disclosure - SCHEDULE OF POTENTIALLY DILUTIVE SECURITIES WERE EXCLUDED FROM CALCULATION OF DILUTED NET LOSS PER SHARE (Details) (Parenthetical)", "shortName": "SCHEDULE OF POTENTIALLY DILUTIVE SECURITIES WERE EXCLUDED FROM CALCULATION OF DILUTED NET LOSS PER SHARE (Details) (Parenthetical)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "parenthetical", "menuCat": "Details", "order": "36", "firstAnchor": { "contextRef": "AsOf2021-06-29_custom_ShareExchangeAgreementMember_us-gaap_WarrantMember", "name": "us-gaap:ClassOfWarrantOrRightOutstanding", "unitRef": "Shares", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "span", "link:footnote", "i", "span", "td", "tr", "table", "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock", "us-gaap:EarningsPerShareTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "form10-k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "AsOf2021-06-29_custom_ShareExchangeAgreementMember_us-gaap_WarrantMember", "name": "us-gaap:ClassOfWarrantOrRightOutstanding", "unitRef": "Shares", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "span", "link:footnote", "i", "span", "td", "tr", "table", "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock", "us-gaap:EarningsPerShareTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "form10-k.htm", "first": true, "unique": true } }, "R37": { "role": "http://qualisinnovations.com/role/ScheduleOfComputationOfBasicAndDilutedNetIncomePerShareDetails", "longName": "00000037 - Disclosure - SCHEDULE OF COMPUTATION OF BASIC AND DILUTED NET INCOME PER SHARE (Details)", "shortName": "SCHEDULE OF COMPUTATION OF BASIC AND DILUTED NET INCOME PER SHARE (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "37", "firstAnchor": { "contextRef": "From2023-01-01to2023-12-31", "name": "us-gaap:NetIncomeLoss", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "td", "tr", "table", "body", "html" ], "reportCount": 1, "baseRef": "form10-k.htm", "first": true }, "uniqueAnchor": null }, "R38": { "role": "http://qualisinnovations.com/role/CommitmentsAndContingenciesDetailsNarrative", "longName": "00000038 - Disclosure - COMMITMENTS AND CONTINGENCIES (Details Narrative)", "shortName": "COMMITMENTS AND CONTINGENCIES (Details Narrative)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "38", "firstAnchor": { "contextRef": "From2023-01-01to2023-12-31", "name": "us-gaap:IssuanceOfStockAndWarrantsForServicesOrClaims", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "td", "tr", "table", "body", "html" ], "reportCount": 1, "baseRef": "form10-k.htm", "first": true }, "uniqueAnchor": { "contextRef": "AsOf2022-10-03_custom_IndependentContractorServicesAgreementMember", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized", "unitRef": "Shares", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "span", "span", "p", "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "form10-k.htm", "unique": true } }, "R39": { "role": "http://qualisinnovations.com/role/SubsequentEventsDetailsNarrative", "longName": "00000039 - Disclosure - SUBSEQUENT EVENTS (Details Narrative)", "shortName": "SUBSEQUENT EVENTS (Details Narrative)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "39", "firstAnchor": { "contextRef": "From2022-01-012022-12-31", "name": "us-gaap:StockIssuedDuringPeriodValueNewIssues", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "td", "tr", "table", "body", "html" ], "reportCount": 1, "baseRef": "form10-k.htm", "first": true }, "uniqueAnchor": null } }, "tag": { "us-gaap_AccountingPoliciesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AccountingPoliciesAbstract", "lang": { "en-us": { "role": { "label": "Accounting Policies [Abstract]" } } }, "auth_ref": [] }, "us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AccountsPayableAndAccruedLiabilitiesCurrent", "crdr": "credit", "calculation": { "http://qualisinnovations.com/role/BalanceSheets": { "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://qualisinnovations.com/role/BalanceSheets" ], "lang": { "en-us": { "role": { "label": "Accounts payable and accrued expenses", "documentation": "Sum of the carrying values as of the balance sheet date of obligations incurred through that date and due within one year (or the operating cycle, if longer), including liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received, taxes, interest, rent and utilities, accrued salaries and bonuses, payroll taxes and fringe benefits." } } }, "auth_ref": [ "r23" ] }, "us-gaap_AccountsPayableCurrentAndNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AccountsPayableCurrentAndNoncurrent", "crdr": "credit", "presentation": [ "http://qualisinnovations.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Accounts payable", "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business." } } }, "auth_ref": [ "r53", "r539" ] }, "us-gaap_AccruedLiabilitiesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AccruedLiabilitiesCurrent", "crdr": "credit", "presentation": [ "http://qualisinnovations.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Accrued expenses", "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)." } } }, "auth_ref": [ "r25" ] }, "us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment", "crdr": "credit", "presentation": [ "http://qualisinnovations.com/role/ScheduleOfPropertyAndEquipmentDetails" ], "lang": { "en-us": { "role": { "negatedLabel": "Accumulated depreciation", "label": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment", "documentation": "Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services." } } }, "auth_ref": [ "r40", "r112", "r337" ] }, "us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AccumulatedOtherComprehensiveIncomeLossLineItems", "presentation": [ "http://qualisinnovations.com/role/StockholdersDeficitEquityDetailsNarrative", "http://qualisinnovations.com/role/SummaryOfWarrantsOutstandingDetails" ], "lang": { "en-us": { "role": { "label": "Accumulated Other Comprehensive Income (Loss) [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r121", "r122", "r295", "r296", "r297", "r298", "r299", "r300" ] }, "us-gaap_AccumulatedOtherComprehensiveIncomeLossTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AccumulatedOtherComprehensiveIncomeLossTable", "presentation": [ "http://qualisinnovations.com/role/StockholdersDeficitEquityDetailsNarrative", "http://qualisinnovations.com/role/SummaryOfWarrantsOutstandingDetails" ], "lang": { "en-us": { "role": { "label": "Accumulated Other Comprehensive Income (Loss) [Table]", "documentation": "Disclosure of information about components of accumulated other comprehensive income (loss)." } } }, "auth_ref": [ "r121", "r122", "r295", "r296", "r297", "r298", "r299", "r300" ] }, "us-gaap_AdditionalPaidInCapital": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AdditionalPaidInCapital", "crdr": "credit", "calculation": { "http://qualisinnovations.com/role/BalanceSheets": { "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://qualisinnovations.com/role/BalanceSheets" ], "lang": { "en-us": { "role": { "label": "Additional paid-in-capital", "documentation": "Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock." } } }, "auth_ref": [ "r60", "r442", "r543" ] }, "us-gaap_AdditionalPaidInCapitalMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AdditionalPaidInCapitalMember", "presentation": [ "http://qualisinnovations.com/role/StatementsOfChangesInStockholdersDeficitEquity", "http://qualisinnovations.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Additional Paid-in Capital [Member]", "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders." } } }, "auth_ref": [ "r250", "r251", "r252", "r365", "r486", "r487", "r488", "r531", "r546" ] }, "us-gaap_AdjustmentOfWarrantsGrantedForServices": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AdjustmentOfWarrantsGrantedForServices", "crdr": "debit", "calculation": { "http://qualisinnovations.com/role/StatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://qualisinnovations.com/role/StatementsOfCashFlows" ], "lang": { "en-us": { "role": { "verboseLabel": "Warrants issued for services", "label": "Adjustment of Warrants Granted for Services", "documentation": "Adjustment for noncash service expenses paid for by granting of warrants." } } }, "auth_ref": [ "r7" ] }, "QLIS_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationRelatedParties": { "xbrltype": "monetaryItemType", "nsuri": "http://qualisinnovations.com/20231231", "localname": "AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationRelatedParties", "crdr": "debit", "presentation": [ "http://qualisinnovations.com/role/StatementsOfChangesInStockholdersDeficitEquity" ], "lang": { "en-us": { "role": { "verboseLabel": "Stock based compensation - related party", "documentation": "Stock based compensation - related party.", "label": "AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationRelatedParties" } } }, "auth_ref": [] }, "us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition", "crdr": "credit", "presentation": [ "http://qualisinnovations.com/role/StatementsOfChangesInStockholdersDeficitEquity" ], "lang": { "en-us": { "role": { "label": "Options issued to third parties in conjunction with services", "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for option under share-based payment arrangement." } } }, "auth_ref": [] }, "us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AdjustmentsToAdditionalPaidInCapitalWarrantIssued", "crdr": "credit", "presentation": [ "http://qualisinnovations.com/role/StatementsOfChangesInStockholdersDeficitEquity" ], "lang": { "en-us": { "role": { "label": "Warrants issued to third parties in conjunction with services", "documentation": "Amount of increase in additional paid in capital (APIC) resulting from the issuance of warrants. Includes allocation of proceeds of debt securities issued with detachable stock purchase warrants." } } }, "auth_ref": [ "r11", "r41", "r81" ] }, "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract", "presentation": [ "http://qualisinnovations.com/role/StatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Adjustments to reconcile net loss to net cash used in operating activities:" } } }, "auth_ref": [] }, "us-gaap_AdvertisingCostsPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AdvertisingCostsPolicyTextBlock", "presentation": [ "http://qualisinnovations.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "label": "Advertising and Marketing Costs", "documentation": "Disclosure of accounting policy for advertising cost." } } }, "auth_ref": [ "r96" ] }, "QLIS_AffiliateMember": { "xbrltype": "domainItemType", "nsuri": "http://qualisinnovations.com/20231231", "localname": "AffiliateMember", "presentation": [ "http://qualisinnovations.com/role/StockholdersDeficitEquityDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Affiliate [Member]", "documentation": "Affiliate [Member]" } } }, "auth_ref": [] }, "QLIS_AhmetDemirBingolMember": { "xbrltype": "domainItemType", "nsuri": "http://qualisinnovations.com/20231231", "localname": "AhmetDemirBingolMember", "presentation": [ "http://qualisinnovations.com/role/CommitmentsAndContingenciesDetailsNarrative", "http://qualisinnovations.com/role/StockholdersDeficitEquityDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Ahmet Demir Bingol [Member]", "documentation": "Ahmet Demir Bingol [Member]" } } }, "auth_ref": [] }, "dei_AmendmentDescription": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AmendmentDescription", "presentation": [ "http://qualisinnovations.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Amendment Description", "documentation": "Description of changes contained within amended document." } } }, "auth_ref": [] }, "dei_AmendmentFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AmendmentFlag", "presentation": [ "http://qualisinnovations.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Amendment Flag", "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission." } } }, "auth_ref": [] }, "dei_AnnualInformationForm": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AnnualInformationForm", "presentation": [ "http://qualisinnovations.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Annual Information Form", "documentation": "Boolean flag with value true on a form if it is an annual report containing an annual information form." } } }, "auth_ref": [ "r469" ] }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "presentation": [ "http://qualisinnovations.com/role/ScheduleOfPotentiallyDilutiveSecuritiesWereExcludedFromCalculationOfDilutedNetLossPerShareDetails", "http://qualisinnovations.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Antidilutive securities excluded from computation of earnings per share, amount", "verboseLabel": "Total potentially dilutive shares", "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented." } } }, "auth_ref": [ "r158" ] }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis", "presentation": [ "http://qualisinnovations.com/role/ScheduleOfPotentiallyDilutiveSecuritiesWereExcludedFromCalculationOfDilutedNetLossPerShareDetails" ], "lang": { "en-us": { "role": { "label": "Antidilutive Securities [Axis]", "documentation": "Information by type of antidilutive security." } } }, "auth_ref": [ "r34" ] }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems", "presentation": [ "http://qualisinnovations.com/role/ScheduleOfPotentiallyDilutiveSecuritiesWereExcludedFromCalculationOfDilutedNetLossPerShareDetails" ], "lang": { "en-us": { "role": { "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [] }, "us-gaap_AntidilutiveSecuritiesNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AntidilutiveSecuritiesNameDomain", "presentation": [ "http://qualisinnovations.com/role/ScheduleOfPotentiallyDilutiveSecuritiesWereExcludedFromCalculationOfDilutedNetLossPerShareDetails" ], "lang": { "en-us": { "role": { "documentation": "Incremental common shares attributable to securities that were not included in diluted earnings per share (EPS) because to do so would increase EPS amounts or decrease loss per share amounts for the period presented." } } }, "auth_ref": [ "r34" ] }, "QLIS_AprilOneTwoThousandTwentyTwoMember": { "xbrltype": "domainItemType", "nsuri": "http://qualisinnovations.com/20231231", "localname": "AprilOneTwoThousandTwentyTwoMember", "presentation": [ "http://qualisinnovations.com/role/ScheduleOfPotentiallyDilutiveSecuritiesWereExcludedFromCalculationOfDilutedNetLossPerShareDetails" ], "lang": { "en-us": { "role": { "label": "April 1, 2022 [Member]", "documentation": "April 1, 2022 [Member]" } } }, "auth_ref": [] }, "us-gaap_ArrangementsAndNonarrangementTransactionsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ArrangementsAndNonarrangementTransactionsMember", "presentation": [ "http://qualisinnovations.com/role/OrganizationAndPrincipalActivitiesDetailsNarrative", "http://qualisinnovations.com/role/ScheduleOfPotentiallyDilutiveSecuritiesWereExcludedFromCalculationOfDilutedNetLossPerShareDetailsParenthetical" ], "lang": { "en-us": { "role": { "documentation": "Collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations." } } }, "auth_ref": [ "r279" ] }, "us-gaap_Assets": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "Assets", "crdr": "debit", "calculation": { "http://qualisinnovations.com/role/BalanceSheets": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://qualisinnovations.com/role/BalanceSheets" ], "lang": { "en-us": { "role": { "totalLabel": "Total assets", "label": "Assets", "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events." } } }, "auth_ref": [ "r88", "r113", "r132", "r163", "r169", "r173", "r181", "r191", "r192", "r193", "r194", "r195", "r196", "r197", "r198", "r199", "r280", "r282", "r294", "r330", "r389", "r442", "r454", "r498", "r499", "r536" ] }, "us-gaap_AssetsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AssetsAbstract", "presentation": [ "http://qualisinnovations.com/role/BalanceSheets" ], "lang": { "en-us": { "role": { "label": "ASSETS" } } }, "auth_ref": [] }, "us-gaap_AssetsCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AssetsCurrent", "crdr": "debit", "calculation": { "http://qualisinnovations.com/role/BalanceSheets": { "parentTag": "us-gaap_Assets", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://qualisinnovations.com/role/BalanceSheets" ], "lang": { "en-us": { "role": { "totalLabel": "Total current assets", "label": "Assets, Current", "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events." } } }, "auth_ref": [ "r108", "r117", "r132", "r181", "r191", "r192", "r193", "r194", "r195", "r196", "r197", "r198", "r199", "r280", "r282", "r294", "r442", "r498", "r499", "r536" ] }, "us-gaap_AssetsCurrentAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AssetsCurrentAbstract", "presentation": [ "http://qualisinnovations.com/role/BalanceSheets" ], "lang": { "en-us": { "role": { "label": "Current assets:" } } }, "auth_ref": [] }, "dei_AuditedAnnualFinancialStatements": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AuditedAnnualFinancialStatements", "presentation": [ "http://qualisinnovations.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Audited Annual Financial Statements", "documentation": "Boolean flag with value true on a form if it is an annual report containing audited financial statements." } } }, "auth_ref": [ "r469" ] }, "dei_AuditorFirmId": { "xbrltype": "nonemptySequenceNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AuditorFirmId", "presentation": [ "http://qualisinnovations.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Auditor Firm ID", "documentation": "PCAOB issued Audit Firm Identifier" } } }, "auth_ref": [ "r466", "r468", "r469" ] }, "dei_AuditorLocation": { "xbrltype": "internationalNameItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AuditorLocation", "presentation": [ "http://qualisinnovations.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Auditor Location" } } }, "auth_ref": [ "r466", "r468", "r469" ] }, "dei_AuditorName": { "xbrltype": "internationalNameItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AuditorName", "presentation": [ "http://qualisinnovations.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Auditor Name" } } }, "auth_ref": [ "r466", "r468", "r469" ] }, "us-gaap_AwardTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AwardTypeAxis", "presentation": [ "http://qualisinnovations.com/role/ScheduleOfPotentiallyDilutiveSecuritiesWereExcludedFromCalculationOfDilutedNetLossPerShareDetails" ], "lang": { "en-us": { "role": { "label": "Award Type [Axis]", "documentation": "Information by type of award under share-based payment arrangement." } } }, "auth_ref": [ "r221", "r222", "r223", "r225", "r226", "r227", "r228", "r229", "r230", "r231", "r232", "r233", "r234", "r235", "r236", "r237", "r238", "r239", "r240", "r241", "r242", "r245", "r246", "r247", "r248", "r249" ] }, "us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "BasisOfPresentationAndSignificantAccountingPoliciesTextBlock", "presentation": [ "http://qualisinnovations.com/role/BasisOfPresentation" ], "lang": { "en-us": { "role": { "label": "BASIS OF PRESENTATION", "documentation": "The entire disclosure for the basis of presentation and significant accounting policies concepts. Basis of presentation describes the underlying basis used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS). Accounting policies describe all significant accounting policies of the reporting entity." } } }, "auth_ref": [ "r73" ] }, "us-gaap_CapitalizedContractCostNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CapitalizedContractCostNet", "crdr": "debit", "presentation": [ "http://qualisinnovations.com/role/CommitmentsAndContingenciesDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Cost of contract", "documentation": "Amount, after accumulated amortization and accumulated impairment loss, of asset recognized from cost incurred to obtain or fulfill contract with customer." } } }, "auth_ref": [ "r187" ] }, "us-gaap_Cash": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "Cash", "crdr": "debit", "calculation": { "http://qualisinnovations.com/role/BalanceSheets": { "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://qualisinnovations.com/role/BalanceSheets" ], "lang": { "en-us": { "role": { "label": "Cash", "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Excludes cash and cash equivalents within disposal group and discontinued operation." } } }, "auth_ref": [ "r94", "r331", "r366", "r384", "r442", "r454", "r478" ] }, "us-gaap_CashAndCashEquivalentsPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CashAndCashEquivalentsPolicyTextBlock", "presentation": [ "http://qualisinnovations.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "verboseLabel": "Cash", "label": "Cash and Cash Equivalents, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value." } } }, "auth_ref": [ "r32" ] }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations", "crdr": "debit", "presentation": [ "http://qualisinnovations.com/role/StatementsOfCashFlows" ], "lang": { "en-us": { "role": { "periodStartLabel": "Cash at beginning of period", "periodEndLabel": "Cash at end of period", "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Including Disposal Group and Discontinued Operations", "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including, but not limited to, disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates." } } }, "auth_ref": [ "r31", "r70", "r129" ] }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "crdr": "debit", "calculation": { "http://qualisinnovations.com/role/StatementsOfCashFlows": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://qualisinnovations.com/role/StatementsOfCashFlows" ], "lang": { "en-us": { "role": { "totalLabel": "Net (decrease) increase in cash", "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect", "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates." } } }, "auth_ref": [ "r4", "r70" ] }, "us-gaap_CashFDICInsuredAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CashFDICInsuredAmount", "crdr": "debit", "presentation": [ "http://qualisinnovations.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "FDIC cash", "documentation": "The amount of cash deposited in financial institutions as of the balance sheet date that is insured by the Federal Deposit Insurance Corporation." } } }, "auth_ref": [] }, "srt_ChiefExecutiveOfficerMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "ChiefExecutiveOfficerMember", "presentation": [ "http://qualisinnovations.com/role/ShortTermLoanDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Chief Executive Officer [Member]" } } }, "auth_ref": [ "r490" ] }, "dei_CityAreaCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CityAreaCode", "presentation": [ "http://qualisinnovations.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "City Area Code", "documentation": "Area code of city" } } }, "auth_ref": [] }, "us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1", "presentation": [ "http://qualisinnovations.com/role/CommitmentsAndContingenciesDetailsNarrative", "http://qualisinnovations.com/role/OrganizationAndPrincipalActivitiesDetailsNarrative", "http://qualisinnovations.com/role/StockholdersDeficitEquityDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Warrants exercise price", "documentation": "Exercise price per share or per unit of warrants or rights outstanding." } } }, "auth_ref": [ "r215" ] }, "us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights", "presentation": [ "http://qualisinnovations.com/role/CommitmentsAndContingenciesDetailsNarrative", "http://qualisinnovations.com/role/OrganizationAndPrincipalActivitiesDetailsNarrative", "http://qualisinnovations.com/role/StockholdersDeficitEquityDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Warrants issued", "verboseLabel": "Number of common stock for purchase", "terseLabel": "Warrants to purchase of common stock", "documentation": "Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares." } } }, "auth_ref": [ "r215" ] }, "us-gaap_ClassOfWarrantOrRightOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ClassOfWarrantOrRightOutstanding", "presentation": [ "http://qualisinnovations.com/role/OrganizationAndPrincipalActivitiesDetailsNarrative", "http://qualisinnovations.com/role/ScheduleOfPotentiallyDilutiveSecuritiesWereExcludedFromCalculationOfDilutedNetLossPerShareDetailsParenthetical", "http://qualisinnovations.com/role/StockholdersDeficitEquityDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Warrants to purchase shares", "verboseLabel": "Number of warrants", "documentation": "Number of warrants or rights outstanding." } } }, "auth_ref": [] }, "us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems", "presentation": [ "http://qualisinnovations.com/role/OrganizationAndPrincipalActivitiesDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r279" ] }, "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CommitmentsAndContingenciesDisclosureAbstract", "lang": { "en-us": { "role": { "label": "Commitments and Contingencies Disclosure [Abstract]" } } }, "auth_ref": [] }, "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CommitmentsAndContingenciesDisclosureTextBlock", "presentation": [ "http://qualisinnovations.com/role/CommitmentsAndContingencies" ], "lang": { "en-us": { "role": { "label": "COMMITMENTS AND CONTINGENCIES", "documentation": "The entire disclosure for commitments and contingencies." } } }, "auth_ref": [ "r78", "r188", "r189", "r431", "r493" ] }, "us-gaap_CommonStockCapitalSharesReservedForFutureIssuance": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CommonStockCapitalSharesReservedForFutureIssuance", "presentation": [ "http://qualisinnovations.com/role/CommitmentsAndContingenciesDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Common stock reserved for issuance", "documentation": "Aggregate number of common shares reserved for future issuance." } } }, "auth_ref": [ "r28" ] }, "us-gaap_CommonStockMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CommonStockMember", "presentation": [ "http://qualisinnovations.com/role/StatementsOfChangesInStockholdersDeficitEquity", "http://qualisinnovations.com/role/StockholdersDeficitEquityDetailsNarrative", "http://qualisinnovations.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Common Stock [Member]", "documentation": "Stock that is subordinate to all other stock of the issuer." } } }, "auth_ref": [ "r444", "r445", "r446", "r448", "r449", "r450", "r451", "r486", "r487", "r531", "r542", "r546" ] }, "us-gaap_CommonStockParOrStatedValuePerShare": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CommonStockParOrStatedValuePerShare", "presentation": [ "http://qualisinnovations.com/role/BalanceSheetsParenthetical", "http://qualisinnovations.com/role/StockholdersDeficitEquityDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Common stock, par value", "documentation": "Face amount or stated value per share of common stock." } } }, "auth_ref": [ "r59" ] }, "us-gaap_CommonStockSharesAuthorized": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CommonStockSharesAuthorized", "presentation": [ "http://qualisinnovations.com/role/BalanceSheetsParenthetical", "http://qualisinnovations.com/role/StockholdersDeficitEquityDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Common stock, shares authorized", "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws." } } }, "auth_ref": [ "r59", "r376" ] }, "us-gaap_CommonStockSharesIssued": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CommonStockSharesIssued", "presentation": [ "http://qualisinnovations.com/role/BalanceSheetsParenthetical" ], "lang": { "en-us": { "role": { "label": "Common stock, shares issued", "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury." } } }, "auth_ref": [ "r59" ] }, "us-gaap_CommonStockSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CommonStockSharesOutstanding", "presentation": [ "http://qualisinnovations.com/role/BalanceSheetsParenthetical", "http://qualisinnovations.com/role/OrganizationAndPrincipalActivitiesDetailsNarrative", "http://qualisinnovations.com/role/StockholdersDeficitEquityDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Common stock, shares outstanding", "verboseLabel": "Common stock, outstanding", "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation." } } }, "auth_ref": [ "r11", "r59", "r376", "r395", "r546", "r547" ] }, "us-gaap_CommonStockValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CommonStockValue", "crdr": "credit", "calculation": { "http://qualisinnovations.com/role/BalanceSheets": { "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://qualisinnovations.com/role/BalanceSheets" ], "lang": { "en-us": { "role": { "label": "Common stock, $0.001 par value, 750,000,000 shares authorized; 8,439,950 and 8,475,950 shares issued and outstanding at December 31, 2023 and 2022, respectively", "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity." } } }, "auth_ref": [ "r59", "r333", "r442" ] }, "us-gaap_ComputerEquipmentMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ComputerEquipmentMember", "presentation": [ "http://qualisinnovations.com/role/ScheduleOfPropertyAndEquipmentDetails" ], "lang": { "en-us": { "role": { "label": "Computer Equipment [Member]", "documentation": "Long lived, depreciable assets that are used in the creation, maintenance and utilization of information systems." } } }, "auth_ref": [] }, "us-gaap_ConcentrationRiskCreditRisk": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ConcentrationRiskCreditRisk", "presentation": [ "http://qualisinnovations.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "label": "Concentrations, Risks, and Uncertainties", "documentation": "Disclosure of accounting policy for credit risk." } } }, "auth_ref": [ "r54", "r99" ] }, "dei_CountryRegion": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CountryRegion", "presentation": [ "http://qualisinnovations.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Country Region", "documentation": "Region code of country" } } }, "auth_ref": [] }, "dei_CoverAbstract": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CoverAbstract", "lang": { "en-us": { "role": { "label": "Cover [Abstract]", "documentation": "Cover page." } } }, "auth_ref": [] }, "QLIS_CreoMedIncMember": { "xbrltype": "domainItemType", "nsuri": "http://qualisinnovations.com/20231231", "localname": "CreoMedIncMember", "presentation": [ "http://qualisinnovations.com/role/OrganizationAndPrincipalActivitiesDetailsNarrative", "http://qualisinnovations.com/role/ScheduleOfPotentiallyDilutiveSecuritiesWereExcludedFromCalculationOfDilutedNetLossPerShareDetails", "http://qualisinnovations.com/role/ScheduleOfPotentiallyDilutiveSecuritiesWereExcludedFromCalculationOfDilutedNetLossPerShareDetailsParenthetical", "http://qualisinnovations.com/role/StockholdersDeficitEquityDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "CreoMed Inc [Member]", "documentation": "CreoMed Inc [Member]" } } }, "auth_ref": [] }, "dei_CurrentFiscalYearEndDate": { "xbrltype": "gMonthDayItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CurrentFiscalYearEndDate", "presentation": [ "http://qualisinnovations.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Current Fiscal Year End Date", "documentation": "End date of current fiscal year in the format --MM-DD." } } }, "auth_ref": [] }, "QLIS_DasenMember": { "xbrltype": "domainItemType", "nsuri": "http://qualisinnovations.com/20231231", "localname": "DasenMember", "presentation": [ "http://qualisinnovations.com/role/OrganizationAndPrincipalActivitiesDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Dasen [Member]", "documentation": "Dasen [Member]" } } }, "auth_ref": [] }, "us-gaap_DebtDisclosureAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtDisclosureAbstract", "lang": { "en-us": { "role": { "label": "Debt Disclosure [Abstract]" } } }, "auth_ref": [] }, "us-gaap_DebtInstrumentFaceAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtInstrumentFaceAmount", "crdr": "credit", "presentation": [ "http://qualisinnovations.com/role/ShortTermLoanDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Principal balance due", "documentation": "Face (par) amount of debt instrument at time of issuance." } } }, "auth_ref": [ "r51", "r52", "r200", "r302", "r438", "r439" ] }, "us-gaap_DebtInstrumentInterestRateStatedPercentage": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtInstrumentInterestRateStatedPercentage", "presentation": [ "http://qualisinnovations.com/role/ShortTermLoanDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Interest percentage", "documentation": "Contractual interest rate for funds borrowed, under the debt agreement." } } }, "auth_ref": [ "r27", "r201" ] }, "us-gaap_DeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsLineItems", "presentation": [ "http://qualisinnovations.com/role/ShortTermLoanDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Deferred Compensation Arrangement with Individual, Excluding Share-Based Payments and Postretirement Benefits [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [] }, "QLIS_DeferredTaxAssetsDepreciationAndAmortization": { "xbrltype": "monetaryItemType", "nsuri": "http://qualisinnovations.com/20231231", "localname": "DeferredTaxAssetsDepreciationAndAmortization", "crdr": "debit", "calculation": { "http://qualisinnovations.com/role/ScheduleOfDeferredTaxAssetsDetails": { "parentTag": "us-gaap_DeferredTaxAssetsNet", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://qualisinnovations.com/role/ScheduleOfDeferredTaxAssetsDetails" ], "lang": { "en-us": { "role": { "label": "Depreciation and amortization", "documentation": "Deferred tax assets depreciation and amortization." } } }, "auth_ref": [] }, "us-gaap_DeferredTaxAssetsGrossAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DeferredTaxAssetsGrossAbstract", "presentation": [ "http://qualisinnovations.com/role/ScheduleOfDeferredTaxAssetsDetails" ], "lang": { "en-us": { "role": { "label": "Deferred tax assets:" } } }, "auth_ref": [] }, "QLIS_DeferredTaxAssetsImpairmentOfIntangibleAssets": { "xbrltype": "monetaryItemType", "nsuri": "http://qualisinnovations.com/20231231", "localname": "DeferredTaxAssetsImpairmentOfIntangibleAssets", "crdr": "debit", "calculation": { "http://qualisinnovations.com/role/ScheduleOfDeferredTaxAssetsDetails": { "parentTag": "us-gaap_DeferredTaxAssetsNet", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://qualisinnovations.com/role/ScheduleOfDeferredTaxAssetsDetails" ], "lang": { "en-us": { "role": { "label": "Impairment of Intangible asset", "documentation": "Deferred tax assets impairment of intangible assets." } } }, "auth_ref": [] }, "us-gaap_DeferredTaxAssetsNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DeferredTaxAssetsNet", "crdr": "debit", "calculation": { "http://qualisinnovations.com/role/ScheduleOfDeferredTaxAssetsDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://qualisinnovations.com/role/ScheduleOfDeferredTaxAssetsDetails" ], "lang": { "en-us": { "role": { "totalLabel": "Deferred tax assets, net", "label": "Deferred Tax Assets, Net of Valuation Allowance", "documentation": "Amount after allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards." } } }, "auth_ref": [ "r528" ] }, "us-gaap_DeferredTaxAssetsOperatingLossCarryforwards": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DeferredTaxAssetsOperatingLossCarryforwards", "crdr": "debit", "calculation": { "http://qualisinnovations.com/role/ScheduleOfDeferredTaxAssetsDetails": { "parentTag": "us-gaap_DeferredTaxAssetsNet", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://qualisinnovations.com/role/ScheduleOfDeferredTaxAssetsDetails" ], "lang": { "en-us": { "role": { "label": "Net operating loss carry forwards", "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards." } } }, "auth_ref": [ "r50", "r529" ] }, "us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost", "crdr": "debit", "calculation": { "http://qualisinnovations.com/role/ScheduleOfDeferredTaxAssetsDetails": { "parentTag": "us-gaap_DeferredTaxAssetsNet", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://qualisinnovations.com/role/ScheduleOfDeferredTaxAssetsDetails" ], "lang": { "en-us": { "role": { "label": "Stock based compensation", "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from share-based compensation." } } }, "auth_ref": [ "r50", "r529" ] }, "us-gaap_DeferredTaxAssetsValuationAllowance": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DeferredTaxAssetsValuationAllowance", "crdr": "credit", "calculation": { "http://qualisinnovations.com/role/ScheduleOfDeferredTaxAssetsDetails": { "parentTag": "us-gaap_DeferredTaxAssetsNet", "weight": -1.0, "order": 5.0 } }, "presentation": [ "http://qualisinnovations.com/role/ScheduleOfDeferredTaxAssetsDetails" ], "lang": { "en-us": { "role": { "negatedLabel": "Valuation allowance", "label": "Deferred Tax Assets, Valuation Allowance", "documentation": "Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized." } } }, "auth_ref": [ "r267" ] }, "QLIS_DemirBingolMember": { "xbrltype": "domainItemType", "nsuri": "http://qualisinnovations.com/20231231", "localname": "DemirBingolMember", "presentation": [ "http://qualisinnovations.com/role/ScheduleOfPotentiallyDilutiveSecuritiesWereExcludedFromCalculationOfDilutedNetLossPerShareDetails" ], "lang": { "en-us": { "role": { "label": "Demir Bingol [Member]", "documentation": "Demir Bingol [Member]" } } }, "auth_ref": [] }, "us-gaap_DepositContractsPolicy": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DepositContractsPolicy", "presentation": [ "http://qualisinnovations.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "verboseLabel": "Deposits", "label": "Deposit Contracts, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy for the treatment of funds received from or paid to insureds, insurers and reinsurers on contracts for which the criteria for transferring or assuming insurance risk has not been satisfied by the insurer or reinsurer." } } }, "auth_ref": [ "r0" ] }, "us-gaap_DepositsAssetsCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DepositsAssetsCurrent", "crdr": "debit", "calculation": { "http://qualisinnovations.com/role/BalanceSheets": { "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://qualisinnovations.com/role/BalanceSheets" ], "lang": { "en-us": { "role": { "label": "Deposits", "documentation": "Carrying value of amounts transferred to third parties for security purposes that are expected to be returned or applied towards payment within one year or during the operating cycle, if shorter." } } }, "auth_ref": [ "r479" ] }, "us-gaap_Depreciation": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "Depreciation", "crdr": "debit", "calculation": { "http://qualisinnovations.com/role/StatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://qualisinnovations.com/role/PropertyAndEquipmentDetailsNarrative", "http://qualisinnovations.com/role/StatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Depreciation expense", "documentation": "The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation." } } }, "auth_ref": [ "r7", "r39" ] }, "dei_DocumentAccountingStandard": { "xbrltype": "accountingStandardItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentAccountingStandard", "presentation": [ "http://qualisinnovations.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Accounting Standard", "documentation": "The basis of accounting the registrant has used to prepare the financial statements included in this filing This can either be 'U.S. GAAP', 'International Financial Reporting Standards', or 'Other'." } } }, "auth_ref": [ "r468" ] }, "dei_DocumentAnnualReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentAnnualReport", "presentation": [ "http://qualisinnovations.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Annual Report", "documentation": "Boolean flag that is true only for a form used as an annual report." } } }, "auth_ref": [ "r466", "r468", "r469" ] }, "dei_DocumentFinStmtErrorCorrectionFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentFinStmtErrorCorrectionFlag", "presentation": [ "http://qualisinnovations.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Financial Statement Error Correction [Flag]", "documentation": "Indicates whether any of the financial statement period in the filing include a restatement due to error correction." } } }, "auth_ref": [ "r466", "r468", "r469", "r471" ] }, "dei_DocumentFiscalPeriodFocus": { "xbrltype": "fiscalPeriodItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentFiscalPeriodFocus", "presentation": [ "http://qualisinnovations.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Fiscal Period Focus", "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY." } } }, "auth_ref": [] }, "dei_DocumentFiscalYearFocus": { "xbrltype": "gYearItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentFiscalYearFocus", "presentation": [ "http://qualisinnovations.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Fiscal Year Focus", "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006." } } }, "auth_ref": [] }, "dei_DocumentPeriodEndDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentPeriodEndDate", "presentation": [ "http://qualisinnovations.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Period End Date", "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD." } } }, "auth_ref": [] }, "dei_DocumentPeriodStartDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentPeriodStartDate", "presentation": [ "http://qualisinnovations.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Period Start Date", "documentation": "The start date of the period covered in the document, in YYYY-MM-DD format." } } }, "auth_ref": [] }, "dei_DocumentQuarterlyReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentQuarterlyReport", "presentation": [ "http://qualisinnovations.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Quarterly Report", "documentation": "Boolean flag that is true only for a form used as an quarterly report." } } }, "auth_ref": [ "r467" ] }, "dei_DocumentRegistrationStatement": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentRegistrationStatement", "presentation": [ "http://qualisinnovations.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Registration Statement", "documentation": "Boolean flag that is true only for a form used as a registration statement." } } }, "auth_ref": [ "r455" ] }, "dei_DocumentShellCompanyEventDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentShellCompanyEventDate", "presentation": [ "http://qualisinnovations.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Shell Company Event Date", "documentation": "Date of event requiring a shell company report." } } }, "auth_ref": [ "r468" ] }, "dei_DocumentShellCompanyReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentShellCompanyReport", "presentation": [ "http://qualisinnovations.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Shell Company Report", "documentation": "Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act." } } }, "auth_ref": [ "r468" ] }, "dei_DocumentTransitionReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentTransitionReport", "presentation": [ "http://qualisinnovations.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Transition Report", "documentation": "Boolean flag that is true only for a form used as a transition report." } } }, "auth_ref": [ "r470" ] }, "dei_DocumentType": { "xbrltype": "submissionTypeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentType", "presentation": [ "http://qualisinnovations.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Type", "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'." } } }, "auth_ref": [] }, "dei_DocumentsIncorporatedByReferenceTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentsIncorporatedByReferenceTextBlock", "presentation": [ "http://qualisinnovations.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Documents Incorporated by Reference [Text Block]", "documentation": "Documents incorporated by reference." } } }, "auth_ref": [ "r458" ] }, "QLIS_DonxonMember": { "xbrltype": "domainItemType", "nsuri": "http://qualisinnovations.com/20231231", "localname": "DonxonMember", "presentation": [ "http://qualisinnovations.com/role/OrganizationAndPrincipalActivitiesDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Donxon [Member]", "documentation": "Donxon [Member]" } } }, "auth_ref": [] }, "QLIS_DrJosephPergolizziMember": { "xbrltype": "domainItemType", "nsuri": "http://qualisinnovations.com/20231231", "localname": "DrJosephPergolizziMember", "presentation": [ "http://qualisinnovations.com/role/OrganizationAndPrincipalActivitiesDetailsNarrative", "http://qualisinnovations.com/role/StockholdersDeficitEquityDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Dr Joseph Pergolizzi [Member]", "documentation": "Dr Joseph Pergolizzi [Member]" } } }, "auth_ref": [] }, "us-gaap_EarningsPerShareAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EarningsPerShareAbstract", "lang": { "en-us": { "role": { "label": "Earnings Per Share [Abstract]" } } }, "auth_ref": [] }, "us-gaap_EarningsPerShareBasic": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EarningsPerShareBasic", "presentation": [ "http://qualisinnovations.com/role/ScheduleOfComputationOfBasicAndDilutedNetIncomePerShareDetails", "http://qualisinnovations.com/role/StatementsOfOperations" ], "lang": { "en-us": { "role": { "label": "Net loss per share, basic", "verboseLabel": "Loss per share basic", "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period." } } }, "auth_ref": [ "r124", "r139", "r140", "r141", "r142", "r143", "r148", "r150", "r155", "r156", "r157", "r161", "r292", "r293", "r327", "r341", "r435" ] }, "us-gaap_EarningsPerShareDiluted": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EarningsPerShareDiluted", "presentation": [ "http://qualisinnovations.com/role/ScheduleOfComputationOfBasicAndDilutedNetIncomePerShareDetails", "http://qualisinnovations.com/role/StatementsOfOperations" ], "lang": { "en-us": { "role": { "label": "Net loss per share, diluted", "verboseLabel": "Loss per share diluted", "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period." } } }, "auth_ref": [ "r124", "r139", "r140", "r141", "r142", "r143", "r150", "r155", "r156", "r157", "r161", "r292", "r293", "r327", "r341", "r435" ] }, "us-gaap_EarningsPerSharePolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EarningsPerSharePolicyTextBlock", "presentation": [ "http://qualisinnovations.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "label": "Basic and diluted earnings per share", "documentation": "Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements." } } }, "auth_ref": [ "r34", "r35" ] }, "us-gaap_EarningsPerShareTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EarningsPerShareTextBlock", "presentation": [ "http://qualisinnovations.com/role/EarningsPerShare" ], "lang": { "en-us": { "role": { "label": "EARNINGS PER SHARE", "documentation": "The entire disclosure for earnings per share." } } }, "auth_ref": [ "r147", "r158", "r159", "r160" ] }, "QLIS_EchoResourcesLLLPMember": { "xbrltype": "domainItemType", "nsuri": "http://qualisinnovations.com/20231231", "localname": "EchoResourcesLLLPMember", "presentation": [ "http://qualisinnovations.com/role/OrganizationAndPrincipalActivitiesDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Echo Resources LLLP [Member]", "documentation": "Echo Resources LLLP [Member]" } } }, "auth_ref": [] }, "us-gaap_EffectiveIncomeTaxRateContinuingOperations": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EffectiveIncomeTaxRateContinuingOperations", "calculation": { "http://qualisinnovations.com/role/ScheduleOfReconciliationOfStatutoryIncomeTaxRatesDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://qualisinnovations.com/role/ScheduleOfReconciliationOfStatutoryIncomeTaxRatesDetails" ], "lang": { "en-us": { "role": { "totalLabel": "Provision for income taxes", "label": "Effective Income Tax Rate Reconciliation, Percent", "documentation": "Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations." } } }, "auth_ref": [ "r263" ] }, "us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate", "calculation": { "http://qualisinnovations.com/role/ScheduleOfReconciliationOfStatutoryIncomeTaxRatesDetails": { "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://qualisinnovations.com/role/ScheduleOfReconciliationOfStatutoryIncomeTaxRatesDetails" ], "lang": { "en-us": { "role": { "label": "Statutory U.S. federal rate", "documentation": "Percentage of domestic federal statutory tax rate applicable to pretax income (loss)." } } }, "auth_ref": [ "r133", "r263", "r275" ] }, "us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance", "calculation": { "http://qualisinnovations.com/role/ScheduleOfReconciliationOfStatutoryIncomeTaxRatesDetails": { "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://qualisinnovations.com/role/ScheduleOfReconciliationOfStatutoryIncomeTaxRatesDetails" ], "lang": { "en-us": { "role": { "label": "Valuation allowance", "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to changes in the valuation allowance for deferred tax assets." } } }, "auth_ref": [ "r527", "r530" ] }, "us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate", "calculation": { "http://qualisinnovations.com/role/ScheduleOfReconciliationOfStatutoryIncomeTaxRatesDetails": { "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://qualisinnovations.com/role/ScheduleOfReconciliationOfStatutoryIncomeTaxRatesDetails" ], "lang": { "en-us": { "role": { "label": "Permanent differences", "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to changes in the income tax rates." } } }, "auth_ref": [ "r275", "r527" ] }, "us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes", "calculation": { "http://qualisinnovations.com/role/ScheduleOfReconciliationOfStatutoryIncomeTaxRatesDetails": { "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://qualisinnovations.com/role/ScheduleOfReconciliationOfStatutoryIncomeTaxRatesDetails" ], "lang": { "en-us": { "role": { "label": "State income tax, net of federal benefit", "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations applicable to state and local income tax expense (benefit), net of federal tax expense (benefit)." } } }, "auth_ref": [ "r527", "r530" ] }, "dei_EntityAddressAddressLine1": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressAddressLine1", "presentation": [ "http://qualisinnovations.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line One", "documentation": "Address Line 1 such as Attn, Building Name, Street Name" } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine2": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressAddressLine2", "presentation": [ "http://qualisinnovations.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line Two", "documentation": "Address Line 2 such as Street or Suite number" } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine3": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressAddressLine3", "presentation": [ "http://qualisinnovations.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line Three", "documentation": "Address Line 3 such as an Office Park" } } }, "auth_ref": [] }, "dei_EntityAddressCityOrTown": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressCityOrTown", "presentation": [ "http://qualisinnovations.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, City or Town", "documentation": "Name of the City or Town" } } }, "auth_ref": [] }, "dei_EntityAddressCountry": { "xbrltype": "countryCodeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressCountry", "presentation": [ "http://qualisinnovations.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Country", "documentation": "ISO 3166-1 alpha-2 country code." } } }, "auth_ref": [] }, "dei_EntityAddressPostalZipCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressPostalZipCode", "presentation": [ "http://qualisinnovations.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Postal Zip Code", "documentation": "Code for the postal or zip code" } } }, "auth_ref": [] }, "dei_EntityAddressStateOrProvince": { "xbrltype": "stateOrProvinceItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressStateOrProvince", "presentation": [ "http://qualisinnovations.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, State or Province", "documentation": "Name of the state or province." } } }, "auth_ref": [] }, "dei_EntityBankruptcyProceedingsReportingCurrent": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityBankruptcyProceedingsReportingCurrent", "presentation": [ "http://qualisinnovations.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Bankruptcy Proceedings, Reporting Current", "documentation": "For registrants involved in bankruptcy proceedings during the preceding five years, the value Yes indicates that the registrant has filed all documents and reports required to be filed by Section 12, 13 or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court; the value No indicates the registrant has not. Registrants not involved in bankruptcy proceedings during the preceding five years should not report this element." } } }, "auth_ref": [ "r461" ] }, "dei_EntityCentralIndexKey": { "xbrltype": "centralIndexKeyItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityCentralIndexKey", "presentation": [ "http://qualisinnovations.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Central Index Key", "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK." } } }, "auth_ref": [ "r457" ] }, "dei_EntityCommonStockSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityCommonStockSharesOutstanding", "presentation": [ "http://qualisinnovations.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Common Stock, Shares Outstanding", "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument." } } }, "auth_ref": [] }, "dei_EntityCurrentReportingStatus": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityCurrentReportingStatus", "presentation": [ "http://qualisinnovations.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Current Reporting Status", "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure." } } }, "auth_ref": [] }, "dei_EntityDomain": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityDomain", "presentation": [ "http://qualisinnovations.com/role/OrganizationAndPrincipalActivitiesDetailsNarrative", "http://qualisinnovations.com/role/ScheduleOfPotentiallyDilutiveSecuritiesWereExcludedFromCalculationOfDilutedNetLossPerShareDetailsParenthetical", "http://qualisinnovations.com/role/StockholdersDeficitEquityDetailsNarrative" ], "lang": { "en-us": { "role": { "documentation": "All the names of the entities being reported upon in a document. Any legal structure used to conduct activities or to hold assets. Some examples of such structures are corporations, partnerships, limited liability companies, grantor trusts, and other trusts. This item does not include business and geographical segments which are included in the geographical or business segments domains." } } }, "auth_ref": [] }, "dei_EntityEmergingGrowthCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityEmergingGrowthCompany", "presentation": [ "http://qualisinnovations.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Emerging Growth Company", "documentation": "Indicate if registrant meets the emerging growth company criteria." } } }, "auth_ref": [ "r457" ] }, "dei_EntityExTransitionPeriod": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityExTransitionPeriod", "presentation": [ "http://qualisinnovations.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Elected Not To Use the Extended Transition Period", "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards." } } }, "auth_ref": [ "r475" ] }, "dei_EntityFileNumber": { "xbrltype": "fileNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityFileNumber", "presentation": [ "http://qualisinnovations.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity File Number", "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen." } } }, "auth_ref": [] }, "dei_EntityFilerCategory": { "xbrltype": "filerCategoryItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityFilerCategory", "presentation": [ "http://qualisinnovations.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Filer Category", "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure." } } }, "auth_ref": [ "r457" ] }, "dei_EntityIncorporationStateCountryCode": { "xbrltype": "edgarStateCountryItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityIncorporationStateCountryCode", "presentation": [ "http://qualisinnovations.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Incorporation, State or Country Code", "documentation": "Two-character EDGAR code representing the state or country of incorporation." } } }, "auth_ref": [] }, "dei_EntityInteractiveDataCurrent": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityInteractiveDataCurrent", "presentation": [ "http://qualisinnovations.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Interactive Data Current", "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files)." } } }, "auth_ref": [ "r472" ] }, "dei_EntityPrimarySicNumber": { "xbrltype": "sicNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityPrimarySicNumber", "presentation": [ "http://qualisinnovations.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Primary SIC Number", "documentation": "Primary Standard Industrial Classification (SIC) Number for the Entity." } } }, "auth_ref": [ "r469" ] }, "dei_EntityPublicFloat": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityPublicFloat", "crdr": "credit", "presentation": [ "http://qualisinnovations.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Public Float", "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter." } } }, "auth_ref": [] }, "dei_EntityRegistrantName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityRegistrantName", "presentation": [ "http://qualisinnovations.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Registrant Name", "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC." } } }, "auth_ref": [ "r457" ] }, "dei_EntityShellCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityShellCompany", "presentation": [ "http://qualisinnovations.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Shell Company", "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act." } } }, "auth_ref": [ "r457" ] }, "dei_EntitySmallBusiness": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntitySmallBusiness", "presentation": [ "http://qualisinnovations.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Small Business", "documentation": "Indicates that the company is a Smaller Reporting Company (SRC)." } } }, "auth_ref": [ "r457" ] }, "dei_EntityTaxIdentificationNumber": { "xbrltype": "employerIdItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityTaxIdentificationNumber", "presentation": [ "http://qualisinnovations.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Tax Identification Number", "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS." } } }, "auth_ref": [ "r457" ] }, "dei_EntityVoluntaryFilers": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityVoluntaryFilers", "presentation": [ "http://qualisinnovations.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Voluntary Filers", "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act." } } }, "auth_ref": [] }, "dei_EntityWellKnownSeasonedIssuer": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityWellKnownSeasonedIssuer", "presentation": [ "http://qualisinnovations.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Well-known Seasoned Issuer", "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A." } } }, "auth_ref": [ "r473" ] }, "us-gaap_EquityAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EquityAbstract", "lang": { "en-us": { "role": { "label": "Equity [Abstract]" } } }, "auth_ref": [] }, "us-gaap_EquityComponentDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EquityComponentDomain", "presentation": [ "http://qualisinnovations.com/role/CommitmentsAndContingenciesDetailsNarrative", "http://qualisinnovations.com/role/OrganizationAndPrincipalActivitiesDetailsNarrative", "http://qualisinnovations.com/role/ScheduleOfPotentiallyDilutiveSecuritiesWereExcludedFromCalculationOfDilutedNetLossPerShareDetailsParenthetical", "http://qualisinnovations.com/role/StatementsOfChangesInStockholdersDeficitEquity", "http://qualisinnovations.com/role/StockholdersDeficitEquityDetailsNarrative", "http://qualisinnovations.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative", "http://qualisinnovations.com/role/SummaryOfWarrantsOutstandingDetails" ], "lang": { "en-us": { "role": { "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc." } } }, "auth_ref": [ "r11", "r106", "r121", "r122", "r123", "r134", "r135", "r136", "r138", "r144", "r146", "r162", "r182", "r183", "r216", "r250", "r251", "r252", "r271", "r272", "r284", "r285", "r286", "r287", "r288", "r289", "r291", "r295", "r296", "r297", "r298", "r299", "r300", "r303", "r350", "r351", "r352", "r365", "r418" ] }, "srt_EquityMethodInvesteeNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "EquityMethodInvesteeNameDomain", "presentation": [ "http://qualisinnovations.com/role/OrganizationAndPrincipalActivitiesDetailsNarrative" ], "auth_ref": [ "r178", "r179", "r180" ] }, "us-gaap_EquityMethodInvestmentOwnershipPercentage": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EquityMethodInvestmentOwnershipPercentage", "presentation": [ "http://qualisinnovations.com/role/OrganizationAndPrincipalActivitiesDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Equity ownership percentage", "documentation": "The percentage of ownership of common stock or equity participation in the investee accounted for under the equity method of accounting." } } }, "auth_ref": [ "r178" ] }, "dei_Extension": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "Extension", "presentation": [ "http://qualisinnovations.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Extension", "documentation": "Extension number for local phone number." } } }, "auth_ref": [] }, "QLIS_FDHMember": { "xbrltype": "domainItemType", "nsuri": "http://qualisinnovations.com/20231231", "localname": "FDHMember", "presentation": [ "http://qualisinnovations.com/role/OrganizationAndPrincipalActivitiesDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "FDH [Member]", "documentation": "FDH [Member]" } } }, "auth_ref": [] }, "QLIS_FDSCMember": { "xbrltype": "domainItemType", "nsuri": "http://qualisinnovations.com/20231231", "localname": "FDSCMember", "presentation": [ "http://qualisinnovations.com/role/OrganizationAndPrincipalActivitiesDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "FDSC [Member]", "documentation": "FDSC [Member]" } } }, "auth_ref": [] }, "us-gaap_FairValueAdjustmentOfWarrants": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueAdjustmentOfWarrants", "crdr": "debit", "presentation": [ "http://qualisinnovations.com/role/CommitmentsAndContingenciesDetailsNarrative", "http://qualisinnovations.com/role/StockholdersDeficitEquityDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Warrants modification expense", "documentation": "Amount of expense (income) related to adjustment to fair value of warrant liability." } } }, "auth_ref": [ "r3", "r7" ] }, "us-gaap_FairValueMeasurementPolicyPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueMeasurementPolicyPolicyTextBlock", "presentation": [ "http://qualisinnovations.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "label": "Fair Value Measurements", "documentation": "Disclosure of accounting policy for fair value measurements of financial and non-financial assets, liabilities and instruments classified in shareholders' equity. Disclosures include, but are not limited to, how an entity that manages a group of financial assets and liabilities on the basis of its net exposure measures the fair value of those assets and liabilities." } } }, "auth_ref": [] }, "us-gaap_FairValueOfFinancialInstrumentsPolicy": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueOfFinancialInstrumentsPolicy", "presentation": [ "http://qualisinnovations.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "label": "Fair Value of Financial Instruments", "documentation": "Disclosure of accounting policy for determining the fair value of financial instruments." } } }, "auth_ref": [ "r9", "r21" ] }, "QLIS_FebruaryFourteenTwoThousandTwentyOneMember": { "xbrltype": "domainItemType", "nsuri": "http://qualisinnovations.com/20231231", "localname": "FebruaryFourteenTwoThousandTwentyOneMember", "presentation": [ "http://qualisinnovations.com/role/ScheduleOfPotentiallyDilutiveSecuritiesWereExcludedFromCalculationOfDilutedNetLossPerShareDetails" ], "lang": { "en-us": { "role": { "label": "February 14, 2021 [Member]", "documentation": "February 14, 2021 [Member]" } } }, "auth_ref": [] }, "QLIS_GainOnCancellationOfSharesForServices": { "xbrltype": "monetaryItemType", "nsuri": "http://qualisinnovations.com/20231231", "localname": "GainOnCancellationOfSharesForServices", "crdr": "credit", "calculation": { "http://qualisinnovations.com/role/StatementsOfOperations": { "parentTag": "us-gaap_NonoperatingIncomeExpense", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://qualisinnovations.com/role/StatementsOfOperations" ], "lang": { "en-us": { "role": { "negatedLabel": "Gain on cancellation of shares for services", "documentation": "Gain on cancellation of shares for services.", "label": "GainOnCancellationOfSharesForServices" } } }, "auth_ref": [] }, "us-gaap_GainsLossesOnExtinguishmentOfDebt": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "GainsLossesOnExtinguishmentOfDebt", "crdr": "credit", "calculation": { "http://qualisinnovations.com/role/StatementsOfOperations": { "parentTag": "us-gaap_NonoperatingIncomeExpense", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://qualisinnovations.com/role/StatementsOfOperations" ], "lang": { "en-us": { "role": { "negatedLabel": "Settlement of dispute", "label": "Gain (Loss) on Extinguishment of Debt", "documentation": "Difference between the fair value of payments made and the carrying amount of debt which is extinguished prior to maturity." } } }, "auth_ref": [ "r7", "r42", "r43" ] }, "us-gaap_GeneralAndAdministrativeExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "GeneralAndAdministrativeExpense", "crdr": "debit", "calculation": { "http://qualisinnovations.com/role/StatementsOfOperations": { "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://qualisinnovations.com/role/StatementsOfOperations" ], "lang": { "en-us": { "role": { "label": "General and administrative", "documentation": "The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line." } } }, "auth_ref": [ "r68", "r400" ] }, "us-gaap_GrossProfit": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "GrossProfit", "crdr": "credit", "calculation": { "http://qualisinnovations.com/role/StatementsOfOperations": { "parentTag": "us-gaap_OperatingIncomeLoss", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://qualisinnovations.com/role/StatementsOfOperations" ], "lang": { "en-us": { "role": { "totalLabel": "Gross Profit", "label": "Gross Profit", "documentation": "Aggregate revenue less cost of goods and services sold or operating expenses directly attributable to the revenue generation activity." } } }, "auth_ref": [ "r67", "r132", "r163", "r168", "r172", "r174", "r181", "r191", "r192", "r193", "r194", "r195", "r196", "r197", "r198", "r199", "r294", "r437", "r498" ] }, "dei_IcfrAuditorAttestationFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "IcfrAuditorAttestationFlag", "presentation": [ "http://qualisinnovations.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "ICFR Auditor Attestation Flag" } } }, "auth_ref": [ "r466", "r468", "r469" ] }, "us-gaap_ImpairmentOfIntangibleAssetsFinitelived": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ImpairmentOfIntangibleAssetsFinitelived", "crdr": "debit", "calculation": { "http://qualisinnovations.com/role/StatementsOfOperations": { "parentTag": "us-gaap_NonoperatingIncomeExpense", "weight": -1.0, "order": 2.0 }, "http://qualisinnovations.com/role/StatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://qualisinnovations.com/role/StatementsOfCashFlows", "http://qualisinnovations.com/role/StatementsOfOperations", "http://qualisinnovations.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Impairment of assets", "documentation": "The amount of impairment loss recognized in the period resulting from the write-down of the carrying amount of a finite-lived intangible asset to fair value." } } }, "auth_ref": [ "r484", "r492" ] }, "QLIS_ImpairmentOfToolingMember": { "xbrltype": "domainItemType", "nsuri": "http://qualisinnovations.com/20231231", "localname": "ImpairmentOfToolingMember", "presentation": [ "http://qualisinnovations.com/role/ScheduleOfPropertyAndEquipmentDetails" ], "lang": { "en-us": { "role": { "label": "Impairment of Tooling [Member]", "documentation": "Impairment of Tooling [Member]" } } }, "auth_ref": [] }, "us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock", "presentation": [ "http://qualisinnovations.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "label": "Impairment of Long-lived Assets", "documentation": "Disclosure of accounting policy for recognizing and measuring the impairment of long-lived assets. An entity also may disclose its accounting policy for long-lived assets to be sold. This policy excludes goodwill and intangible assets." } } }, "auth_ref": [ "r1", "r77" ] }, "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "crdr": "credit", "calculation": { "http://qualisinnovations.com/role/StatementsOfOperations": { "parentTag": "us-gaap_NetIncomeLoss", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://qualisinnovations.com/role/StatementsOfOperations" ], "lang": { "en-us": { "role": { "totalLabel": "Loss before income taxes", "label": "Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest", "documentation": "Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest." } } }, "auth_ref": [ "r2", "r65", "r91", "r163", "r168", "r172", "r174", "r328", "r339", "r437" ] }, "us-gaap_IncomeStatementAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncomeStatementAbstract", "lang": { "en-us": { "role": { "label": "Income Statement [Abstract]" } } }, "auth_ref": [] }, "us-gaap_IncomeTaxDisclosureAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncomeTaxDisclosureAbstract", "lang": { "en-us": { "role": { "label": "Income Tax Disclosure [Abstract]" } } }, "auth_ref": [] }, "us-gaap_IncomeTaxDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncomeTaxDisclosureTextBlock", "presentation": [ "http://qualisinnovations.com/role/IncomeTaxes" ], "lang": { "en-us": { "role": { "label": "INCOME TAXES", "documentation": "The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information." } } }, "auth_ref": [ "r133", "r259", "r264", "r265", "r269", "r273", "r276", "r277", "r278", "r361" ] }, "us-gaap_IncomeTaxExpenseBenefit": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncomeTaxExpenseBenefit", "crdr": "debit", "calculation": { "http://qualisinnovations.com/role/StatementsOfOperations": { "parentTag": "us-gaap_NetIncomeLoss", "weight": -1.0, "order": 2.0 } }, "presentation": [ "http://qualisinnovations.com/role/StatementsOfOperations" ], "lang": { "en-us": { "role": { "label": "Income taxes", "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations." } } }, "auth_ref": [ "r93", "r105", "r145", "r146", "r166", "r262", "r274", "r343" ] }, "us-gaap_IncomeTaxPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncomeTaxPolicyTextBlock", "presentation": [ "http://qualisinnovations.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "label": "Income Taxes", "documentation": "Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements." } } }, "auth_ref": [ "r120", "r260", "r261", "r265", "r266", "r268", "r270", "r358" ] }, "us-gaap_IncomeTaxesPaidNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncomeTaxesPaidNet", "crdr": "credit", "presentation": [ "http://qualisinnovations.com/role/StatementsOfCashFlows" ], "lang": { "en-us": { "role": { "verboseLabel": "Income taxes", "label": "Income Taxes Paid, Net", "documentation": "The amount of cash paid during the current period to foreign, federal, state, and local authorities as taxes on income, net of any cash received during the current period as refunds for the overpayment of taxes." } } }, "auth_ref": [ "r33" ] }, "us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncreaseDecreaseInAccountsPayableAndAccruedLiabilities", "crdr": "debit", "calculation": { "http://qualisinnovations.com/role/StatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 11.0 } }, "presentation": [ "http://qualisinnovations.com/role/StatementsOfCashFlows" ], "lang": { "en-us": { "role": { "verboseLabel": "Accounts payable and accrued expenses", "label": "Increase (Decrease) in Accounts Payable and Accrued Liabilities", "documentation": "The increase (decrease) during the reporting period in the amounts payable to vendors for goods and services received and the amount of obligations and expenses incurred but not paid." } } }, "auth_ref": [ "r6" ] }, "us-gaap_IncreaseDecreaseInInventories": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncreaseDecreaseInInventories", "crdr": "credit", "calculation": { "http://qualisinnovations.com/role/StatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0, "order": 9.0 } }, "presentation": [ "http://qualisinnovations.com/role/StatementsOfCashFlows" ], "lang": { "en-us": { "role": { "negatedLabel": "Inventory", "label": "Increase (Decrease) in Inventories", "documentation": "The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities." } } }, "auth_ref": [ "r6" ] }, "us-gaap_IncreaseDecreaseInNotesPayableCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncreaseDecreaseInNotesPayableCurrent", "crdr": "debit", "calculation": { "http://qualisinnovations.com/role/StatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 12.0 } }, "presentation": [ "http://qualisinnovations.com/role/StatementsOfCashFlows" ], "lang": { "en-us": { "role": { "verboseLabel": "Short-term note payable", "label": "Increase (Decrease) in Notes Payable, Current", "documentation": "The increase (decrease) during the reporting period in current portion (due within one year or one business cycle) of obligations evidenced by formal promissory notes." } } }, "auth_ref": [ "r6" ] }, "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncreaseDecreaseInOperatingCapitalAbstract", "presentation": [ "http://qualisinnovations.com/role/StatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Changes in operating assets and liabilities:" } } }, "auth_ref": [] }, "us-gaap_IncreaseDecreaseInOtherCurrentAssets": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncreaseDecreaseInOtherCurrentAssets", "crdr": "credit", "calculation": { "http://qualisinnovations.com/role/StatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0, "order": 10.0 } }, "presentation": [ "http://qualisinnovations.com/role/StatementsOfCashFlows" ], "lang": { "en-us": { "role": { "negatedLabel": "Other current assets", "label": "Increase (Decrease) in Other Current Assets", "documentation": "Amount of increase (decrease) in current assets classified as other." } } }, "auth_ref": [ "r483" ] }, "us-gaap_IncreaseDecreaseInOtherCurrentLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncreaseDecreaseInOtherCurrentLiabilities", "crdr": "debit", "calculation": { "http://qualisinnovations.com/role/StatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 13.0 } }, "presentation": [ "http://qualisinnovations.com/role/StatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Other current liabilities", "documentation": "Amount of increase (decrease) in current liabilities classified as other." } } }, "auth_ref": [ "r483" ] }, "us-gaap_IncrementalCommonSharesAttributableToCallOptionsAndWarrants": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncrementalCommonSharesAttributableToCallOptionsAndWarrants", "presentation": [ "http://qualisinnovations.com/role/ScheduleOfComputationOfBasicAndDilutedNetIncomePerShareDetails" ], "lang": { "en-us": { "role": { "label": "Dilutive effect of options and warrants", "documentation": "Additional shares included in the calculation of diluted EPS as a result of the potentially dilutive effect of call options and warrants using the treasury stock method." } } }, "auth_ref": [ "r151", "r152", "r153", "r157" ] }, "QLIS_IndependentContractorServicesAgreementMember": { "xbrltype": "domainItemType", "nsuri": "http://qualisinnovations.com/20231231", "localname": "IndependentContractorServicesAgreementMember", "presentation": [ "http://qualisinnovations.com/role/CommitmentsAndContingenciesDetailsNarrative", "http://qualisinnovations.com/role/StockholdersDeficitEquityDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Independent Contractor Services Agreement [Member]", "documentation": "Independent Contractor Services Agreement [Member]" } } }, "auth_ref": [] }, "QLIS_InsurancePolicyFinancedByShorttermNotePayable": { "xbrltype": "monetaryItemType", "nsuri": "http://qualisinnovations.com/20231231", "localname": "InsurancePolicyFinancedByShorttermNotePayable", "crdr": "credit", "presentation": [ "http://qualisinnovations.com/role/StatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Insurance policy financed by short-term note payable", "documentation": "Insurance policy financed by shortterm note payable." } } }, "auth_ref": [] }, "us-gaap_InterestPaidNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "InterestPaidNet", "crdr": "credit", "presentation": [ "http://qualisinnovations.com/role/StatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Interest", "documentation": "Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount." } } }, "auth_ref": [ "r125", "r127", "r128" ] }, "QLIS_InventoryAdjustment": { "xbrltype": "monetaryItemType", "nsuri": "http://qualisinnovations.com/20231231", "localname": "InventoryAdjustment", "crdr": "debit", "calculation": { "http://qualisinnovations.com/role/StatementsOfOperations": { "parentTag": "us-gaap_NonoperatingIncomeExpense", "weight": -1.0, "order": 3.0 } }, "presentation": [ "http://qualisinnovations.com/role/StatementsOfOperations" ], "lang": { "en-us": { "role": { "label": "Inventory adjustment", "documentation": "Inventory adjustment." } } }, "auth_ref": [] }, "us-gaap_InventoryNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "InventoryNet", "crdr": "debit", "calculation": { "http://qualisinnovations.com/role/BalanceSheets": { "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://qualisinnovations.com/role/BalanceSheets" ], "lang": { "en-us": { "role": { "label": "Inventory", "documentation": "Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer." } } }, "auth_ref": [ "r115", "r433", "r442" ] }, "us-gaap_InventoryPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "InventoryPolicyTextBlock", "presentation": [ "http://qualisinnovations.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "label": "Inventories", "documentation": "Disclosure of inventory accounting policy for inventory classes, including, but not limited to, basis for determining inventory amounts, methods by which amounts are added and removed from inventory classes, loss recognition on impairment of inventories, and situations in which inventories are stated above cost." } } }, "auth_ref": [ "r95", "r110", "r114", "r184", "r185", "r186", "r313", "r434" ] }, "QLIS_IssuanceOfCommonStockForServices": { "xbrltype": "monetaryItemType", "nsuri": "http://qualisinnovations.com/20231231", "localname": "IssuanceOfCommonStockForServices", "crdr": "debit", "calculation": { "http://qualisinnovations.com/role/StatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 7.0 } }, "presentation": [ "http://qualisinnovations.com/role/StatementsOfCashFlows" ], "lang": { "en-us": { "role": { "verboseLabel": "Issuance of common stock for services", "documentation": "Issuance of common stock for services.", "label": "Issuance of common stock for services [Default Label]" } } }, "auth_ref": [] }, "QLIS_IssuanceOfOptionsServicesOrClaims": { "xbrltype": "monetaryItemType", "nsuri": "http://qualisinnovations.com/20231231", "localname": "IssuanceOfOptionsServicesOrClaims", "crdr": "debit", "presentation": [ "http://qualisinnovations.com/role/StockholdersDeficitEquityDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Value of options granted", "documentation": "Issuance of options services or claims." } } }, "auth_ref": [] }, "QLIS_IssuanceOfStockAndWarrantsForServices": { "xbrltype": "monetaryItemType", "nsuri": "http://qualisinnovations.com/20231231", "localname": "IssuanceOfStockAndWarrantsForServices", "crdr": "debit", "calculation": { "http://qualisinnovations.com/role/StatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 5.0 } }, "presentation": [ "http://qualisinnovations.com/role/StatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Options issued for services", "documentation": "Issuance of stock and warrants for services." } } }, "auth_ref": [] }, "us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IssuanceOfStockAndWarrantsForServicesOrClaims", "crdr": "debit", "calculation": { "http://qualisinnovations.com/role/StatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 8.0 } }, "presentation": [ "http://qualisinnovations.com/role/CommitmentsAndContingenciesDetailsNarrative", "http://qualisinnovations.com/role/StatementsOfCashFlows", "http://qualisinnovations.com/role/StockholdersDeficitEquityDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Issuance of common stock in settlement of dispute", "verboseLabel": "Value of warrants granted", "documentation": "Fair value of share-based compensation granted to nonemployees as payment for services rendered or acknowledged claims." } } }, "auth_ref": [ "r7" ] }, "QLIS_JimHoltMember": { "xbrltype": "domainItemType", "nsuri": "http://qualisinnovations.com/20231231", "localname": "JimHoltMember", "presentation": [ "http://qualisinnovations.com/role/StockholdersDeficitEquityDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Jim Holt [Member]", "documentation": "Jim Holt [Member]" } } }, "auth_ref": [] }, "dei_LegalEntityAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "LegalEntityAxis", "presentation": [ "http://qualisinnovations.com/role/OrganizationAndPrincipalActivitiesDetailsNarrative", "http://qualisinnovations.com/role/ScheduleOfPotentiallyDilutiveSecuritiesWereExcludedFromCalculationOfDilutedNetLossPerShareDetailsParenthetical", "http://qualisinnovations.com/role/StockholdersDeficitEquityDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Legal Entity [Axis]", "documentation": "The set of legal entities associated with a report." } } }, "auth_ref": [] }, "us-gaap_Liabilities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "Liabilities", "crdr": "credit", "calculation": { "http://qualisinnovations.com/role/BalanceSheets": { "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://qualisinnovations.com/role/BalanceSheets" ], "lang": { "en-us": { "role": { "totalLabel": "Total liabilities", "label": "Liabilities", "documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future." } } }, "auth_ref": [ "r24", "r132", "r181", "r191", "r192", "r193", "r194", "r195", "r196", "r197", "r198", "r199", "r281", "r282", "r283", "r294", "r375", "r436", "r454", "r498", "r536", "r537" ] }, "us-gaap_LiabilitiesAndStockholdersEquity": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LiabilitiesAndStockholdersEquity", "crdr": "credit", "calculation": { "http://qualisinnovations.com/role/BalanceSheets": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://qualisinnovations.com/role/BalanceSheets" ], "lang": { "en-us": { "role": { "totalLabel": "Total liabilities and stockholders\u2019 (deficit) equity", "label": "Liabilities and Equity", "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any." } } }, "auth_ref": [ "r64", "r90", "r335", "r442", "r485", "r491", "r533" ] }, "us-gaap_LiabilitiesAndStockholdersEquityAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LiabilitiesAndStockholdersEquityAbstract", "presentation": [ "http://qualisinnovations.com/role/BalanceSheets" ], "lang": { "en-us": { "role": { "label": "LIABILITIES AND STOCKHOLDERS\u2019 (DEFICIT) EQUITY" } } }, "auth_ref": [] }, "us-gaap_LiabilitiesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LiabilitiesCurrent", "crdr": "credit", "calculation": { "http://qualisinnovations.com/role/BalanceSheets": { "parentTag": "us-gaap_Liabilities", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://qualisinnovations.com/role/BalanceSheets" ], "lang": { "en-us": { "role": { "totalLabel": "Total current liabilities", "label": "Liabilities, Current", "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer." } } }, "auth_ref": [ "r26", "r109", "r132", "r181", "r191", "r192", "r193", "r194", "r195", "r196", "r197", "r198", "r199", "r281", "r282", "r283", "r294", "r442", "r498", "r536", "r537" ] }, "us-gaap_LiabilitiesCurrentAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LiabilitiesCurrentAbstract", "presentation": [ "http://qualisinnovations.com/role/BalanceSheets" ], "lang": { "en-us": { "role": { "label": "Current liabilities:" } } }, "auth_ref": [] }, "dei_LocalPhoneNumber": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "LocalPhoneNumber", "presentation": [ "http://qualisinnovations.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Local Phone Number", "documentation": "Local phone number for entity." } } }, "auth_ref": [] }, "QLIS_MPathixMember": { "xbrltype": "domainItemType", "nsuri": "http://qualisinnovations.com/20231231", "localname": "MPathixMember", "presentation": [ "http://qualisinnovations.com/role/OrganizationAndPrincipalActivitiesDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "MPathix [Member]", "documentation": "MPathix [Member]" } } }, "auth_ref": [] }, "QLIS_MarchSixteenTwoThousandTwentyOneMember": { "xbrltype": "domainItemType", "nsuri": "http://qualisinnovations.com/20231231", "localname": "MarchSixteenTwoThousandTwentyOneMember", "presentation": [ "http://qualisinnovations.com/role/ScheduleOfPotentiallyDilutiveSecuritiesWereExcludedFromCalculationOfDilutedNetLossPerShareDetails" ], "lang": { "en-us": { "role": { "label": "March 16, 2021 [Member]", "documentation": "March 16, 2021 [Member]" } } }, "auth_ref": [] }, "us-gaap_MarketingAndAdvertisingExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "MarketingAndAdvertisingExpense", "crdr": "debit", "presentation": [ "http://qualisinnovations.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Advertising and marketing expense", "documentation": "The total expense recognized in the period for promotion, public relations, and brand or product advertising." } } }, "auth_ref": [ "r68" ] }, "QLIS_MrBingolMember": { "xbrltype": "domainItemType", "nsuri": "http://qualisinnovations.com/20231231", "localname": "MrBingolMember", "presentation": [ "http://qualisinnovations.com/role/ScheduleOfPotentiallyDilutiveSecuritiesWereExcludedFromCalculationOfDilutedNetLossPerShareDetailsParenthetical" ], "lang": { "en-us": { "role": { "label": "Mr Bingol [Member]", "documentation": "Mr Bingol [Member]" } } }, "auth_ref": [] }, "QLIS_MrHoltMember": { "xbrltype": "domainItemType", "nsuri": "http://qualisinnovations.com/20231231", "localname": "MrHoltMember", "presentation": [ "http://qualisinnovations.com/role/StockholdersDeficitEquityDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Mr. Holt [Member]", "documentation": "Mr. Holt [Member]" } } }, "auth_ref": [] }, "us-gaap_NetCashProvidedByUsedInFinancingActivities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NetCashProvidedByUsedInFinancingActivities", "crdr": "debit", "calculation": { "http://qualisinnovations.com/role/StatementsOfCashFlows": { "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://qualisinnovations.com/role/StatementsOfCashFlows" ], "lang": { "en-us": { "role": { "totalLabel": "Net cash provided by financing activities", "label": "Net Cash Provided by (Used in) Financing Activities", "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit." } } }, "auth_ref": [ "r126" ] }, "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract", "presentation": [ "http://qualisinnovations.com/role/StatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Cash flows from financing activities:" } } }, "auth_ref": [] }, "us-gaap_NetCashProvidedByUsedInInvestingActivities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NetCashProvidedByUsedInInvestingActivities", "crdr": "debit", "calculation": { "http://qualisinnovations.com/role/StatementsOfCashFlows": { "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://qualisinnovations.com/role/StatementsOfCashFlows" ], "lang": { "en-us": { "role": { "totalLabel": "Net cash used in investing activities", "label": "Net Cash Provided by (Used in) Investing Activities", "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets." } } }, "auth_ref": [ "r126" ] }, "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract", "presentation": [ "http://qualisinnovations.com/role/StatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Cash flows from investing activities:" } } }, "auth_ref": [] }, "us-gaap_NetCashProvidedByUsedInOperatingActivities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NetCashProvidedByUsedInOperatingActivities", "calculation": { "http://qualisinnovations.com/role/StatementsOfCashFlows": { "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://qualisinnovations.com/role/BasisOfPresentationDetailsNarrative", "http://qualisinnovations.com/role/StatementsOfCashFlows" ], "lang": { "en-us": { "role": { "totalLabel": "Net cash used in operating activities", "negatedLabel": "Net cash used in operating activities", "label": "Net Cash Provided by (Used in) Operating Activities", "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities." } } }, "auth_ref": [ "r70", "r71", "r72" ] }, "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract", "presentation": [ "http://qualisinnovations.com/role/StatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Cash flows from operating activities:" } } }, "auth_ref": [] }, "us-gaap_NetIncomeLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NetIncomeLoss", "crdr": "credit", "calculation": { "http://qualisinnovations.com/role/StatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 1.0 }, "http://qualisinnovations.com/role/StatementsOfOperations": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://qualisinnovations.com/role/BasisOfPresentationDetailsNarrative", "http://qualisinnovations.com/role/ScheduleOfComputationOfBasicAndDilutedNetIncomePerShareDetails", "http://qualisinnovations.com/role/StatementsOfCashFlows", "http://qualisinnovations.com/role/StatementsOfChangesInStockholdersDeficitEquity", "http://qualisinnovations.com/role/StatementsOfOperations" ], "lang": { "en-us": { "role": { "totalLabel": "Net loss", "label": "Net loss", "negatedLabel": "Net loss", "verboseLabel": "Net loss attributable to the common stockholders", "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent." } } }, "auth_ref": [ "r66", "r72", "r92", "r107", "r118", "r119", "r123", "r132", "r137", "r139", "r140", "r141", "r142", "r145", "r146", "r154", "r163", "r168", "r172", "r174", "r181", "r191", "r192", "r193", "r194", "r195", "r196", "r197", "r198", "r199", "r293", "r294", "r340", "r397", "r416", "r417", "r437", "r452", "r498" ] }, "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock", "presentation": [ "http://qualisinnovations.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "label": "Recent Accounting Pronouncements", "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact." } } }, "auth_ref": [] }, "dei_NoTradingSymbolFlag": { "xbrltype": "trueItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "NoTradingSymbolFlag", "presentation": [ "http://qualisinnovations.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "No Trading Symbol Flag", "documentation": "Boolean flag that is true only for a security having no trading symbol." } } }, "auth_ref": [] }, "QLIS_NonCashEquityTransactionsPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://qualisinnovations.com/20231231", "localname": "NonCashEquityTransactionsPolicyTextBlock", "presentation": [ "http://qualisinnovations.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "label": "Non-Cash Equity Transactions", "documentation": "Non Cash Equity Transactions [Policy Text Block]" } } }, "auth_ref": [] }, "QLIS_NonEmployeeShareBasedCompensationOptionAndIncentivePlansPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://qualisinnovations.com/20231231", "localname": "NonEmployeeShareBasedCompensationOptionAndIncentivePlansPolicyTextBlock", "presentation": [ "http://qualisinnovations.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "label": "Non-Employee Stock Based Compensation", "documentation": "Non Employee Share Based Compensation Option And Incentive Plans [Policy Text Block]" } } }, "auth_ref": [] }, "us-gaap_NoncashInvestingAndFinancingItemsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NoncashInvestingAndFinancingItemsAbstract", "presentation": [ "http://qualisinnovations.com/role/StatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Non-cash investing and financing activities:" } } }, "auth_ref": [] }, "us-gaap_NonoperatingIncomeExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NonoperatingIncomeExpense", "crdr": "credit", "calculation": { "http://qualisinnovations.com/role/StatementsOfOperations": { "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://qualisinnovations.com/role/StatementsOfOperations" ], "lang": { "en-us": { "role": { "negatedTotalLabel": "Total other expenses", "label": "Nonoperating Income (Expense)", "documentation": "The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business)." } } }, "auth_ref": [ "r69" ] }, "us-gaap_NonoperatingIncomeExpenseAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NonoperatingIncomeExpenseAbstract", "presentation": [ "http://qualisinnovations.com/role/StatementsOfOperations" ], "lang": { "en-us": { "role": { "label": "Operating (income) expenses:" } } }, "auth_ref": [] }, "us-gaap_OfficersCompensation": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OfficersCompensation", "crdr": "debit", "presentation": [ "http://qualisinnovations.com/role/CommitmentsAndContingenciesDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Annual base salary", "documentation": "Amount of expense for salary and wage arising from service rendered by officer. Excludes allocated cost, labor-related nonsalary expense, and direct and overhead labor cost included in cost of good and service sold." } } }, "auth_ref": [ "r480" ] }, "us-gaap_OperatingExpenses": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OperatingExpenses", "crdr": "debit", "calculation": { "http://qualisinnovations.com/role/StatementsOfOperations": { "parentTag": "us-gaap_OperatingIncomeLoss", "weight": -1.0, "order": 2.0 } }, "presentation": [ "http://qualisinnovations.com/role/StatementsOfOperations" ], "lang": { "en-us": { "role": { "label": "Total operating expenses", "documentation": "Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense." } } }, "auth_ref": [] }, "us-gaap_OperatingExpensesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OperatingExpensesAbstract", "presentation": [ "http://qualisinnovations.com/role/StatementsOfOperations" ], "lang": { "en-us": { "role": { "label": "Operating expenses:" } } }, "auth_ref": [] }, "us-gaap_OperatingIncomeLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OperatingIncomeLoss", "crdr": "credit", "calculation": { "http://qualisinnovations.com/role/StatementsOfOperations": { "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://qualisinnovations.com/role/StatementsOfOperations" ], "lang": { "en-us": { "role": { "totalLabel": "Loss from operations", "label": "Operating Income (Loss)", "documentation": "The net result for the period of deducting operating expenses from operating revenues." } } }, "auth_ref": [ "r163", "r168", "r172", "r174", "r437" ] }, "us-gaap_OperatingLossCarryforwards": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OperatingLossCarryforwards", "crdr": "debit", "presentation": [ "http://qualisinnovations.com/role/IncomeTaxesDetailsNarrative" ], "lang": { "en-us": { "role": { "verboseLabel": "Net operating loss carry forwards", "label": "Operating Loss Carryforwards", "documentation": "Amount of operating loss carryforward, before tax effects, available to reduce future taxable income under enacted tax laws." } } }, "auth_ref": [ "r49" ] }, "us-gaap_OperatingLossCarryforwardsLimitationsOnUse": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OperatingLossCarryforwardsLimitationsOnUse", "presentation": [ "http://qualisinnovations.com/role/IncomeTaxesDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Carryforwards limited description", "documentation": "A description of the limitations on the use of all operating loss carryforwards available to reduce future taxable income." } } }, "auth_ref": [] }, "QLIS_OptionsToPurchaseSharesOfCommonStockMember": { "xbrltype": "domainItemType", "nsuri": "http://qualisinnovations.com/20231231", "localname": "OptionsToPurchaseSharesOfCommonStockMember", "presentation": [ "http://qualisinnovations.com/role/ScheduleOfPotentiallyDilutiveSecuritiesWereExcludedFromCalculationOfDilutedNetLossPerShareDetails" ], "lang": { "en-us": { "role": { "label": "Options to Purchase Shares of Common Stock [Member]", "documentation": "Options to Purchase Shares of Common Stock [Member]" } } }, "auth_ref": [] }, "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract", "lang": { "en-us": { "role": { "label": "Organization, Consolidation and Presentation of Financial Statements [Abstract]" } } }, "auth_ref": [] }, "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock", "presentation": [ "http://qualisinnovations.com/role/OrganizationAndPrincipalActivities" ], "lang": { "en-us": { "role": { "label": "ORGANIZATION AND PRINCIPAL ACTIVITIES", "documentation": "The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure." } } }, "auth_ref": [ "r56", "r87", "r355", "r356" ] }, "us-gaap_OtherAssetsCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OtherAssetsCurrent", "crdr": "debit", "calculation": { "http://qualisinnovations.com/role/BalanceSheets": { "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://qualisinnovations.com/role/BalanceSheets" ], "lang": { "en-us": { "role": { "label": "Other current assets", "documentation": "Amount of current assets classified as other." } } }, "auth_ref": [ "r116", "r442" ] }, "us-gaap_OtherIncome": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OtherIncome", "crdr": "credit", "calculation": { "http://qualisinnovations.com/role/StatementsOfOperations": { "parentTag": "us-gaap_NonoperatingIncomeExpense", "weight": 1.0, "order": 5.0 } }, "presentation": [ "http://qualisinnovations.com/role/StatementsOfOperations" ], "lang": { "en-us": { "role": { "negatedLabel": "Other income", "label": "Other Income", "documentation": "Amount of revenue and income classified as other." } } }, "auth_ref": [ "r342", "r398", "r426", "r427", "r428" ] }, "dei_OtherReportingStandardItemNumber": { "xbrltype": "otherReportingStandardItemNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "OtherReportingStandardItemNumber", "presentation": [ "http://qualisinnovations.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Other Reporting Standard Item Number", "documentation": "\"Item 17\" or \"Item 18\" specified when the basis of accounting is neither US GAAP nor IFRS." } } }, "auth_ref": [ "r468" ] }, "us-gaap_ParentMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ParentMember", "presentation": [ "http://qualisinnovations.com/role/OrganizationAndPrincipalActivitiesDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Parent [Member]", "documentation": "Portion of equity, or net assets, in the consolidated entity attributable, directly or indirectly, to the parent. Excludes noncontrolling interests." } } }, "auth_ref": [] }, "us-gaap_PaymentsForProceedsFromOtherInvestingActivities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PaymentsForProceedsFromOtherInvestingActivities", "crdr": "credit", "calculation": { "http://qualisinnovations.com/role/StatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0, "order": 1.0 } }, "presentation": [ "http://qualisinnovations.com/role/StatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "None", "documentation": "Amount of cash (inflow) outflow from investing activities classified as other." } } }, "auth_ref": [ "r476", "r481" ] }, "us-gaap_PlanNameAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PlanNameAxis", "presentation": [ "http://qualisinnovations.com/role/CommitmentsAndContingenciesDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Plan Name [Axis]", "documentation": "Information by plan name for share-based payment arrangement." } } }, "auth_ref": [ "r501", "r502", "r503", "r504", "r505", "r506", "r507", "r508", "r509", "r510", "r511", "r512", "r513", "r514", "r515", "r516", "r517", "r518", "r519", "r520", "r521", "r522", "r523", "r524", "r525", "r526" ] }, "us-gaap_PlanNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PlanNameDomain", "presentation": [ "http://qualisinnovations.com/role/CommitmentsAndContingenciesDetailsNarrative" ], "lang": { "en-us": { "role": { "documentation": "Plan name for share-based payment arrangement." } } }, "auth_ref": [ "r501", "r502", "r503", "r504", "r505", "r506", "r507", "r508", "r509", "r510", "r511", "r512", "r513", "r514", "r515", "r516", "r517", "r518", "r519", "r520", "r521", "r522", "r523", "r524", "r525", "r526" ] }, "dei_PreCommencementIssuerTenderOffer": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "PreCommencementIssuerTenderOffer", "presentation": [ "http://qualisinnovations.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Pre-commencement Issuer Tender Offer", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act." } } }, "auth_ref": [ "r462" ] }, "dei_PreCommencementTenderOffer": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "PreCommencementTenderOffer", "presentation": [ "http://qualisinnovations.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Pre-commencement Tender Offer", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act." } } }, "auth_ref": [ "r463" ] }, "us-gaap_PreferredStockParOrStatedValuePerShare": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PreferredStockParOrStatedValuePerShare", "presentation": [ "http://qualisinnovations.com/role/BalanceSheetsParenthetical", "http://qualisinnovations.com/role/StockholdersDeficitEquityDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Preferred stock, par value", "documentation": "Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer." } } }, "auth_ref": [ "r58", "r203" ] }, "us-gaap_PreferredStockSharesAuthorized": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PreferredStockSharesAuthorized", "presentation": [ "http://qualisinnovations.com/role/BalanceSheetsParenthetical", "http://qualisinnovations.com/role/StockholdersDeficitEquityDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Preferred stock, shares authorized", "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws." } } }, "auth_ref": [ "r58", "r376" ] }, "us-gaap_PreferredStockSharesIssued": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PreferredStockSharesIssued", "presentation": [ "http://qualisinnovations.com/role/BalanceSheetsParenthetical" ], "lang": { "en-us": { "role": { "label": "Preferred stock, shares issued", "documentation": "Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt." } } }, "auth_ref": [ "r58", "r203" ] }, "us-gaap_PreferredStockSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PreferredStockSharesOutstanding", "presentation": [ "http://qualisinnovations.com/role/BalanceSheetsParenthetical", "http://qualisinnovations.com/role/StockholdersDeficitEquityDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Preferred stock, shares outstanding", "documentation": "Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased." } } }, "auth_ref": [ "r58", "r376", "r395", "r546", "r547" ] }, "us-gaap_PreferredStockValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PreferredStockValue", "crdr": "credit", "calculation": { "http://qualisinnovations.com/role/BalanceSheets": { "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://qualisinnovations.com/role/BalanceSheets" ], "lang": { "en-us": { "role": { "label": "Preferred stock, $0.001 par value, 25,000,000 shares authorized, no shares issued and outstanding at December 31, 2023 and 2022, respectively", "documentation": "Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity." } } }, "auth_ref": [ "r58", "r332", "r442" ] }, "us-gaap_ProceedsFromIssuanceOfCommonStock": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ProceedsFromIssuanceOfCommonStock", "crdr": "debit", "calculation": { "http://qualisinnovations.com/role/StatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://qualisinnovations.com/role/StatementsOfCashFlows" ], "lang": { "en-us": { "role": { "verboseLabel": "Issuance of common stock for cash", "label": "Proceeds from Issuance of Common Stock", "documentation": "The cash inflow from the additional capital contribution to the entity." } } }, "auth_ref": [ "r5" ] }, "us-gaap_ProceedsFromRelatedPartyDebt": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ProceedsFromRelatedPartyDebt", "crdr": "debit", "calculation": { "http://qualisinnovations.com/role/StatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://qualisinnovations.com/role/StatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Advance from shareholder", "documentation": "The cash inflow from a long-term borrowing made from related parties where one party can exercise control or significant influence over another party; including affiliates, owners or officers and their immediate families, pension trusts, and so forth. Alternate caption: Proceeds from Advances from Affiliates." } } }, "auth_ref": [ "r30" ] }, "us-gaap_ProductLiabilityContingencyLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ProductLiabilityContingencyLineItems", "presentation": [ "http://qualisinnovations.com/role/CommitmentsAndContingenciesDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Product Liability Contingency [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r190", "r494", "r495", "r496" ] }, "us-gaap_ProductLiabilityContingencyTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ProductLiabilityContingencyTable", "presentation": [ "http://qualisinnovations.com/role/CommitmentsAndContingenciesDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Product Liability Contingency [Table]", "documentation": "Information and financial data about the reasonably possible loss or the recognized and additional reasonably possible loss from product liability related to an individual product." } } }, "auth_ref": [ "r190", "r494", "r495", "r496" ] }, "srt_ProductOrServiceAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "ProductOrServiceAxis", "presentation": [ "http://qualisinnovations.com/role/CommitmentsAndContingenciesDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Product and Service [Axis]" } } }, "auth_ref": [ "r175", "r314", "r344", "r345", "r346", "r347", "r348", "r349", "r432", "r440", "r443", "r477", "r496", "r497", "r500", "r541" ] }, "srt_ProductsAndServicesDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "ProductsAndServicesDomain", "presentation": [ "http://qualisinnovations.com/role/CommitmentsAndContingenciesDetailsNarrative" ], "auth_ref": [ "r175", "r314", "r344", "r345", "r346", "r347", "r348", "r349", "r432", "r440", "r443", "r477", "r496", "r497", "r500", "r541" ] }, "us-gaap_ProfessionalFees": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ProfessionalFees", "crdr": "debit", "presentation": [ "http://qualisinnovations.com/role/CommitmentsAndContingenciesDetailsNarrative", "http://qualisinnovations.com/role/StockholdersDeficitEquityDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Consulting fee", "documentation": "A fee charged for services from professionals such as doctors, lawyers and accountants. The term is often expanded to include other professions, for example, pharmacists charging to maintain a medicinal profile of a client or customer." } } }, "auth_ref": [ "r452", "r544", "r545" ] }, "us-gaap_PropertyPlantAndEquipmentAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PropertyPlantAndEquipmentAbstract", "lang": { "en-us": { "role": { "label": "Property, Plant and Equipment [Abstract]" } } }, "auth_ref": [] }, "us-gaap_PropertyPlantAndEquipmentByTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PropertyPlantAndEquipmentByTypeAxis", "presentation": [ "http://qualisinnovations.com/role/ScheduleOfPropertyAndEquipmentDetails", "http://qualisinnovations.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Long-Lived Tangible Asset [Axis]", "documentation": "Information by type of long-lived, physical assets used to produce goods and services and not intended for resale." } } }, "auth_ref": [ "r8" ] }, "us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PropertyPlantAndEquipmentDisclosureTextBlock", "presentation": [ "http://qualisinnovations.com/role/PropertyAndEquipment" ], "lang": { "en-us": { "role": { "label": "PROPERTY AND EQUIPMENT", "documentation": "The entire disclosure for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections." } } }, "auth_ref": [ "r75", "r100", "r103", "r104" ] }, "us-gaap_PropertyPlantAndEquipmentGross": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PropertyPlantAndEquipmentGross", "crdr": "debit", "presentation": [ "http://qualisinnovations.com/role/ScheduleOfPropertyAndEquipmentDetails" ], "lang": { "en-us": { "role": { "label": "Property and equipment, gross", "documentation": "Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures." } } }, "auth_ref": [ "r76", "r111", "r338" ] }, "us-gaap_PropertyPlantAndEquipmentLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PropertyPlantAndEquipmentLineItems", "presentation": [ "http://qualisinnovations.com/role/ScheduleOfPropertyAndEquipmentDetails", "http://qualisinnovations.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Property, Plant and Equipment [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [] }, "us-gaap_PropertyPlantAndEquipmentNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PropertyPlantAndEquipmentNet", "crdr": "debit", "calculation": { "http://qualisinnovations.com/role/BalanceSheets": { "parentTag": "us-gaap_Assets", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://qualisinnovations.com/role/BalanceSheets", "http://qualisinnovations.com/role/ScheduleOfPropertyAndEquipmentDetails" ], "lang": { "en-us": { "role": { "label": "Property and equipment, net", "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures." } } }, "auth_ref": [ "r8", "r329", "r338", "r442" ] }, "us-gaap_PropertyPlantAndEquipmentPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PropertyPlantAndEquipmentPolicyTextBlock", "presentation": [ "http://qualisinnovations.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "label": "Property and Equipment", "documentation": "Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections." } } }, "auth_ref": [ "r8", "r100", "r103", "r336" ] }, "us-gaap_PropertyPlantAndEquipmentTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PropertyPlantAndEquipmentTextBlock", "presentation": [ "http://qualisinnovations.com/role/PropertyAndEquipmentTables" ], "lang": { "en-us": { "role": { "label": "SCHEDULE OF PROPERTY AND EQUIPMENT", "documentation": "Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation." } } }, "auth_ref": [ "r8" ] }, "us-gaap_PropertyPlantAndEquipmentTypeDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PropertyPlantAndEquipmentTypeDomain", "presentation": [ "http://qualisinnovations.com/role/ScheduleOfPropertyAndEquipmentDetails", "http://qualisinnovations.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" ], "lang": { "en-us": { "role": { "documentation": "Listing of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software." } } }, "auth_ref": [ "r76" ] }, "us-gaap_PropertyPlantAndEquipmentUsefulLife": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PropertyPlantAndEquipmentUsefulLife", "presentation": [ "http://qualisinnovations.com/role/ScheduleOfPropertyAndEquipmentDetails", "http://qualisinnovations.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Estimated useful lives", "verboseLabel": "Estimated Life", "documentation": "Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment." } } }, "auth_ref": [] }, "QLIS_RecapitalizationOfQualisInConjunctionWithReverseAcquisitionRate": { "xbrltype": "percentItemType", "nsuri": "http://qualisinnovations.com/20231231", "localname": "RecapitalizationOfQualisInConjunctionWithReverseAcquisitionRate", "presentation": [ "http://qualisinnovations.com/role/OrganizationAndPrincipalActivitiesDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Recapitalization of qualis in conjunction with reverse acquisition, rate", "documentation": "Recapitalization of Qualis in conjunction with reverse acquisition, rate." } } }, "auth_ref": [] }, "QLIS_RelatedPartiesPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://qualisinnovations.com/20231231", "localname": "RelatedPartiesPolicyTextBlock", "presentation": [ "http://qualisinnovations.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "label": "Related Parties", "documentation": "Related Parties [Policy Text Block]" } } }, "auth_ref": [] }, "us-gaap_RelatedPartyDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RelatedPartyDomain", "presentation": [ "http://qualisinnovations.com/role/CommitmentsAndContingenciesDetailsNarrative", "http://qualisinnovations.com/role/ScheduleOfPotentiallyDilutiveSecuritiesWereExcludedFromCalculationOfDilutedNetLossPerShareDetails", "http://qualisinnovations.com/role/ScheduleOfPotentiallyDilutiveSecuritiesWereExcludedFromCalculationOfDilutedNetLossPerShareDetailsParenthetical", "http://qualisinnovations.com/role/StockholdersDeficitEquityDetailsNarrative", "http://qualisinnovations.com/role/SubsequentEventsDetailsNarrative" ], "lang": { "en-us": { "role": { "documentation": "Related parties include affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests." } } }, "auth_ref": [ "r219", "r307", "r308", "r369", "r370", "r371", "r373", "r374", "r394", "r396", "r425" ] }, "us-gaap_RelatedPartyTransactionsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RelatedPartyTransactionsAbstract", "lang": { "en-us": { "role": { "label": "Related Party Transactions [Abstract]" } } }, "auth_ref": [] }, "us-gaap_RelatedPartyTransactionsByRelatedPartyAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RelatedPartyTransactionsByRelatedPartyAxis", "presentation": [ "http://qualisinnovations.com/role/CommitmentsAndContingenciesDetailsNarrative", "http://qualisinnovations.com/role/ScheduleOfPotentiallyDilutiveSecuritiesWereExcludedFromCalculationOfDilutedNetLossPerShareDetails", "http://qualisinnovations.com/role/ScheduleOfPotentiallyDilutiveSecuritiesWereExcludedFromCalculationOfDilutedNetLossPerShareDetailsParenthetical", "http://qualisinnovations.com/role/StockholdersDeficitEquityDetailsNarrative", "http://qualisinnovations.com/role/SubsequentEventsDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Related Party, Type [Axis]", "documentation": "Information by type of related party. Related parties include, but not limited to, affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests." } } }, "auth_ref": [ "r219", "r307", "r308", "r315", "r316", "r317", "r318", "r319", "r320", "r321", "r322", "r323", "r324", "r325", "r326", "r369", "r370", "r371", "r373", "r374", "r394", "r396", "r425", "r535" ] }, "us-gaap_RelatedPartyTransactionsDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RelatedPartyTransactionsDisclosureTextBlock", "presentation": [ "http://qualisinnovations.com/role/RelatedPartyTransactions" ], "lang": { "en-us": { "role": { "label": "RELATED PARTY TRANSACTIONS", "documentation": "The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates." } } }, "auth_ref": [ "r304", "r305", "r306", "r308", "r309", "r362", "r363", "r364", "r401", "r402", "r403", "r422", "r424" ] }, "us-gaap_RepaymentsOfDebt": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RepaymentsOfDebt", "crdr": "credit", "presentation": [ "http://qualisinnovations.com/role/ShortTermLoanDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Repayments debt", "documentation": "Amount of cash outflow for short-term and long-term debt. Excludes payment of lease obligation." } } }, "auth_ref": [ "r482" ] }, "us-gaap_ResearchAndDevelopmentExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ResearchAndDevelopmentExpense", "crdr": "debit", "calculation": { "http://qualisinnovations.com/role/StatementsOfOperations": { "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://qualisinnovations.com/role/StatementsOfOperations" ], "lang": { "en-us": { "role": { "label": "Research and development", "documentation": "The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use." } } }, "auth_ref": [ "r55", "r258", "r538" ] }, "us-gaap_ResearchAndDevelopmentExpensePolicy": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ResearchAndDevelopmentExpensePolicy", "presentation": [ "http://qualisinnovations.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "label": "Research and Development", "documentation": "Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process." } } }, "auth_ref": [ "r257" ] }, "us-gaap_RetainedEarningsAccumulatedDeficit": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RetainedEarningsAccumulatedDeficit", "crdr": "credit", "calculation": { "http://qualisinnovations.com/role/BalanceSheets": { "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://qualisinnovations.com/role/BalanceSheets", "http://qualisinnovations.com/role/BasisOfPresentationDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Accumulated deficit", "negatedLabel": "Accumulated deficit", "documentation": "Amount of accumulated undistributed earnings (deficit)." } } }, "auth_ref": [ "r61", "r81", "r334", "r353", "r354", "r360", "r377", "r442" ] }, "us-gaap_RetainedEarningsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RetainedEarningsMember", "presentation": [ "http://qualisinnovations.com/role/StatementsOfChangesInStockholdersDeficitEquity" ], "lang": { "en-us": { "role": { "label": "Retained Earnings [Member]", "documentation": "Accumulated undistributed earnings (deficit)." } } }, "auth_ref": [ "r106", "r134", "r135", "r136", "r138", "r144", "r146", "r182", "r183", "r250", "r251", "r252", "r271", "r272", "r284", "r286", "r287", "r289", "r291", "r350", "r352", "r365", "r546" ] }, "us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RevenueFromContractWithCustomerExcludingAssessedTax", "crdr": "credit", "calculation": { "http://qualisinnovations.com/role/StatementsOfOperations": { "parentTag": "us-gaap_GrossProfit", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://qualisinnovations.com/role/StatementsOfOperations" ], "lang": { "en-us": { "role": { "label": "Net revenue", "documentation": "Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise." } } }, "auth_ref": [ "r164", "r165", "r167", "r170", "r171", "r175", "r176", "r177", "r217", "r218", "r314" ] }, "QLIS_SOLACEDeviceMember": { "xbrltype": "domainItemType", "nsuri": "http://qualisinnovations.com/20231231", "localname": "SOLACEDeviceMember", "presentation": [ "http://qualisinnovations.com/role/CommitmentsAndContingenciesDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "SOLACE Device [Member]", "documentation": "SOLACE Device [Member]" } } }, "auth_ref": [] }, "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable", "presentation": [ "http://qualisinnovations.com/role/ScheduleOfPotentiallyDilutiveSecuritiesWereExcludedFromCalculationOfDilutedNetLossPerShareDetails" ], "lang": { "en-us": { "role": { "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]", "documentation": "Schedule for securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by Antidilutive Securities." } } }, "auth_ref": [ "r34" ] }, "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock", "presentation": [ "http://qualisinnovations.com/role/EarningsPerShareTables" ], "lang": { "en-us": { "role": { "label": "SCHEDULE OF POTENTIALLY DILUTIVE SECURITIES WERE EXCLUDED FROM CALCULATION OF DILUTED NET LOSS PER SHARE", "documentation": "Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities." } } }, "auth_ref": [ "r34" ] }, "us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable", "presentation": [ "http://qualisinnovations.com/role/OrganizationAndPrincipalActivitiesDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Table]", "documentation": "Disclosure of information about collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations." } } }, "auth_ref": [ "r279" ] }, "us-gaap_ScheduleOfDeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsByTitleOfIndividualAndByTypeOfDeferredCompensationTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfDeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsByTitleOfIndividualAndByTypeOfDeferredCompensationTable", "presentation": [ "http://qualisinnovations.com/role/ShortTermLoanDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Schedule of Deferred Compensation Arrangement with Individual, Excluding Share-Based Payments and Postretirement Benefits, by Title of Individual and by Type of Deferred Compensation [Table]", "documentation": "Schedule, table or text reflecting arrangements that are not equity-based payments, or pension and other postretirement benefits, with individual employees. The arrangements (for example, profit sharing, deferred bonuses or certain split-dollar life insurance arrangements) are generally based on employment contracts between the entity and one or more selected officers or key employees, and which contain a promise by the employer to pay certain amounts at designated future dates, sometimes including a period after retirement, upon compliance with stipulated requirements. This type of arrangement is distinguished from broader based employee benefit plans as it is usually tailored to the employee. Disclosure also typically includes the amount of related compensation expense recognized during the reporting period and the carrying amount as of the balance sheet date of the related liability." } } }, "auth_ref": [ "r44", "r83" ] }, "us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock", "presentation": [ "http://qualisinnovations.com/role/IncomeTaxesTables" ], "lang": { "en-us": { "role": { "label": "SCHEDULE OF DEFERRED TAX ASSETS", "documentation": "Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets." } } }, "auth_ref": [ "r86" ] }, "us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "presentation": [ "http://qualisinnovations.com/role/EarningsPerShareTables" ], "lang": { "en-us": { "role": { "label": "SCHEDULE OF COMPUTATION OF BASIC AND DILUTED NET INCOME PER SHARE", "documentation": "Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations." } } }, "auth_ref": [ "r489" ] }, "us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock", "presentation": [ "http://qualisinnovations.com/role/IncomeTaxesTables" ], "lang": { "en-us": { "role": { "label": "SCHEDULE OF RECONCILIATION OF STATUTORY INCOME TAX RATES", "documentation": "Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations." } } }, "auth_ref": [ "r85" ] }, "srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis", "presentation": [ "http://qualisinnovations.com/role/OrganizationAndPrincipalActivitiesDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Investment, Name [Axis]" } } }, "auth_ref": [ "r178", "r179", "r180" ] }, "us-gaap_ScheduleOfPropertyPlantAndEquipmentTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfPropertyPlantAndEquipmentTable", "presentation": [ "http://qualisinnovations.com/role/ScheduleOfPropertyAndEquipmentDetails", "http://qualisinnovations.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Property, Plant and Equipment [Table]", "documentation": "Disclosure of information about physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation." } } }, "auth_ref": [ "r8" ] }, "us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "presentation": [ "http://qualisinnovations.com/role/StockholdersDeficitEquityTables" ], "lang": { "en-us": { "role": { "label": "SUMMARY OF STOCK OPTIONS OUTSTANDING", "documentation": "Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value." } } }, "auth_ref": [ "r18", "r19", "r48" ] }, "us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock", "presentation": [ "http://qualisinnovations.com/role/StockholdersDeficitEquityTables" ], "lang": { "en-us": { "role": { "label": "SUMMARY OF WARRANTS OUTSTANDING", "documentation": "Tabular disclosure of warrants or rights issued. Warrants and rights outstanding are derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months. Disclose the title of issue of securities called for by warrants and rights outstanding, the aggregate amount of securities called for by warrants and rights outstanding, the date from which the warrants or rights are exercisable, and the price at which the warrant or right is exercisable." } } }, "auth_ref": [ "r45" ] }, "dei_Security12bTitle": { "xbrltype": "securityTitleItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "Security12bTitle", "presentation": [ "http://qualisinnovations.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Title of 12(b) Security", "documentation": "Title of a 12(b) registered security." } } }, "auth_ref": [ "r456" ] }, "dei_Security12gTitle": { "xbrltype": "securityTitleItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "Security12gTitle", "presentation": [ "http://qualisinnovations.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Title of 12(g) Security", "documentation": "Title of a 12(g) registered security." } } }, "auth_ref": [ "r460" ] }, "dei_SecurityExchangeName": { "xbrltype": "edgarExchangeCodeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "SecurityExchangeName", "presentation": [ "http://qualisinnovations.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Security Exchange Name", "documentation": "Name of the Exchange on which a security is registered." } } }, "auth_ref": [ "r459" ] }, "dei_SecurityReportingObligation": { "xbrltype": "securityReportingObligationItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "SecurityReportingObligation", "presentation": [ "http://qualisinnovations.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Security Reporting Obligation", "documentation": "15(d), indicating whether the security has a reporting obligation under that section of the Exchange Act." } } }, "auth_ref": [ "r464" ] }, "us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SellingGeneralAndAdministrativeExpensesPolicyTextBlock", "presentation": [ "http://qualisinnovations.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "label": "General and Administrative Expenses", "documentation": "Disclosure of accounting policy for inclusion of significant items in the selling, general and administrative (or similar) expense report caption." } } }, "auth_ref": [ "r10" ] }, "us-gaap_ShareBasedCompensation": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensation", "crdr": "debit", "calculation": { "http://qualisinnovations.com/role/StatementsOfOperations": { "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0, "order": 3.0 }, "http://qualisinnovations.com/role/StatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 6.0 } }, "presentation": [ "http://qualisinnovations.com/role/StatementsOfCashFlows", "http://qualisinnovations.com/role/StatementsOfOperations" ], "lang": { "en-us": { "role": { "label": "Stock based compensation - related party", "verboseLabel": "Stock based compensation - related parties", "documentation": "Amount of noncash expense for share-based payment arrangement." } } }, "auth_ref": [ "r6" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised", "presentation": [ "http://qualisinnovations.com/role/SummaryOfWarrantsOutstandingDetails" ], "lang": { "en-us": { "role": { "label": "Warrants, Exercised", "documentation": "Number of non-option equity instruments exercised by participants." } } }, "auth_ref": [ "r15" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures", "presentation": [ "http://qualisinnovations.com/role/StockholdersDeficitEquityDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Number of warrants cancelled", "documentation": "Number of shares under non-option equity instrument agreements that were cancelled as a result of occurrence of a terminating event." } } }, "auth_ref": [ "r16" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeituresAndExpirations": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeituresAndExpirations", "presentation": [ "http://qualisinnovations.com/role/SummaryOfWarrantsOutstandingDetails" ], "lang": { "en-us": { "role": { "negatedLabel": "Warrants, Expired/Forfeited", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Non-Option Equity Instruments, Forfeitures and Expirations", "documentation": "Number of shares under non-option equity instrument agreements that were either cancelled or expired." } } }, "auth_ref": [ "r17" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted", "presentation": [ "http://qualisinnovations.com/role/CommitmentsAndContingenciesDetailsNarrative", "http://qualisinnovations.com/role/StockholdersDeficitEquityDetailsNarrative", "http://qualisinnovations.com/role/SummaryOfWarrantsOutstandingDetails" ], "lang": { "en-us": { "role": { "label": "Warrants, Granted", "verboseLabel": "Warrants granted", "documentation": "Net number of non-option equity instruments granted to participants." } } }, "auth_ref": [ "r14" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber", "presentation": [ "http://qualisinnovations.com/role/SummaryOfWarrantsOutstandingDetails" ], "lang": { "en-us": { "role": { "periodStartLabel": "Warrants Outstanding, Beginning balance", "periodEndLabel": "Warrants Outstanding, Ending balance", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Non-Option Equity Instruments, Outstanding, Number", "documentation": "Number of equity instruments other than options outstanding, including both vested and non-vested instruments." } } }, "auth_ref": [ "r12", "r13" ] }, "QLIS_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsTermsOfAward": { "xbrltype": "stringItemType", "nsuri": "http://qualisinnovations.com/20231231", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsTermsOfAward", "presentation": [ "http://qualisinnovations.com/role/StockholdersDeficitEquityDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Warrants exercisable period", "documentation": "Share based compensation arrangement by share based payment award non option equity instruments terms of award." } } }, "auth_ref": [] }, "QLIS_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsExercisableIntrinsicValue": { "xbrltype": "monetaryItemType", "nsuri": "http://qualisinnovations.com/20231231", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsExercisableIntrinsicValue", "crdr": "debit", "presentation": [ "http://qualisinnovations.com/role/SummaryOfWarrantsOutstandingDetails" ], "lang": { "en-us": { "role": { "periodEndLabel": "Average Intrinsic Value, Exercisable", "documentation": "Share-based compensation arrangement by share-based payment award, non-options, exercisable, aggregate intrinsic value.", "label": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsExercisableIntrinsicValue" } } }, "auth_ref": [] }, "QLIS_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsExercisableNumber": { "xbrltype": "sharesItemType", "nsuri": "http://qualisinnovations.com/20231231", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsExercisableNumber", "presentation": [ "http://qualisinnovations.com/role/SummaryOfWarrantsOutstandingDetails" ], "lang": { "en-us": { "role": { "periodEndLabel": "Warrants, Exercisable", "documentation": "Share based compensation arrangement by share based payment award non options exercisable number.", "label": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsExercisableNumber" } } }, "auth_ref": [] }, "QLIS_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsExercisesInPeriodIntrinsicValue": { "xbrltype": "monetaryItemType", "nsuri": "http://qualisinnovations.com/20231231", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsExercisesInPeriodIntrinsicValue", "crdr": "debit", "presentation": [ "http://qualisinnovations.com/role/SummaryOfWarrantsOutstandingDetails" ], "lang": { "en-us": { "role": { "label": "Aggregate Intrinsic Value, Exercised", "documentation": "Share-based compensation arrangement by share-based payment award, non-options, exercises and in period intrinsic value." } } }, "auth_ref": [] }, "QLIS_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsExpectedToBeVested": { "xbrltype": "sharesItemType", "nsuri": "http://qualisinnovations.com/20231231", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsExpectedToBeVested", "presentation": [ "http://qualisinnovations.com/role/SummaryOfWarrantsOutstandingDetails" ], "lang": { "en-us": { "role": { "periodEndLabel": "Warrants, Expected to be vested", "documentation": "Share based compensation arrangement by share based payment award non options expected to be vested.", "label": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsExpectedToBeVested" } } }, "auth_ref": [] }, "QLIS_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsExpectedToBeVestedIntrinsicValue": { "xbrltype": "monetaryItemType", "nsuri": "http://qualisinnovations.com/20231231", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsExpectedToBeVestedIntrinsicValue", "crdr": "debit", "presentation": [ "http://qualisinnovations.com/role/SummaryOfWarrantsOutstandingDetails" ], "lang": { "en-us": { "role": { "periodEndLabel": "Average Intrinsic Value, Expected to be vested", "documentation": "Share-based compensation arrangement by share-based payment award, non-options, expected to be vested, aggregate intrinsic value.", "label": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsExpectedToBeVestedIntrinsicValue" } } }, "auth_ref": [] }, "QLIS_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsForfeituresAndExpirationsInPeriodIntrinsicValue": { "xbrltype": "monetaryItemType", "nsuri": "http://qualisinnovations.com/20231231", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsForfeituresAndExpirationsInPeriodIntrinsicValue", "crdr": "debit", "presentation": [ "http://qualisinnovations.com/role/SummaryOfWarrantsOutstandingDetails" ], "lang": { "en-us": { "role": { "negatedLabel": "Average Intrinsic Value, Expired/Forfeited", "documentation": "Share-based compensation arrangement by share-based payment award, non-options, forfeitures and expirations in period intrinsic value.", "label": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsForfeituresAndExpirationsInPeriodIntrinsicValue" } } }, "auth_ref": [] }, "QLIS_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsGrantsInPeriodIntrinsicValue": { "xbrltype": "monetaryItemType", "nsuri": "http://qualisinnovations.com/20231231", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsGrantsInPeriodIntrinsicValue", "crdr": "debit", "presentation": [ "http://qualisinnovations.com/role/SummaryOfWarrantsOutstandingDetails" ], "lang": { "en-us": { "role": { "label": "Aggregate Intrinsic Value, Granted", "documentation": "Share-based compensation arrangement by share-based payment award, non-options, grants in period intrinsic value." } } }, "auth_ref": [] }, "QLIS_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingIntrinsicValue": { "xbrltype": "monetaryItemType", "nsuri": "http://qualisinnovations.com/20231231", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingIntrinsicValue", "crdr": "debit", "presentation": [ "http://qualisinnovations.com/role/SummaryOfWarrantsOutstandingDetails" ], "lang": { "en-us": { "role": { "periodStartLabel": "Aggregate Intrinsic Value, Beginning balance", "periodEndLabel": "Aggregate Intrinsic Value, Ending balance", "documentation": "Share-based compensation arrangement by share-based payment award, non-options, outstanding intrinsic value.", "label": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingIntrinsicValue" } } }, "auth_ref": [] }, "QLIS_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsWeightedAverageExercisePriceExercisable": { "xbrltype": "perShareItemType", "nsuri": "http://qualisinnovations.com/20231231", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsWeightedAverageExercisePriceExercisable", "presentation": [ "http://qualisinnovations.com/role/SummaryOfWarrantsOutstandingDetails" ], "lang": { "en-us": { "role": { "periodEndLabel": "Weighted Average Exercise Price Outstanding, Exercisable", "documentation": "Share-based compensation arrangement by share-based payment award, non-options, Weighted average exercise price exercisable.", "label": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsWeightedAverageExercisePriceExercisable" } } }, "auth_ref": [] }, "QLIS_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsWeightedAverageExercisePriceExpectedToBeVested": { "xbrltype": "perShareItemType", "nsuri": "http://qualisinnovations.com/20231231", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsWeightedAverageExercisePriceExpectedToBeVested", "presentation": [ "http://qualisinnovations.com/role/SummaryOfWarrantsOutstandingDetails" ], "lang": { "en-us": { "role": { "periodEndLabel": "Weighted Average Exercise Price Outstanding, Expected to be vested", "documentation": "Share-based compensation arrangement by share-based payment award, non-options, expected to be vested, exercisable, aggregate intrinsic value.", "label": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsWeightedAverageExercisePriceExpectedToBeVested" } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized", "presentation": [ "http://qualisinnovations.com/role/CommitmentsAndContingenciesDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Common stock to be issued", "documentation": "Number of shares authorized for issuance under share-based payment arrangement." } } }, "auth_ref": [ "r441" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber", "presentation": [ "http://qualisinnovations.com/role/SummaryOfStockOptionsOutstandingDetails" ], "lang": { "en-us": { "role": { "periodEndLabel": "Options, Exercisable", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Number", "documentation": "The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan." } } }, "auth_ref": [ "r227" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice", "presentation": [ "http://qualisinnovations.com/role/SummaryOfStockOptionsOutstandingDetails" ], "lang": { "en-us": { "role": { "periodEndLabel": "Options, Weighted Average Exercise Price, Exercisable", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Exercise Price", "documentation": "The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan." } } }, "auth_ref": [ "r227" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod", "presentation": [ "http://qualisinnovations.com/role/SummaryOfStockOptionsOutstandingDetails" ], "lang": { "en-us": { "role": { "label": "Options, Expired/Forfeited", "documentation": "For presentations that combine terminations, the number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan or that expired." } } }, "auth_ref": [ "r507" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice", "presentation": [ "http://qualisinnovations.com/role/SummaryOfStockOptionsOutstandingDetails", "http://qualisinnovations.com/role/SummaryOfWarrantsOutstandingDetails" ], "lang": { "en-us": { "role": { "label": "Weighted Average Exercise Price, Expired/Forfeited", "verboseLabel": "Options, Weighted Average Exercise Price, Expired/Forfeited", "documentation": "Weighted average price of options that were either forfeited or expired." } } }, "auth_ref": [ "r507" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross", "presentation": [ "http://qualisinnovations.com/role/SummaryOfStockOptionsOutstandingDetails" ], "lang": { "en-us": { "role": { "label": "Options, Granted", "documentation": "Gross number of share options (or share units) granted during the period." } } }, "auth_ref": [ "r229" ] }, "QLIS_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodIntrinsicValue": { "xbrltype": "monetaryItemType", "nsuri": "http://qualisinnovations.com/20231231", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodIntrinsicValue", "crdr": "debit", "presentation": [ "http://qualisinnovations.com/role/SummaryOfStockOptionsOutstandingDetails" ], "lang": { "en-us": { "role": { "label": "Options, Aggregate Intrinsic Value, Granted", "documentation": "Share based compensation arrangement by share based payment award options grants in period intrinsic value." } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue", "crdr": "debit", "presentation": [ "http://qualisinnovations.com/role/SummaryOfStockOptionsOutstandingDetails" ], "lang": { "en-us": { "role": { "periodStartLabel": "Options, Aggregate Intrinsic Value, Beginning balance", "periodEndLabel": "Options, Aggregate Intrinsic Value, Ending balance", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Intrinsic Value", "documentation": "Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding." } } }, "auth_ref": [ "r46" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber", "presentation": [ "http://qualisinnovations.com/role/SummaryOfStockOptionsOutstandingDetails" ], "lang": { "en-us": { "role": { "periodStartLabel": "Options outstanding, Beginning balance", "periodEndLabel": "Options outstanding, Ending balance", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number", "documentation": "Number of options outstanding, including both vested and non-vested options." } } }, "auth_ref": [ "r225", "r226" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice", "presentation": [ "http://qualisinnovations.com/role/SummaryOfStockOptionsOutstandingDetails", "http://qualisinnovations.com/role/SummaryOfWarrantsOutstandingDetails" ], "lang": { "en-us": { "role": { "periodStartLabel": "Weighted Average Exercise Price Outstanding, Beginning balance", "periodEndLabel": "Weighted Average Exercise Price Outstanding, Ending balance", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price", "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan." } } }, "auth_ref": [ "r225", "r226" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue", "crdr": "debit", "presentation": [ "http://qualisinnovations.com/role/SummaryOfStockOptionsOutstandingDetails" ], "lang": { "en-us": { "role": { "periodEndLabel": "Options, Aggregate Intrinsic Value, Expected to be vested", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Exercisable, Aggregate Intrinsic Value", "documentation": "Amount by which current fair value of underlying stock exceeds exercise price of fully vested and expected to vest exercisable or convertible options. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur." } } }, "auth_ref": [ "r242" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber", "presentation": [ "http://qualisinnovations.com/role/SummaryOfStockOptionsOutstandingDetails" ], "lang": { "en-us": { "role": { "periodEndLabel": "Options, Expected to be vested", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number", "documentation": "Number of fully vested and expected to vest options outstanding that can be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur." } } }, "auth_ref": [ "r241" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice", "presentation": [ "http://qualisinnovations.com/role/SummaryOfStockOptionsOutstandingDetails" ], "lang": { "en-us": { "role": { "periodEndLabel": "Options, Weighted Average Exercise Price, Expected to be vested", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price", "documentation": "Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur." } } }, "auth_ref": [ "r241" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardTermsOfAward": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardTermsOfAward", "presentation": [ "http://qualisinnovations.com/role/StockholdersDeficitEquityDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Options exercisable period", "documentation": "Description of terms of award under share-based payment arrangement." } } }, "auth_ref": [ "r47" ] }, "QLIS_ShareBasedCompensationArrangementByShareBasedPaymentAwardUnvestedWarrantsExpired": { "xbrltype": "sharesItemType", "nsuri": "http://qualisinnovations.com/20231231", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardUnvestedWarrantsExpired", "presentation": [ "http://qualisinnovations.com/role/CommitmentsAndContingenciesDetailsNarrative", "http://qualisinnovations.com/role/StockholdersDeficitEquityDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Unvested warrants expired", "documentation": "Share based compensation arrangement by share based payment award unvested warrants expired." } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain", "presentation": [ "http://qualisinnovations.com/role/ScheduleOfPotentiallyDilutiveSecuritiesWereExcludedFromCalculationOfDilutedNetLossPerShareDetails" ], "lang": { "en-us": { "role": { "documentation": "Award under share-based payment arrangement." } } }, "auth_ref": [ "r221", "r222", "r223", "r225", "r226", "r227", "r228", "r229", "r230", "r231", "r232", "r233", "r234", "r235", "r236", "r237", "r238", "r239", "r240", "r241", "r242", "r245", "r246", "r247", "r248", "r249" ] }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice", "presentation": [ "http://qualisinnovations.com/role/SummaryOfStockOptionsOutstandingDetails", "http://qualisinnovations.com/role/SummaryOfWarrantsOutstandingDetails" ], "lang": { "en-us": { "role": { "label": "Weighted Average Exercise Price, Exercised", "verboseLabel": "Options, Weighted Average Exercise Price, Exercised", "documentation": "Weighted average price at which option holders acquired shares when converting their stock options into shares." } } }, "auth_ref": [ "r230" ] }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice", "presentation": [ "http://qualisinnovations.com/role/SummaryOfStockOptionsOutstandingDetails", "http://qualisinnovations.com/role/SummaryOfWarrantsOutstandingDetails" ], "lang": { "en-us": { "role": { "label": "Weighted Average Exercise Price, Granted", "verboseLabel": "Options, Weighted Average Exercise Price, Granted", "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options." } } }, "auth_ref": [ "r229" ] }, "us-gaap_ShareBasedCompensationAwardTrancheOneMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationAwardTrancheOneMember", "presentation": [ "http://qualisinnovations.com/role/CommitmentsAndContingenciesDetailsNarrative", "http://qualisinnovations.com/role/StockholdersDeficitEquityDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Share-Based Payment Arrangement, Tranche One [Member]", "documentation": "First portion of award under share-based payment arrangement differentiated by vesting feature, including, but not limited to, performance measure or service period." } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensationAwardTrancheTwoMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationAwardTrancheTwoMember", "presentation": [ "http://qualisinnovations.com/role/StockholdersDeficitEquityDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Share-Based Payment Arrangement, Tranche Two [Member]", "documentation": "Second portion of award under share-based payment arrangement differentiated by vesting feature, including, but not limited to, performance measure or service period." } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationOptionAndIncentivePlansPolicy", "presentation": [ "http://qualisinnovations.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "label": "Employee Stock Based Compensation", "documentation": "Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost." } } }, "auth_ref": [ "r220", "r224", "r243", "r244", "r245", "r246", "r249", "r253", "r254", "r255", "r256" ] }, "QLIS_ShareExchangeAgreementMember": { "xbrltype": "domainItemType", "nsuri": "http://qualisinnovations.com/20231231", "localname": "ShareExchangeAgreementMember", "presentation": [ "http://qualisinnovations.com/role/OrganizationAndPrincipalActivitiesDetailsNarrative", "http://qualisinnovations.com/role/ScheduleOfPotentiallyDilutiveSecuritiesWereExcludedFromCalculationOfDilutedNetLossPerShareDetailsParenthetical" ], "lang": { "en-us": { "role": { "label": "Share Exchange Agreement [Member]", "documentation": "Share Exchange Agreement [Member]" } } }, "auth_ref": [] }, "us-gaap_SharePrice": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SharePrice", "presentation": [ "http://qualisinnovations.com/role/OrganizationAndPrincipalActivitiesDetailsNarrative", "http://qualisinnovations.com/role/StockholdersDeficitEquityDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Share price", "verboseLabel": "Share exercise price", "documentation": "Price of a single share of a number of saleable stocks of a company." } } }, "auth_ref": [] }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage", "presentation": [ "http://qualisinnovations.com/role/StockholdersDeficitEquityDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Vesting percentage", "documentation": "Percentage of vesting of award under share-based payment arrangement." } } }, "auth_ref": [ "r501" ] }, "QLIS_SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsExercisableWeightedAverageRemainingContractualTerm1": { "xbrltype": "durationItemType", "nsuri": "http://qualisinnovations.com/20231231", "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsExercisableWeightedAverageRemainingContractualTerm1", "presentation": [ "http://qualisinnovations.com/role/SummaryOfWarrantsOutstandingDetails" ], "lang": { "en-us": { "role": { "label": "Weighted Average Contractual Term (in Years), Exercisable", "documentation": "Share-based compensation arrangement by share-based payment award, non-options, exercisable, Weighted average remaining contractual term." } } }, "auth_ref": [] }, "QLIS_SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsExpectedToBeVestedWeightedAverageRemainingContractualTerm1": { "xbrltype": "durationItemType", "nsuri": "http://qualisinnovations.com/20231231", "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsExpectedToBeVestedWeightedAverageRemainingContractualTerm1", "presentation": [ "http://qualisinnovations.com/role/SummaryOfWarrantsOutstandingDetails" ], "lang": { "en-us": { "role": { "label": "Weighted Average Contractual Term (in Years), Expected to be vested", "documentation": "Share-based compensation arrangement by share-based payment award, non-options, expected to be vested, Weighted average remaining contractual term." } } }, "auth_ref": [] }, "QLIS_SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsGrantedWeightedAverageRemainingContractualTerm1": { "xbrltype": "durationItemType", "nsuri": "http://qualisinnovations.com/20231231", "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsGrantedWeightedAverageRemainingContractualTerm1", "presentation": [ "http://qualisinnovations.com/role/SummaryOfWarrantsOutstandingDetails" ], "lang": { "en-us": { "role": { "label": "Weighted Average Contractual Term (in Years), Granted", "documentation": "Share-based compensation arrangement by share-based payment award, non-options, granted, Weighted average remaining contractual term." } } }, "auth_ref": [] }, "QLIS_SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsOutstandingWeightedAverageRemainingContractualTerm2": { "xbrltype": "durationItemType", "nsuri": "http://qualisinnovations.com/20231231", "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsOutstandingWeightedAverageRemainingContractualTerm2", "presentation": [ "http://qualisinnovations.com/role/SummaryOfWarrantsOutstandingDetails" ], "lang": { "en-us": { "role": { "label": "Weighted Average Contractual Term (in Years), Outstanding", "documentation": "Share-based compensation arrangement by share-based payment award, non-options, outstanding, Weighted average remaining contractual term." } } }, "auth_ref": [] }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1", "crdr": "debit", "presentation": [ "http://qualisinnovations.com/role/SummaryOfStockOptionsOutstandingDetails" ], "lang": { "en-us": { "role": { "periodEndLabel": "Options, Aggregate Intrinsic Value, Exercisable", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Intrinsic Value", "documentation": "Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable." } } }, "auth_ref": [ "r46" ] }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1", "presentation": [ "http://qualisinnovations.com/role/SummaryOfStockOptionsOutstandingDetails", "http://qualisinnovations.com/role/SummaryOfWarrantsOutstandingDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Options, Weighted Average Contractual Term (in Years), Outstanding", "label": "Options, Weighted Average Contractual Term (in Years), Exercisable", "documentation": "Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days." } } }, "auth_ref": [ "r46" ] }, "QLIS_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantedInPeriodWeightedAverageRemainingContractualTerm1": { "xbrltype": "durationItemType", "nsuri": "http://qualisinnovations.com/20231231", "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantedInPeriodWeightedAverageRemainingContractualTerm1", "presentation": [ "http://qualisinnovations.com/role/SummaryOfStockOptionsOutstandingDetails" ], "lang": { "en-us": { "role": { "label": "Options, Weighted Average Contractual Term (in Years), Granted", "documentation": "Share based compensation arrangement by share based payment award options granted in period weighted average remaining contractual term." } } }, "auth_ref": [] }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2", "presentation": [ "http://qualisinnovations.com/role/SummaryOfStockOptionsOutstandingDetails", "http://qualisinnovations.com/role/SummaryOfWarrantsOutstandingDetails" ], "lang": { "en-us": { "role": { "label": "Options, Weighted Average Contractual Term (in Years), Outstanding", "documentation": "Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days." } } }, "auth_ref": [ "r84" ] }, "QLIS_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTermExpectedToBeVested": { "xbrltype": "durationItemType", "nsuri": "http://qualisinnovations.com/20231231", "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTermExpectedToBeVested", "presentation": [ "http://qualisinnovations.com/role/SummaryOfStockOptionsOutstandingDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Weighted Average Contractual Term (in Years), Expected to be vested", "documentation": "Sharebased compensation arrangement by sharebased payment award options outstanding weighted average remaining contractual term expected to be vested.", "label": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTermExpectedToBeVested" } } }, "auth_ref": [] }, "us-gaap_SharesIssuedPricePerShare": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SharesIssuedPricePerShare", "presentation": [ "http://qualisinnovations.com/role/OrganizationAndPrincipalActivitiesDetailsNarrative" ], "lang": { "en-us": { "role": { "verboseLabel": "Share price", "label": "Shares Issued, Price Per Share", "documentation": "Per share or per unit amount of equity securities issued." } } }, "auth_ref": [] }, "us-gaap_SharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SharesOutstanding", "presentation": [ "http://qualisinnovations.com/role/StatementsOfChangesInStockholdersDeficitEquity" ], "lang": { "en-us": { "role": { "periodStartLabel": "Balance, shares", "periodEndLabel": "Balance, shares", "label": "Shares, Outstanding", "documentation": "Number of shares issued which are neither cancelled nor held in the treasury." } } }, "auth_ref": [] }, "us-gaap_ShortTermBankLoansAndNotesPayable": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShortTermBankLoansAndNotesPayable", "crdr": "credit", "calculation": { "http://qualisinnovations.com/role/BalanceSheets": { "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://qualisinnovations.com/role/BalanceSheets" ], "lang": { "en-us": { "role": { "label": "Short-term note payable", "documentation": "Amount of borrowings from a bank classified as other, maturing within one year or operating cycle, if longer." } } }, "auth_ref": [ "r22", "r372", "r540" ] }, "us-gaap_ShortTermBorrowings": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShortTermBorrowings", "crdr": "credit", "presentation": [ "http://qualisinnovations.com/role/ShortTermLoanDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Short term loan", "documentation": "Reflects the total carrying amount as of the balance sheet date of debt having initial terms less than one year or the normal operating cycle, if longer." } } }, "auth_ref": [ "r57", "r89", "r442", "r540" ] }, "us-gaap_ShortTermDebtTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShortTermDebtTextBlock", "presentation": [ "http://qualisinnovations.com/role/ShortTermLoan" ], "lang": { "en-us": { "role": { "label": "SHORT TERM LOAN", "documentation": "The entire disclosure for short-term debt." } } }, "auth_ref": [ "r79" ] }, "QLIS_ShorttermShareSettlement": { "xbrltype": "monetaryItemType", "nsuri": "http://qualisinnovations.com/20231231", "localname": "ShorttermShareSettlement", "crdr": "credit", "calculation": { "http://qualisinnovations.com/role/BalanceSheets": { "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://qualisinnovations.com/role/BalanceSheets" ], "lang": { "en-us": { "role": { "label": "Short-term \u2013 share settlement", "documentation": "Short-term \u2013 share settlement." } } }, "auth_ref": [] }, "us-gaap_SignificantAccountingPoliciesTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SignificantAccountingPoliciesTextBlock", "presentation": [ "http://qualisinnovations.com/role/SummaryOfSignificantAccountingPolicies" ], "lang": { "en-us": { "role": { "label": "SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES", "documentation": "The entire disclosure for all significant accounting policies of the reporting entity." } } }, "auth_ref": [ "r73", "r130" ] }, "QLIS_SolaceMember": { "xbrltype": "domainItemType", "nsuri": "http://qualisinnovations.com/20231231", "localname": "SolaceMember", "presentation": [ "http://qualisinnovations.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Solace [Member]", "documentation": "Solace [Member]" } } }, "auth_ref": [] }, "dei_SolicitingMaterial": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "SolicitingMaterial", "presentation": [ "http://qualisinnovations.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Soliciting Material", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act." } } }, "auth_ref": [ "r465" ] }, "us-gaap_StatementEquityComponentsAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StatementEquityComponentsAxis", "presentation": [ "http://qualisinnovations.com/role/CommitmentsAndContingenciesDetailsNarrative", "http://qualisinnovations.com/role/OrganizationAndPrincipalActivitiesDetailsNarrative", "http://qualisinnovations.com/role/ScheduleOfPotentiallyDilutiveSecuritiesWereExcludedFromCalculationOfDilutedNetLossPerShareDetailsParenthetical", "http://qualisinnovations.com/role/StatementsOfChangesInStockholdersDeficitEquity", "http://qualisinnovations.com/role/StockholdersDeficitEquityDetailsNarrative", "http://qualisinnovations.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative", "http://qualisinnovations.com/role/SummaryOfWarrantsOutstandingDetails" ], "lang": { "en-us": { "role": { "label": "Equity Components [Axis]", "documentation": "Information by component of equity." } } }, "auth_ref": [ "r11", "r29", "r106", "r121", "r122", "r123", "r134", "r135", "r136", "r138", "r144", "r146", "r162", "r182", "r183", "r216", "r250", "r251", "r252", "r271", "r272", "r284", "r285", "r286", "r287", "r288", "r289", "r291", "r295", "r296", "r297", "r298", "r299", "r300", "r303", "r350", "r351", "r352", "r365", "r418" ] }, "us-gaap_StatementLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StatementLineItems", "presentation": [ "http://qualisinnovations.com/role/ScheduleOfPotentiallyDilutiveSecuritiesWereExcludedFromCalculationOfDilutedNetLossPerShareDetailsParenthetical", "http://qualisinnovations.com/role/StatementsOfChangesInStockholdersDeficitEquity" ], "lang": { "en-us": { "role": { "label": "Statement [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r134", "r135", "r136", "r162", "r314", "r357", "r367", "r368", "r369", "r370", "r371", "r373", "r374", "r376", "r379", "r380", "r381", "r382", "r383", "r385", "r386", "r387", "r388", "r390", "r391", "r392", "r393", "r394", "r396", "r399", "r400", "r404", "r405", "r406", "r407", "r408", "r409", "r410", "r411", "r412", "r413", "r414", "r415", "r418", "r447" ] }, "us-gaap_StatementOfCashFlowsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StatementOfCashFlowsAbstract", "lang": { "en-us": { "role": { "label": "Statement of Cash Flows [Abstract]" } } }, "auth_ref": [] }, "us-gaap_StatementOfFinancialPositionAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StatementOfFinancialPositionAbstract", "lang": { "en-us": { "role": { "label": "Statement of Financial Position [Abstract]" } } }, "auth_ref": [] }, "us-gaap_StatementOfStockholdersEquityAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StatementOfStockholdersEquityAbstract", "auth_ref": [] }, "us-gaap_StatementTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StatementTable", "presentation": [ "http://qualisinnovations.com/role/ScheduleOfPotentiallyDilutiveSecuritiesWereExcludedFromCalculationOfDilutedNetLossPerShareDetailsParenthetical", "http://qualisinnovations.com/role/StatementsOfChangesInStockholdersDeficitEquity" ], "lang": { "en-us": { "role": { "label": "Statement [Table]", "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed." } } }, "auth_ref": [ "r134", "r135", "r136", "r162", "r314", "r357", "r367", "r368", "r369", "r370", "r371", "r373", "r374", "r376", "r379", "r380", "r381", "r382", "r383", "r385", "r386", "r387", "r388", "r390", "r391", "r392", "r393", "r394", "r396", "r399", "r400", "r404", "r405", "r406", "r407", "r408", "r409", "r410", "r411", "r412", "r413", "r414", "r415", "r418", "r447" ] }, "us-gaap_StockIssuedDuringPeriodSharesAcquisitions": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockIssuedDuringPeriodSharesAcquisitions", "presentation": [ "http://qualisinnovations.com/role/OrganizationAndPrincipalActivitiesDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Recapitalization of qualis in conjunction with reverse acquisition, shares", "documentation": "Number of shares of stock issued during the period pursuant to acquisitions." } } }, "auth_ref": [ "r58", "r59", "r81" ] }, "QLIS_StockIssuedDuringPeriodSharesCancelled": { "xbrltype": "sharesItemType", "nsuri": "http://qualisinnovations.com/20231231", "localname": "StockIssuedDuringPeriodSharesCancelled", "presentation": [ "http://qualisinnovations.com/role/CommitmentsAndContingenciesDetailsNarrative", "http://qualisinnovations.com/role/StockholdersDeficitEquityDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Number of shares cancelled", "verboseLabel": "Number of common shares cancelled", "documentation": "Stock issued during period shares cancelled." } } }, "auth_ref": [] }, "us-gaap_StockIssuedDuringPeriodSharesIssuedForServices": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockIssuedDuringPeriodSharesIssuedForServices", "presentation": [ "http://qualisinnovations.com/role/StatementsOfChangesInStockholdersDeficitEquity", "http://qualisinnovations.com/role/StockholdersDeficitEquityDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Issuance of common stock for services, shares", "verboseLabel": "Number of common stock for services", "documentation": "Number of shares issued in lieu of cash for services contributed to the entity. Number of shares includes, but is not limited to, shares issued for services contributed by vendors and founders." } } }, "auth_ref": [] }, "us-gaap_StockIssuedDuringPeriodSharesNewIssues": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockIssuedDuringPeriodSharesNewIssues", "presentation": [ "http://qualisinnovations.com/role/OrganizationAndPrincipalActivitiesDetailsNarrative", "http://qualisinnovations.com/role/StatementsOfChangesInStockholdersDeficitEquity", "http://qualisinnovations.com/role/StockholdersDeficitEquityDetailsNarrative", "http://qualisinnovations.com/role/SubsequentEventsDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Issuance of common stock for cash, shares", "verboseLabel": "Stock issued during period, shares", "terseLabel": "Number of shares issued", "documentation": "Number of new stock issued during the period." } } }, "auth_ref": [ "r11", "r58", "r59", "r81", "r359", "r418", "r429" ] }, "us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensationForfeited": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockIssuedDuringPeriodSharesShareBasedCompensationForfeited", "presentation": [ "http://qualisinnovations.com/role/StatementsOfChangesInStockholdersDeficitEquity", "http://qualisinnovations.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" ], "lang": { "en-us": { "role": { "negatedLabel": "Cancellation of common stock for services, shares", "label": "Number of cancellation of common shares", "documentation": "Number of shares (or other type of equity) forfeited during the period." } } }, "auth_ref": [] }, "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised", "presentation": [ "http://qualisinnovations.com/role/SummaryOfStockOptionsOutstandingDetails" ], "lang": { "en-us": { "role": { "label": "Options, Exercised", "documentation": "Number of share options (or share units) exercised during the current period." } } }, "auth_ref": [ "r11", "r58", "r59", "r81", "r230" ] }, "us-gaap_StockIssuedDuringPeriodValueAcquisitions": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockIssuedDuringPeriodValueAcquisitions", "crdr": "credit", "presentation": [ "http://qualisinnovations.com/role/OrganizationAndPrincipalActivitiesDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Recapitalization of qualis in conjunction with reverse acquisition", "documentation": "Value of stock issued pursuant to acquisitions during the period." } } }, "auth_ref": [ "r11", "r29", "r81" ] }, "us-gaap_StockIssuedDuringPeriodValueIssuedForServices": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockIssuedDuringPeriodValueIssuedForServices", "crdr": "credit", "presentation": [ "http://qualisinnovations.com/role/CommitmentsAndContingenciesDetailsNarrative", "http://qualisinnovations.com/role/StatementsOfChangesInStockholdersDeficitEquity", "http://qualisinnovations.com/role/StockholdersDeficitEquityDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Issuance of common stock for services", "verboseLabel": "Number of common stock for services, value", "documentation": "Value of stock issued in lieu of cash for services contributed to the entity. Value of the stock issued includes, but is not limited to, services contributed by vendors and founders." } } }, "auth_ref": [] }, "us-gaap_StockIssuedDuringPeriodValueNewIssues": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockIssuedDuringPeriodValueNewIssues", "crdr": "credit", "presentation": [ "http://qualisinnovations.com/role/StatementsOfChangesInStockholdersDeficitEquity", "http://qualisinnovations.com/role/StockholdersDeficitEquityDetailsNarrative", "http://qualisinnovations.com/role/SubsequentEventsDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Issuance of common stock for cash", "verboseLabel": "Aggregate gross proceeds", "documentation": "Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering." } } }, "auth_ref": [ "r11", "r58", "r59", "r81", "r365", "r418", "r429", "r453" ] }, "us-gaap_StockIssuedDuringPeriodValueShareBasedCompensationForfeited": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockIssuedDuringPeriodValueShareBasedCompensationForfeited", "crdr": "debit", "presentation": [ "http://qualisinnovations.com/role/StatementsOfChangesInStockholdersDeficitEquity", "http://qualisinnovations.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" ], "lang": { "en-us": { "role": { "negatedLabel": "Cancellation of common stock for services", "label": "Additional paid in capital", "documentation": "Value of forfeited shares issued under share-based payment arrangement. Excludes employee stock ownership plan (ESOP)." } } }, "auth_ref": [ "r20" ] }, "us-gaap_StockholdersEquity": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockholdersEquity", "crdr": "credit", "calculation": { "http://qualisinnovations.com/role/BalanceSheets": { "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://qualisinnovations.com/role/BalanceSheets", "http://qualisinnovations.com/role/BasisOfPresentationDetailsNarrative", "http://qualisinnovations.com/role/StatementsOfChangesInStockholdersDeficitEquity" ], "lang": { "en-us": { "role": { "totalLabel": "Total stockholders\u2019 (deficit) equity", "periodStartLabel": "Balance", "periodEndLabel": "Balance", "negatedLabel": "Working capital deficit", "label": "Equity, Attributable to Parent", "documentation": "Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest." } } }, "auth_ref": [ "r59", "r62", "r63", "r74", "r378", "r395", "r419", "r420", "r442", "r454", "r485", "r491", "r533", "r546" ] }, "us-gaap_StockholdersEquityAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockholdersEquityAbstract", "presentation": [ "http://qualisinnovations.com/role/BalanceSheets" ], "lang": { "en-us": { "role": { "label": "Stockholders\u2019(deficit) equity" } } }, "auth_ref": [] }, "us-gaap_StockholdersEquityNoteDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockholdersEquityNoteDisclosureTextBlock", "presentation": [ "http://qualisinnovations.com/role/StockholdersDeficitEquity" ], "lang": { "en-us": { "role": { "label": "STOCKHOLDERS\u2019 (DEFICIT) EQUITY", "documentation": "The entire disclosure for equity." } } }, "auth_ref": [ "r80", "r131", "r202", "r204", "r205", "r206", "r207", "r208", "r209", "r210", "r211", "r212", "r213", "r214", "r216", "r290", "r421", "r423", "r430" ] }, "us-gaap_StockholdersEquityReverseStockSplit": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockholdersEquityReverseStockSplit", "presentation": [ "http://qualisinnovations.com/role/OrganizationAndPrincipalActivitiesDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Reverse stock split", "documentation": "Description of the reverse stock split arrangement. Also provide the retroactive effect given by the reverse split that occurs after the balance sheet date but before the release of financial statements." } } }, "auth_ref": [ "r82" ] }, "us-gaap_SubsequentEventLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SubsequentEventLineItems", "presentation": [ "http://qualisinnovations.com/role/SubsequentEventsDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Subsequent Event [Line Items]", "documentation": "Detail information of subsequent event by type. User is expected to use existing line items from elsewhere in the taxonomy as the primary line items for this disclosure, which is further associated with dimension and member elements pertaining to a subsequent event." } } }, "auth_ref": [ "r301", "r311" ] }, "us-gaap_SubsequentEventMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SubsequentEventMember", "presentation": [ "http://qualisinnovations.com/role/StockholdersDeficitEquityDetailsNarrative", "http://qualisinnovations.com/role/SubsequentEventsDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Subsequent Event [Member]", "documentation": "Identifies event that occurred after the balance sheet date but before financial statements are issued or available to be issued." } } }, "auth_ref": [ "r301", "r311" ] }, "us-gaap_SubsequentEventTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SubsequentEventTable", "presentation": [ "http://qualisinnovations.com/role/SubsequentEventsDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Subsequent Event [Table]", "documentation": "Discloses pertinent information about one or more significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued." } } }, "auth_ref": [ "r301", "r311" ] }, "us-gaap_SubsequentEventTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SubsequentEventTypeAxis", "presentation": [ "http://qualisinnovations.com/role/StockholdersDeficitEquityDetailsNarrative", "http://qualisinnovations.com/role/SubsequentEventsDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Subsequent Event Type [Axis]", "documentation": "Information by event that occurred after the balance sheet date but before financial statements are issued or available to be issued." } } }, "auth_ref": [ "r301", "r311" ] }, "us-gaap_SubsequentEventTypeDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SubsequentEventTypeDomain", "presentation": [ "http://qualisinnovations.com/role/StockholdersDeficitEquityDetailsNarrative", "http://qualisinnovations.com/role/SubsequentEventsDetailsNarrative" ], "lang": { "en-us": { "role": { "documentation": "Event that occurred after the balance sheet date but before financial statements are issued or available to be issued." } } }, "auth_ref": [ "r301", "r311" ] }, "us-gaap_SubsequentEventsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SubsequentEventsAbstract", "lang": { "en-us": { "role": { "label": "Subsequent Events [Abstract]" } } }, "auth_ref": [] }, "us-gaap_SubsequentEventsTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SubsequentEventsTextBlock", "presentation": [ "http://qualisinnovations.com/role/SubsequentEvents" ], "lang": { "en-us": { "role": { "label": "SUBSEQUENT EVENTS", "documentation": "The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business." } } }, "auth_ref": [ "r310", "r312" ] }, "us-gaap_SupplementalCashFlowInformationAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SupplementalCashFlowInformationAbstract", "presentation": [ "http://qualisinnovations.com/role/StatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Supplemental disclosures of cash flow information:" } } }, "auth_ref": [] }, "us-gaap_SupplementalCashFlowInformationRelatedText": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SupplementalCashFlowInformationRelatedText", "presentation": [ "http://qualisinnovations.com/role/StatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Cash paid during the period for:", "documentation": "Additional textual information about cash receipts or disbursements in the period required to be supplementally disclosed." } } }, "auth_ref": [ "r71" ] }, "QLIS_ThirdPartyMember": { "xbrltype": "domainItemType", "nsuri": "http://qualisinnovations.com/20231231", "localname": "ThirdPartyMember", "presentation": [ "http://qualisinnovations.com/role/StockholdersDeficitEquityDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Third Party [Member]", "documentation": "Third Party [Member]" } } }, "auth_ref": [] }, "srt_TitleOfIndividualAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "TitleOfIndividualAxis", "presentation": [ "http://qualisinnovations.com/role/CommitmentsAndContingenciesDetailsNarrative", "http://qualisinnovations.com/role/OrganizationAndPrincipalActivitiesDetailsNarrative", "http://qualisinnovations.com/role/ShortTermLoanDetailsNarrative", "http://qualisinnovations.com/role/StockholdersDeficitEquityDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Title of Individual [Axis]" } } }, "auth_ref": [ "r490", "r534" ] }, "srt_TitleOfIndividualWithRelationshipToEntityDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "TitleOfIndividualWithRelationshipToEntityDomain", "presentation": [ "http://qualisinnovations.com/role/CommitmentsAndContingenciesDetailsNarrative", "http://qualisinnovations.com/role/OrganizationAndPrincipalActivitiesDetailsNarrative", "http://qualisinnovations.com/role/ShortTermLoanDetailsNarrative", "http://qualisinnovations.com/role/StockholdersDeficitEquityDetailsNarrative" ], "auth_ref": [] }, "us-gaap_ToolsDiesAndMoldsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ToolsDiesAndMoldsMember", "presentation": [ "http://qualisinnovations.com/role/ScheduleOfPropertyAndEquipmentDetails" ], "lang": { "en-us": { "role": { "label": "Tools, Dies and Molds [Member]", "documentation": "Equipment commonly used to cut, shape, and form metal and other materials into goods for sale." } } }, "auth_ref": [] }, "dei_TradingSymbol": { "xbrltype": "tradingSymbolItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "TradingSymbol", "presentation": [ "http://qualisinnovations.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Trading Symbol", "documentation": "Trading symbol of an instrument as listed on an exchange." } } }, "auth_ref": [] }, "QLIS_TwoAffiliateMember": { "xbrltype": "domainItemType", "nsuri": "http://qualisinnovations.com/20231231", "localname": "TwoAffiliateMember", "presentation": [ "http://qualisinnovations.com/role/StockholdersDeficitEquityDetailsNarrative", "http://qualisinnovations.com/role/SubsequentEventsDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Two Affiliate [Member]", "documentation": "Two Affiliate [Member]" } } }, "auth_ref": [] }, "QLIS_TwoThousandTwentyOnePlanMember": { "xbrltype": "domainItemType", "nsuri": "http://qualisinnovations.com/20231231", "localname": "TwoThousandTwentyOnePlanMember", "presentation": [ "http://qualisinnovations.com/role/CommitmentsAndContingenciesDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "2021 Plan [Member]", "documentation": "Two Thousand Twenty One Plan [Member]" } } }, "auth_ref": [] }, "us-gaap_TypeOfArrangementAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "TypeOfArrangementAxis", "presentation": [ "http://qualisinnovations.com/role/OrganizationAndPrincipalActivitiesDetailsNarrative", "http://qualisinnovations.com/role/ScheduleOfPotentiallyDilutiveSecuritiesWereExcludedFromCalculationOfDilutedNetLossPerShareDetailsParenthetical" ], "lang": { "en-us": { "role": { "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Axis]", "documentation": "Information by collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations." } } }, "auth_ref": [ "r279" ] }, "us-gaap_UseOfEstimates": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "UseOfEstimates", "presentation": [ "http://qualisinnovations.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "label": "Use of Estimates", "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles." } } }, "auth_ref": [ "r36", "r37", "r38", "r97", "r98", "r101", "r102" ] }, "us-gaap_VestingAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "VestingAxis", "presentation": [ "http://qualisinnovations.com/role/CommitmentsAndContingenciesDetailsNarrative", "http://qualisinnovations.com/role/StockholdersDeficitEquityDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Vesting [Axis]", "documentation": "Information by vesting schedule of award under share-based payment arrangement." } } }, "auth_ref": [ "r501", "r502", "r503", "r504", "r505", "r506", "r507", "r508", "r509", "r510", "r511", "r512", "r513", "r514", "r515", "r516", "r517", "r518", "r519", "r520", "r521", "r522", "r523", "r524", "r525", "r526" ] }, "us-gaap_VestingDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "VestingDomain", "presentation": [ "http://qualisinnovations.com/role/CommitmentsAndContingenciesDetailsNarrative", "http://qualisinnovations.com/role/StockholdersDeficitEquityDetailsNarrative" ], "lang": { "en-us": { "role": { "documentation": "Vesting schedule of award under share-based payment arrangement." } } }, "auth_ref": [ "r501", "r502", "r503", "r504", "r505", "r506", "r507", "r508", "r509", "r510", "r511", "r512", "r513", "r514", "r515", "r516", "r517", "r518", "r519", "r520", "r521", "r522", "r523", "r524", "r525", "r526" ] }, "us-gaap_WarrantMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "WarrantMember", "presentation": [ "http://qualisinnovations.com/role/CommitmentsAndContingenciesDetailsNarrative", "http://qualisinnovations.com/role/ScheduleOfPotentiallyDilutiveSecuritiesWereExcludedFromCalculationOfDilutedNetLossPerShareDetailsParenthetical", "http://qualisinnovations.com/role/StockholdersDeficitEquityDetailsNarrative", "http://qualisinnovations.com/role/SummaryOfWarrantsOutstandingDetails" ], "lang": { "en-us": { "role": { "label": "Warrant [Member]", "documentation": "Security that gives the holder the right to purchase shares of stock in accordance with the terms of the instrument, usually upon payment of a specified amount." } } }, "auth_ref": [ "r444", "r445", "r448", "r449", "r450", "r451" ] }, "us-gaap_WarrantsAndRightsOutstanding": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "WarrantsAndRightsOutstanding", "crdr": "credit", "presentation": [ "http://qualisinnovations.com/role/StockholdersDeficitEquityDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Warrants, value", "documentation": "Value of outstanding derivative securities that permit the holder the right to purchase securities (usually equity) from the issuer at a specified price." } } }, "auth_ref": [] }, "us-gaap_WarrantsAndRightsOutstandingTerm": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "WarrantsAndRightsOutstandingTerm", "presentation": [ "http://qualisinnovations.com/role/CommitmentsAndContingenciesDetailsNarrative", "http://qualisinnovations.com/role/OrganizationAndPrincipalActivitiesDetailsNarrative", "http://qualisinnovations.com/role/StockholdersDeficitEquityDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Warrants term", "verboseLabel": "Warrants exercisable term", "documentation": "Period between issuance and expiration of outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days." } } }, "auth_ref": [ "r532" ] }, "QLIS_WarrantsIssuedForServicesNetOfForfeited": { "xbrltype": "monetaryItemType", "nsuri": "http://qualisinnovations.com/20231231", "localname": "WarrantsIssuedForServicesNetOfForfeited", "crdr": "debit", "calculation": { "http://qualisinnovations.com/role/StatementsOfOperations": { "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://qualisinnovations.com/role/StatementsOfOperations" ], "lang": { "en-us": { "role": { "label": "Warrants issued for services", "documentation": "Warrants issued for services, net of forfeited." } } }, "auth_ref": [] }, "QLIS_WarrantsToPurchaseSharesOfCommonStockMember": { "xbrltype": "domainItemType", "nsuri": "http://qualisinnovations.com/20231231", "localname": "WarrantsToPurchaseSharesOfCommonStockMember", "presentation": [ "http://qualisinnovations.com/role/ScheduleOfPotentiallyDilutiveSecuritiesWereExcludedFromCalculationOfDilutedNetLossPerShareDetails" ], "lang": { "en-us": { "role": { "label": "Warrants to Purchase Shares of Common Stock [Member]", "documentation": "Warrants to Purchase Shares of Common Stock [Member]" } } }, "auth_ref": [] }, "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "WeightedAverageNumberOfDilutedSharesOutstanding", "presentation": [ "http://qualisinnovations.com/role/ScheduleOfComputationOfBasicAndDilutedNetIncomePerShareDetails", "http://qualisinnovations.com/role/StatementsOfOperations" ], "lang": { "en-us": { "role": { "label": "Weighted average number of shares outstanding, diluted", "verboseLabel": "Diluted weighted average common stock and common stock equivalents", "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period." } } }, "auth_ref": [ "r149", "r157" ] }, "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "WeightedAverageNumberOfSharesOutstandingBasic", "presentation": [ "http://qualisinnovations.com/role/ScheduleOfComputationOfBasicAndDilutedNetIncomePerShareDetails", "http://qualisinnovations.com/role/StatementsOfOperations" ], "lang": { "en-us": { "role": { "label": "Weighted average number of shares outstanding, basic", "verboseLabel": "Basic weighted average outstanding shares of common stock", "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period." } } }, "auth_ref": [ "r148", "r157" ] }, "QLIS_WorkingCapital": { "xbrltype": "monetaryItemType", "nsuri": "http://qualisinnovations.com/20231231", "localname": "WorkingCapital", "crdr": "credit", "presentation": [ "http://qualisinnovations.com/role/BasisOfPresentationDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Working capital", "documentation": "Working capital." } } }, "auth_ref": [] }, "dei_WrittenCommunications": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "WrittenCommunications", "presentation": [ "http://qualisinnovations.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Written Communications", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act." } } }, "auth_ref": [ "r474" ] }, "QLIS_XKTMember": { "xbrltype": "domainItemType", "nsuri": "http://qualisinnovations.com/20231231", "localname": "XKTMember", "presentation": [ "http://qualisinnovations.com/role/OrganizationAndPrincipalActivitiesDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "XKT [Member]", "documentation": "XKT [Member]" } } }, "auth_ref": [] } } } }, "std_ref": { "r0": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "05", "Paragraph": "1", "SubTopic": "825", "Topic": "944", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479524/944-825-05-1" }, "r1": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "05", "Paragraph": "4", "SubTopic": "10", "Topic": "360", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482338/360-10-05-4" }, "r2": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "25", "Paragraph": "1", "SubTopic": "20", "Topic": "940", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481913/940-20-25-1" }, "r3": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "25", "Paragraph": "13", "SubTopic": "10", "Topic": "480", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481766/480-10-25-13" }, "r4": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "SubTopic": "230", "Topic": "830", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481877/830-230-45-1" }, "r5": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "14", "Subparagraph": "(a)", "SubTopic": "10", "Topic": "230", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-14" }, "r6": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Subparagraph": "(a)", "SubTopic": "10", "Topic": "230", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28" }, "r7": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Subparagraph": "(b)", "SubTopic": "10", "Topic": "230", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28" }, "r8": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "SubTopic": "10", "Topic": "360", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-1" }, "r9": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "SubTopic": "10", "Topic": "825", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-1" }, "r10": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "SubTopic": "35", "Topic": "720", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483406/720-35-50-1" }, "r11": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "SubTopic": "10", "Topic": "505", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-2" }, "r12": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(i)", "SubTopic": "10", "Topic": "718", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r13": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(ii)", "SubTopic": "10", "Topic": "718", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r14": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(1)", "SubTopic": "10", "Topic": "718", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r15": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(2)", "SubTopic": "10", "Topic": "718", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r16": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(3)", "SubTopic": "10", "Topic": "718", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r17": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(3)-(4)", "SubTopic": "10", "Topic": "718", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r18": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)", "SubTopic": "10", "Topic": "718", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r19": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(e)", "SubTopic": "10", "Topic": "718", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r20": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "c(1)", "SubTopic": "10", "Topic": "718", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r21": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "60", "Paragraph": "1", "SubTopic": "10", "Topic": "820", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482053/820-10-60-1" }, "r22": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.19(a)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r23": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.19,20)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r24": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.19-26)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r25": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.20)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r26": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.21)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r27": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.22(a)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r28": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.29)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r29": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.29-31)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r30": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "45", "Paragraph": "14", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-14" }, "r31": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "45", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-4" }, "r32": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-1" }, "r33": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-2" }, "r34": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "260", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-1" }, "r35": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "260", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-2" }, "r36": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "275", "SubTopic": "10", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-4" }, "r37": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "275", "SubTopic": "10", "Section": "50", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-8" }, "r38": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "275", "SubTopic": "10", "Section": "50", "Paragraph": "9", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-9" }, "r39": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "360", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-1" }, "r40": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "360", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-1" }, "r41": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "470", "SubTopic": "20", "Section": "25", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481284/470-20-25-2" }, "r42": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "470", "SubTopic": "50", "Section": "40", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481303/470-50-40-2" }, "r43": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "470", "SubTopic": "50", "Section": "40", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481303/470-50-40-4" }, "r44": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "710", "SubTopic": "10", "Section": "25", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483070/710-10-25-11" }, "r45": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "718", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-1" }, "r46": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "718", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r47": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "718", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r48": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "718", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r49": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "740", "SubTopic": "10", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-3" }, "r50": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "740", "SubTopic": "10", "Section": "50", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-8" }, "r51": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "835", "SubTopic": "30", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482925/835-30-45-2" }, "r52": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "835", "SubTopic": "30", "Section": "55", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482949/835-30-55-8" }, "r53": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "942", "SubTopic": "210", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03.15(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1" }, "r54": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "942", "SubTopic": "825", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480981/942-825-50-1" }, "r55": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "985", "SubTopic": "20", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481283/985-20-50-1" }, "r56": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "205", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//205/tableOfContent" }, "r57": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(19)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r58": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(28))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r59": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(29))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r60": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(30)(a)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r61": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(30)(a)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r62": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(30))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r63": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(31))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r64": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(32))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r65": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(10))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r66": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(20))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r67": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03.1,2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r68": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03.4)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r69": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03.7)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r70": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "24", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-24" }, "r71": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "25", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-25" }, "r72": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28" }, "r73": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "235", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//235/tableOfContent" }, "r74": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SAB Topic 4.E)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480418/310-10-S99-2" }, "r75": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "360", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//360/tableOfContent" }, "r76": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "360", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-1" }, "r77": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "360", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SAB Topic 5.CC)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480091/360-10-S99-2" }, "r78": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "440", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//440/tableOfContent" }, "r79": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "470", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//470/tableOfContent" }, "r80": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "505", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//505/tableOfContent" }, "r81": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.3-04)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480008/505-10-S99-1" }, "r82": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "4", "Subparagraph": "(SAB Topic 4.C)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480008/505-10-S99-4" }, "r83": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "710", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "30", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483043/710-10-30-1" }, "r84": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "718", "SubTopic": "10", "Subparagraph": "(e)(1)", "Name": "Accounting Standards Codification", "Paragraph": "2", "Section": "50", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r85": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Paragraph": "12", "Section": "50", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-12" }, "r86": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Paragraph": "2", "Section": "50", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-2" }, "r87": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "810", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//810/tableOfContent" }, "r88": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(11))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1" }, "r89": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(13))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1" }, "r90": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(23))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1" }, "r91": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04(15))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1" }, "r92": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04(22))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1" }, "r93": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Subparagraph": "(a)", "SubTopic": "20", "Topic": "740", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482659/740-20-45-2" }, "r94": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "SubTopic": "210", "Topic": "946", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480555/946-210-45-20" }, "r95": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "6", "Subparagraph": "(a)", "SubTopic": "10", "Topic": "270", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482989/270-10-45-6" }, "r96": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "SubTopic": "35", "Topic": "720", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483406/720-35-50-1" }, "r97": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "SubTopic": "10", "Topic": "275", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-1" }, "r98": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "SubTopic": "10", "Topic": "275", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-1" }, "r99": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "SubTopic": "10", "Topic": "275", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-1" }, "r100": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "SubTopic": "360", "Topic": "958", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480321/958-360-50-1" }, "r101": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "SubTopic": "10", "Topic": "275", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-11" }, "r102": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12", "SubTopic": "10", "Topic": "275", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-12" }, "r103": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "SubTopic": "360", "Topic": "958", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480321/958-360-50-6" }, "r104": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "SubTopic": "360", "Topic": "958", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480321/958-360-50-7" }, "r105": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(h))", "SubTopic": "10", "Topic": "235", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1" }, "r106": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "105", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479343/105-10-65-6" }, "r107": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483499/205-20-50-7" }, "r108": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-1" }, "r109": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-5" }, "r110": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483489/210-10-50-1" }, "r111": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(13))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r112": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(14))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r113": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(18))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r114": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(6)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r115": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(6))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r116": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(8))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r117": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(9))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r118": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1A", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-1A" }, "r119": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-1B" }, "r120": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-1" }, "r121": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-4" }, "r122": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-5" }, "r123": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-6" }, "r124": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(25))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r125": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "17", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-17" }, "r126": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "24", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-24" }, "r127": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "25", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-25" }, "r128": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-2" }, "r129": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-8" }, "r130": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483426/235-10-50-1" }, "r131": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(e)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1" }, "r132": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(g)(1)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1" }, "r133": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(h)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1" }, "r134": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "23", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-23" }, "r135": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "24", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-24" }, "r136": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "5", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-5" }, "r137": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-1" }, "r138": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-1" }, "r139": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-11" }, "r140": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-11" }, "r141": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-3" }, "r142": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-4" }, "r143": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-7" }, "r144": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-7" }, "r145": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-8" }, "r146": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-9" }, "r147": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//260/tableOfContent" }, "r148": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-10" }, "r149": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "16", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-16" }, "r150": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-2" }, "r151": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "22", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-22" }, "r152": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "23", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-23" }, "r153": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "26", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-26" }, "r154": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "60B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-60B" }, "r155": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "60B", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-60B" }, "r156": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-7" }, "r157": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-1" }, "r158": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-1" }, "r159": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-2" }, "r160": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-3" }, "r161": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "15", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482635/260-10-55-15" }, "r162": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "272", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483014/272-10-45-1" }, "r163": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22" }, "r164": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22" }, "r165": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22" }, "r166": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(h)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22" }, "r167": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "30", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30" }, "r168": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "30", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30" }, "r169": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "30", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30" }, "r170": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32" }, "r171": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32" }, "r172": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32" }, "r173": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32" }, "r174": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32" }, "r175": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "40", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-40" }, "r176": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "41", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-41" }, "r177": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "42", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-42" }, "r178": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "323", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481687/323-10-50-3" }, "r179": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "323", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481687/323-10-50-3" }, "r180": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "323", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481687/323-10-50-3" }, "r181": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "323", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481687/323-10-50-3" }, "r182": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "4", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479654/326-10-65-4" }, "r183": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "5", "Subparagraph": "(c)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479654/326-10-65-5" }, "r184": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "330", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//330/tableOfContent" }, "r185": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "330", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483080/330-10-50-1" }, "r186": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "330", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483080/330-10-50-4" }, "r187": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "340", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479483/340-40-50-3" }, "r188": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "440", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482648/440-10-50-4" }, "r189": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "440", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482648/440-10-50-4" }, "r190": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 5.Y.Q2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480102/450-20-S99-1" }, "r191": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(i))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A" }, "r192": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A" }, "r193": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(iv))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A" }, "r194": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A" }, "r195": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(4)(i))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B" }, "r196": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B" }, "r197": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B" }, "r198": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(4)(iv))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B" }, "r199": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B" }, "r200": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B" }, "r201": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B" }, "r202": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13" }, "r203": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13" }, "r204": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13" }, "r205": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(g)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13" }, "r206": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(h)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13" }, "r207": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13" }, "r208": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "14", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-14" }, "r209": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "14", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-14" }, "r210": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "14", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-14" }, "r211": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "16", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-16" }, "r212": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-18" }, "r213": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-18" }, "r214": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-18" }, "r215": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-3" }, "r216": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.3-04)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480008/505-10-S99-1" }, "r217": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-4" }, "r218": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-5" }, "r219": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(n)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r220": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//718/tableOfContent" }, "r221": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r222": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r223": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r224": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r225": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r226": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r227": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r228": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r229": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r230": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(02)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r231": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r232": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(04)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r233": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r234": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r235": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r236": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r237": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)(02)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r238": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r239": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r240": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r241": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(e)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r242": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(e)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r243": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r244": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r245": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r246": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r247": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r248": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(iv)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r249": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(v)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r250": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "15", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480336/718-10-65-15" }, "r251": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "15", "Subparagraph": "(f)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480336/718-10-65-15" }, "r252": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "15", "Subparagraph": "(f)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480336/718-10-65-15" }, "r253": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 14.C.Q3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479830/718-10-S99-1" }, "r254": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 14.D.1.Q5)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479830/718-10-S99-1" }, "r255": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 14.D.2.Q6)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479830/718-10-S99-1" }, "r256": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 14.D.3.Q2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479830/718-10-S99-1" }, "r257": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "730", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "05", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483044/730-10-05-1" }, "r258": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "730", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482916/730-10-50-1" }, "r259": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//740/tableOfContent" }, "r260": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "25", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482525/740-10-45-25" }, "r261": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482525/740-10-45-28" }, "r262": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-10" }, "r263": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-12" }, "r264": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "14", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-14" }, "r265": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "17", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-17" }, "r266": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "19", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-19" }, "r267": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-2" }, "r268": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "20", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-20" }, "r269": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "21", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-21" }, "r270": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-9" }, "r271": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "8", "Subparagraph": "(d)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482615/740-10-65-8" }, "r272": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "8", "Subparagraph": "(d)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482615/740-10-65-8" }, "r273": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB TOPIC 6.I.5.Q1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-1" }, "r274": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB TOPIC 6.I.7)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-1" }, "r275": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 6.I.Fact.4)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-1" }, "r276": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SAB Topic 11.C)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-2" }, "r277": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "270", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482526/740-270-50-1" }, "r278": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482603/740-30-50-2" }, "r279": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "808", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479402/808-10-50-1" }, "r280": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "25", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-25" }, "r281": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "25", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-25" }, "r282": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(bb)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-3" }, "r283": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-3" }, "r284": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6" }, "r285": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(h)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6" }, "r286": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(h)(1)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6" }, "r287": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(h)(1)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6" }, "r288": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(h)(1)(iv)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6" }, "r289": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(i)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6" }, "r290": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480237/815-40-50-6" }, "r291": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(e)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1" }, "r292": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(e)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1" }, "r293": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1" }, "r294": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "825", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "28", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-28" }, "r295": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "17", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-17" }, "r296": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20" }, "r297": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20" }, "r298": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20" }, "r299": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20" }, "r300": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481674/830-30-50-1" }, "r301": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481674/830-30-50-2" }, "r302": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "835", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482900/835-30-50-1" }, "r303": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "848", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(a)(3)(iii)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483550/848-10-65-2" }, "r304": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "850", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//850/tableOfContent" }, "r305": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "850", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-1" }, "r306": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "850", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-1" }, "r307": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "850", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-1" }, "r308": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "850", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-1" }, "r309": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "850", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-6" }, "r310": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "855", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//855/tableOfContent" }, "r311": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "855", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483399/855-10-50-2" }, "r312": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "855", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483399/855-10-50-2" }, "r313": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "912", "SubTopic": "330", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482105/912-330-50-1" }, "r314": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "924", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 11.L)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479941/924-10-S99-1" }, "r315": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "15", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-15" }, "r316": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "15", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-15" }, "r317": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "20", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-20" }, "r318": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "20", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-20" }, "r319": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "28", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-28" }, "r320": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "28", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-28" }, "r321": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "33", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-33" }, "r322": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "33", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-33" }, "r323": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "35A", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-35A" }, "r324": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "35A", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-35A" }, "r325": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-8" }, "r326": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Subparagraph": "(c)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-8" }, "r327": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04(27))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1" }, "r328": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-05(b)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479557/942-235-S99-1" }, "r329": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480842/942-360-50-1" }, "r330": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(12))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r331": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r332": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(21))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r333": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(22))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r334": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r335": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(25))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r336": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(8)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r337": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(8)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r338": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(8))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r339": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(11))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1" }, "r340": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(18))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1" }, "r341": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(23))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1" }, "r342": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1" }, "r343": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(9))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1" }, "r344": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-17(Column A))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-2" }, "r345": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-17(Column B))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-2" }, "r346": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-17(Column C))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-2" }, "r347": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-17(Column D))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-2" }, "r348": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-17(Column E))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-2" }, "r349": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-17(Column F))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-2" }, "r350": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2" }, "r351": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(f)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2" }, "r352": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(f)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2" }, "r353": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(g)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2" }, "r354": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(h)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2" }, "r355": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480424/946-10-50-1" }, "r356": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480424/946-10-50-2" }, "r357": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-03(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3" }, "r358": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-03(h)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3" }, "r359": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-03(i)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3" }, "r360": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480990/946-20-50-11" }, "r361": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480990/946-20-50-13" }, "r362": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480990/946-20-50-2" }, "r363": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480990/946-20-50-5" }, "r364": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480990/946-20-50-6" }, "r365": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480767/946-205-45-4" }, "r366": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "21", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480555/946-210-45-21" }, "r367": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480555/946-210-45-4" }, "r368": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r369": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(12)(b)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r370": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(12)(b)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r371": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(12)(b)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r372": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(13)(a)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r373": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(13)(a)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r374": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(13)(a)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r375": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(14))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r376": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(16)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r377": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(17))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r378": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(19))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r379": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(2)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r380": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(2)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r381": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(3)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r382": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(3)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r383": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(3)(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r384": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r385": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(6)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r386": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(6)(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r387": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(6)(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r388": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(6)(e))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r389": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(8))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r390": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(9)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r391": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(9)(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r392": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(9)(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r393": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(9)(e))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r394": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.6-05(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-2" }, "r395": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.6-05(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-2" }, "r396": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483581/946-220-45-3" }, "r397": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483581/946-220-45-7" }, "r398": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(1)(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r399": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r400": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(2)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r401": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(2)(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r402": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(2)(e))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r403": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(2)(g)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r404": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r405": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r406": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r407": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r408": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(6))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r409": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r410": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r411": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r412": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r413": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r414": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(6))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r415": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r416": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(9))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r417": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(1)(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3" }, "r418": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(4)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3" }, "r419": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(6))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3" }, "r420": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3" }, "r421": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481062/946-235-50-2" }, "r422": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481062/946-235-50-2" }, "r423": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481062/946-235-50-2" }, "r424": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481062/946-235-50-2" }, "r425": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480833/946-310-45-1" }, "r426": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "6", "Subparagraph": "(SX 210.12-14(Column E)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6" }, "r427": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "6", "Subparagraph": "(SX 210.12-14(Column E)(Footnote 4))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6" }, "r428": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "6", "Subparagraph": "(SX 210.12-14(Column E)(Footnote 6)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6" }, "r429": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "505", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-2" }, "r430": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "505", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-6" }, "r431": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "954", "SubTopic": "440", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480327/954-440-50-1" }, "r432": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "13H", "Subparagraph": "(a)", "SubTopic": "40", "Topic": "944", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480046/944-40-55-13H" }, "r433": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-1" }, "r434": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483426/235-10-50-4" }, "r435": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "52", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482635/260-10-55-52" }, "r436": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "30", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30" }, "r437": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "31", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-31" }, "r438": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "69B", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481568/470-20-55-69B" }, "r439": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "69C", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481568/470-20-55-69C" }, "r440": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "91", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479777/606-10-55-91" }, "r441": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r442": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "852", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481372/852-10-55-10" }, "r443": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "944", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479401/944-30-55-2" }, "r444": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-1" }, "r445": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6" }, "r446": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480493/946-210-55-1" }, "r447": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480833/946-310-45-1" }, "r448": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2)(i))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1" }, "r449": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-2" }, "r450": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 1)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3" }, "r451": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "6", "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6" }, "r452": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "830", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480167/946-830-55-10" }, "r453": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "830", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480167/946-830-55-11" }, "r454": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "830", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "12", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480167/946-830-55-12" }, "r455": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12" }, "r456": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b" }, "r457": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b-2" }, "r458": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b-23" }, "r459": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "d1-1" }, "r460": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "g" }, "r461": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12, 13, 15d" }, "r462": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "13e", "Subsection": "4c" }, "r463": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "14d", "Subsection": "2b" }, "r464": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "15", "Subsection": "d" }, "r465": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Section": "14a", "Number": "240", "Subsection": "12" }, "r466": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 10-K", "Number": "249", "Section": "310" }, "r467": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 10-Q", "Number": "240", "Section": "308", "Subsection": "a" }, "r468": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Number": "249", "Section": "220", "Subsection": "f" }, "r469": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Number": "249", "Section": "240", "Subsection": "f" }, "r470": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Section": "13", "Subsection": "a-1" }, "r471": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w" }, "r472": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-T", "Number": "232", "Section": "405" }, "r473": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "230", "Section": "405" }, "r474": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "230", "Section": "425" }, "r475": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "7A", "Section": "B", "Subsection": "2" }, "r476": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "12", "SubTopic": "10", "Topic": "230", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-12" }, "r477": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4H", "SubTopic": "40", "Topic": "944", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480081/944-40-50-4H" }, "r478": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r479": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(8))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r480": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r481": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "13", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-13" }, "r482": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "15", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-15" }, "r483": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28" }, "r484": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28" }, "r485": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(g)(1)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1" }, "r486": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "23", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-23" }, "r487": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "24", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-24" }, "r488": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "5", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-5" }, "r489": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-1" }, "r490": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "13", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481990/310-10-45-13" }, "r491": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "323", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481687/323-10-50-3" }, "r492": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-3" }, "r493": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "450", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//450/tableOfContent" }, "r494": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483076/450-20-50-1" }, "r495": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483076/450-20-50-4" }, "r496": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483076/450-20-50-9" }, "r497": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 5.Y.Q2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480102/450-20-S99-1" }, "r498": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A" }, "r499": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(iii))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A" }, "r500": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-5" }, "r501": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r502": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r503": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r504": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r505": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r506": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r507": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r508": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r509": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(02)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r510": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r511": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(04)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r512": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r513": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r514": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r515": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r516": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)(02)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r517": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r518": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r519": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r520": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(e)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r521": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(e)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r522": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r523": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r524": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r525": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(iv)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r526": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(v)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r527": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-12" }, "r528": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-2" }, "r529": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-6" }, "r530": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 6.I.Fact.4)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-1" }, "r531": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(e)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1" }, "r532": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(bbb)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2" }, "r533": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "825", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "28", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-28" }, "r534": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "850", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-2" }, "r535": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "850", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-3" }, "r536": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "852", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481404/852-10-50-7" }, "r537": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "852", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481404/852-10-50-7" }, "r538": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "912", "SubTopic": "730", "Name": "Accounting Standards Codification", "Section": "25", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482517/912-730-25-1" }, "r539": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(15)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r540": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(16)(a)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r541": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479432/944-30-50-2B" }, "r542": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480767/946-205-45-4" }, "r543": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(18))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r544": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3", "Subparagraph": "(k)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483581/946-220-45-3" }, "r545": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(2)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r546": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(4)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3" }, "r547": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3" } } } ZIP 58 0001493152-24-014351-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001493152-24-014351-xbrl.zip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form10-k_htm.xml IDEA: XBRL DOCUMENT 0001871181 2023-01-01 2023-12-31 0001871181 2023-06-30 0001871181 2024-04-11 0001871181 2023-12-31 0001871181 2022-12-31 0001871181 2022-01-01 2022-12-31 0001871181 us-gaap:CommonStockMember 2021-12-31 0001871181 us-gaap:AdditionalPaidInCapitalMember 2021-12-31 0001871181 us-gaap:RetainedEarningsMember 2021-12-31 0001871181 2021-12-31 0001871181 us-gaap:CommonStockMember 2022-12-31 0001871181 us-gaap:AdditionalPaidInCapitalMember 2022-12-31 0001871181 us-gaap:RetainedEarningsMember 2022-12-31 0001871181 us-gaap:CommonStockMember 2022-01-01 2022-12-31 0001871181 us-gaap:AdditionalPaidInCapitalMember 2022-01-01 2022-12-31 0001871181 us-gaap:RetainedEarningsMember 2022-01-01 2022-12-31 0001871181 us-gaap:CommonStockMember 2023-01-01 2023-12-31 0001871181 us-gaap:AdditionalPaidInCapitalMember 2023-01-01 2023-12-31 0001871181 us-gaap:RetainedEarningsMember 2023-01-01 2023-12-31 0001871181 us-gaap:CommonStockMember 2023-12-31 0001871181 us-gaap:AdditionalPaidInCapitalMember 2023-12-31 0001871181 us-gaap:RetainedEarningsMember 2023-12-31 0001871181 QLIS:FDHMember QLIS:ShareExchangeAgreementMember 2011-05-05 2011-05-05 0001871181 QLIS:FDHMember QLIS:ShareExchangeAgreementMember 2011-05-05 0001871181 QLIS:DonxonMember 2011-05-05 0001871181 QLIS:DasenMember 2011-05-05 0001871181 QLIS:FDSCMember 2011-05-05 0001871181 QLIS:XKTMember 2011-05-05 0001871181 2018-02-12 2018-02-13 0001871181 QLIS:EchoResourcesLLLPMember 2018-02-13 0001871181 us-gaap:ParentMember 2018-02-13 0001871181 QLIS:MPathixMember QLIS:ShareExchangeAgreementMember 2021-06-29 2021-06-29 0001871181 QLIS:MPathixMember QLIS:ShareExchangeAgreementMember 2021-06-29 0001871181 QLIS:MPathixMember QLIS:DrJosephPergolizziMember QLIS:ShareExchangeAgreementMember QLIS:CreoMedIncMember 2021-06-29 0001871181 QLIS:SolaceMember 2023-01-01 2023-12-31 0001871181 us-gaap:ToolsDiesAndMoldsMember 2023-12-31 0001871181 us-gaap:ToolsDiesAndMoldsMember 2022-12-31 0001871181 us-gaap:ComputerEquipmentMember 2023-12-31 0001871181 us-gaap:ComputerEquipmentMember 2022-12-31 0001871181 QLIS:ImpairmentOfToolingMember 2023-12-31 0001871181 QLIS:ImpairmentOfToolingMember 2022-12-31 0001871181 srt:ChiefExecutiveOfficerMember 2023-12-31 0001871181 srt:ChiefExecutiveOfficerMember 2022-12-31 0001871181 srt:ChiefExecutiveOfficerMember 2023-01-01 2023-12-31 0001871181 srt:ChiefExecutiveOfficerMember 2022-01-01 2022-12-31 0001871181 QLIS:TwoAffiliateMember us-gaap:CommonStockMember us-gaap:SubsequentEventMember 2024-01-01 2024-01-31 0001871181 QLIS:IndependentContractorServicesAgreementMember 2022-10-02 2022-10-03 0001871181 QLIS:IndependentContractorServicesAgreementMember 2023-01-01 2023-12-31 0001871181 QLIS:AffiliateMember 2022-07-20 2022-07-20 0001871181 QLIS:AhmetDemirBingolMember us-gaap:WarrantMember 2021-03-16 2021-03-16 0001871181 QLIS:AhmetDemirBingolMember us-gaap:WarrantMember 2021-03-16 0001871181 QLIS:AhmetDemirBingolMember us-gaap:WarrantMember us-gaap:ShareBasedCompensationAwardTrancheOneMember 2022-04-15 2022-04-15 0001871181 QLIS:AhmetDemirBingolMember us-gaap:WarrantMember 2022-04-15 2022-04-15 0001871181 QLIS:AhmetDemirBingolMember us-gaap:WarrantMember 2022-01-01 2022-12-31 0001871181 QLIS:ThirdPartyMember us-gaap:WarrantMember 2022-02-01 2022-02-01 0001871181 QLIS:ThirdPartyMember us-gaap:WarrantMember 2022-02-01 0001871181 QLIS:DrJosephPergolizziMember us-gaap:WarrantMember QLIS:CreoMedIncMember 2022-03-29 2022-03-29 0001871181 QLIS:DrJosephPergolizziMember us-gaap:WarrantMember QLIS:CreoMedIncMember 2022-03-29 0001871181 QLIS:ThirdPartyMember 2022-08-01 2022-08-01 0001871181 QLIS:ThirdPartyMember 2022-08-01 0001871181 QLIS:ThirdPartyMember 2022-09-01 2022-09-01 0001871181 QLIS:ThirdPartyMember 2022-09-01 0001871181 QLIS:ThirdPartyMember us-gaap:ShareBasedCompensationAwardTrancheOneMember 2022-09-01 2022-09-01 0001871181 QLIS:ThirdPartyMember us-gaap:ShareBasedCompensationAwardTrancheTwoMember 2022-09-01 2022-09-01 0001871181 QLIS:JimHoltMember 2023-04-03 2023-04-03 0001871181 QLIS:JimHoltMember 2023-04-03 0001871181 QLIS:MrHoltMember us-gaap:WarrantMember 2023-12-13 0001871181 QLIS:MrHoltMember us-gaap:WarrantMember 2023-12-13 2023-12-13 0001871181 us-gaap:WarrantMember 2021-12-31 0001871181 us-gaap:WarrantMember 2022-01-01 2022-12-31 0001871181 us-gaap:WarrantMember 2022-12-31 0001871181 us-gaap:WarrantMember 2023-01-01 2023-12-31 0001871181 us-gaap:WarrantMember 2023-12-31 0001871181 QLIS:OptionsToPurchaseSharesOfCommonStockMember 2023-01-01 2023-12-31 0001871181 QLIS:OptionsToPurchaseSharesOfCommonStockMember 2022-01-01 2022-12-31 0001871181 QLIS:WarrantsToPurchaseSharesOfCommonStockMember QLIS:FebruaryFourteenTwoThousandTwentyOneMember QLIS:CreoMedIncMember 2023-01-01 2023-12-31 0001871181 QLIS:WarrantsToPurchaseSharesOfCommonStockMember QLIS:FebruaryFourteenTwoThousandTwentyOneMember QLIS:CreoMedIncMember 2022-01-01 2022-12-31 0001871181 QLIS:WarrantsToPurchaseSharesOfCommonStockMember QLIS:MarchSixteenTwoThousandTwentyOneMember QLIS:DemirBingolMember 2023-01-01 2023-12-31 0001871181 QLIS:WarrantsToPurchaseSharesOfCommonStockMember QLIS:MarchSixteenTwoThousandTwentyOneMember QLIS:DemirBingolMember 2022-01-01 2022-12-31 0001871181 QLIS:WarrantsToPurchaseSharesOfCommonStockMember QLIS:AprilOneTwoThousandTwentyTwoMember QLIS:CreoMedIncMember 2023-01-01 2023-12-31 0001871181 QLIS:WarrantsToPurchaseSharesOfCommonStockMember QLIS:AprilOneTwoThousandTwentyTwoMember QLIS:CreoMedIncMember 2022-01-01 2022-12-31 0001871181 QLIS:WarrantsToPurchaseSharesOfCommonStockMember 2023-01-01 2023-12-31 0001871181 QLIS:WarrantsToPurchaseSharesOfCommonStockMember 2022-01-01 2022-12-31 0001871181 us-gaap:WarrantMember QLIS:ShareExchangeAgreementMember 2021-06-29 0001871181 QLIS:MrBingolMember us-gaap:WarrantMember QLIS:ShareExchangeAgreementMember 2021-06-29 0001871181 us-gaap:WarrantMember QLIS:ShareExchangeAgreementMember QLIS:CreoMedIncMember 2021-06-29 0001871181 QLIS:TwoThousandTwentyOnePlanMember 2021-06-01 0001871181 QLIS:AhmetDemirBingolMember 2021-03-16 2021-03-16 0001871181 QLIS:SOLACEDeviceMember 2022-01-27 0001871181 QLIS:IndependentContractorServicesAgreementMember 2022-10-03 0001871181 QLIS:TwoAffiliateMember us-gaap:SubsequentEventMember 2024-01-01 2024-01-31 iso4217:USD shares iso4217:USD shares pure false FY 0001871181 10-K true 2023-12-31 --12-31 2023 false 333-260982 QUALIS INNOVATIONS, INC. NV 84-2488498 6898 S. University Blvd Suite 100 Centennial CO 80122 (484) 483-2134 No No Yes Yes Non-accelerated Filer true true true false false false 1915000 20439950 6651 Victor Mokuolu CPA PLLC Houston, Texas 2431 69858 40175 54000 92170 2431 256203 39258 2431 295461 16285 40315 500000 9102 31192 525387 71507 525387 71507 0.001 0.001 25000000 25000000 0 0 0 0 0.001 0.001 750000000 750000000 8439950 8439950 8475950 8475950 8440 8476 3898912 3840765 -4430308 -3625287 -522956 223954 2431 295461 1500 76360 30348 342024 45763 -94101 152630 596232 230241 920515 -230241 -920515 -500000 76008 40175 18000 23403 -574780 -805021 -920515 -805021 -920515 -0.09 -0.09 -0.11 -0.11 8475950 8475950 8333660 8333660 8239950 8240 3466947 -2704772 770415 342024 342024 -94101 -94101 8131 8131 200000 200 99800 100000 36000 36 17964 18000 -920515 -920515 8475950 8476 3840765 -3625287 223954 8475950 8476 3840765 -3625287 223954 8475950 8476 3840765 -3625287 223954 30348 30348 45763 45763 36000 36 17964 18000 -805021 -805021 8439950 8440 3897485 -4430308 -522956 8439950 8440 3897485 -4430308 -522956 -805021 -920515 17250 17102 76008 30348 342024 8131 45763 -94101 18000 500000 -40175 -20100 -92170 -8974 -42030 22067 -31192 31192 -11400 -76529 -558426 9102 100000 9102 100000 -67427 -458426 69858 528284 2431 69858 62384 NOTE 1 – ORGANIZATION AND PRINCIPAL ACTIVITIES Corporate History and Background Qualis Innovations, Inc. (the “Company” or “Qualis”), formerly known as Hoopsoft Development Corp., Yellowstone Mining, Inc. and Sky Digital Holding Corp. was incorporated in the state of Nevada on March 23, 2006 under the name Hoopsoft Development Corp (“Hoopsoft”). On January 12, 2007, the Company entered into an agreement and plan of merger (“Agreement and Plan of Merger”) with Yellowcake Mining, Inc. (“Yellowcake”), a Nevada corporation and wholly-owned subsidiary of Hoopsoft Development Corp., incorporated for the sole purpose of effecting the merger. Pursuant to the terms of the Agreement and Plan of Merger, Yellowcake merged with and into Hoopsoft, with Hoopsoft carrying on as the surviving corporation under the name “Yellowcake Mining, Inc.” On April 6, 2011, Yellowcake restated its articles of incorporation and changed its name to Sky Digital Stores Corp (“SKYC”). On May 5, 2011, the Company entered into a Share Exchange Agreement (“Exchange Agreement”) by and among SKYC and Hong Kong First Digital Holding Ltd. (“First Digital”), and the shareholders of First Digital (the “FDH Shareholders”) entered into a Share “FDH”), and the shareholders of FDH (the “FDH Shareholders”). The closing of the transaction (the “Closing”) took place on May 5, 2011 (the “Closing Date”). On the Closing Date, pursuant to the terms of the Exchange Agreement, the Company acquired all of the outstanding shares (the “Shares”) of FDH from the FDH Shareholders; and FDH Shareholders transferred and contributed all of their Shares to us. In exchange, the Company issued to the FDH Shareholders, their designees or assigns, an aggregate of <span id="xdx_90D_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_pid_c20110505__20110505__us-gaap--TypeOfArrangementAxis__custom--ShareExchangeAgreementMember__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--FDHMember_zxZTsR71Cu6j" title="Stock issued during period, shares">23,716,035 shares (the “Shares Component”) or <span id="xdx_901_eus-gaap--EquityMethodInvestmentOwnershipPercentage_iI_pid_dp_uPure_c20110505__us-gaap--TypeOfArrangementAxis__custom--ShareExchangeAgreementMember__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--FDHMember_zyFeVaa2RcZh" title="Stock issued and outstanding percentage">97.56% of the shares of common stock of the Company issued and outstanding after the Closing (the “Share Exchange”), at $<span id="xdx_907_eus-gaap--SharePrice_iI_c20110505__us-gaap--TypeOfArrangementAxis__custom--ShareExchangeAgreementMember__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--FDHMember_z1OScnfroCOh" title="Share price">0.20 per share. Mr. Lin Xiangfeng planned, organized and executed the Share Exchange. Prior to the Share Exchange, Mr. Lin Xiangfeng was the largest shareholder and sole officer of FDH. He was also the CEO of SKYC but did not own any shares of the Company. The parties involved in the Share Exchange Agreement are SKYC, FDH and all FDH Shareholders. Mr. Lin Jinshui, an FDH Shareholder, is the father of Mr. Lin Xiangfeng and Mr. Lin Xiuzi, an FDH Shareholder, is the brother of Mr. Lin Xiangfeng. Other than Mr. Lin Xiangfeng, no third party played a substantial role in the agreement. FDH owned (i) 100% of the issued and outstanding capital stock of Shenzhen Dong Sen Mobile Communication Technology Co., Ltd (also known and doing business as Shenzhen Donxon Mobile Communication Technology Co., Ltd, “Donxon”), a company organized under the laws of the People’s Republic of China (“China” or the “PRC”); and (ii) 100% of the issued and outstanding capital stock of Shenzhen Xing Tian Kong Digital Company Limited (“XTK”), a PRC company. XTK was the holder of 100% of the issued and outstanding capital stock of Shenzhen Da Sheng Communication Technology Company Limited (also known and do business as Shenzhen Dasen Communication Technology Company Limited, “Dasen”), a PRC company. Dasen is the holder of 70% of the issued and outstanding capital stock of Foshan Da Sheng Communication Chain Service Company Limited (also known and do business as Foshan Dasen Communication Chain Service Co. Ltd, “FDSC”), a PRC company. Pursuant to the Exchange Agreement, FDH became a wholly-owned subsidiary of the Company, and the Company owned <span id="xdx_901_eus-gaap--EquityMethodInvestmentOwnershipPercentage_iI_pid_dp_c20110505__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--DonxonMember_zduwmQ0PtkGc" title="Equity ownership percentage">100% of Donxon, 100% of XKT, 100% of Dasen and <span id="xdx_903_eus-gaap--EquityMethodInvestmentOwnershipPercentage_iI_pid_dp_c20110505__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--FDSCMember_zxdmJrFpits9" title="Equity ownership percentage">70% of FDSC indirectly through FDH. On February 13, 2018, a change of control occurred, and new officers and directors of the Company were appointed. The name change of ‘Sky Digital Stores Corp.’ (SKYC) to Qualis Innovations, Inc. and the 1 – 1,000 reverse split was announced on FINRA’s Daily List. Echo Resources LLLP took over control of Qualis owning 232,689 of the 396,650 common shares outstanding. Since that event Qualis did not have any business operations or any assets or liabilities. In July, 2019, John Ballard and Charles Achoa, formed a new company named EMF Medical Devices Inc. for the development, maintenance, marketing and sale of an electronic device for the treatment of pain that would make use of certain intellectual property interests held by LCMD. In May 2021 the Company changed its name to mPathix Health Inc. John Ballard is the Company’s previous Chief Financial Officer and Charles Achoa does not participate in any management or board position. On June 28, 2021, the Company entered into a Share Exchange Agreement (“Exchange Agreement”) by and among mPathix Health, Inc. (formerly EMF Medical Devices, Inc., a Delaware corporation) (“mPathix”) and Qualis. The closing of the transaction (the “Closing”) took place on June 29, 2021 (the “Closing Date”). On the Closing Date, pursuant to the terms of the Exchange Agreement, the Company acquired all of the outstanding shares (the “Shares”) of mPathix. In exchange, the Company issued to the mPathix shareholder’s, their designees or assigns, an aggregate of <span id="xdx_902_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_pid_c20210629__20210629__us-gaap--TypeOfArrangementAxis__custom--ShareExchangeAgreementMember__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--MPathixMember_zBsZ2zYJDtR9" title="Stock issued during period, shares">6,988,300 shares of Company common stock (the “Shares Component”) or <span id="xdx_90E_eus-gaap--EquityMethodInvestmentOwnershipPercentage_iI_pid_dp_c20210629__us-gaap--TypeOfArrangementAxis__custom--ShareExchangeAgreementMember__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--MPathixMember_zknrTcrhhq53" title="Equity ownership percentage">93.36% of the shares of common stock of the Company issued and outstanding after the Closing (the “Share Exchange”), at a valuation of $<span id="xdx_908_eus-gaap--SharesIssuedPricePerShare_iI_pid_c20210629__us-gaap--TypeOfArrangementAxis__custom--ShareExchangeAgreementMember__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--MPathixMember_zkFngTGnjEdb" title="Share price">0.50 per share, and the Company issued warrants to purchase an additional <span id="xdx_905_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_pid_c20210629__us-gaap--TypeOfArrangementAxis__custom--ShareExchangeAgreementMember__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--MPathixMember_ztkvVhdPPue9" title="Warrants to purchase shares">1,098,830 shares (<span id="xdx_902_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_pid_c20210629__us-gaap--TypeOfArrangementAxis__custom--ShareExchangeAgreementMember__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--MPathixMember_zWMXzwQp8sH3" title="Warrants issued">698,830 warrants issued to the Company’s previous CEO and <span id="xdx_90F_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_pid_c20210629__us-gaap--TypeOfArrangementAxis__custom--ShareExchangeAgreementMember__dei--LegalEntityAxis__custom--CreoMedIncMember__srt--TitleOfIndividualAxis__custom--DrJosephPergolizziMember__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--MPathixMember_zlgImGmXiQYk" title="Warrants issued">400,000 to CreoMed which is beneficially owned by Dr. Joseph Pergolizzi, the Company’s acting CEO and chairman of the board) of the Company’s common stock, exercisable for <span id="xdx_905_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dtY_c20210629__us-gaap--TypeOfArrangementAxis__custom--ShareExchangeAgreementMember__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--MPathixMember_zkf1XRGIxM4j" title="Warrants term">10 years at a $<span id="xdx_904_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20210629__us-gaap--TypeOfArrangementAxis__custom--ShareExchangeAgreementMember__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--MPathixMember_zmYQAUMJMg5j" title="Warrants exercise price">0.50 per share exercise price, subject to adjustment. In connection with the closing of the mPathix acquisition, the officers and directors of mPathix were appointed as the officers and directors of the Company. On June 29, 2021, the Company issued <span id="xdx_905_eus-gaap--StockIssuedDuringPeriodSharesAcquisitions_pid_c20210629__20210629__us-gaap--TypeOfArrangementAxis__custom--ShareExchangeAgreementMember__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--MPathixMember_zUkE3bs6EtM7" title="Recapitalization of qualis in conjunction with reverse acquisition, shares">496,650 common shares for the recapitalization of Qualis in conjunction with the reverse acquisition for a net book value of $<span id="xdx_900_eus-gaap--StockIssuedDuringPeriodValueAcquisitions_pid_c20210629__20210629__us-gaap--TypeOfArrangementAxis__custom--ShareExchangeAgreementMember__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--MPathixMember_zhx6dnNnj3Ce" title="Recapitalization of qualis in conjunction with reverse acquisition">0. The acquisition was accounted for as a “reverse merger’’ and recapitalization since the stockholders of mPathix owned a majority of the outstanding shares of the common stock immediately following the completion of the transaction assuming that holders of <span id="xdx_90B_ecustom--RecapitalizationOfQualisInConjunctionWithReverseAcquisitionRate_pid_dp_uPure_c20210629__20210629__us-gaap--TypeOfArrangementAxis__custom--ShareExchangeAgreementMember__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--MPathixMember_zLNXDmK4Zgpg" title="Recapitalization of qualis in conjunction with reverse acquisition, rate">10% of the Public Shares exercise their conversion rights. mPathix was deemed to be the accounting acquirer in the transaction and, consequently, the transaction was treated as a recapitalization of mPathix. As a result, Qualis was considered to be the continuation of the predecessor mPathix. Accordingly, the assets and liabilities and the historical operations that are reflected in the consolidated financial statements are those of mPathix and are recorded at the historical cost basis of mPathix. Qualis’s assets, liabilities and results of operations will be consolidated with the assets, liabilities and results of operations of mPathix after consummation of the acquisition. 23716035 0.9756 0.20 1 1 1 0.70 1 1 1 0.70 1 – 1,000 reverse split 232689 396650 6988300 0.9336 0.50 1098830 698830 400000 P10Y 0.50 496650 0 0.10 NOTE 2 – BASIS OF PRESENTATION The accompanying consolidated financial statements have been prepared in conformity with accounting principles generally accepted in the United States of America (“GAAP”) and stated in U.S. dollars. Any reference in these notes to applicable guidance is meant to refer to the authoritative GAAP as found in the Accounting Standards Codification and Accounting Standards Updates (“ASU”) of the Financial Accounting Standards Board (“FASB”). The Company currently operates in one business segment. The Company is not organized by market and is managed and operated as one business. A single management team reports to the chief operating decision maker, the Chief Executive Officer, who comprehensively manages the entire business. The Company does not currently operate any separate lines of businesses or separate business entities. Going Concern The accompanying consolidated financial statements have been prepared assuming the Company will continue as a going concern, which contemplates, among other things, the realization of assets and satisfaction of liabilities in the normal course of business. The Company had an accumulated deficit of $4,430,308 at December 31, 2023, had a working capital deficit of $522,956 and working capital of $184,696 at December 31, 2023 and December 31, 2022, respectively, had a net loss of $805,021 and $920,515 for years ended December 31, 2023 and 2022, respectively, and net cash used in operating activities of $76,529 and $558,426 or years ended December 31, 2023 and 2022, respectively, with no revenue earned since inception, and a lack of operational history. These matters raise substantial doubt about the Company’s ability to continue as a going concern. While the Company is attempting to expand operations and generate revenues, the Company’s cash position may not be significant enough to support the Company’s daily operations. Management intends to raise additional funds by way of a private offering. Management believes that the actions presently being taken to further implement its business plan and generate revenues provide the opportunity for the Company to continue as a going concern. While management believes in the viability of its strategy to generate revenues and in its ability to raise additional funds or transact an asset sale, there can be no assurances to that effect or on terms acceptable to the Company. The ability of the Company to continue as a going concern is dependent upon the Company’s ability to further implement its business plan and generate revenues. The consolidated financial statements do not include any adjustments that might be necessary if the Company is unable to continue as a going concern. -4430308 -522956 184696 184696 -805021 -920515 -76529 -558426 NOTE 3 – SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES This summary of significant accounting policies of the Company is presented to assist in understanding the Company’s consolidated financial statements. The consolidated financial statements and notes are representations of the Company’s management, which is responsible for their integrity and objectivity. These accounting policies conform to GAAP and have been consistently applied in the preparation of the consolidated financial statements. Use of Estimates The preparation of these consolidated financial statements in accordance with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosures of contingent assets and liabilities at the dates of the consolidated financial statements and the reported amounts of net sales and expenses during the reported periods. Actual results may differ from those estimates and such differences may be material to the consolidated financial statements. The more significant estimates and assumptions by management include among others: common stock valuation, amortization of intangible assets, depreciation of property and equipment, the recoverability of intangibles. The current economic environment has increased the degree of uncertainty inherent in these estimates and assumptions. For the year ended December 31, 2023, the accompanying consolidated financial statements includes a change in accounting estimate of accrued expenses that resulted in a $41,403 reduction in expenses from operations comprised of accounts payable of $23,403, common stock of $<span id="xdx_907_eus-gaap--StockIssuedDuringPeriodValueShareBasedCompensationForfeited_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zPBcf442uhrg" title="Common stock value">36, and additional paid in capital of $<span id="xdx_905_eus-gaap--StockIssuedDuringPeriodValueShareBasedCompensationForfeited_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--AdditionalPaidInCapitalMember_zP6H4hnLcNTk" title="Additional paid in capital">17,964 (due to the cancellation of <span id="xdx_906_eus-gaap--StockIssuedDuringPeriodSharesShareBasedCompensationForfeited_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zpeKaWD1FmA" title="Number of cancellation of common shares">36,000 common shares). The Financial Accounting Standards Board’s, ASC 250-10-45-17 requires specific financial statement disclosures to include the effect on income from operations, net income, and any related per-share amounts. Cash The Company’s cash is held in bank accounts in the United States and is insured by the Federal Deposit Insurance Corporation (FDIC) up to $250,000. The Company has not experienced any cash losses. Related Parties The Company follows ASC 850, “Related Party Disclosures,” for the identification of related parties and disclosure of related party transactions. Related parties are any entities or individuals that, through employment, ownership or other means, possess the ability to direct or cause the direction of the management and policies of the Company. Income Taxes Income taxes are accounted for under an asset and liability approach. This process involves calculating the temporary and permanent differences between the carrying amounts of the assets and liabilities for financial reporting purposes and the amounts used for income tax purposes. The temporary differences result in deferred tax assets and liabilities, which would be recorded on the Balance Sheets in accordance with ASC 740, which established financial accounting and reporting standards for the effect of income taxes. The likelihood that its deferred tax assets will be recovered from future taxable income must be assessed and, to the extent that recovery is not likely, a valuation allowance is established. Changes in the valuation allowance in a period are recorded through the income tax provision in the consolidated Statements of Operations. ASC 740-10 clarifies the accounting for uncertainty in income taxes recognized in an entity’s consolidated financial statements and prescribes a recognition threshold and measurement attributes for financial statement disclosure of tax positions taken or expected to be taken on a tax return. Under ASC 740-10, the impact of an uncertain income tax position on the income tax return must be recognized at the largest amount that is more-likely-than-not to be sustained upon audit by the relevant taxing authority. An uncertain income tax position will not be recognized if it has less than a 50% likelihood of being sustained. Additionally, ASC 740-10 provides guidance on derecognition, classification, interest and penalties, accounting in interim periods, disclosure and transition. The Company does not have a liability for unrecognized income tax benefits. Advertising and Marketing Costs Advertising and marketing expenses are recorded as marketing expenses when they are incurred. The Company had no advertising and marketing expense for the years ended December 31, 2023 and 2022, respectively. Research and Development All research and development costs are expensed as incurred. Research and development expenses comprise costs incurred in performing research and development activities, including clinical trial costs, manufacturing costs for both clinical and pre-clinical materials as well as other contracted services, license fees, and other external costs. Nonrefundable advance payments for goods and services that will be used in future research and development activities are expensed when the activity is performed or when the goods have been received, rather than when payment is made, in accordance with ASC 730, Research and Development. With respect to the current status of the patent, there has been no movement during the period ended December 31, 2023 and to date. The Company has a disagreement with the specific vendor and the project relating to collection of data, testing and filing the patent application has been kept on hold. The Company and the vendor are trying to resolve this disagreement, about achieving a particular milestone, which they expect to be completed later in fiscal 2023. General and Administrative Expenses General and administrative expenses consisted of professional service fees, and other general and administrative overhead costs. Expenses are recognized when incurred. Inventories Inventories are valued at the lower of cost or net realizable value. The Company’s inventories are valued under the first in, first out (FIFO) method or average cost method. Net realizable value is estimated based on current selling prices. The Company records a provision for excess and obsolete inventory based primarily on forecasted product demand and production requirements. Once inventory provisions are established, the written-down value of the inventory becomes its new cost basis. Deposits Deposits consist of amounts paid to a vendor in advance to manufacture pain treatment products. Deposits are included in current assets in the accompanying Condensed Consolidated Balance Sheets. Property and Equipment Property and equipment are carried at cost and are depreciated on a straight-line basis over the estimated useful lives of the assets, generally five years. The cost of repairs and maintenance is expensed as incurred; major replacements and improvements are capitalized. When assets are retired or disposed of, the cost and accumulated depreciation are removed from the accounts, and any resulting gains or losses are included in income in the year of disposition. Fixed assets are examined for the possibility of decreases in value when events or changes in circumstances reflect the fact that their recorded value may not be recoverable. Impairment of Long-lived Assets The Company periodically evaluates whether the carrying value of property, equipment and intangible assets has been impaired when circumstances indicate the carrying value of those assets may not be recoverable. The carrying amount is not recoverable if it exceeds the sum of the undiscounted cash flows expected to result from the use and eventual disposition of the asset. If the carrying value is not recoverable, the impairment loss is measured as the excess of the asset’s carrying value over its fair value. The Company’s impairment analyses require management to apply judgment in estimating future cash flows as well as asset fair values, including forecasting useful lives of the assets, assessing the probability of different outcomes, and selecting the discount rate that reflects the risk inherent in future cash flows. If the carrying value is not recoverable, we assess the fair value of long-lived assets using commonly accepted techniques, and may use more than one method, including, but not limited to, recent third-party comparable sales and discounted cash flow models. If actual results are not consistent with the Company’s assumptions and estimates, or the assumptions and estimates change due to new information, the Company may be exposed to an impairment charge in the future. In the 4th quarter of 2023, the Company determined that the third party manufacturer of its SOLACE device was unable to deliver the remaining SOLACE devices and that it may not be economically feasible to pursue the manufacturer for the return of the tooling and deposits. As a result, the Company determined that the value of the tooling and deposits related to its SOLACE device was $0 and recorded an impairment of assets totaling $76,008 in the year ended December 31, 2023 and is classified in other expenses in the consolidated Statements of Operations. Fair Value of Financial Instruments The provisions of accounting guidance, FASB Topic ASC 825 requires all entities to disclose the fair value of financial instruments, both assets and liabilities recognized and not recognized on the balance sheet, for which it is practicable to estimate fair value, and defines fair value of a financial instrument as the amount at which the instrument could be exchanged in a current transaction between willing parties. As of December 31, 2023, there were no financial instruments requiring fair value. Fair Value Measurements Fair value is defined as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability, in an orderly transaction between market participants on the measurement date. Valuation techniques used to measure fair value must maximize the use of observable inputs and minimize the use of unobservable inputs. The fair value hierarchy is based on three levels of inputs, of which the first two are considered observable and the last unobservable, as follows: <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"> </td> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in">●</td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Level 1 – Quoted prices in active markets for identical assets or liabilities.</td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif">●</td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Level 2 – Inputs other than Level 1 that are observable, either directly or indirectly, such as quoted prices for similar assets or liabilities; quoted prices in markets that are not active; or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities.</td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif">●</td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Level 3 – Unobservable inputs that are supported by little or no market activity and that are significant to the measurement of the fair value of the assets or liabilities</td></tr> </table> The carrying value of financial assets and liabilities recorded at fair value are measured on a recurring or nonrecurring basis. Financial assets and liabilities measured on a non-recurring basis are those that are adjusted to fair value when a significant event occurs. There were no financial assets or liabilities carried and measured on a nonrecurring basis during the reporting periods. Financial assets and liabilities measured on a recurring basis are those that are adjusted to fair value each time a financial statement is prepared. There have been no transfers between levels. Basic and diluted earnings per share The computation of net profit (loss) per share included in the Statements of Operations, represents the net profit (loss) per share that would have been reported had the Company been subject to ASC 260, “Earnings Per Share as a corporation for all periods presented. Diluted earnings (loss) per share are computed on the basis of the weighted average number of common shares (including common stock subject to redemption) plus dilutive potential common shares outstanding for the reporting period. In periods where losses are reported, the weighted-average number of common stock outstanding excludes common stock equivalents, because their inclusion would be anti-dilutive. Potentially dilutive securities were excluded from the calculation of diluted net loss per share because the effects were anti-dilutive based on the application of the treasury stock method and because the Company incurred net losses during the period. There were <span id="xdx_90F_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20230101__20231231_z9JyBrhy7Auj" title="Antidilutive securities excluded from computation of earnings per share, amount">1,710,000 and <span id="xdx_903_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20220101__20221231_zO1sGiakUl5c" title="Antidilutive securities excluded from computation of earnings per share, amount">1,610,000 dilutive securities outstanding for the years ended December 31, 2023 and 2022, respectively. These potential dilutive securities outstanding have not been considered as the inclusion would be anti-dilutive. Employee Stock Based Compensation Stock based compensation issued to employees and members of our board of directors is measured at the date of grant based on the estimated fair value of the award, net of estimated forfeitures. The grant date fair value of a stock-based award is recognized as an expense over the requisite service period of the award on a straight-line basis. For purposes of determining the variables used in the calculation of stock-based compensation issued to employees, the Company performs an analysis of current market data and historical data to calculate an estimate of implied volatility, the expected term of the option and the expected forfeiture rate. With the exception of the expected forfeiture rate, which is not an input, we use these estimates as variables in the Black-Scholes option pricing model. Depending upon the number of stock options granted any fluctuations in these calculations could have a material effect on the results presented in our consolidated statements of operations. In addition, any differences between estimated forfeitures and actual forfeitures could also have a material impact on our consolidated financial statements. Non-Employee Stock Based Compensation Issuances of the Company’s common stock or warrants for acquiring goods or services are measured at the fair value of the consideration received or the fair value of the equity instruments issued, whichever is more reliably measurable. The measurement date for the fair value of the equity instruments issued to consultants or vendors is determined at the earlier of (i) the date at which a commitment for performance to earn the equity instruments is reached (a “performance commitment” which would include a penalty considered to be of a magnitude that is a sufficiently large disincentive for nonperformance) or (ii) the date at which performance is complete. Although situations may arise in which counter performance may be required over a period of time, the equity award granted to the party performing the service is fully vested and non-forfeitable on the date of the agreement. As a result, in this situation in which vesting periods do not exist as the instruments fully vested on the date of agreement, the Company determines such date to be the measurement date and will record the estimated fair market value of the instruments granted as a prepaid expense and amortize such amount to general and administrative expense in the accompanying statement of operations over the contract period. When it is appropriate for the Company to recognize the cost of a transaction during financial reporting periods prior to the measurement date, for purposes of recognition of costs during those periods, the equity instrument is measured at the then-current fair values at each of those interim financial reporting dates. Non-Cash Equity Transactions Shares of equity instruments issued for non-cash consideration are recorded at the fair value of the consideration received based on the market value of services to be rendered, or at the value of the stock given, considered in reference to contemporaneous cash sale of stock. Concentrations, Risks, and Uncertainties Business Risk Substantial business risks and uncertainties are inherent to an entity, including the potential risk of business failure. The Company is headquartered and operates in the United States. To date, the Company has generated no revenues from operations. There can be no assurance that the Company will be able to raise additional capital and failure to do so would have a material adverse effect on the Company’s financial position, results of operations and cash flows. Also, the success of the Company’s operations is subject to numerous contingencies, some of which are beyond management’s control. Currently, these contingencies include general economic conditions, price of components, competition, and governmental and political conditions. Interest rate risk Financial assets and liabilities do not have material interest rate risk. Credit risk The Company is not exposed to credit risk. Seasonality The business is not subject to substantial seasonal fluctuations. Major Suppliers The Company has not entered into any contracts that obligate it to purchase a minimum quantity or exclusively from any supplier. Recent Accounting Pronouncements Recently issued accounting updates are not expected to have a material impact on the Company’s consolidated financial statements. Use of Estimates The preparation of these consolidated financial statements in accordance with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosures of contingent assets and liabilities at the dates of the consolidated financial statements and the reported amounts of net sales and expenses during the reported periods. Actual results may differ from those estimates and such differences may be material to the consolidated financial statements. The more significant estimates and assumptions by management include among others: common stock valuation, amortization of intangible assets, depreciation of property and equipment, the recoverability of intangibles. The current economic environment has increased the degree of uncertainty inherent in these estimates and assumptions. For the year ended December 31, 2023, the accompanying consolidated financial statements includes a change in accounting estimate of accrued expenses that resulted in a $41,403 reduction in expenses from operations comprised of accounts payable of $23,403, common stock of $<span id="xdx_907_eus-gaap--StockIssuedDuringPeriodValueShareBasedCompensationForfeited_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zPBcf442uhrg" title="Common stock value">36, and additional paid in capital of $<span id="xdx_905_eus-gaap--StockIssuedDuringPeriodValueShareBasedCompensationForfeited_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--AdditionalPaidInCapitalMember_zP6H4hnLcNTk" title="Additional paid in capital">17,964 (due to the cancellation of <span id="xdx_906_eus-gaap--StockIssuedDuringPeriodSharesShareBasedCompensationForfeited_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zpeKaWD1FmA" title="Number of cancellation of common shares">36,000 common shares). The Financial Accounting Standards Board’s, ASC 250-10-45-17 requires specific financial statement disclosures to include the effect on income from operations, net income, and any related per-share amounts. 41403 23403 36 17964 36000 Cash The Company’s cash is held in bank accounts in the United States and is insured by the Federal Deposit Insurance Corporation (FDIC) up to $250,000. The Company has not experienced any cash losses. 250000 Related Parties The Company follows ASC 850, “Related Party Disclosures,” for the identification of related parties and disclosure of related party transactions. Related parties are any entities or individuals that, through employment, ownership or other means, possess the ability to direct or cause the direction of the management and policies of the Company. Income Taxes Income taxes are accounted for under an asset and liability approach. This process involves calculating the temporary and permanent differences between the carrying amounts of the assets and liabilities for financial reporting purposes and the amounts used for income tax purposes. The temporary differences result in deferred tax assets and liabilities, which would be recorded on the Balance Sheets in accordance with ASC 740, which established financial accounting and reporting standards for the effect of income taxes. The likelihood that its deferred tax assets will be recovered from future taxable income must be assessed and, to the extent that recovery is not likely, a valuation allowance is established. Changes in the valuation allowance in a period are recorded through the income tax provision in the consolidated Statements of Operations. ASC 740-10 clarifies the accounting for uncertainty in income taxes recognized in an entity’s consolidated financial statements and prescribes a recognition threshold and measurement attributes for financial statement disclosure of tax positions taken or expected to be taken on a tax return. Under ASC 740-10, the impact of an uncertain income tax position on the income tax return must be recognized at the largest amount that is more-likely-than-not to be sustained upon audit by the relevant taxing authority. An uncertain income tax position will not be recognized if it has less than a 50% likelihood of being sustained. Additionally, ASC 740-10 provides guidance on derecognition, classification, interest and penalties, accounting in interim periods, disclosure and transition. The Company does not have a liability for unrecognized income tax benefits. Advertising and Marketing Costs Advertising and marketing expenses are recorded as marketing expenses when they are incurred. The Company had no advertising and marketing expense for the years ended December 31, 2023 and 2022, respectively. 0 0 Research and Development All research and development costs are expensed as incurred. Research and development expenses comprise costs incurred in performing research and development activities, including clinical trial costs, manufacturing costs for both clinical and pre-clinical materials as well as other contracted services, license fees, and other external costs. Nonrefundable advance payments for goods and services that will be used in future research and development activities are expensed when the activity is performed or when the goods have been received, rather than when payment is made, in accordance with ASC 730, Research and Development. With respect to the current status of the patent, there has been no movement during the period ended December 31, 2023 and to date. The Company has a disagreement with the specific vendor and the project relating to collection of data, testing and filing the patent application has been kept on hold. The Company and the vendor are trying to resolve this disagreement, about achieving a particular milestone, which they expect to be completed later in fiscal 2023. General and Administrative Expenses General and administrative expenses consisted of professional service fees, and other general and administrative overhead costs. Expenses are recognized when incurred. Inventories Inventories are valued at the lower of cost or net realizable value. The Company’s inventories are valued under the first in, first out (FIFO) method or average cost method. Net realizable value is estimated based on current selling prices. The Company records a provision for excess and obsolete inventory based primarily on forecasted product demand and production requirements. Once inventory provisions are established, the written-down value of the inventory becomes its new cost basis. Deposits Deposits consist of amounts paid to a vendor in advance to manufacture pain treatment products. Deposits are included in current assets in the accompanying Condensed Consolidated Balance Sheets. Property and Equipment Property and equipment are carried at cost and are depreciated on a straight-line basis over the estimated useful lives of the assets, generally five years. The cost of repairs and maintenance is expensed as incurred; major replacements and improvements are capitalized. When assets are retired or disposed of, the cost and accumulated depreciation are removed from the accounts, and any resulting gains or losses are included in income in the year of disposition. Fixed assets are examined for the possibility of decreases in value when events or changes in circumstances reflect the fact that their recorded value may not be recoverable. P5Y Impairment of Long-lived Assets The Company periodically evaluates whether the carrying value of property, equipment and intangible assets has been impaired when circumstances indicate the carrying value of those assets may not be recoverable. The carrying amount is not recoverable if it exceeds the sum of the undiscounted cash flows expected to result from the use and eventual disposition of the asset. If the carrying value is not recoverable, the impairment loss is measured as the excess of the asset’s carrying value over its fair value. The Company’s impairment analyses require management to apply judgment in estimating future cash flows as well as asset fair values, including forecasting useful lives of the assets, assessing the probability of different outcomes, and selecting the discount rate that reflects the risk inherent in future cash flows. If the carrying value is not recoverable, we assess the fair value of long-lived assets using commonly accepted techniques, and may use more than one method, including, but not limited to, recent third-party comparable sales and discounted cash flow models. If actual results are not consistent with the Company’s assumptions and estimates, or the assumptions and estimates change due to new information, the Company may be exposed to an impairment charge in the future. In the 4th quarter of 2023, the Company determined that the third party manufacturer of its SOLACE device was unable to deliver the remaining SOLACE devices and that it may not be economically feasible to pursue the manufacturer for the return of the tooling and deposits. As a result, the Company determined that the value of the tooling and deposits related to its SOLACE device was $0 and recorded an impairment of assets totaling $76,008 in the year ended December 31, 2023 and is classified in other expenses in the consolidated Statements of Operations. 0 76008 Fair Value of Financial Instruments The provisions of accounting guidance, FASB Topic ASC 825 requires all entities to disclose the fair value of financial instruments, both assets and liabilities recognized and not recognized on the balance sheet, for which it is practicable to estimate fair value, and defines fair value of a financial instrument as the amount at which the instrument could be exchanged in a current transaction between willing parties. As of December 31, 2023, there were no financial instruments requiring fair value. Fair Value Measurements Fair value is defined as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability, in an orderly transaction between market participants on the measurement date. Valuation techniques used to measure fair value must maximize the use of observable inputs and minimize the use of unobservable inputs. The fair value hierarchy is based on three levels of inputs, of which the first two are considered observable and the last unobservable, as follows: <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"> </td> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in">●</td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Level 1 – Quoted prices in active markets for identical assets or liabilities.</td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif">●</td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Level 2 – Inputs other than Level 1 that are observable, either directly or indirectly, such as quoted prices for similar assets or liabilities; quoted prices in markets that are not active; or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities.</td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif">●</td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Level 3 – Unobservable inputs that are supported by little or no market activity and that are significant to the measurement of the fair value of the assets or liabilities</td></tr> </table> The carrying value of financial assets and liabilities recorded at fair value are measured on a recurring or nonrecurring basis. Financial assets and liabilities measured on a non-recurring basis are those that are adjusted to fair value when a significant event occurs. There were no financial assets or liabilities carried and measured on a nonrecurring basis during the reporting periods. Financial assets and liabilities measured on a recurring basis are those that are adjusted to fair value each time a financial statement is prepared. There have been no transfers between levels. Basic and diluted earnings per share The computation of net profit (loss) per share included in the Statements of Operations, represents the net profit (loss) per share that would have been reported had the Company been subject to ASC 260, “Earnings Per Share as a corporation for all periods presented. Diluted earnings (loss) per share are computed on the basis of the weighted average number of common shares (including common stock subject to redemption) plus dilutive potential common shares outstanding for the reporting period. In periods where losses are reported, the weighted-average number of common stock outstanding excludes common stock equivalents, because their inclusion would be anti-dilutive. Potentially dilutive securities were excluded from the calculation of diluted net loss per share because the effects were anti-dilutive based on the application of the treasury stock method and because the Company incurred net losses during the period. There were <span id="xdx_90F_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20230101__20231231_z9JyBrhy7Auj" title="Antidilutive securities excluded from computation of earnings per share, amount">1,710,000 and <span id="xdx_903_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20220101__20221231_zO1sGiakUl5c" title="Antidilutive securities excluded from computation of earnings per share, amount">1,610,000 dilutive securities outstanding for the years ended December 31, 2023 and 2022, respectively. These potential dilutive securities outstanding have not been considered as the inclusion would be anti-dilutive. 1710000 1610000 Employee Stock Based Compensation Stock based compensation issued to employees and members of our board of directors is measured at the date of grant based on the estimated fair value of the award, net of estimated forfeitures. The grant date fair value of a stock-based award is recognized as an expense over the requisite service period of the award on a straight-line basis. For purposes of determining the variables used in the calculation of stock-based compensation issued to employees, the Company performs an analysis of current market data and historical data to calculate an estimate of implied volatility, the expected term of the option and the expected forfeiture rate. With the exception of the expected forfeiture rate, which is not an input, we use these estimates as variables in the Black-Scholes option pricing model. Depending upon the number of stock options granted any fluctuations in these calculations could have a material effect on the results presented in our consolidated statements of operations. In addition, any differences between estimated forfeitures and actual forfeitures could also have a material impact on our consolidated financial statements. Non-Employee Stock Based Compensation Issuances of the Company’s common stock or warrants for acquiring goods or services are measured at the fair value of the consideration received or the fair value of the equity instruments issued, whichever is more reliably measurable. The measurement date for the fair value of the equity instruments issued to consultants or vendors is determined at the earlier of (i) the date at which a commitment for performance to earn the equity instruments is reached (a “performance commitment” which would include a penalty considered to be of a magnitude that is a sufficiently large disincentive for nonperformance) or (ii) the date at which performance is complete. Although situations may arise in which counter performance may be required over a period of time, the equity award granted to the party performing the service is fully vested and non-forfeitable on the date of the agreement. As a result, in this situation in which vesting periods do not exist as the instruments fully vested on the date of agreement, the Company determines such date to be the measurement date and will record the estimated fair market value of the instruments granted as a prepaid expense and amortize such amount to general and administrative expense in the accompanying statement of operations over the contract period. When it is appropriate for the Company to recognize the cost of a transaction during financial reporting periods prior to the measurement date, for purposes of recognition of costs during those periods, the equity instrument is measured at the then-current fair values at each of those interim financial reporting dates. Non-Cash Equity Transactions Shares of equity instruments issued for non-cash consideration are recorded at the fair value of the consideration received based on the market value of services to be rendered, or at the value of the stock given, considered in reference to contemporaneous cash sale of stock. Concentrations, Risks, and Uncertainties Business Risk Substantial business risks and uncertainties are inherent to an entity, including the potential risk of business failure. The Company is headquartered and operates in the United States. To date, the Company has generated no revenues from operations. There can be no assurance that the Company will be able to raise additional capital and failure to do so would have a material adverse effect on the Company’s financial position, results of operations and cash flows. Also, the success of the Company’s operations is subject to numerous contingencies, some of which are beyond management’s control. Currently, these contingencies include general economic conditions, price of components, competition, and governmental and political conditions. Interest rate risk Financial assets and liabilities do not have material interest rate risk. Credit risk The Company is not exposed to credit risk. Seasonality The business is not subject to substantial seasonal fluctuations. Major Suppliers The Company has not entered into any contracts that obligate it to purchase a minimum quantity or exclusively from any supplier. Recent Accounting Pronouncements Recently issued accounting updates are not expected to have a material impact on the Company’s consolidated financial statements. NOTE 4 –PROPERTY AND EQUIPMENT Property and equipment consisted of the following as of: SCHEDULE OF PROPERTY AND EQUIPMENT <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td> </td><td> </td> <td> </td><td> </td> <td colspan="2" style="text-align: center">December 31,</td><td> </td><td> </td> <td colspan="2" style="text-align: center">December 31,</td><td> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: center">Estimated Life</td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">2023</td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">2022</td><td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td> </td> <td> </td><td> </td> <td colspan="2"> </td><td> </td><td> </td> <td colspan="2"> </td><td> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 48%">Tooling</td><td style="width: 2%"> </td> <td style="width: 14%; text-align: center">5 years</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_980_eus-gaap--PropertyPlantAndEquipmentGross_iI_c20231231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--ToolsDiesAndMoldsMember_zOEo8FefanB9" style="width: 14%; text-align: right" title="Property and equipment, gross">82,530</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_981_eus-gaap--PropertyPlantAndEquipmentGross_iI_c20221231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--ToolsDiesAndMoldsMember_zl6K8Abo0ZXd" style="width: 14%; text-align: right" title="Property and equipment, gross">82,530</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Computer Equipment</td><td> </td> <td style="text-align: center">3 years</td><td> </td> <td style="text-align: left"> </td><td id="xdx_983_eus-gaap--PropertyPlantAndEquipmentGross_iI_c20231231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--ComputerEquipmentMember_zE8QtnmFV75h" style="text-align: right" title="Property and equipment, gross">1,787</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_988_eus-gaap--PropertyPlantAndEquipmentGross_iI_c20221231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--ComputerEquipmentMember_zb5SP9osuaFb" style="text-align: right" title="Property and equipment, gross">1,787</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Impairment of tooling</td><td> </td> <td style="text-align: center"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_984_eus-gaap--PropertyPlantAndEquipmentGross_iI_di_c20231231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--ImpairmentOfToolingMember_z1nMwYiUSfv1" style="text-align: right" title="Property and equipment, gross">(22,008</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td id="xdx_985_eus-gaap--PropertyPlantAndEquipmentGross_iI_c20221231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--ImpairmentOfToolingMember_z0taCsCaa6Ee" style="text-align: right" title="Property and equipment, gross">-</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1.5pt">Accumulated depreciation</td><td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_98A_eus-gaap--AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_iNI_di_c20231231_zcjubFZhEvk6" style="border-bottom: Black 1.5pt solid; text-align: right" title="Accumulated depreciation">(62,309</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_988_eus-gaap--AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_iNI_di_c20221231_zMMXEIWU4D" style="border-bottom: Black 1.5pt solid; text-align: right" title="Accumulated depreciation">(45,059</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 2.5pt">Total</td><td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_987_eus-gaap--PropertyPlantAndEquipmentNet_iI_c20231231_zKB9J3RV6cW6" style="border-bottom: Black 2.5pt double; text-align: right" title="Property and equipment, net">-</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98B_eus-gaap--PropertyPlantAndEquipmentNet_iI_c20221231_zCpMc3v9yy7c" style="border-bottom: Black 2.5pt double; text-align: right" title="Property and equipment, net">39,258</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> Depreciation expense was $17,250 and $17,102 for the years ended December 31, 2023 and 2022, respectively, and is classified in general and administrative expenses in the consolidated Statements of Operations. Property and equipment consisted of the following as of: SCHEDULE OF PROPERTY AND EQUIPMENT <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td> </td><td> </td> <td> </td><td> </td> <td colspan="2" style="text-align: center">December 31,</td><td> </td><td> </td> <td colspan="2" style="text-align: center">December 31,</td><td> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: center">Estimated Life</td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">2023</td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">2022</td><td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td> </td> <td> </td><td> </td> <td colspan="2"> </td><td> </td><td> </td> <td colspan="2"> </td><td> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 48%">Tooling</td><td style="width: 2%"> </td> <td style="width: 14%; text-align: center">5 years</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_980_eus-gaap--PropertyPlantAndEquipmentGross_iI_c20231231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--ToolsDiesAndMoldsMember_zOEo8FefanB9" style="width: 14%; text-align: right" title="Property and equipment, gross">82,530</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_981_eus-gaap--PropertyPlantAndEquipmentGross_iI_c20221231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--ToolsDiesAndMoldsMember_zl6K8Abo0ZXd" style="width: 14%; text-align: right" title="Property and equipment, gross">82,530</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Computer Equipment</td><td> </td> <td style="text-align: center">3 years</td><td> </td> <td style="text-align: left"> </td><td id="xdx_983_eus-gaap--PropertyPlantAndEquipmentGross_iI_c20231231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--ComputerEquipmentMember_zE8QtnmFV75h" style="text-align: right" title="Property and equipment, gross">1,787</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_988_eus-gaap--PropertyPlantAndEquipmentGross_iI_c20221231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--ComputerEquipmentMember_zb5SP9osuaFb" style="text-align: right" title="Property and equipment, gross">1,787</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Impairment of tooling</td><td> </td> <td style="text-align: center"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_984_eus-gaap--PropertyPlantAndEquipmentGross_iI_di_c20231231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--ImpairmentOfToolingMember_z1nMwYiUSfv1" style="text-align: right" title="Property and equipment, gross">(22,008</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td id="xdx_985_eus-gaap--PropertyPlantAndEquipmentGross_iI_c20221231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--ImpairmentOfToolingMember_z0taCsCaa6Ee" style="text-align: right" title="Property and equipment, gross">-</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1.5pt">Accumulated depreciation</td><td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_98A_eus-gaap--AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_iNI_di_c20231231_zcjubFZhEvk6" style="border-bottom: Black 1.5pt solid; text-align: right" title="Accumulated depreciation">(62,309</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_988_eus-gaap--AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_iNI_di_c20221231_zMMXEIWU4D" style="border-bottom: Black 1.5pt solid; text-align: right" title="Accumulated depreciation">(45,059</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 2.5pt">Total</td><td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_987_eus-gaap--PropertyPlantAndEquipmentNet_iI_c20231231_zKB9J3RV6cW6" style="border-bottom: Black 2.5pt double; text-align: right" title="Property and equipment, net">-</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98B_eus-gaap--PropertyPlantAndEquipmentNet_iI_c20221231_zCpMc3v9yy7c" style="border-bottom: Black 2.5pt double; text-align: right" title="Property and equipment, net">39,258</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> P5Y 82530 82530 P3Y 1787 1787 22008 62309 45059 39258 17250 17102 NOTE 5 – SHORT TERM LOAN The Company borrows funds from the Company’s CEO for working capital purposes from time to time. The Company has recorded the principal balance due of $9,102 and $0 under short term note payable in the accompanying Balance Sheets at December 31, 2023 and 2022, respectively. The Company received advances of $9,102 and $0 and no repayments for the years ended December 31, 2023 and 2022. The advance from our CEO was not made pursuant to any loan agreements or promissory notes, are interest bearing at 10% per annum and due on demand. 9102 0 9102 0 0 0 0.10 NOTE 6 – STOCKHOLDERS’ (DEFICIT) EQUITY The Company has authorized 25,000,000 preferred stock with a par value of $0.001 with no preferred shares outstanding at December 31, 2023 and December 31, 2022. The Company has authorized 750,000,000 shares of par value $0.001 common stock, of which 8,439,950 and 8,475,950 shares are outstanding at December 31, 2023 and December 31, 2022, respectively. Common Stock In January 2024, the Company issued a total of <span id="xdx_906_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_pid_c20240101__20240131__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--TwoAffiliateMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_z2TsIEEwwPU6" title="Number of shares issued">10,000,000 common shares valued at $<span id="xdx_904_eus-gaap--StockIssuedDuringPeriodValueNewIssues_pid_c20240101__20240131__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--TwoAffiliateMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zdL3rqDZWpZ" title="Stock issued during period value">500,000 (based on the estimated fair value of the stock on the date of grant) to two affiliates in settlement of a dispute. On October 3, 2022, the Company entered into an Independent Contractor Services Agreement (“Agreement”) with a third party to provide professional services to the Company. The Agreement terminates January 3, 2023. Under this Agreement, the contractor will be entitled to a monthly consulting fee of $<span id="xdx_90D_eus-gaap--ProfessionalFees_c20221002__20221003__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--IndependentContractorServicesAgreementMember_zPykJBn4Di74" title="Consulting fee">6,000 and a total of <span id="xdx_904_eus-gaap--StockIssuedDuringPeriodSharesIssuedForServices_pid_c20221002__20221003__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--IndependentContractorServicesAgreementMember_z0m8B8axSWQ6" title="Number of common stock for services">36,000 common shares, valued at $<span id="xdx_90A_eus-gaap--StockIssuedDuringPeriodValueIssuedForServices_c20221002__20221003__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--IndependentContractorServicesAgreementMember_zId98Ufdbhxe" title="Number of common stock for services, value">18,000 (based on the estimated fair value of the stock on the date of grant) for services rendered. In 2023, the Agreement was mutually cancelled with <span id="xdx_902_eus-gaap--ProfessionalFees_do_c20230101__20231231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--IndependentContractorServicesAgreementMember_zFdiI7KG3XPb" title="Consulting fee">no consulting fees paid and the <span id="xdx_909_ecustom--StockIssuedDuringPeriodSharesCancelled_pid_c20230101__20231231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--IndependentContractorServicesAgreementMember_zUbDkQsQHW9l" title="Number of shares cancelled">36,000 common shares cancelled. On July 20, 2022, the Company issued <span id="xdx_90A_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_pid_c20220720__20220720__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--AffiliateMember_zbCRQ4cQ5cb4" title="Number of shares issued">200,000 common shares to an affiliate for aggregate gross proceeds of $<span id="xdx_90F_eus-gaap--StockIssuedDuringPeriodValueNewIssues_c20220720__20220720__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--AffiliateMember_zeuKhHu5aOwl" title="Aggregate gross proceeds">100,000. Warrants On March 16, 2021, the Company granted <span id="xdx_90E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_pid_c20210316__20210316__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__srt--TitleOfIndividualAxis__custom--AhmetDemirBingolMember_zrxyQiWtgzvk" title="Warrants, Granted">698,830 warrants to purchase <span id="xdx_903_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_pid_c20210316__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__srt--TitleOfIndividualAxis__custom--AhmetDemirBingolMember_zHDIuyXejiWi" title="Warrants issued">698,830 of the Company’s common stock to Ahmet Demir Bingol, valued at $<span id="xdx_902_eus-gaap--IssuanceOfStockAndWarrantsForServicesOrClaims_c20210316__20210316__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__srt--TitleOfIndividualAxis__custom--AhmetDemirBingolMember_zjUwdzHSH8Ne" title="Value of warrants granted">165,378 (based on the Black Scholes valuation model on the date of grant), pursuant to his Employment Agreement. The warrants are exercisable for a period of <span id="xdx_90F_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dc_c20210316__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__srt--TitleOfIndividualAxis__custom--AhmetDemirBingolMember_zAIKDLclGps9" title="Warrants term">ten years at $<span id="xdx_901_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20210316__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__srt--TitleOfIndividualAxis__custom--AhmetDemirBingolMember_zXyMs9mcyg2f" title="Warrants exercise price">0.50 per share in whole or in part, as either a cash exercise or as a cashless exercise, and fully vest at grant date. On February 24, 2022, Mr. Bingol, the Company’s previous CEO, entered into a separation agreement whereby he will terminate his employment effective April 15, 2022. He received no severance payment and there were no disagreements between he or the Company. A total of <span id="xdx_908_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_pid_c20220415__20220415__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__srt--TitleOfIndividualAxis__custom--AhmetDemirBingolMember__us-gaap--VestingAxis__us-gaap--ShareBasedCompensationAwardTrancheOneMember_zejyzucReLih" title="Warrants, Granted">300,000 warrants have vested with the remaining <span id="xdx_901_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardUnvestedWarrantsExpired_pid_c20220415__20220415__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__srt--TitleOfIndividualAxis__custom--AhmetDemirBingolMember_z246k17602E1" title="Unvested warrants expired">398,830 unvested warrants expiring. As a result of Mr. Bingol’s termination, the Company reversed the remaining warrant modification balance of $<span id="xdx_90A_eus-gaap--FairValueAdjustmentOfWarrants_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__srt--TitleOfIndividualAxis__custom--AhmetDemirBingolMember_zAWVeK5OyoD8" title="Warrants modification expense">94,101 during the year ended December 31, 2022. On February 1, 2022, the Company granted <span id="xdx_903_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_pid_c20220201__20220201__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__srt--TitleOfIndividualAxis__custom--ThirdPartyMember_zD9ySfDdtcY7">30,000 warrants to purchase <span id="xdx_905_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_pid_c20220201__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__srt--TitleOfIndividualAxis__custom--ThirdPartyMember_zuFfsBDERi75">30,000 of the Company’s common stock to a third party for consulting services, valued at $<span id="xdx_900_eus-gaap--IssuanceOfStockAndWarrantsForServicesOrClaims_c20220201__20220201__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__srt--TitleOfIndividualAxis__custom--ThirdPartyMember_zZ7BLFmbaSOa">13,547 (based on the Black Scholes valuation model on the date of grant). The options are exercisable for a period of <span id="xdx_902_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dc_c20220201__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__srt--TitleOfIndividualAxis__custom--ThirdPartyMember_zdhKN80jy6Gb" title="Warrants term">three years at $<span id="xdx_90C_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20220201__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__srt--TitleOfIndividualAxis__custom--ThirdPartyMember_zURBTzKPkIx" title="Warrants exercise price">1.00 per share in whole or in part, and fully vest at grant date. On March 29, 2022, the Board of Directors approved the granting of <span id="xdx_907_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_pid_c20220329__20220329__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__dei--LegalEntityAxis__custom--CreoMedIncMember__srt--TitleOfIndividualAxis__custom--DrJosephPergolizziMember_z0RWfZseIKS1" title="Warrants, Granted">400,000 warrants, with effect from April 1, 2022, convertible to the Company’s common shares with an exercise price of $<span id="xdx_909_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20220329__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__dei--LegalEntityAxis__custom--CreoMedIncMember__srt--TitleOfIndividualAxis__custom--DrJosephPergolizziMember_zeOZdgd5J226" title="Warrants exercise price">1.10, valued at $<span id="xdx_908_eus-gaap--IssuanceOfStockAndWarrantsForServicesOrClaims_c20220329__20220329__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__dei--LegalEntityAxis__custom--CreoMedIncMember__srt--TitleOfIndividualAxis__custom--DrJosephPergolizziMember_zq7f7sBmNqF8" title="Value of warrants granted">290,276 (based on the Black Scholes valuation model on the date of grant), to our acting CEO and Chairman Joseph V. Pergolizzi Jr., MD through his company, CreoMed Inc with an expiration period of <span id="xdx_900_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dtY_c20220329__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__dei--LegalEntityAxis__custom--CreoMedIncMember__srt--TitleOfIndividualAxis__custom--DrJosephPergolizziMember_ztcnodL68Du6" title="Warrants term">10 years. These warrants were issued as compensation for the first quarter to Joseph V. Pergolizzi Jr., MD. On August 1, 2022, based on a revised agreement signed by the relevant parties, the Company granted <span id="xdx_90B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_c20220801__20220801__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--ThirdPartyMember_zmUKnn0Mn9t4" title="Warrants granted">60,000 warrants to purchase <span id="xdx_903_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_pid_c20220801__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--ThirdPartyMember_z47uZmY2V1V8" title="Number of common stock for purchase">60,000 of the Company’s common stock to a third party for consulting services, valued at $7,632 (based on the Black Scholes valuation model on the date of grant). The options are exercisable for a period of <span id="xdx_90D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardTermsOfAward_c20220801__20220801__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--ThirdPartyMember_zhInpp3DAZ33" title="Options exercisable period">three years at $1.10 per share in whole or in part, and fully vest at grant date. On September 1, 2022, the Company granted <span id="xdx_903_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_c20220901__20220901__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--ThirdPartyMember_zLftvm3ni8gl" title="Warrants granted">300,000 warrants to purchase <span id="xdx_904_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_pid_c20220901__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--ThirdPartyMember_zgWz5BQi0AFh" title="Number of common stock for purchase">300,000 of the Company’s common stock to a third party for consulting services, valued at $60,916 (based on the Black Scholes valuation model on the date of grant). The options are exercisable for a period of <span id="xdx_90C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardTermsOfAward_c20220901__20220901__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--ThirdPartyMember_z5ulXzHJrMk" title="Options exercisable period">four years at $1.10 per share in whole or in part and vest <span id="xdx_90F_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_pid_dp_uPure_c20220901__20220901__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--ThirdPartyMember__us-gaap--VestingAxis__us-gaap--ShareBasedCompensationAwardTrancheOneMember_zS1AduURPsyc" title="Vesting percentage">50% in six months and the remaining <span id="xdx_908_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_pid_dp_uPure_c20220901__20220901__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--ThirdPartyMember__us-gaap--VestingAxis__us-gaap--ShareBasedCompensationAwardTrancheTwoMember_zViTIH3XFQ7e" title="Vesting percentage">50% in twelve months from the grant date. On April 3, 2023, the Company granted <span id="xdx_902_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_c20230403__20230403__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--JimHoltMember_zkBLfUpJwD28" title="Warrants granted">3,333,333 shares warrants to purchase <span id="xdx_90B_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_pid_c20230403__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--JimHoltMember_zRNAKIQ0Mpsl" title="Number of common stock for purchase">3,333,333 of the Company’s common stock to Jim Holt, the Company’s previous CEO, valued at $1,597,635 (based on the Black Scholes valuation model on the date of grant). The warrants are exercisable for a period of <span id="xdx_902_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsTermsOfAward_c20230403__20230403__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--JimHoltMember_z4sX67IJE8ya" title="Warrants exercisable period">seven years at $<span id="xdx_90B_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20230403__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--JimHoltMember_zBazn1NjyQ61" title="Warrants exercise price">0.03 per share in whole or in part and vest immediately. On December 13, 2023, Mr. Holt, entered into a cancellation agreement whereby a total of <span id="xdx_905_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20231213__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--MrHoltMember_zpsjDxIKxmp6" title="Number of warrants">100,000 warrants, valued at $<span id="xdx_904_eus-gaap--WarrantsAndRightsOutstanding_iI_pid_c20231213__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--MrHoltMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zn2uWXr3TO17" title="Warrants, value">45,763 (based on the Black Scholes valuation model on the date of cancellation) have vested with the remaining <span id="xdx_908_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures_pid_c20231213__20231213__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--MrHoltMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zqTWnPZq3Vv3" title="Number of warrants cancelled">3,233,333 warrants cancelled. The warrants are exercisable for a period of <span id="xdx_902_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsTermsOfAward_c20231213__20231213__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--MrHoltMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zbSJQGP29XHa" title="Warrants exercisable period">three years at $<span id="xdx_90E_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20231213__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--MrHoltMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zaqWZ1kuSUY6" title="Warrants exercise price">0.03 per share in whole or in part and vest immediately. The following represents a summary of the warrants outstanding at December 31, 2023 and changes during the periods then ended: SUMMARY OF WARRANTS OUTSTANDING <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">Warrants</td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">Weighted Average Exercise Price</td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">Weighted Average Contract Life (in Years)</td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">Aggregate Intrinsic Value *</td><td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 40%">Outstanding at January 1, 2022</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iS_pid_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zQAyxrzPnk8c" style="width: 11%; text-align: right" title="Warrants Outstanding, Beginning balance">1,098,830</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_pid_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zuMOTCNTdrw4" style="width: 11%; text-align: right" title="Weighted Average Exercise Price Outstanding, Beginning balance">0.50</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 11%; text-align: right"><span id="xdx_905_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zUzFjLcdHrCl" title="Options, Weighted Average Contractual Term (in Years), Outstanding">8.4</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_98A_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingIntrinsicValue_iS_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_fKg_____z0xidPiaRxl5" style="width: 11%; text-align: right" title="Aggregate Intrinsic Value, Beginning balance">769,181</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt">Granted</td><td> </td> <td style="text-align: left"> </td><td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_pid_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_z6ghcSkFvmV7" style="text-align: right" title="Warrants, Granted">790,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zO24mO6vRJJh" style="text-align: right" title="Weighted Average Exercise Price, Granted">0.82</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_90C_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsGrantedWeightedAverageRemainingContractualTerm1_dtY_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zyhEJRXzk1gc" title="Weighted Average Contractual Term (in Years), Granted">6.7</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_988_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsGrantsInPeriodIntrinsicValue_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_fKg_____z9VBZ0M3t1rl" style="text-align: right" title="Aggregate Intrinsic Value, Granted">-</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt">Exercised</td><td> </td> <td style="text-align: left"> </td><td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_pid_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zwFknqd7wO1a" style="text-align: right" title="Warrants, Exercised">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zAfQFsHyepy6" style="text-align: right" title="Weighted Average Exercise Price, Exercised">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98D_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsExercisesInPeriodIntrinsicValue_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_fKg_____z9a6tRPWF0Vl" style="text-align: right" title="Aggregate Intrinsic Value, Exercised">-</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 1.5pt; padding-left: 10pt">Expired/Forfeited</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeituresAndExpirations_iN_pid_di_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_z06EcHrsmAj4" style="border-bottom: Black 1.5pt solid; text-align: right" title="Warrants, Expired/Forfeited">(398,830</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zkvg0ofcvcS1" style="border-bottom: Black 1.5pt solid; text-align: right" title="Weighted Average Exercise Price, Expired/Forfeited">0.50</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_982_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsForfeituresAndExpirationsInPeriodIntrinsicValue_iN_di_c20220101__20221231_fKg_____zO3cx06ryoi9" style="border-bottom: Black 1.5pt solid; text-align: right" title="Average Intrinsic Value, Expired/Forfeited">(538,421</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Outstanding at December 31, 2022</td><td> </td> <td style="text-align: left"> </td><td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iS_pid_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zodFobNP2sml" style="text-align: right" title="Warrants Outstanding, Beginning balance">1,490,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_z5AvZ5O04iZb" style="text-align: right" title="Weighted Average Exercise Price Outstanding, Beginning balance">0.50</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_90E_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_dtY_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zrWkD8hfjNd" title="Options, Weighted Average Contractual Term (in Years), Outstanding">8.4</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_987_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingIntrinsicValue_iS_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_fKg_____zJT0mmuDzYeg" style="text-align: right" title="Aggregate Intrinsic Value, Beginning balance">-</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt">Granted</td><td> </td> <td style="text-align: left"> </td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_pid_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zsYKpxfUn1pg" style="text-align: right" title="Warrants, Granted">100,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zM8a7yb9npm4" style="text-align: right" title="Weighted Average Exercise Price, Granted">0.05</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_90F_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsGrantedWeightedAverageRemainingContractualTerm1_dtY_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zWmrp9FcQxVk" title="Weighted Average Contractual Term (in Years), Granted">3.0</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_980_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsGrantsInPeriodIntrinsicValue_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_fKg_____zNgiTi3hRvq6" style="text-align: right" title="Aggregate Intrinsic Value, Granted">52,000</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt">Exercised</td><td> </td> <td style="text-align: left"> </td><td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_pid_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_z7GpN1hECbL6" style="text-align: right" title="Warrants, Exercised">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zivURfDCCSZc" style="text-align: right" title="Weighted Average Exercise Price, Exercised">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98B_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsExercisesInPeriodIntrinsicValue_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_fKg_____zsiwXZ8ouem6" style="text-align: right" title="Aggregate Intrinsic Value, Exercised">-</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 1.5pt; padding-left: 10pt">Expired/Forfeited</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeituresAndExpirations_iN_pid_di_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_ze3gCrZ8Cmq2" style="border-bottom: Black 1.5pt solid; text-align: right" title="Warrants, Expired/Forfeited">-</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zQjASU0U51r4" style="border-bottom: Black 1.5pt solid; text-align: right" title="Weighted Average Exercise Price, Expired/Forfeited">-</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_98F_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsForfeituresAndExpirationsInPeriodIntrinsicValue_iN_di_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_fKg_____zFNi1xrDbrga" style="border-bottom: Black 1.5pt solid; text-align: right" title="Average Intrinsic Value, Expired/Forfeited">-</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 2.5pt">Outstanding at December 31, 2023</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iE_pid_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zlZDwh1v4M2k" style="border-bottom: Black 2.5pt double; text-align: right" title="Warrants Outstanding, Ending balance">1,590,000</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iE_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zVjpqAuZVL1k" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted Average Exercise Price Outstanding, Ending balance">0.77</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_908_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zPgmf1MsROpf" title="Weighted Average Contractual Term (in Years), Outstanding">5.5</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98F_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingIntrinsicValue_iE_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_fKg_____zbgOnkFalks4" style="border-bottom: Black 2.5pt double; text-align: right" title="Aggregate Intrinsic Value, Ending balance">101,000</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 2.5pt">Exercisable at December 31, 2023</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_98E_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsExercisableNumber_iE_pid_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zF0gkk71Jwa" style="border-bottom: Black 2.5pt double; text-align: right" title="Warrants, Exercisable">1,590,000</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_984_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsWeightedAverageExercisePriceExercisable_iE_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zvfMPVmyVkye" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted Average Exercise Price Outstanding, Exercisable">0.77</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_902_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsExercisableWeightedAverageRemainingContractualTerm1_dtY_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zKLxsoPYONd1" title="Weighted Average Contractual Term (in Years), Exercisable">5.5</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_989_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsExercisableIntrinsicValue_iE_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_fKg_____zF570AHX7XV8" style="border-bottom: Black 2.5pt double; text-align: right" title="Average Intrinsic Value, Exercisable">101,000</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 2.5pt">Expected to be vested</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_983_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsExpectedToBeVested_iE_pid_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zpx7tvO4gsQg" style="border-bottom: Black 2.5pt double; text-align: right" title="Warrants, Expected to be vested">1,590,000</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_989_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsWeightedAverageExercisePriceExpectedToBeVested_iE_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zIJoPSRxKM9e" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted Average Exercise Price Outstanding, Expected to be vested">0.77</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_90D_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsExpectedToBeVestedWeightedAverageRemainingContractualTerm1_dtY_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zyf94MVH7h21" title="Weighted Average Contractual Term (in Years), Expected to be vested">5.5</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98C_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsExpectedToBeVestedIntrinsicValue_iE_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_fKg_____zbcz5zGvv288" style="border-bottom: Black 2.5pt double; text-align: right" title="Average Intrinsic Value, Expected to be vested">101,000</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: right">*</td> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.1in"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Based on the fair value of the Company’s stock on December 31, 2023 and December 31, 2022, respectively</td></tr> </table> Options The following represents a summary of the options outstanding at December 31, 2023 and changes during the periods then ended: SUMMARY OF STOCK OPTIONS OUTSTANDING <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">Options</td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">Weighted Average Exercise Price</td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">Weighted Average Contract Life (in Years)</td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">Aggregate Intrinsic Value *</td><td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 40%">Outstanding at January 1, 2022</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_pid_c20220101__20221231_zL54uFsO0ce5" style="width: 11%; text-align: right" title="Options outstanding, Beginning balance">120,000</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_pid_c20220101__20221231_zHblju0yRFq7" style="width: 11%; text-align: right" title="Options, Weighted Average Exercise Price, Beginning balance">0.50</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 11%; text-align: right"><span id="xdx_900_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantedInPeriodWeightedAverageRemainingContractualTerm1_dtY_c20220101__20221231_zj1WmpcYDTx" title="Options, Weighted Average Contractual Term (in Years), Granted">5.2</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iS_c20220101__20221231_fKg_____zu6InS4tAZP9" style="width: 11%; text-align: right" title="Options, Aggregate Intrinsic Value, Beginning balance">84,000</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt">Granted</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_pid_c20220101__20221231_z8hIVcdl0IZj" style="text-align: right" title="Options, Granted">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_pid_c20220101__20221231_z0mg160uMWK2" style="text-align: right" title="Options, Weighted Average Exercise Price, Granted">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_980_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodIntrinsicValue_c20220101__20221231_fKg_____zFQ2vLnntQd1" style="text-align: right" title="Options, Aggregate Intrinsic Value, Granted">-</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt">Exercised</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98B_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_pid_c20220101__20221231_zHvX1yVQQTlg" style="text-align: right" title="Options, Exercised">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_pid_c20220101__20221231_z4XT57H8onAc" style="text-align: right" title="Options, Weighted Average Exercise Price, Exercised">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">-</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 1.5pt; padding-left: 10pt">Expired/Forfeited</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_pid_c20220101__20221231_zuUQ7ceCGID" style="border-bottom: Black 1.5pt solid; text-align: right" title="Options, Expired/Forfeited">-</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_pid_c20220101__20221231_zJO3Q1VScYni" style="border-bottom: Black 1.5pt solid; text-align: right" title="Options, Weighted Average Exercise Price, Expired/Forfeited">-</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Outstanding at December 31, 2022</td><td> </td> <td style="text-align: left"> </td><td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_pid_c20230101__20231231_zyOizGtVSaKf" style="text-align: right" title="Options outstanding, Beginning balance">120,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_pid_c20230101__20231231_zxz0xtp3VmDh" style="text-align: right" title="Options, Weighted Average Exercise Price, Beginning balance">0.50</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_906_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantedInPeriodWeightedAverageRemainingContractualTerm1_dtY_c20230101__20231231_zkaYqFVKdgtf" title="Options, Weighted Average Contractual Term (in Years), Granted">4.2</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iS_c20230101__20231231_fKg_____zAGeqXoxlssb" style="text-align: right" title="Options, Aggregate Intrinsic Value, Beginning balance">-</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt">Granted</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_pid_c20230101__20231231_zJZGmRC0LCW1" style="text-align: right" title="Options, Granted">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_pid_c20230101__20231231_z4ijAFvDrLpi" style="text-align: right" title="Options, Weighted Average Exercise Price, Granted">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98A_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodIntrinsicValue_c20230101__20231231_fKg_____zVapEJvM9rF1" style="text-align: right" title="Options, Aggregate Intrinsic Value, Granted">-</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt">Exercised</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98A_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_pid_c20230101__20231231_zExg3m8NEYW4" style="text-align: right" title="Options, Exercised">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_pid_c20230101__20231231_znEMPYHBg6Kj" style="text-align: right" title="Options, Weighted Average Exercise Price, Exercised">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">-</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 1.5pt; padding-left: 10pt">Expired/Forfeited</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_pid_c20230101__20231231_zZrfITCynD14" style="border-bottom: Black 1.5pt solid; text-align: right" title="Options, Expired/Forfeited">-</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_pid_c20230101__20231231_z3h1ISvcV9B9" style="border-bottom: Black 1.5pt solid; text-align: right" title="Options, Weighted Average Exercise Price, Expired/Forfeited">-</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 2.5pt">Outstanding at December 31, 2023</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iE_pid_c20230101__20231231_zWc0sMYXldv5" style="border-bottom: Black 2.5pt double; text-align: right" title="Options outstanding, Ending balance">120,000</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iE_pid_c20230101__20231231_zplAOLFkN06" style="border-bottom: Black 2.5pt double; text-align: right" title="Options, Weighted Average Exercise Price, Ending balance">0.50</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_905_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20230101__20231231_zfP8Fg72eExa" title="Options, Weighted Average Contractual Term (in Years), Outstanding">3.2</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iE_c20230101__20231231_fKg_____zOIbAx6Sh0if" style="border-bottom: Black 2.5pt double; text-align: right" title="Options, Aggregate Intrinsic Value, Ending balance">8,400</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 2.5pt">Exercisable at December 31, 2023</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iE_pid_c20230101__20231231_zVmAJXDqqIU9" style="border-bottom: Black 2.5pt double; text-align: right" title="Options, Exercisable">120,000</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_iE_pid_c20230101__20231231_zdEqtwciQFBe" style="border-bottom: Black 2.5pt double; text-align: right" title="Options, Weighted Average Exercise Price, Exercisable">0.50</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_907_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_dtY_c20230101__20231231_zaA2hIXDRqF" title="Options, Weighted Average Contractual Term (in Years), Exercisable">3.2</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98B_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_iE_c20230101__20231231_fKg_____zTokuoy2L8zc" style="border-bottom: Black 2.5pt double; text-align: right" title="Options, Aggregate Intrinsic Value, Exercisable">8,400</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 2.5pt">Expected to be vested</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_iE_pid_c20230101__20231231_zYWoYzTy8xyf" style="border-bottom: Black 2.5pt double; text-align: right" title="Options, Expected to be vested">120,000</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_iE_pid_c20230101__20231231_z4KDFPR9BWva" style="border-bottom: Black 2.5pt double; text-align: right" title="Options, Weighted Average Exercise Price, Expected to be vested">0.50</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_906_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTermExpectedToBeVested_dtY_c20230101__20231231_zzzQjF8QZgI8" title="Weighted Average Contractual Term (in Years), Expected to be vested">4.0</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue_iE_c20230101__20231231_fKg_____zai4v7FEdIxd" style="border-bottom: Black 2.5pt double; text-align: right" title="Options, Aggregate Intrinsic Value, Expected to be vested">-</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td id="xdx_F0B_z9F5yB2mKcJl" style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: right">*</td> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.1in"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Based on the fair value of the Company’s stock on December 31, 2023 and 2022, respectively</td></tr> </table> 25000000 25000000 0.001 0.001 0 0 750000000 750000000 0.001 0.001 8439950 8475950 10000000 500000 6000 36000 18000 0 36000 200000 100000 698830 698830 165378 P10Y 0.50 300000 398830 94101 30000 30000 13547 P3Y 1.00 400000 1.10 290276 P10Y 60000 60000 7632 three years 1.10 300000 300000 60916 four years 1.10 0.50 0.50 3333333 3333333 1597635 seven years 0.03 100000 45763 3233333 three years 0.03 The following represents a summary of the warrants outstanding at December 31, 2023 and changes during the periods then ended: SUMMARY OF WARRANTS OUTSTANDING <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">Warrants</td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">Weighted Average Exercise Price</td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">Weighted Average Contract Life (in Years)</td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">Aggregate Intrinsic Value *</td><td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 40%">Outstanding at January 1, 2022</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iS_pid_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zQAyxrzPnk8c" style="width: 11%; text-align: right" title="Warrants Outstanding, Beginning balance">1,098,830</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_pid_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zuMOTCNTdrw4" style="width: 11%; text-align: right" title="Weighted Average Exercise Price Outstanding, Beginning balance">0.50</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 11%; text-align: right"><span id="xdx_905_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zUzFjLcdHrCl" title="Options, Weighted Average Contractual Term (in Years), Outstanding">8.4</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_98A_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingIntrinsicValue_iS_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_fKg_____z0xidPiaRxl5" style="width: 11%; text-align: right" title="Aggregate Intrinsic Value, Beginning balance">769,181</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt">Granted</td><td> </td> <td style="text-align: left"> </td><td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_pid_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_z6ghcSkFvmV7" style="text-align: right" title="Warrants, Granted">790,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zO24mO6vRJJh" style="text-align: right" title="Weighted Average Exercise Price, Granted">0.82</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_90C_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsGrantedWeightedAverageRemainingContractualTerm1_dtY_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zyhEJRXzk1gc" title="Weighted Average Contractual Term (in Years), Granted">6.7</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_988_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsGrantsInPeriodIntrinsicValue_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_fKg_____z9VBZ0M3t1rl" style="text-align: right" title="Aggregate Intrinsic Value, Granted">-</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt">Exercised</td><td> </td> <td style="text-align: left"> </td><td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_pid_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zwFknqd7wO1a" style="text-align: right" title="Warrants, Exercised">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zAfQFsHyepy6" style="text-align: right" title="Weighted Average Exercise Price, Exercised">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98D_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsExercisesInPeriodIntrinsicValue_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_fKg_____z9a6tRPWF0Vl" style="text-align: right" title="Aggregate Intrinsic Value, Exercised">-</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 1.5pt; padding-left: 10pt">Expired/Forfeited</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeituresAndExpirations_iN_pid_di_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_z06EcHrsmAj4" style="border-bottom: Black 1.5pt solid; text-align: right" title="Warrants, Expired/Forfeited">(398,830</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zkvg0ofcvcS1" style="border-bottom: Black 1.5pt solid; text-align: right" title="Weighted Average Exercise Price, Expired/Forfeited">0.50</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_982_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsForfeituresAndExpirationsInPeriodIntrinsicValue_iN_di_c20220101__20221231_fKg_____zO3cx06ryoi9" style="border-bottom: Black 1.5pt solid; text-align: right" title="Average Intrinsic Value, Expired/Forfeited">(538,421</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Outstanding at December 31, 2022</td><td> </td> <td style="text-align: left"> </td><td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iS_pid_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zodFobNP2sml" style="text-align: right" title="Warrants Outstanding, Beginning balance">1,490,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_z5AvZ5O04iZb" style="text-align: right" title="Weighted Average Exercise Price Outstanding, Beginning balance">0.50</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_90E_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_dtY_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zrWkD8hfjNd" title="Options, Weighted Average Contractual Term (in Years), Outstanding">8.4</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_987_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingIntrinsicValue_iS_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_fKg_____zJT0mmuDzYeg" style="text-align: right" title="Aggregate Intrinsic Value, Beginning balance">-</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt">Granted</td><td> </td> <td style="text-align: left"> </td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_pid_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zsYKpxfUn1pg" style="text-align: right" title="Warrants, Granted">100,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zM8a7yb9npm4" style="text-align: right" title="Weighted Average Exercise Price, Granted">0.05</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_90F_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsGrantedWeightedAverageRemainingContractualTerm1_dtY_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zWmrp9FcQxVk" title="Weighted Average Contractual Term (in Years), Granted">3.0</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_980_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsGrantsInPeriodIntrinsicValue_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_fKg_____zNgiTi3hRvq6" style="text-align: right" title="Aggregate Intrinsic Value, Granted">52,000</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt">Exercised</td><td> </td> <td style="text-align: left"> </td><td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_pid_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_z7GpN1hECbL6" style="text-align: right" title="Warrants, Exercised">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zivURfDCCSZc" style="text-align: right" title="Weighted Average Exercise Price, Exercised">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98B_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsExercisesInPeriodIntrinsicValue_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_fKg_____zsiwXZ8ouem6" style="text-align: right" title="Aggregate Intrinsic Value, Exercised">-</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 1.5pt; padding-left: 10pt">Expired/Forfeited</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeituresAndExpirations_iN_pid_di_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_ze3gCrZ8Cmq2" style="border-bottom: Black 1.5pt solid; text-align: right" title="Warrants, Expired/Forfeited">-</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zQjASU0U51r4" style="border-bottom: Black 1.5pt solid; text-align: right" title="Weighted Average Exercise Price, Expired/Forfeited">-</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_98F_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsForfeituresAndExpirationsInPeriodIntrinsicValue_iN_di_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_fKg_____zFNi1xrDbrga" style="border-bottom: Black 1.5pt solid; text-align: right" title="Average Intrinsic Value, Expired/Forfeited">-</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 2.5pt">Outstanding at December 31, 2023</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iE_pid_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zlZDwh1v4M2k" style="border-bottom: Black 2.5pt double; text-align: right" title="Warrants Outstanding, Ending balance">1,590,000</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iE_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zVjpqAuZVL1k" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted Average Exercise Price Outstanding, Ending balance">0.77</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_908_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zPgmf1MsROpf" title="Weighted Average Contractual Term (in Years), Outstanding">5.5</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98F_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingIntrinsicValue_iE_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_fKg_____zbgOnkFalks4" style="border-bottom: Black 2.5pt double; text-align: right" title="Aggregate Intrinsic Value, Ending balance">101,000</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 2.5pt">Exercisable at December 31, 2023</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_98E_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsExercisableNumber_iE_pid_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zF0gkk71Jwa" style="border-bottom: Black 2.5pt double; text-align: right" title="Warrants, Exercisable">1,590,000</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_984_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsWeightedAverageExercisePriceExercisable_iE_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zvfMPVmyVkye" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted Average Exercise Price Outstanding, Exercisable">0.77</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_902_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsExercisableWeightedAverageRemainingContractualTerm1_dtY_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zKLxsoPYONd1" title="Weighted Average Contractual Term (in Years), Exercisable">5.5</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_989_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsExercisableIntrinsicValue_iE_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_fKg_____zF570AHX7XV8" style="border-bottom: Black 2.5pt double; text-align: right" title="Average Intrinsic Value, Exercisable">101,000</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 2.5pt">Expected to be vested</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_983_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsExpectedToBeVested_iE_pid_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zpx7tvO4gsQg" style="border-bottom: Black 2.5pt double; text-align: right" title="Warrants, Expected to be vested">1,590,000</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_989_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsWeightedAverageExercisePriceExpectedToBeVested_iE_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zIJoPSRxKM9e" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted Average Exercise Price Outstanding, Expected to be vested">0.77</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_90D_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsExpectedToBeVestedWeightedAverageRemainingContractualTerm1_dtY_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zyf94MVH7h21" title="Weighted Average Contractual Term (in Years), Expected to be vested">5.5</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98C_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsExpectedToBeVestedIntrinsicValue_iE_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_fKg_____zbcz5zGvv288" style="border-bottom: Black 2.5pt double; text-align: right" title="Average Intrinsic Value, Expected to be vested">101,000</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: right">*</td> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.1in"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Based on the fair value of the Company’s stock on December 31, 2023 and December 31, 2022, respectively</td></tr> </table> 1098830 0.50 P8Y4M24D 769181 790000 0.82 P6Y8M12D 398830 0.50 538421 1490000 0.50 P8Y4M24D 100000 0.05 P3Y 52000 1590000 0.77 P5Y6M 101000 1590000 0.77 P5Y6M 101000 1590000 0.77 P5Y6M 101000 The following represents a summary of the options outstanding at December 31, 2023 and changes during the periods then ended: SUMMARY OF STOCK OPTIONS OUTSTANDING <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">Options</td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">Weighted Average Exercise Price</td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">Weighted Average Contract Life (in Years)</td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">Aggregate Intrinsic Value *</td><td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 40%">Outstanding at January 1, 2022</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_pid_c20220101__20221231_zL54uFsO0ce5" style="width: 11%; text-align: right" title="Options outstanding, Beginning balance">120,000</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_pid_c20220101__20221231_zHblju0yRFq7" style="width: 11%; text-align: right" title="Options, Weighted Average Exercise Price, Beginning balance">0.50</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 11%; text-align: right"><span id="xdx_900_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantedInPeriodWeightedAverageRemainingContractualTerm1_dtY_c20220101__20221231_zj1WmpcYDTx" title="Options, Weighted Average Contractual Term (in Years), Granted">5.2</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iS_c20220101__20221231_fKg_____zu6InS4tAZP9" style="width: 11%; text-align: right" title="Options, Aggregate Intrinsic Value, Beginning balance">84,000</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt">Granted</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_pid_c20220101__20221231_z8hIVcdl0IZj" style="text-align: right" title="Options, Granted">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_pid_c20220101__20221231_z0mg160uMWK2" style="text-align: right" title="Options, Weighted Average Exercise Price, Granted">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_980_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodIntrinsicValue_c20220101__20221231_fKg_____zFQ2vLnntQd1" style="text-align: right" title="Options, Aggregate Intrinsic Value, Granted">-</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt">Exercised</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98B_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_pid_c20220101__20221231_zHvX1yVQQTlg" style="text-align: right" title="Options, Exercised">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_pid_c20220101__20221231_z4XT57H8onAc" style="text-align: right" title="Options, Weighted Average Exercise Price, Exercised">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">-</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 1.5pt; padding-left: 10pt">Expired/Forfeited</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_pid_c20220101__20221231_zuUQ7ceCGID" style="border-bottom: Black 1.5pt solid; text-align: right" title="Options, Expired/Forfeited">-</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_pid_c20220101__20221231_zJO3Q1VScYni" style="border-bottom: Black 1.5pt solid; text-align: right" title="Options, Weighted Average Exercise Price, Expired/Forfeited">-</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Outstanding at December 31, 2022</td><td> </td> <td style="text-align: left"> </td><td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_pid_c20230101__20231231_zyOizGtVSaKf" style="text-align: right" title="Options outstanding, Beginning balance">120,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_pid_c20230101__20231231_zxz0xtp3VmDh" style="text-align: right" title="Options, Weighted Average Exercise Price, Beginning balance">0.50</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_906_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantedInPeriodWeightedAverageRemainingContractualTerm1_dtY_c20230101__20231231_zkaYqFVKdgtf" title="Options, Weighted Average Contractual Term (in Years), Granted">4.2</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iS_c20230101__20231231_fKg_____zAGeqXoxlssb" style="text-align: right" title="Options, Aggregate Intrinsic Value, Beginning balance">-</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt">Granted</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_pid_c20230101__20231231_zJZGmRC0LCW1" style="text-align: right" title="Options, Granted">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_pid_c20230101__20231231_z4ijAFvDrLpi" style="text-align: right" title="Options, Weighted Average Exercise Price, Granted">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98A_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodIntrinsicValue_c20230101__20231231_fKg_____zVapEJvM9rF1" style="text-align: right" title="Options, Aggregate Intrinsic Value, Granted">-</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt">Exercised</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98A_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_pid_c20230101__20231231_zExg3m8NEYW4" style="text-align: right" title="Options, Exercised">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_pid_c20230101__20231231_znEMPYHBg6Kj" style="text-align: right" title="Options, Weighted Average Exercise Price, Exercised">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">-</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 1.5pt; padding-left: 10pt">Expired/Forfeited</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_pid_c20230101__20231231_zZrfITCynD14" style="border-bottom: Black 1.5pt solid; text-align: right" title="Options, Expired/Forfeited">-</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_pid_c20230101__20231231_z3h1ISvcV9B9" style="border-bottom: Black 1.5pt solid; text-align: right" title="Options, Weighted Average Exercise Price, Expired/Forfeited">-</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 2.5pt">Outstanding at December 31, 2023</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iE_pid_c20230101__20231231_zWc0sMYXldv5" style="border-bottom: Black 2.5pt double; text-align: right" title="Options outstanding, Ending balance">120,000</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iE_pid_c20230101__20231231_zplAOLFkN06" style="border-bottom: Black 2.5pt double; text-align: right" title="Options, Weighted Average Exercise Price, Ending balance">0.50</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_905_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20230101__20231231_zfP8Fg72eExa" title="Options, Weighted Average Contractual Term (in Years), Outstanding">3.2</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iE_c20230101__20231231_fKg_____zOIbAx6Sh0if" style="border-bottom: Black 2.5pt double; text-align: right" title="Options, Aggregate Intrinsic Value, Ending balance">8,400</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 2.5pt">Exercisable at December 31, 2023</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iE_pid_c20230101__20231231_zVmAJXDqqIU9" style="border-bottom: Black 2.5pt double; text-align: right" title="Options, Exercisable">120,000</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_iE_pid_c20230101__20231231_zdEqtwciQFBe" style="border-bottom: Black 2.5pt double; text-align: right" title="Options, Weighted Average Exercise Price, Exercisable">0.50</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_907_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_dtY_c20230101__20231231_zaA2hIXDRqF" title="Options, Weighted Average Contractual Term (in Years), Exercisable">3.2</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98B_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_iE_c20230101__20231231_fKg_____zTokuoy2L8zc" style="border-bottom: Black 2.5pt double; text-align: right" title="Options, Aggregate Intrinsic Value, Exercisable">8,400</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 2.5pt">Expected to be vested</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_iE_pid_c20230101__20231231_zYWoYzTy8xyf" style="border-bottom: Black 2.5pt double; text-align: right" title="Options, Expected to be vested">120,000</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_iE_pid_c20230101__20231231_z4KDFPR9BWva" style="border-bottom: Black 2.5pt double; text-align: right" title="Options, Weighted Average Exercise Price, Expected to be vested">0.50</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_906_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTermExpectedToBeVested_dtY_c20230101__20231231_zzzQjF8QZgI8" title="Weighted Average Contractual Term (in Years), Expected to be vested">4.0</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue_iE_c20230101__20231231_fKg_____zai4v7FEdIxd" style="border-bottom: Black 2.5pt double; text-align: right" title="Options, Aggregate Intrinsic Value, Expected to be vested">-</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td id="xdx_F0B_z9F5yB2mKcJl" style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: right">*</td> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.1in"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Based on the fair value of the Company’s stock on December 31, 2023 and 2022, respectively</td></tr> </table> 120000 0.50 P5Y2M12D 84000 120000 0.50 P4Y2M12D 120000 0.50 P3Y2M12D 8400 120000 0.50 P3Y2M12D 8400 120000 0.50 P4Y NOTE 7 – RELATED PARTY TRANSACTIONS Other than as set forth below, and as disclosed in Notes 5, 6 and 10, there have not been any transaction entered into or been a participant in which a related person had or will have a direct or indirect material interest. NOTE 8 – INCOME TAXES At December 31, 2023, net operating loss carry forwards for Federal and state income tax purposes totaling approximately $617,000 are available to reduce future income which under the Tax Cuts and Jobs Act of 2018, allows for an indefinite carryforward period, with carryforwards limited to 80% of each subsequent year’s net income. There is no income tax affect due to the recognition of a full valuation allowance on the expected tax benefits of future loss carry forwards based on uncertainty surrounding realization of such assets. A reconciliation of the statutory income tax rates and the effective tax rate is as follows: SCHEDULE OF RECONCILIATION OF STATUTORY INCOME TAX RATES <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 95%; margin-left: 0.25in"> <tr style="vertical-align: bottom"> <td> </td><td> </td> <td colspan="2" id="xdx_494_20230101__20231231_zV1AFpH38oU3" style="text-align: center">Year Ended</td><td> </td><td> </td> <td colspan="2" id="xdx_49E_20220101__20221231_zcQWxW32kEjf" style="text-align: center">Year Ended</td><td> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">December 31, 2023</td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">December 31, 2022</td><td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td> </td> <td colspan="2"> </td><td> </td><td> </td> <td colspan="2"> </td><td> </td></tr> <tr id="xdx_401_eus-gaap--EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_pid_dp_maLS_z00FWbiKgjS6" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 58%; text-align: left">Statutory U.S. federal rate</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 16%; text-align: right">21.0</td><td style="width: 2%; text-align: left">%</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 16%; text-align: right">21.0</td><td style="width: 2%; text-align: left">%</td></tr> <tr id="xdx_400_eus-gaap--EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_pid_dp_maLS_zFHJjfPaEylc" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">State income tax, net of federal benefit</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">3.7</td><td style="text-align: left">%</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">3.7</td><td style="text-align: left">%</td></tr> <tr id="xdx_40D_eus-gaap--EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate_pid_dp_maLS_zcX6Z2YoDz6j" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Permanent differences</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">0.0</td><td style="text-align: left">%</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">0.0</td><td style="text-align: left">%</td></tr> <tr id="xdx_409_eus-gaap--EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_pid_dp_maLS_zjXXDGYop2s5" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1.5pt">Valuation allowance</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">(24.7</td><td style="padding-bottom: 1.5pt; text-align: left">)%</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">(24.7</td><td style="padding-bottom: 1.5pt; text-align: left">)%</td></tr> <tr id="xdx_40A_eus-gaap--EffectiveIncomeTaxRateContinuingOperations_iT_pid_dp_mtLS_zP3iPf0eAuu1" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 2.5pt">Provision for income taxes</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; text-align: right">0.0</td><td style="padding-bottom: 2.5pt; text-align: left">%</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; text-align: right">0.0</td><td style="padding-bottom: 2.5pt; text-align: left">%</td></tr> </table> The tax effects of the temporary differences and carry forwards that give rise to deferred tax assets consist of the following: SCHEDULE OF DEFERRED TAX ASSETS <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 95%; margin-left: 0.25in"> <tr style="display: none; vertical-align: bottom"> <td> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_496_20231231_zH8XMyHQIvG2" style="border-bottom: Black 1.5pt solid; text-align: center">2023</td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_497_20221231_zeOOqPNsxp82" style="border-bottom: Black 1.5pt solid; text-align: center">2022</td><td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="6" style="border-bottom: Black 1.5pt solid; text-align: center">December 31,</td><td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">2023</td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">2022</td><td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td> </td> <td colspan="2" style="text-align: center"> </td><td> </td><td> </td> <td colspan="2"> </td><td> </td></tr> <tr id="xdx_404_eus-gaap--DeferredTaxAssetsGrossAbstract_iB_zKxVYLNnxay8" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Deferred tax assets:</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_407_eus-gaap--DeferredTaxAssetsOperatingLossCarryforwards_i01I_maDTANzd7h_zMZ6wKoWZ6T2" style="vertical-align: bottom; background-color: White"> <td style="width: 60%; text-align: left; padding-left: 10pt">Net operating loss carry forwards</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">617,573</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">470,354</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_409_ecustom--DeferredTaxAssetsDepreciationAndAmortization_i01I_maDTANzd7h_zSYEsHwclMNe" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-left: 10pt">Depreciation and amortization</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">253,712</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">249,495</td><td style="text-align: left"> </td></tr> <tr id="xdx_40B_ecustom--DeferredTaxAssetsImpairmentOfIntangibleAssets_i01I_maDTANzd7h_zekNmStwDmU3" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-left: 10pt">Impairment of Intangible asset</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">63,964</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">35,316</td><td style="text-align: left"> </td></tr> <tr id="xdx_40D_eus-gaap--DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_i01I_maDTANzd7h_zbVgOxebfepb" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-left: 10pt">Stock based compensation</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">157,163</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">138,748</td><td style="text-align: left"> </td></tr> <tr id="xdx_401_eus-gaap--DeferredTaxAssetsValuationAllowance_i01NI_di_msDTANzd7h_zc4Ug8lHUwsj" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1.5pt">Valuation allowance</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">(1,092,412</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">(893,912</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr> <tr id="xdx_403_eus-gaap--DeferredTaxAssetsNet_i01TI_mtDTANzd7h_zgtnNhJOPSba" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 2.5pt">Deferred tax assets, net</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">-</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">-</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> Major tax jurisdictions are the United States and Delaware All of the tax years will remain open three and four years for examination by the Federal and state tax authorities, respectively, from the date of utilization of the net operating loss. There are no tax audits pending. 617000 Tax Cuts and Jobs Act of 2018, allows for an indefinite carryforward period, with carryforwards limited to 80% of each subsequent year’s net income A reconciliation of the statutory income tax rates and the effective tax rate is as follows: SCHEDULE OF RECONCILIATION OF STATUTORY INCOME TAX RATES <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 95%; margin-left: 0.25in"> <tr style="vertical-align: bottom"> <td> </td><td> </td> <td colspan="2" id="xdx_494_20230101__20231231_zV1AFpH38oU3" style="text-align: center">Year Ended</td><td> </td><td> </td> <td colspan="2" id="xdx_49E_20220101__20221231_zcQWxW32kEjf" style="text-align: center">Year Ended</td><td> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">December 31, 2023</td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">December 31, 2022</td><td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td> </td> <td colspan="2"> </td><td> </td><td> </td> <td colspan="2"> </td><td> </td></tr> <tr id="xdx_401_eus-gaap--EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_pid_dp_maLS_z00FWbiKgjS6" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 58%; text-align: left">Statutory U.S. federal rate</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 16%; text-align: right">21.0</td><td style="width: 2%; text-align: left">%</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 16%; text-align: right">21.0</td><td style="width: 2%; text-align: left">%</td></tr> <tr id="xdx_400_eus-gaap--EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_pid_dp_maLS_zFHJjfPaEylc" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">State income tax, net of federal benefit</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">3.7</td><td style="text-align: left">%</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">3.7</td><td style="text-align: left">%</td></tr> <tr id="xdx_40D_eus-gaap--EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate_pid_dp_maLS_zcX6Z2YoDz6j" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Permanent differences</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">0.0</td><td style="text-align: left">%</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">0.0</td><td style="text-align: left">%</td></tr> <tr id="xdx_409_eus-gaap--EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_pid_dp_maLS_zjXXDGYop2s5" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1.5pt">Valuation allowance</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">(24.7</td><td style="padding-bottom: 1.5pt; text-align: left">)%</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">(24.7</td><td style="padding-bottom: 1.5pt; text-align: left">)%</td></tr> <tr id="xdx_40A_eus-gaap--EffectiveIncomeTaxRateContinuingOperations_iT_pid_dp_mtLS_zP3iPf0eAuu1" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 2.5pt">Provision for income taxes</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; text-align: right">0.0</td><td style="padding-bottom: 2.5pt; text-align: left">%</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; text-align: right">0.0</td><td style="padding-bottom: 2.5pt; text-align: left">%</td></tr> </table> 0.210 0.210 0.037 0.037 0.000 0.000 -0.247 -0.247 0.000 0.000 The tax effects of the temporary differences and carry forwards that give rise to deferred tax assets consist of the following: SCHEDULE OF DEFERRED TAX ASSETS <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 95%; margin-left: 0.25in"> <tr style="display: none; vertical-align: bottom"> <td> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_496_20231231_zH8XMyHQIvG2" style="border-bottom: Black 1.5pt solid; text-align: center">2023</td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_497_20221231_zeOOqPNsxp82" style="border-bottom: Black 1.5pt solid; text-align: center">2022</td><td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="6" style="border-bottom: Black 1.5pt solid; text-align: center">December 31,</td><td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">2023</td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">2022</td><td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td> </td> <td colspan="2" style="text-align: center"> </td><td> </td><td> </td> <td colspan="2"> </td><td> </td></tr> <tr id="xdx_404_eus-gaap--DeferredTaxAssetsGrossAbstract_iB_zKxVYLNnxay8" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Deferred tax assets:</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_407_eus-gaap--DeferredTaxAssetsOperatingLossCarryforwards_i01I_maDTANzd7h_zMZ6wKoWZ6T2" style="vertical-align: bottom; background-color: White"> <td style="width: 60%; text-align: left; padding-left: 10pt">Net operating loss carry forwards</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">617,573</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">470,354</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_409_ecustom--DeferredTaxAssetsDepreciationAndAmortization_i01I_maDTANzd7h_zSYEsHwclMNe" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-left: 10pt">Depreciation and amortization</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">253,712</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">249,495</td><td style="text-align: left"> </td></tr> <tr id="xdx_40B_ecustom--DeferredTaxAssetsImpairmentOfIntangibleAssets_i01I_maDTANzd7h_zekNmStwDmU3" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-left: 10pt">Impairment of Intangible asset</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">63,964</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">35,316</td><td style="text-align: left"> </td></tr> <tr id="xdx_40D_eus-gaap--DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_i01I_maDTANzd7h_zbVgOxebfepb" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-left: 10pt">Stock based compensation</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">157,163</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">138,748</td><td style="text-align: left"> </td></tr> <tr id="xdx_401_eus-gaap--DeferredTaxAssetsValuationAllowance_i01NI_di_msDTANzd7h_zc4Ug8lHUwsj" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1.5pt">Valuation allowance</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">(1,092,412</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">(893,912</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr> <tr id="xdx_403_eus-gaap--DeferredTaxAssetsNet_i01TI_mtDTANzd7h_zgtnNhJOPSba" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 2.5pt">Deferred tax assets, net</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">-</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">-</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> 617573 470354 253712 249495 63964 35316 157163 138748 1092412 893912 NOTE 9 – EARNINGS PER SHARE FASB ASC Topic 260, Earnings Per Share, requires a reconciliation of the numerator and denominator of the basic and diluted earnings (loss) per share (EPS) computations. Basic earnings (loss) per share are computed by dividing net earnings available to common shareholders by the weighted-average number of common shares outstanding during the period. Diluted earnings (loss) per share is computed similar to basic earnings per share except that the denominator is increased to include the number of additional common shares that would have been outstanding if the potential common shares had been issued and if the additional common shares were dilutive. In periods where losses are reported, the weighted-average number of common stock outstanding excludes common stock equivalents, because their inclusion would be anti-dilutive. <p id="xdx_89B_eus-gaap--ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_zwPGFlfI7rk9" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">The following potentially dilutive securities were excluded from the calculation of diluted net loss per share because the effects were anti-dilutive based on the application of the treasury stock method and because the Company incurred net losses during the period: SCHEDULE OF POTENTIALLY DILUTIVE SECURITIES WERE EXCLUDED FROM CALCULATION OF DILUTED NET LOSS PER SHARE <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="display: none; vertical-align: bottom"> <td> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_497_20230101__20231231_zTHSOt1Razf8" style="border-bottom: Black 1.5pt solid; text-align: center">2023</td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_493_20220101__20221231_zOITZnfyAGYc" style="border-bottom: Black 1.5pt solid; text-align: center">2022</td><td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="6" style="border-bottom: Black 1.5pt solid; text-align: center">For the Years Ended December 31,</td><td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">2023</td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">2022</td><td style="padding-bottom: 1.5pt"> </td></tr> <tr id="xdx_40F_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--OptionsToPurchaseSharesOfCommonStockMember_z65rNeXTsDw" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 60%; text-align: left">Options to purchase shares of common stock</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 16%; text-align: right">120,000</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 16%; text-align: right">120,000</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_40F_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--WarrantsToPurchaseSharesOfCommonStockMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--CreoMedIncMember__us-gaap--AwardTypeAxis__custom--FebruaryFourteenTwoThousandTwentyOneMember_z1fge2ngNbtd" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Warrants to purchase shares of common stock granted on February 14, 2021 to CreoMed, Inc.*</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">400,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">400,000</td><td style="text-align: left"> </td></tr> <tr id="xdx_40C_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--WarrantsToPurchaseSharesOfCommonStockMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--DemirBingolMember__us-gaap--AwardTypeAxis__custom--MarchSixteenTwoThousandTwentyOneMember_zdd7zIendRq3" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Warrants to purchase shares of common stock granted on March 16, 2021 to Demir Bingol*</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">300,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">300,000</td><td style="text-align: left"> </td></tr> <tr id="xdx_40A_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--WarrantsToPurchaseSharesOfCommonStockMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--CreoMedIncMember__us-gaap--AwardTypeAxis__custom--AprilOneTwoThousandTwentyTwoMember_zWci120Xa5C9" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Warrants to purchase shares of common stock granted on April 1, 2022 to CreoMed, Inc.</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">400,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">400,000</td><td style="text-align: left"> </td></tr> <tr id="xdx_408_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--WarrantsToPurchaseSharesOfCommonStockMember_zS0i8FjK8ira" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1.5pt">Warrants to purchase shares of common stock</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">490,000</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">390,000</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr id="xdx_406_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_zZB9FdX3E42d" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 2.5pt">Total potentially dilutive shares</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; text-align: right">1,710,000</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; text-align: right">1,610,000</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify">*</td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">The Company has cancelled and regranted these warrants to purchase <span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIFBPVEVOVElBTExZIERJTFVUSVZFIFNFQ1VSSVRJRVMgV0VSRSBFWENMVURFRCBGUk9NIENBTENVTEFUSU9OIE9GIERJTFVURUQgTkVUIExPU1MgUEVSIFNIQVJFIChEZXRhaWxzKSAoUGFyZW50aGV0aWNhbCkA" id="xdx_90D_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_pid_c20210629__us-gaap--TypeOfArrangementAxis__custom--ShareExchangeAgreementMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zCkkT1Aq7Twl" title="Warrants to purchase shares">1,098,830 shares (<span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIFBPVEVOVElBTExZIERJTFVUSVZFIFNFQ1VSSVRJRVMgV0VSRSBFWENMVURFRCBGUk9NIENBTENVTEFUSU9OIE9GIERJTFVURUQgTkVUIExPU1MgUEVSIFNIQVJFIChEZXRhaWxzKSAoUGFyZW50aGV0aWNhbCkA" id="xdx_909_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_pid_c20210629__us-gaap--TypeOfArrangementAxis__custom--ShareExchangeAgreementMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--MrBingolMember_zhLr0gDAYDu2" title="Warrants to purchase shares">698,830 warrants issued to the Ahmet Demir Bingol and <span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIFBPVEVOVElBTExZIERJTFVUSVZFIFNFQ1VSSVRJRVMgV0VSRSBFWENMVURFRCBGUk9NIENBTENVTEFUSU9OIE9GIERJTFVURUQgTkVUIExPU1MgUEVSIFNIQVJFIChEZXRhaWxzKSAoUGFyZW50aGV0aWNhbCkA" id="xdx_909_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_pid_c20210629__us-gaap--TypeOfArrangementAxis__custom--ShareExchangeAgreementMember__dei--LegalEntityAxis__custom--CreoMedIncMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zmbXipMstj94" title="Warrants to purchase shares">400,000 to CreoMed Inc.) of the Company’s common stock on June 29, 2021 in conjunction with the share exchange agreement.</td></tr> </table> The following table sets forth the computation of basic and diluted net income per share: SCHEDULE OF COMPUTATION OF BASIC AND DILUTED NET INCOME PER SHARE <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="display: none; vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_49C_20230101__20231231_zLBjHh4EJa89" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_49A_20220101__20221231_zGPh0xt15ESa" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">For the Years Ended December 31,</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr id="xdx_408_eus-gaap--NetIncomeLoss_zEYDxq2dIBPl" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 60%; text-align: left; padding-bottom: 2.5pt">Net loss attributable to the common stockholders</td><td style="width: 2%; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; width: 1%; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; width: 16%; text-align: right">(805,021</td><td style="width: 1%; padding-bottom: 2.5pt; text-align: left">)</td><td style="width: 2%; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; width: 1%; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; width: 16%; text-align: right">(920,515</td><td style="width: 1%; padding-bottom: 2.5pt; text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_400_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_zc1eULJRC2z7" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Basic weighted average outstanding shares of common stock</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">8,475,950</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">8,333,660</td><td style="text-align: left"> </td></tr> <tr id="xdx_407_eus-gaap--IncrementalCommonSharesAttributableToCallOptionsAndWarrants_z4yB11zbwc8g" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1.5pt">Dilutive effect of options and warrants</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr id="xdx_403_eus-gaap--WeightedAverageNumberOfDilutedSharesOutstanding_z4p3oAdID7Oi" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1.5pt">Diluted weighted average common stock and common stock equivalents</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">8,475,950</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">8,333,660</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Loss per share:</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 2.5pt">Basic and diluted</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(0.09</td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(0.11</td><td style="padding-bottom: 2.5pt; text-align: left">)</td></tr> </table> <p id="xdx_89B_eus-gaap--ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_zwPGFlfI7rk9" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">The following potentially dilutive securities were excluded from the calculation of diluted net loss per share because the effects were anti-dilutive based on the application of the treasury stock method and because the Company incurred net losses during the period: SCHEDULE OF POTENTIALLY DILUTIVE SECURITIES WERE EXCLUDED FROM CALCULATION OF DILUTED NET LOSS PER SHARE <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="display: none; vertical-align: bottom"> <td> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_497_20230101__20231231_zTHSOt1Razf8" style="border-bottom: Black 1.5pt solid; text-align: center">2023</td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_493_20220101__20221231_zOITZnfyAGYc" style="border-bottom: Black 1.5pt solid; text-align: center">2022</td><td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="6" style="border-bottom: Black 1.5pt solid; text-align: center">For the Years Ended December 31,</td><td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">2023</td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">2022</td><td style="padding-bottom: 1.5pt"> </td></tr> <tr id="xdx_40F_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--OptionsToPurchaseSharesOfCommonStockMember_z65rNeXTsDw" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 60%; text-align: left">Options to purchase shares of common stock</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 16%; text-align: right">120,000</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 16%; text-align: right">120,000</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_40F_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--WarrantsToPurchaseSharesOfCommonStockMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--CreoMedIncMember__us-gaap--AwardTypeAxis__custom--FebruaryFourteenTwoThousandTwentyOneMember_z1fge2ngNbtd" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Warrants to purchase shares of common stock granted on February 14, 2021 to CreoMed, Inc.*</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">400,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">400,000</td><td style="text-align: left"> </td></tr> <tr id="xdx_40C_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--WarrantsToPurchaseSharesOfCommonStockMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--DemirBingolMember__us-gaap--AwardTypeAxis__custom--MarchSixteenTwoThousandTwentyOneMember_zdd7zIendRq3" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Warrants to purchase shares of common stock granted on March 16, 2021 to Demir Bingol*</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">300,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">300,000</td><td style="text-align: left"> </td></tr> <tr id="xdx_40A_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--WarrantsToPurchaseSharesOfCommonStockMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--CreoMedIncMember__us-gaap--AwardTypeAxis__custom--AprilOneTwoThousandTwentyTwoMember_zWci120Xa5C9" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Warrants to purchase shares of common stock granted on April 1, 2022 to CreoMed, Inc.</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">400,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">400,000</td><td style="text-align: left"> </td></tr> <tr id="xdx_408_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--WarrantsToPurchaseSharesOfCommonStockMember_zS0i8FjK8ira" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1.5pt">Warrants to purchase shares of common stock</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">490,000</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">390,000</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr id="xdx_406_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_zZB9FdX3E42d" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 2.5pt">Total potentially dilutive shares</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; text-align: right">1,710,000</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; text-align: right">1,610,000</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify">*</td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">The Company has cancelled and regranted these warrants to purchase <span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIFBPVEVOVElBTExZIERJTFVUSVZFIFNFQ1VSSVRJRVMgV0VSRSBFWENMVURFRCBGUk9NIENBTENVTEFUSU9OIE9GIERJTFVURUQgTkVUIExPU1MgUEVSIFNIQVJFIChEZXRhaWxzKSAoUGFyZW50aGV0aWNhbCkA" id="xdx_90D_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_pid_c20210629__us-gaap--TypeOfArrangementAxis__custom--ShareExchangeAgreementMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zCkkT1Aq7Twl" title="Warrants to purchase shares">1,098,830 shares (<span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIFBPVEVOVElBTExZIERJTFVUSVZFIFNFQ1VSSVRJRVMgV0VSRSBFWENMVURFRCBGUk9NIENBTENVTEFUSU9OIE9GIERJTFVURUQgTkVUIExPU1MgUEVSIFNIQVJFIChEZXRhaWxzKSAoUGFyZW50aGV0aWNhbCkA" id="xdx_909_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_pid_c20210629__us-gaap--TypeOfArrangementAxis__custom--ShareExchangeAgreementMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--MrBingolMember_zhLr0gDAYDu2" title="Warrants to purchase shares">698,830 warrants issued to the Ahmet Demir Bingol and <span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIFBPVEVOVElBTExZIERJTFVUSVZFIFNFQ1VSSVRJRVMgV0VSRSBFWENMVURFRCBGUk9NIENBTENVTEFUSU9OIE9GIERJTFVURUQgTkVUIExPU1MgUEVSIFNIQVJFIChEZXRhaWxzKSAoUGFyZW50aGV0aWNhbCkA" id="xdx_909_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_pid_c20210629__us-gaap--TypeOfArrangementAxis__custom--ShareExchangeAgreementMember__dei--LegalEntityAxis__custom--CreoMedIncMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zmbXipMstj94" title="Warrants to purchase shares">400,000 to CreoMed Inc.) of the Company’s common stock on June 29, 2021 in conjunction with the share exchange agreement.</td></tr> </table> 120000 120000 400000 400000 300000 300000 400000 400000 490000 390000 1710000 1610000 1098830 698830 400000 The following table sets forth the computation of basic and diluted net income per share: SCHEDULE OF COMPUTATION OF BASIC AND DILUTED NET INCOME PER SHARE <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="display: none; vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_49C_20230101__20231231_zLBjHh4EJa89" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_49A_20220101__20221231_zGPh0xt15ESa" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">For the Years Ended December 31,</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr id="xdx_408_eus-gaap--NetIncomeLoss_zEYDxq2dIBPl" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 60%; text-align: left; padding-bottom: 2.5pt">Net loss attributable to the common stockholders</td><td style="width: 2%; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; width: 1%; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; width: 16%; text-align: right">(805,021</td><td style="width: 1%; padding-bottom: 2.5pt; text-align: left">)</td><td style="width: 2%; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; width: 1%; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; width: 16%; text-align: right">(920,515</td><td style="width: 1%; padding-bottom: 2.5pt; text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_400_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_zc1eULJRC2z7" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Basic weighted average outstanding shares of common stock</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">8,475,950</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">8,333,660</td><td style="text-align: left"> </td></tr> <tr id="xdx_407_eus-gaap--IncrementalCommonSharesAttributableToCallOptionsAndWarrants_z4yB11zbwc8g" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1.5pt">Dilutive effect of options and warrants</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr id="xdx_403_eus-gaap--WeightedAverageNumberOfDilutedSharesOutstanding_z4p3oAdID7Oi" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1.5pt">Diluted weighted average common stock and common stock equivalents</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">8,475,950</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">8,333,660</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Loss per share:</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 2.5pt">Basic and diluted</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(0.09</td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(0.11</td><td style="padding-bottom: 2.5pt; text-align: left">)</td></tr> </table> -805021 -920515 8475950 8333660 8475950 8333660 -0.09 -0.09 -0.11 -0.11 NOTE 10 – COMMITMENTS AND CONTINGENCIES Legal From time to time, various lawsuits and legal proceedings may arise in the ordinary course of business. However, litigation is subject to inherent uncertainties and an adverse result in these or other matters may arise from time to time that may harm our business. We are currently not aware of any legal proceedings or claims that it believes will have a material adverse effect on its business, financial condition or operating results. 2021 Equity Incentive Plan In June 2021, the board of directors of the Company authorized the adoption and implementation of the Company’s 2021 Equity Incentive Plan (the “2021 Plan”). The principal purpose of the 2021 Plan is to attract, retain and motivate employees, officers, directors, consultants, agents, advisors and independent contractors of the Company and its related companies by providing them the opportunity to acquire a proprietary interest in the Company and to link their interests and efforts to the long-term interests of the Company’s shareholders. Under the 2021 Plan, an aggregate of <span id="xdx_908_eus-gaap--CommonStockCapitalSharesReservedForFutureIssuance_iI_pid_c20210601__us-gaap--PlanNameAxis__custom--TwoThousandTwentyOnePlanMember_zzPPif70bTAj" title="Common stock reserved for issuance">1,000,000 shares of the Company’s common stock have initially been reserved for issuance pursuant to a variety of stock-based compensation awards, including stock options, stock awards, restricted stock, restricted stock units and other stock and cash-based awards. The exercise price for each option may not be less than fair market value of the common stock on the date of grant, and shall vest as determined by the Company’s board of directors but shall not exceed a ten-year period. Employment Agreement On March 1, 2021, Mr. Ahmet Demir Bingol, the Company’s Chief Executive Officer (“CEO”) entered into an Employment Agreement with the Company, with an effective date of March 16, 2021, in which he receives an annual base salary of $250,000, plus bonus compensation not to exceed 80% of salary. In addition, Mr. Bingol was granted <span id="xdx_90B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_pid_c20210316__20210316__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__srt--TitleOfIndividualAxis__custom--AhmetDemirBingolMember_zpbPoe1CWrgd" title="Warrants granted">698,830 warrants to purchase <span id="xdx_90F_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_pid_c20210316__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__srt--TitleOfIndividualAxis__custom--AhmetDemirBingolMember_zqnL3Ktyt6Of" title="Warrants to purchase of common stock">698,830 of the Company’s common stock, valued at $<span id="xdx_900_eus-gaap--IssuanceOfStockAndWarrantsForServicesOrClaims_pp0p0_c20210316__20210316__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__srt--TitleOfIndividualAxis__custom--AhmetDemirBingolMember_zsIaBj9L0atj" title="Value of warrants granted">165,378 (based on the Black Scholes valuation model on the date of grant). The warrants are exercisable for a period of <span id="xdx_902_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dc_c20210316__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__srt--TitleOfIndividualAxis__custom--AhmetDemirBingolMember_zhgrwJq9nbxk" title="Warrants exercisable term">ten years at $<span id="xdx_907_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20210316__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__srt--TitleOfIndividualAxis__custom--AhmetDemirBingolMember_zKoTAHGIKV0k" title="Warrants exercise price">0.50 per share in whole or in part, as either a cash exercise or as a cashless exercise, and fully vest at grant date. Mr. Bingol’s employment also provides for medical insurance, disability benefits and one year of severance pay if his employment is terminated without cause or due to a change in control. Mr. Bingol’s compensation was approved by the Company’s Board of Directors on March 1, 2021. On February 24, 2022, Mr. Bingol entered into a separation agreement whereby he will terminate his employment effective April 15, 2022. He received no severance payment and there were no disagreements between he or the Company. A total of <span id="xdx_901_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_pid_c20220415__20220415__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__srt--TitleOfIndividualAxis__custom--AhmetDemirBingolMember__us-gaap--VestingAxis__us-gaap--ShareBasedCompensationAwardTrancheOneMember_z00Jc3f4xuwl" title="Warrants granted">300,000 warrants have vested with the remaining <span id="xdx_902_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardUnvestedWarrantsExpired_c20220415__20220415__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__srt--TitleOfIndividualAxis__custom--AhmetDemirBingolMember_zFaHGiQNwyx2" title="Unvested warrants expired">398,830 unvested warrants expiring. As a result of Mr. Bingol’s termination, the Company reversed the remaining warrant modification balance of $<span id="xdx_903_eus-gaap--FairValueAdjustmentOfWarrants_pp0p0_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__srt--TitleOfIndividualAxis__custom--AhmetDemirBingolMember_zbWwL4T74es8" title="Warrants modification expense">94,101 during the year ended December 31, 2022. Consulting Agreement On January 27, 2022 the Company hired an engineering consultant to assist in completing the design history file, updating new software, system design, pre 510(k) preparation, and testing of the SOLACE device. This work is expected to be completed by the end of September 2022 and the cost of the contract is $77,850. On October 3, 2022, the Company entered into an Independent Contractor Services Agreement (“Agreement”) with a third party to provide professional services to the Company. The Agreement terminates January 3, 2023. Under this Agreement, the contractor will be entitled to a monthly consulting fee of $<span id="xdx_900_eus-gaap--ProfessionalFees_c20221002__20221003__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--IndependentContractorServicesAgreementMember_zi71EfH8vw53" title="Consulting fee">6,000 and a total of <span id="xdx_90F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_iI_pid_c20221003__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--IndependentContractorServicesAgreementMember_zH2DFM6GnWyd" title="Common stock to be issued">36,000 common shares, valued at $<span id="xdx_907_eus-gaap--StockIssuedDuringPeriodValueIssuedForServices_c20221002__20221003__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--IndependentContractorServicesAgreementMember_z2m0SKWnmHhl" title="Number of common stock for services, value">18,000 (based on the estimated fair value of the stock on the date of grant) for services rendered. In 2023, the Agreement was mutually cancelled with <span id="xdx_902_eus-gaap--ProfessionalFees_do_c20230101__20231231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--IndependentContractorServicesAgreementMember_zqI6fQNY11zk" title="Consulting fee">no consulting fees paid and the <span id="xdx_904_ecustom--StockIssuedDuringPeriodSharesCancelled_pid_c20230101__20231231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--IndependentContractorServicesAgreementMember_zaFc9LOHhM55" title="Number of common shares cancelled">36,000 common shares cancelled. 1000000 250000 698830 698830 165378 P10Y 0.50 300000 398830 94101 77850 6000 36000 18000 0 36000 NOTE 11 – SUBSEQUENT EVENTS The Company evaluated all events or transactions that occurred after December 31, 2023 up through the date the consolidated financial statements were available to be issued. During this period, the Company did not have any material recognizable subsequent events required to be disclosed as of and for the period ended December 31, 2023. In January 2024, the Company issued <span id="xdx_90F_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_pid_c20240101__20240131__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--TwoAffiliateMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zgszGOQwam3i" title="Number of shares issued">2,000,000 common shares to two (2) affiliates for aggregate gross proceeds of $<span id="xdx_90A_eus-gaap--StockIssuedDuringPeriodValueNewIssues_c20240101__20240131__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--TwoAffiliateMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zUXLfwu29iIj" title="Aggregate gross proceeds">100,000. 2000000 100000 Based on the fair value of the Company’s stock on December 31, 2023 and December 31, 2022, respectively Based on the fair value of the Company’s stock on December 31, 2023 and 2022, respectively The Company has cancelled and regranted these warrants to purchase 1,098,830 shares (698,830 warrants issued to the Ahmet Demir Bingol and 400,000 to CreoMed Inc.) of the Company’s common stock on June 29, 2021 in conjunction with the share exchange agreement.